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Abstract
Clinical effectiveness and cost-effectiveness of use of
therapeutic monitoring of tumour necrosis factor alpha
(TNF-α) inhibitors [LISA-TRACKER® enzyme-linked
immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA
kits and Promonitor® ELISA kits] versus standard care
in patients with Crohn’s disease: systematic reviews and
economic modelling
Karoline Freeman,1 Martin Connock,1 Peter Auguste,1
Sian Taylor-Phillips,1 Hema Mistry,1 Deepson Shyangdan,1
Rachel Court,1 Ramesh Arasaradnam,2 Paul Sutcliffe1*
and Aileen Clarke1
1Warwick Evidence, Division of Health Sciences, Warwick Medical School, University of Warwick,
Coventry, UK
2Clinical Sciences Research Institute, University of Warwick, University Hospitals Coventry and
Warwickshire NHS Trust, Coventry, UK
*Corresponding author p.a.sutcliffe@warwick.ac.uk
Background and objectives: Systematic reviews and economic modelling of clinical effectiveness and
cost-effectiveness of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [using
LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits (Theradiag, Marne La Vallee, France, or
Alpha Laboratories, Heriot, UK), TNF-α-Blocker ELISA kits (Immundiagnostik AG, Bensheim, Germany) and
Promonitor® ELISA kits (Proteomika, Progenika Biopharma, Bizkaia, Spain)] versus standard care for
Crohn’s disease (CD).
Methods: Multiple electronic databases were searched from inception to December 2014 in order to
identify primary studies and meta-analyses.
Population: Patients with moderate to severe active CD treated with infliximab (IFX) (Remicade®, Merck
Sharp & Dohme Ltd, Kenilworth, NJ, USA) or adalimumab (ADA) (Humira®, AbbVie Inc., North Chicago,
IL, USA).
Intervention: Monitoring of serum anti-TNF-α (IFX or ADA) and/or of anti-drug antibody levels using test
assays with a test–treatment algorithm.
Comparator: Standard care.
Outcomes: Any patient-related outcome, test agreement and cost-effectiveness estimates. The quality
assessments used recognised checklists (Quality Assessment of Diagnostic Accuracy Studies-2, Cochrane,
Philips and Consolidated Health Economic Evaluation Reporting Standards). Evidence was synthesised using
narrative review and meta-analysis. A Markov model was built in TreeAge Pro 2013 (TreeAge Software,
Inc., Williamstown, MA, USA). The model had a 4-week cycle and a 10-year time horizon, adopted a NHS
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and Personal Social Services perspective and used a linked evidence approach. Costs were adjusted to
2013/14 prices and discounted at 3.5%.
Results: We included 68 out of 2434 and 4 out of 2466 studies for the clinical effectiveness and
cost-effectiveness reviews, respectively. Twenty-three studies comparing test methods were identified.
Evidence on test concordance was sparse and contradictory, offering scant data for a linked evidence
approach. Three studies [two randomised controlled trials (RCTs) and one retrospective observational study]
investigated outcomes following implementation of a test algorithm. None used the specified commercial
ELISA immunoassay test kits. Neither of the two RCTs demonstrated clinical benefit of a test–treatment
regimen. A meta-analysis of 31 studies to estimate test accuracy for predicting clinical status indicated
that 20–30% of test results are likely to be inaccurate. The four cost-effectiveness studies suggested that
testing results in small cost reductions. In the economic analysis the base-case analysis showed that
standard practice (no testing/therapeutic monitoring with the intervention tests) was more costly and more
effective than testing for IFX. Sensitivity and scenario analyses gave similar results. The probabilistic
sensitivity analysis indicated a 92% likelihood that the ‘no-testing’ strategy was cost-effective at a
willingness to pay of £20,000 per quality-adjusted life-year.
Strengths and limitations: Rigorous systematic reviews were undertaken; however, the underlying
evidence base was poor or lacking. There was uncertainty about a linked evidence approach and a lack of
gold standard for assay comparison. The only comparative evidence available for economic evaluation was
for assays other than the intervention assays.
Conclusions: Our finding that testing is not cost-effective for IFX should be viewed cautiously in view of
the limited evidence. Clinicians should be mindful of variation in performance of different assays and of
the absence of standardised approaches to patient assessment and treatment algorithms.
Future work recommendations: There is substantial variation in the underlying treatment pathways and
uncertainty in the relative effectiveness of assay- and test-based treatment algorithms, which requires
further investigation. There is very little research evidence on ADA or on drug monitoring in children with
CD, and conclusions on cost-effectiveness could not be reached for these.
Study registration: This study is registered as PROSPERO CRD42014015278.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
C rohn’s disease is a serious chronic inflammatory condition of the digestive tract. It currently affectsabout 115,000 patients in the UK. Severely ill patients can be treated with drugs called infliximab
and adalimumab.
These are expensive drugs for the NHS. Some patients improve on them, whereas others improve initially
but then lose response. One cause of lost response is that the patient develops antibodies against the drug
which cancel out the effect of treatment.
Tests have been developed to measure both the level of drug and the level of antibodies against these
drugs in the patient’s blood. The idea is that treatment can be adapted in response to the test outcomes
to ensure that the patient is on the best treatment for them.
In this assessment we systematically reviewed the literature for three of these new tests and combined the
results to obtain our own estimates of clinical effectiveness and cost-effectiveness.
We found that no test accurately measures levels of drugs or antibodies to drugs and that tests disagree,
which means that it is difficult to assess the effectiveness of new tests. The model drew mainly on
evidence from two randomised controlled trials using infliximab and showed that, compared with standard
care, testing appeared to be more costly and less effective.
We conclude that more evidence is required to tell us how the tests and the treatment options prescribed
by the test results can benefit the management of patients with severe Crohn’s disease.
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Scientific summary
Introduction
Crohn’s disease (CD) is a chronic fluctuating inflammatory condition of the digestive tract. It is currently
estimated to affect approximately 115,000 patients in the UK, with 3000 new cases diagnosed each year.
In severe active CD, biological therapies are used when other treatment options fail and before surgical
removal of the affected bowel is considered. These more recent drugs are monoclonal antibodies that
inactivate tumour necrosis factor alpha (anti-TNF-α). The two anti-TNF-α agents considered here are
infliximab (IFX) (Remicade®, Merck Sharp & Dohme Ltd, Kenilworth, NJ, USA) and adalimumab (ADA)
(Humira®, AbbVie Inc., North Chicago, IL, USA).
Response to anti-TNF-α agents is variable. Loss of response (LOR) is thought to be caused by
subtherapeutic drug levels or the development of anti-drug antibodies that neutralise anti-TNF-α and
hasten clearance from the circulation. This idea has led to the development of test kits able to measure
circulatory levels of anti-TNF-α drugs and the antibodies directed against them, and to the use of test
results in treatment algorithms to bring the anti-TNF-α levels into the therapeutic range and to prevent
continuing use of ineffective agents.
Decision problem
The decision problem for this assessment is:
l Does testing of TNF-α inhibitor levels and antibodies to TNF-α inhibitors (IFX or ADA) represent a
clinically effective and cost-effective use of NHS resources in patients with moderate or severe CD
whose disease responds to treatment or who have lost response to treatment with TNF-α inhibitors?
The comparator for testing is standard care with an appropriate anti-TNF-α.
Three commercially available test kits for estimation of serum anti-TNF-α agents and anti-drug antibodies
have been identified as interventions. These are LISA-TRACKER® enzyme-linked immunosorbent assay
(ELISA) kits (Theradiag, Marne La Vallee, France, or Alpha Laboratories, Heriot, UK), TNF-α-Blocker ELISA
kits (Immundiagnostik AG, Bensheim, Germany) and Promonitor® ELISA kits (Proteomika, Progenika
Biopharma, Bizkaia, Spain).
Objectives
Objective A: review of comparative performance of tests
To review and critique studies:
l that compare two or more intervention tests, or an intervention test with another test method which
can be used to perform a linked evidence assessment
l that report a test threshold analysis to determine the optimal drug cut-off level to predict or
diagnose response.
Objective B: description of algorithms
To describe algorithms used in studies that include data on one or more intervention test or on a test
which allows a linked evidence approach to be performed (i.e. algorithms used in studies identified in
objective C1).
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Objective C1: review of clinical effectiveness of test algorithm combinations
To systematically review the literature comparing the clinical effectiveness of an intervention or other
assays for anti-TNF-α agents and/or for anti-drug antibodies used in conjunction with a treatment
algorithm in patients with CD treated with IFX or ADA with the clinical effectiveness of standard care
(no tests or test-informed algorithm used) in patients with CD treated with the same anti-TNF-α agent.
Objective C2: analysis of correlation between test results and
clinical outcomes
To analyse correlation studies that investigate the relationship between test results for anti-TNF-α and
anti-drug antibody levels, and clinical outcome measured as clinical response. This objective was added
post protocol because of the paucity of studies which address the decision question.
Objective D: review of cost-effectiveness of test algorithm combinations
versus standard care
To assess the cost-effectiveness of employing anti-TNF-α and anti-TNF-α antibody monitoring with
LISA-TRACKER ELISA kits, TNF-α-Blocker ELISA kits and Promonitor ELISA kits compared with standard care
in patients with CD.
In the absence of studies using the intervention tests, to use a linked evidence approach in which evidence
of clinical effectiveness is taken from studies using alternative tests to the intervention tests.
Methods
Clinical effectiveness and cost-effectiveness systematic reviews
Multiple electronic databases were searched from inception up to the point of searching, during October
to December 2014. Supplementary searches were used to identify additional published and unpublished
studies. Reference lists and citation searches of included studies and review articles were undertaken.
Further information was provided by the companies.
Two reviewers independently screened and assessed titles and abstracts of all records. Studies were
included according to the following:
l population – adults and children with moderate to severe active CD treated with IFX or ADA
l intervention – monitoring of serum anti-TNF-α (IFX or ADA) and/or anti-drug antibody levels using
intervention tests or other tests implemented using a test–treatment algorithm
l comparator – standard care (no anti-TNF-α or antibody monitoring)
l outcomes – any patient-related outcome, test agreement, cost-effectiveness estimates
l study design – any primary study design, systematic reviews with meta-analyses.
Study quality assessments were undertaken using an adapted Quality Assessment of Diagnostic Accuracy
Studies-2 checklist, the Cochrane risk-of-bias tool, the Downs and Black checklist, Philips’ checklist and the
Consolidated Health Economic Evaluation Reporting Standards. Data were extracted by one reviewer and
checked by a second reviewer. Disagreements were resolved by consensus or with a third reviewer.
Evidence was synthesised using narrative review and statistical methods when appropriate. Individual
patient data were reconstructed from available Kaplan–Meier plots using the method of Guyot et al.
(Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier
survival curves. BMC Med Res Methodol 2012;12:9). Meta-analyses were undertaken in Stata version 11
(StataCorp LP, College Station, TX, USA) or using ‘MetaAnalyst’ software (Tufts University, Medford, MA,
USA) and RevMan version 5.3 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen,
Denmark). The Harbord and Whiting (Harbord R, Whiting P. metandi: meta-analysis of diagnostic accuracy
using hierarchical logistic regression. Stata J 2009;9:211–29) method of hierarchical meta-analysis was
used for diagnostic studies.
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Cost-effectiveness model
A de novo Markov model was built in TreeAge Pro 2013 (TreeAge Software, Inc., Williamstown, MA, USA)
to evaluate the cost-effectiveness of a test algorithm strategy-based treatment versus standard care. Two
populations were considered: (1) patients responding to treatment and (2) patients who had lost response
to treatment. Two test strategies were assessed: (1) concurrent and reflex testing of drugs and (2) antibodies
to the drugs (i.e. simultaneous or sequential drug and antibody testing). Concurrent testing yields four
possible outcomes: drug+/antibody–, drug+/antibody+, drug–/antibody+ or drug–/antibody–. Reflex testing
(antibody testing if drug tests are negative) yields three outcomes: drug+, drug–/antibody– or drug–/
antibody+. The model structure was informed by the literature search and expert clinical advice. The model
had a 4-week cycle, a 10-year time horizon and adopted a NHS and Personal Social Services perspective.
Costs were adjusted to 2013/14 prices and discounted at 3.5% per annum. The starting point was a
hypothetical cohort of patients aged 30 years. Outcomes are reported as incremental cost-effectiveness
ratios (ICERs), expressed in terms of cost per quality-adjusted life-years (QALYs) gained. A linked evidence
approach was adopted (evidence from studies using tests other than the designated intervention tests was
employed as a proxy for intervention test evidence). A number of sensitivity analyses were undertaken,
including a shortened 1-year time horizon with 4-week cycle lengths and different transition probabilities for
LOR. Probabilistic sensitivity analysis was also undertaken (10,000 model runs).
Results
The searches identified 2434 studies of clinical effectiveness and 2466 studies of cost-effectiveness,
of which 68 and four studies, respectively, were included.
Clinical effectiveness
Twenty-three studies comparing test methods were identified. Most studies did not investigate any of the
three intervention tests. Evidence on concordance between the three intervention assays at a clinically
relevant threshold was sparse and sometimes contradictory. Overall, there was insufficient evidence to
reliably assess comparative performance of the three intervention assays or their performance relative to
other assay methods or to any of the comparators with links to clinical outcomes [homogeneous mobility
shift assay (HMSA), radioimmunoassay (RIA), PROMETHEUS® ELISA (Prometheus Laboratories Inc.,
San Diego, CA, USA) or Leuven in-house ELISA (Vande Casteele N, Ferrante M, Van Assche G, Ballet V,
Compernolle G, Van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with
inflammatory bowel disease. Gastroenterology 2015;148:1320–9)].
Three studies – two randomised controlled trials (RCTs) and one retrospective observational study –
provided comparative evidence on clinical outcomes following implementation of a test algorithm versus a
non-algorithm strategy. None of these studies used the intervention tests; all investigated IFX. Neither of
the RCTs found evidence of clinical benefit for a test–algorithm–treatment regimen. In the Trough level
Adapted infliXImab Treatment trial, which investigated the effectiveness of drug monitoring following dose
optimisation in patients with response to IFX treatment, 131 out of 178 (73.59%) patients with CD were
in clinical remission before dose optimisation and 138 out of 173 (79.77%) after dose optimisation using a
test–treatment algorithm; at 52 weeks post randomisation there was likewise no difference in clinical and
biological remission between the intervention test–treatment group and the control group (p = 0.353).
Both RCTs estimated cost savings in drug expenditure with a test–treatment algorithm compared with
normal care. The retrospective observational study compared a proactive test–treatment algorithm with
normal care and reported greater retention on IFX treatment for the intervention group. However, the
algorithm was ill-defined. Much of the evidence comes from studies, including this retrospective study, that
investigated mixed groups of patients with inflammatory bowel disease [CD and ulcerative colitis (UC)].
Thirty-one studies reported on the correlation between test results and subsequent clinical state (response/
no response). The studies were meta-analysed to estimate test accuracy for predicting clinical status.
Meta-analyses indicated moderate test accuracy; positive and negative predictive value estimates derived
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from meta-analyses indicated that between 20% and 30% of positive and negative test results are likely to
be inaccurate. This was confirmed by re-analysis of three meta-analyses of the ability to predict response/
LOR using drug and/or anti-drug antibody levels.
Among these there were three studies that reported results from both drug and anti-drug antibody tests
for individual patients (one for IFX-treated responders, one for IFX-treated patients with LOR and one for
ADA-treated responders). However, the patients in these studies did not receive treatment according to a
test–treatment algorithm, therefore no outcomes data from the studies were available, and outcomes data
from the RCTs had to be used in the economic modelling.
Cost-effectiveness
The systematic review of cost-effectiveness studies identified four studies. All of these indicated that a
testing strategy might be less costly than alternatives with variable small effects on effectiveness. Use of
standard checklists suggested that all the studies are subject to some limitations. There was insufficient
published information to model an ADA test-based treatment strategy. The model therefore addressed IFX
therapy only.
In the base case, the de novo Markov model showed that for IFX reflex testing dominates concurrent
testing (that means that it is less costly and produces more QALYs); however, no-testing is more costly and
produces more QALYs than reflex testing, with an ICER of approximately £50,800.
However, the probabilistic sensitivity analysis indicated a 92% likelihood that the ‘no-testing’ strategy was
cost-effective at a willingness to pay of £20,000 per QALY.
Discussion and conclusions
Main findings
The meta-analysis indicates that tests have only moderate predictive accuracy for clinical status. There was
insufficient evidence to assess the performance of the intervention tests properly relative to one another or
to tests using alternative methodology. The literature indicates a lack of clinical consensus about which are
the best and most appropriate tests to employ in clinical practice.
The limited RCT evidence from short-term studies indicated that there is little or no benefit from a test
algorithm strategy, although there may be some cost savings.
The base-case cost-effectiveness analysis indicated that standard care, the no-testing strategy, accumulates
slightly greater QALYs, albeit at a higher cost. This strategy is 92% likely to be cost-effective at standard
levels of willingness to pay.
Strengths and limitations
Strengths of the work include a robust and comprehensive systematic review (literature search, data
extraction and analysis) strategy and the building of a de novo Markov model for the cost-effectiveness
assessment.
The main limitation relates to the availability of relevant high-quality evidence. Although we undertook
extensive systematic searches and screened more than 30,000 titles, the findings of the systematic review
warrant a cautious interpretation. Definitions of severity of disease (including response and LOR) lack
standardisation, which impact on the classification of patients in different studies. Consensus on treatment
algorithms is missing, possibly impacting on clinicians’ confidence in using them. The evidence on assay
performance was sparse and sometimes conflicting, with lack of an agreed gold or reference standard for
tests. There were very limited concordance data from studies comparing test performance of different
assays. Evidence on ADA was lacking.
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Populating the economic model with information from the literature was problematic because of the small
size and short duration of the studies and their use of subjective methods for outcomes measurement. None
of the studies used an appropriate standard care arm for economic modelling and many external sources of
data and assumptions were required to populate the model. Inputs for the economic model needed to be
drawn from disparate studies so that conclusions need to be tested with data from further research. Several
studies sourced for model inputs included a proportion of patients with UC; the impact of this on model
outputs is difficult to gauge. Variation in clinical practice in the management of patients with CD further
complicated assumptions for model structure and inputs. We were unable to include adverse events and
their treatment costs, and this may have underestimated the costs.
Implications
Our finding that testing for levels of IFX and its antibodies is not cost-effective should be viewed cautiously
by clinicians and policy-makers, in view of the linked evidence approach required and the poor quality of
the evidence available to us. Clinicians should be mindful of the potential variation in performance of the
different testing methods and strategies in their day-to-day practice.
Research priorities
We found that there is uncertainty about underlying treatment pathways, about the relative effectiveness
of assays in the absence of a gold standard or agreed reference test, about which assays to use under
which circumstances and about which clinical algorithms to follow as a result of testing. There is very little
research on ADA or the use of testing strategies and algorithms in children. The key questions for future
research consideration are:
1. What is the relative performance of methods of measuring anti-TNF-α drug and their antibodies by
ELISA kits compared with other methods, such as RIA and HMSA, and are any potential differences
clinically significant? For example, is there a validated drug threshold that is a useful predictor of
clinical outcome?
2. What are the best criteria for estimating response, non-response and LOR in CD?
3. At what time should assessments of drug and antibody take place?
4. What is the effectiveness of clinical algorithms for disease management in response to testing in the UK?
5. What is the clinical effectiveness and cost-effectiveness of monitoring patients with CD on ADA and for
paediatric patients with CD?
6. What is the relevance of cotreatment with immunosuppressants in the monitoring of anti-TNF-α agents
and their antibodies?
7. Is there a benefit of measuring total drug/antibodies compared with measurements of free drug/
antibody alone?
Study registration
This study is registered as PROSPERO CRD42014015278.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Overview
Anti-tumour necrosis factor alphas (TNF-αs), including infliximab (IFX) (Remicade®, Merck Sharp & Dohme
Ltd, Kenilworth, NJ, USA) and adalimumab (ADA) (Humira®, AbbVie Inc., North Chicago, IL, USA), are
given to patients with inflammatory bowel disease (IBD), including Crohn’s disease (CD), as a second- or
third-line therapy. Response to anti-TNF-α treatment varies among patients treated for inflammatory
chronic conditions. Although some patients stay in response over a long period of time, some are weaned
off the drug because it is no longer needed and others may lose response at some stage during treatment.
Loss of response (LOR) can occur for various reasons, the most common being (1) formation of antibodies
against the drug, which neutralise the drug’s action, rendering it ineffective; and (2) ongoing illness as a
result of inflammation that is not meditated by TNF-α. It has been proposed that measurement of serum
levels of anti-TNF-α and its antibodies can aid the management of patients with chronic diseases on
anti-TNF-α drugs.
Measurement of anti-TNF-α levels and its antibodies can be carried out concurrently (concurrent testing
strategy) or antibody testing can be carried out conditional on the absence of measurable drug levels
(reflex testing strategy).
The linked evidence approach that was adopted in this review is a methodology to handle shortcomings in
the evidence for medical test evaluations.1 The idea is to link evidence from other relevant research to the
expected benefits of the test in question when direct evidence from the test and its effects on patient
outcomes is absent. The decision-analytic model for the cost-effectiveness analysis is informed by
systematically identified indirect evidence to predict the impact of the test under evaluation on patient
outcome. The validity of this approach is dependent on the similarity of the populations, tests and
outcomes across the linkages.1
This report contains reference to confidential information provided as part of the National Institute for
Health and Care Excellence (NICE) appraisal process. This information has been removed from the report
and the results, discussions and conclusions of the report do not include the confidential information.
These sections are clearly marked in the report.
Descriptions of the health problem: Crohn’s disease
Crohn’s disease is a chronic, fluctuating, episodic, inflammatory condition of the digestive tract; it is
uncommon and is currently estimated to affect about 115,000 people in the UK,2 with about 3000 new
cases diagnosed each year.3 The aetiology of CD is still largely unknown but environmental, genetic and
immunological factors are believed to play a role, as are previous infections and smoking.4
Aetiology and pathology
Crohn’s disease can affect adults, adolescents or children. CD manifests mainly during late adolescence or
early adulthood. The first onset most commonly occurs between the ages of 16 and 30 years, with a
second peak between the ages of 60 and 80 years. Women are slightly more frequently affected than
men, but in children it is seen more often in boys than in girls. CD is most common in white people in
westernised countries and has its highest prevalence among Jewish people of European descent.4
Crohn’s disease follows a pattern of acute disease (relapse) interspersed with periods of remission (lack of
symptoms). CD causes inflammation of the lining of the digestive tract, which, depending on the
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individual, occurs at any location from the mouth to the rectum, but most commonly affects the end of
the small intestine (terminal ileum; 35%) or the connection between the small intestine and large intestine
(ileocaecal region; 40%).5 Within individuals the disease location is fairly constant.
Fistulising CD describes the condition in patients who have developed complications in the form of
abnormal connections between the bowel and other organs known as fistulae. Fistulae develop in
between 17% and 43% of people with CD.6 Active luminal CD describes the condition in patients who
have inflammation in the tube of the intestine.
The main symptoms of CD depend on the location of disease. They include abdominal pain, chronic or
nocturnal diarrhoea, anal lesions, rectal bleeding, weight loss and swelling of the abdomen with
tenderness. Complications include strictures, perforations, abdominal obstructions and development of
fistulae. Extraintestinal symptoms related to intestinal inflammation include inflammation of the joints, skin,
liver and the eyes.7 CD in children is often noticed because of growth failure.8 Symptoms range in severity
and the assessment of severity is used to classify CD into mild, moderate or severe disease according to
disease activity scales. A response is defined as a reduction in symptoms.
Measurement of disease activity
Crohn’s disease can be difficult to diagnose because symptoms overlap with those of other gastrointestinal
disorders, such as ulcerative colitis (UC) and irritable bowel syndrome. Investigations to aid diagnosis
include taking the patient’s medical history, physical examination, blood and stool tests and, finally,
endoscopy to confirm diagnosis. As the treatment for CD depends on the location and severity of disease,
an assessment of disease activity once disease is confirmed is important. However, disease activity is
difficult to assess, and a global measure which includes clinical, endoscopic, biochemical and pathological
features to define the heterogeneous disease pattern of CD is not available.9 This means that there is no
‘reference standard’ for the assessment of disease severity, which has important implications for this
assessment. For example, there is no standardised definition for when remission has been achieved.
The two most commonly used measures of disease activity are the Crohn’s Disease Activity Index (CDAI)
and the Harvey–Bradshaw Index (HBI) (a simplified version of the CDAI), which are based on the patient’s
history, physical features and laboratory data. A paediatric CDAI that emphasises the less subjective
laboratory parameters has been developed.10 Additional measures include the Perianal Disease Activity
Index (PDAI), the Inflammatory Bowel Disease Questionnaire (IBDQ) and the Crohn’s Disease Endoscopic
Index of Severity.5 However, these tools have been primarily developed for clinical trials rather than
clinical practice. In clinical practice, the use of endoscopy to assess mucosal healing as an indicator of
response and remission is becoming increasingly important, and the potential of objective laboratory
markers, such as C-reactive protein (CRP) and faecal calprotectin (FC), for the assessment of disease
activity, risk of complications and prediction of relapse, and for monitoring the effect of therapy has
been recognised.11
The variables measured by the CDAI measures include number of liquid stools, abdominal pain, general
well-being, extraintestinal complications, use of anti-diarrhoeal drugs, abdominal mass, haematocrit and
body weight.12 These are weighted according to their ability to predict disease activity, leading to an
individual score ranging from 0 to 600. The CDAI has been criticised for giving too much weight to
relatively subjective items;12 however, more objective measures, such as mucosal healing on endoscopy,
are not infallible either because of the patchy distribution of inflammation in CD. Samples taken for
examination may not necessarily be representative of the whole bowel.2
Although the CDAI uses a symptom diary of the patient over 7 days for the assessment, the HBI uses only
a 1-day diary entry for assessment. Furthermore, the HBI does not take into consideration body weight,
haematocrit and use of drugs for diarrhoea for the measurement of disease activity. HBI scores range from
0 to 20.13
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
2
In the absence of standardised definitions in which scores correspond to the different disease severity
stages, this review adopts the definitions from the NICE guidance technology appraisal 187:6
l Remission is defined as a CDAI score of < 150 points.
l Moderate to severe disease is defined as a CDAI score of > 220 points.
l Severe disease is defined as a CDAI score of > 300 points.
Response (i.e. relief of symptoms) has often been defined as a reduction in the CDAI score of at least
70 points from baseline.14
Severe active CD was defined for the purpose of the indication of IFX or ADA treatment as:
Very poor general health and one or more symptoms such as weight loss, fever, severe abdominal
pain and usually frequent (3–4 or more) diarrhoeal stools daily. People with severe active Crohn’s
disease may or may not develop new fistulae or have extra-intestinal manifestations of the disease.
This clinical definition normally, but not exclusively, corresponds to a Crohn’s Disease Activity Index
(CDAI) score of 300 or more, or a Harvey–Bradshaw score of 8 to 9 or above.
NICE (2010) technology appraisal number 187. Infliximab (Review) and Adalimumab for the
Treatment of Crohn’s Disease. London: NICE. Available from www.nice.org.uk/guidance/TA187.6
Reproduced with permission. This information is accurate at time of publication
Furthermore, the Practice Parameter Committee of the American College of Gastroenterology has
produced definitions of disease severity.7 These are as follows.
Mild to moderate disease
Mild–moderate disease applies to ambulatory patients able to tolerate oral alimentation without
manifestations of dehydration, toxicity (high fevers, rigors, prostration), abdominal tenderness, painful
mass, obstruction, or > 10% weight loss.
Hanauer and Sandborn7
Moderate to severe disease
Moderate–severe disease applies to patients who have failed to respond to treatment for mild–moderate
disease or those with more prominent symptoms of fever, significant weight loss, abdominal pain or
tenderness, intermittent nausea or vomiting (without obstructive findings), or significant anaemia.
Hanauer and Sandborn7
Severe to fulminant disease
Severe–fulminant disease refers to patients with persisting symptoms despite the introduction of
steroids as outpatients, or individuals presenting with high fever, persistent vomiting, evidence of
intestinal obstruction, rebound tenderness, cachexia, or evidence of an abscess.
Hanauer and Sandborn7
Remission
‘Remission’ refers to patients who are asymptomatic or without inflammatory sequelae and includes
patients who have responded to acute medical intervention or have undergone surgical resection
without gross evidence of residual disease. Patients requiring steroids to maintain well-being are
considered to be ‘steroid-dependent’ and are usually not considered to be ‘in remission’.
Hanauer and Sandborn. Reprinted by permission of Nature Publishing Group from Macmillan
Publishers Ltd: The American Journal of Gastroenterology, Hanauer SB, Sandborn W. Management of
Crohn’s disease in adults. Am J Gastroenterol 2001;96:635–43,7 copyright 2001
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Management and care pathway
The treatment of CD is complex; in general, it aims at (1) reducing symptoms through induction and
maintenance of remission, (2) minimising drug-related toxicity and (3) reducing the risk of surgery.15 The
management options for CD include drug therapy [e.g. glucocorticosteroids, 5-aminosalicylic acid (5-ASA),
antibiotics, immunosuppressants, TNF-α inhibitors], enteral nutrition, smoking cessation and, in severe or
chronic active disease, surgery. The choice of treatment among the available drugs is influenced by patient
age, site and activity of disease, previous drug tolerance and response to treatment, and the presence of
extraintestinal manifestations.16,17 Enteral nutrition is widely used as a first-line treatment to facilitate
growth and development in children and young people. Adjuvant therapy commonly coexists and includes
management of extraintestinal manifestations, antibiotics, corticosteroids or immunosuppressant therapy.
Between 50% and 80% of people with CD require surgery because of complications such as strictures
causing symptoms of obstruction, fistula formation, perforation or failure of medical therapy.2
Once remission has been achieved, maintenance therapy can be considered following assessment of the
course and extent of CD, effectiveness and tolerance of previous treatments, presence of biological or
endoscopic signs of inflammation, and potential for complications.15
Induction of remission according to the National Institute for Health and
Care Excellence Clinical Guideline number 1522
Usually, at first presentation, patients with active CD are recommended to receive monotherapy treatment
with conventional steroid therapy (i.e. glucocorticoids including prednisolone, methylprednisolone or
intravenous hydrocortisone), which is aimed at inducing remission as a first-line treatment. Alternatively,
treatment with budesonide, 5-ASA or enteral nutrition may be offered for patients who do not choose to
take or who are intolerant of glucocorticosteroid therapy.
The addition of an immunosuppressant (azathioprine, mercaptopurine or methotrexate) to a conventional
glucocorticosteroid or budesonide is recommended as an add-on therapy for inducing remission in patients
who have active CD and who have experienced two or more inflammatory exacerbations in a 12-month
period, or in whom glucocorticosteroid doses cannot be tapered. As advised in the current online version
of the British National Formulary (BNF)18 or BNF for Children,19 the effects of azathioprine, mercaptopurine
and methotrexate, as well as levels of neutropenia (in patients on azathioprine or mercaptopurine), should
be monitored.15
In adults and children aged 6–17 years with severe active CD who fail to respond to the first line of
treatment with conventional therapy (e.g. immunosuppressants or corticosteroids), or who are intolerant
to or who have contraindications to conventional therapy, anti-TNF-α agents (IFX and ADA) are
recommended as treatment options within their licensed indications. The administration of anti-TNF-α
agents is recommended until 12 months after the start of treatment or until treatment failure (including
the need for surgery), whichever occurs first. Reassessment and monitoring of disease activity (at least
every 12 months) is advised to ascertain the clinical appropriateness of ongoing treatment. Usually,
treatment is initiated with the less expensive drug (i.e. IFX), considering drug administration costs, dose
and product price per dose. The use of anti-TNF-α drugs for the treatment of CD is covered in the 2010
NICE technology appraisal guidance 187 [IFX (review) and ADA for the treatment of CD], which is
summarised in NICE guidelines.6
Surgery should be considered early in the course of the disease for patients whose disease is limited to the
distal ileum or for children and young people who have growth impairment despite optimal medical
treatment and/or who have refractory disease.2
Maintenance of remission according to the National Institute for Health and
Care Excellence clinical guideline 1522
Patients with CD in remission can be managed with or without maintenance treatment. The options for
maintenance (including treatment or no treatment) need to be discussed with patients and parents or
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carers. The discussion should include risk of relapse and the potential side effects of drug treatments.
Patients who decide not to use maintenance treatment should agree follow-up plans (e.g. frequency and
duration of visits) and should receive information on markers and symptoms of relapse (e.g. unintended
weight loss, abdominal pain, diarrhoea or general ill-health) to ensure that they keep their disease
appropriately under review with their health-care professionals.
Patients with CD in remission who choose to receive maintenance therapy may be offered a single drug such
as azathioprine or mercaptopurine if remission has been induced using a conventional glucocorticosteroid or
budesonide. Methotrexate can be offered if remission was induced by methotrexate or to patients who are
not able to tolerate, or who have contraindications to, azathioprine or mercaptopurine. Treatment with
5-ASA can be used to maintain remission after surgery.
If remission has been achieved with anti-TNF-α medication, then maintenance with anti-TNF-α with or
without an immunosuppressant can be used. Continuation of treatment with IFX or ADA during remission
is advised only if there is evidence of ongoing active disease assessed by clinical symptoms, biological
markers and endoscopy, if necessary. The balance between harms and benefits of ongoing treatment
should be taken into account. The guideline states that patients who relapse after anti-TNF-α treatment
may start it again.15
National Institute for Health and Care Excellence guidelines
The NICE guideline technology appraisal 1876 describes when IFX or ADA should be used to treat patients
with severe active or fistulising CD in the NHS in England and Wales.
Infliximab
The guideline states:
Infliximab has a UK marketing authorisation for the treatment of:
l severe, active Crohn’s disease in people whose disease has not responded despite a full and
adequate course of therapy with a corticosteroid and/or an immunosuppressant, or who are
intolerant to or have medical contraindications for such therapies
l fistulising, active Crohn’s disease in people whose disease has not responded despite a full and
adequate course of therapy with conventional treatment (including antibiotics, drainage and
immunosuppressive therapy)
l severe, active Crohn’s disease in people aged 6–17 years whose disease has not responded to
conventional therapy, including a corticosteroid, an immunomodulator and primary nutrition
therapy, or who are intolerant to or have contraindications for such therapies.
NICE (2010) technology appraisal number 187. Infliximab (Review) and Adalimumab for the
Treatment of Crohn’s Disease. London: NICE. Available from www.nice.org.uk/guidance/TA187.6
Reproduced with permission. This information is accurate at time of publication
Administration of IFX should follow this pattern:
. . . 5-mg/kg intravenous infusion over a 2-hour period followed by another 5-mg/kg infusion 2 weeks
after the first. If a person’s disease does not respond after two doses, no additional treatment with
infliximab should be given. In people whose disease responds, infliximab regimens include
maintenance treatment (another 5-mg/kg infusion at 6 weeks after the initial dose, followed by
infusions every 8 weeks) or re-administration, otherwise known as episodic treatment (an infusion of
5-mg/kg if signs and symptoms of the disease recur).
NICE (2010) technology appraisal number 187. Infliximab (Review) and Adalimumab for the
Treatment of Crohn’s Disease. London: NICE. Available from www.nice.org.uk/guidance/TA187.6
Reproduced with permission. This information is accurate at time of publication
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For fistulising disease, the first three doses at weeks 0, 2 and 6 are considered as induction therapy and
additional IFX therapy should not be given if the first three doses have not induced a response. The patient
pathway for people responding to IFX induction therapy and moving onto maintenance therapy is given
in Figure 1.
Adalimumab
Adalimumab can be used to treat severe active CD in adults whose disease has not responded to
treatment with an immunosuppressant and/or corticosteroid, or who are intolerant to or have
contraindications to such therapies.
Administration of ADA should follow this pattern:
The adalimumab induction treatment dose regimen for adults with severe Crohn’s disease is 80 mg via
subcutaneous injection, followed by 40 mg 2 weeks later. After induction treatment the recommended
dose is 40 mg every other week. This can be increased to 40 mg every week in people whose disease
shows a decrease in response to treatment.
NICE (2010) technology appraisal number 187. Infliximab (Review) and Adalimumab for the
Treatment of Crohn’s Disease. London: NICE. Available from www.nice.org.uk/guidance/TA187.6
Reproduced with permission. This information is accurate at time of publication
Anti-tumour necrosis factor alpha agents
Crohn’s disease is associated with elevated levels of the immune regulatory protein, TNF-α. The reasons for
this elevation in CD are still largely unknown. TNF-α is a small cell signalling protein (cytokine) involved in
Patients on IFX
maintenance (week 14)
Respond Lose response
Respond
(d) Surgery
Do not respond
Respond Do not respond
Respond Do not respond
(b) Add another agent
(a) Increase dose or
reduce interval
(c) Switch to another anti-TNF-α inhibitor,
i.e. ADA
Stay as
responder
Lose response – 
go to (a)
Stay as
responder
Lose response – 
go to (b)
Stay as
responder
Lose response – 
go to (c)
Stay as
responder
Lose response – 
go to (d)
FIGURE 1 Patient pathway of patients with CD on IFX therapy.
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inflammatory responses primarily by influencing regulation of various effector cells of the immune system.
TNF-α has been shown to have a role in several inflammatory diseases including CD, UC, rheumatoid
arthritis and ankylosing spondylitis. Anti-TNF-α agents bind to cell surface TNF-α and free TNF-α, and block
their activity. Blocking of TNF-α with anti-TNF-α drugs has been shown to be successful for some patients
with inflammatory diseases, including CD. Anti-TNF-α agents recommended by NICE for the treatment of
CD are IFX and ADA. These monoclonal antibodies are introduced into the human body to bind and block
TNF-α. They are classed as monoclonal antibodies because they are derived from genetically engineered
immune cells, which are all daughters of a single parent cell, so that in culture they generate and secrete
antibodies that are all of identical structure to and affinity for TNF-α.15
Infliximab
Infliximab is a chimeric (mouse–human) monoclonal antibody. It is said to be chimeric because the genetic
code determining its amino acid sequences is partly derived from the mouse genome and partly from the
human genome. IFX belongs to the immunoglobulin gamma type 1 (IgG1) group of antibody molecules
(Figure 2). It should be borne in mind that IgG1 molecules are globular (not linear as in the diagram) and
that they are glycoproteins, which have carbohydrate chains attached (not shown in Figure 2). As IFX is
generated from cultured mouse cells, the carbohydrate part of the molecule corresponds to that of mouse
rather than human glycoproteins.15
Infliximab is composed of human IgG1 heavy-chain constant regions and human kappa light-chain
constant regions (together representing 70% of the genetic make-up of the molecule), plus mouse-derived
heavy- and light-chain variable regions (30% of the genetic make-up, 4/12 domains), which carry the
binding sites with high affinity and specificity to TNF-α (see Figure 2). IFX was the first anti-TNF-α agent
that was approved and licensed for treating severe active CD and active fistulising CD in adults and
children aged > 6 years. It is administered intravenously over 1–2 hours.
HC
Fab
Fc
LC
LC
Variable regions
Hinge
HOOC
H2N NH2
NH2 H2N
COOH
HOOC COOH
FIGURE 2 Diagrammatic representation of the structure of an IgG1 antibody molecule. The molecule has two
heavy chains and two light chains; the heavy chains are joined by disulphide bonds (S–S) and each light chain is
joined to a heavy chain by S–S bonding. The light and heavy chains have a variable region (different from all other
antibodies) at the amino (NH2) end of the chain; these variable regions are responsible for binding antigen. The
rest of the heavy and light chains are identical to other IgG1 antibodies and are called constant regions. The
proteolytic enzymes papain and pepsin cut the molecule just above or below the S–S bonds holding the heavy
chains together. When the split is below the heavy chain S–S bond, this generates a fragment crystallising (Fc)
product and a fragment antigen-binding (Fab) product. When the split is above the heavy chain S–S bond, two
antigen-binding fragments are formed [F(ab)2]. COOH, carboxylic acid; HC, heavy chain; LC, light chain.
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Side effects of IFX include:
l allergic reaction to the infusion (or IFX) apparent by:
¢ hives (red, raised, itchy patches of skin) or other skin rashes
¢ difficulty swallowing or breathing
¢ pains in the chest or muscle, or joint pain, fever or chills
¢ swelling of the face or hands
¢ headaches or a sore throat.
l serious viral or bacterial infections including tuberculosis, especially in people aged > 65 years
l skin reactions including psoriasis (red scaly patches), rashes, skin lesions, ulcers and hives, and swollen
face and lips
l worsening of heart problems
l increased risk of cancer or lymphoma
l liver inflammation.
Many of the side effects are reversible if the drug is stopped.15
Adalimumab
Adalimumab is a purely human IgG1 monoclonal antibody. ADA is a more recent anti-TNF-α therapy that
was approved for treating CD in adults only. It is administered as a subcutaneous injection by a doctor or
nurse, or can be self-injected by the patient or a family member.15
Side effects of ADA include:
l reactions to the injection including pain, swelling, redness, bruising and itching
l allergic reaction to ADA including:
¢ rashes or hives
¢ swollen face, hands and feet
¢ trouble breathing.
l greater susceptibility to infections such as colds, influenza, pneumonia, sepsis and tuberculosis
l skin reactions including psoriasis (scaly patches), eczema, other skin rashes and ulcers
l skin cancer, lymphoma or leukaemia
l damage to nerves (demyelination)
l lupus.
Many of the side effects are reversible if the drug is stopped.15
Significance to the NHS and current service cost
The aim of successful therapies in CD is to prolong remission and to minimise relapse. Patients’ quality of
life (QoL) fluctuates through time and, unsurprisingly, has been found to be better during remission.
Studies using various disease-specific health-related QoL measures (such as McMaster’s IBDQ, IBDQ-36,
short IBDQ, Rating Form of IBD Patient Concerns, Cleveland Clinic questionnaire and Gastrointestinal
Quality of Life Index) show a clear correlation between health-related QoL and symptoms. These measures
in patients with CD have allowed utility estimates to be developed for patients in various clinical states.20
QoL has been found to be somewhat worse in CD than in UC, and substantially worse in relapse than in
healthy matched individuals. It has also been found to be similar or worse to that experienced in many
other medical conditions.21 Gastroenterologists tend to rely on global clinical judgement, which tends to
be less reproducible than QoL assessment tools, but is, of course, simpler for decision-making in everyday
clinical practice.9
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Patients with CD can be cared for in primary or secondary care depending on symptom severity. Although
general practitioners manage patients in remission or with mild symptoms, patients with more severe
active disease are managed in secondary care. These are patients who are likely to be steroid dependent,
on immunosuppressants or anti-TNF-αs, or requiring surgery. It has been estimated that about 50%
of patients with CD experience at least one flare per year. Of these, 20% of patients will require
hospitalisation.22 Disease flares have been found to be associated with a two- to threefold increase in
hospitalisation and a 20-fold increase in cost compared with managing patients in remission.23 Audit data
show that anti-TNF-α agents are potentially cost-saving by successfully maintaining patients in remission
and reducing hospital admissions. Cost reductions of £138 per patient at 6 months24 and £2750 per
patient at 12 months (excluding IFX costs) have been demonstrated in a before-and-after study of IFX
therapy.25 However, in that study both non-responders (£3608) as well as responders (£1656) incurred a
considerably higher annual cost than the mean annual costs of long-term care in CD of £631/£762 (UK)
and £838/£796 (Europe) estimated in another study using decision modelling.26 Using 2008 prevalence
figures, the total annual cost to the NHS for the approximate 60,000 patients with CD was estimated at
£38M. Updating this figure with more recent prevalence data (115,000), but still using 2008 prices, would
double that cost to £73M. This, however, might be a modest estimate when considering the wide range
of measured 6-month costs for individual patients with CD (£73–£33,254).23 The main drivers of costs
were hospital admission, surgery and anti-TNF-α treatment.26 In the 2003 Health Technology Assessment
(HTA) publication by Clark et al.,3 the average cost of a single 5-mg/kg IFX infusion for a 70-kg patient was
reported to be £1804.80. No comparable data for ADA are available.
The significance of CD to the NHS is increased by the fact that the prevalence of CD is increasing and
the disease affects many people at a young age. The lifetime care costs for patients with CD are now
comparable to the costs of caring for patients with other major chronic diseases, such as diabetes mellitus
and cancer.22 This argues not only clinically but also economically for interventions that keep patients in
remission and out of hospital. This review focuses on whether or not monitoring anti-TNF-α agents and
their antibodies with enzyme-linked immunosorbent assays (ELISAs) could potentially contribute to
this aim.
Rationale for measuring anti-tumour necrosis factor alpha drug
and anti-drug antibody levels
Responders and non-responders definitions and incidence rates
Similar to other treatment regimens for CD, anti-TNF-α treatment aims to induce remission (defined as
< 150 points on CDAI and no draining fistulae), in which case it is described as induction therapy, and to
prevent relapse (maintenance therapy). However, failure to induce a response and LOR to anti-TNF-α are
common problems in clinical practice. The lack of consensus regarding clear definitions for response and
remission result in inconsistencies in the reported incidence rates of non-response and LOR covered in
this section.
Primary non-response
Patients not achieving at least a 70-point reduction on the CDAI during induction therapy are classed as
primary non-responders. Incidence rates of primary non-response vary greatly depending on the clinical
outcome measured (response/remission) and on the time point that the assessment of response is
undertaken. For example, A Crohn’s disease Clinical trial Evaluating infliximab in a New long-term Treatment
regimen (ACCENT) I, a randomised controlled trial (RCT) that investigated the benefit of maintenance IFX
therapy in 573 active CD patients, assessed response after a single IFX infusion at 2 weeks.27 The ACCENT II
study was a post hoc analysis to determine the efficacy and safety of IFX therapy in patients with fistulising
CD in which patients were assessed at 10 weeks.28 The Crohn’s trial of the fully Human Antibody
adalimumab for Remission Maintenance RCT assessed response to ADA at 4 weeks to evaluate the drug’s
efficacy and safety in the maintenance of response and remission in 854 patients with moderate to severe
CD.29 However, Ben-Horin and Chowers30 stated that in clinical practice non-response should not be assessed
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before 8–12 weeks, as remission might still be induced at this time. It is therefore not surprising that a review
of incidence rates found that non-response ranged from 20% to 40% in clinical trials and from 10% to 20%
in ‘real-life’ series.30 In contrast, lack of remission at week 4 in patients with luminal CD was reported to be
as high as 67% for IFX and 64% for ADA.31,32 The true magnitude of the rate of primary non-response is
therefore difficult to determine.
Factors associated with non-response are believed to include:30,33,34
l severity of disease
l duration of disease
l smoking
l drug elimination
l drug binding
l anti-drug antibodies
l alternative non-TNF-α-mediated disease pathways
l concomitant treatment with immunosuppressants
l prior failure of other anti-TNF-α.
Loss of response
Patients with an initial response to anti-TNF-α treatment can lose response at any time during induction
or maintenance therapy despite intensification of treatment (i.e. increase in dose or decrease in dosing
interval). Again, lack of a clear definition, assessment at different time points, different outcome measures
and different drug doses mean that reported incidence rates of secondary LOR vary considerably across
studies. The true extent of this problem is largely unknown. Gisbert and Panes,35 in their review, reported
a range of LOR to IFX of 11–48% (mean 37%) for varying lengths of follow-up, and de Boer et al.33
reported a range of 21–46% for LOR to ADA. For this reason the incidence of LOR is better expressed as
the annual risk of LOR per patient-year (13% for IFX35 and 20.3% for ADA36). LOR to ADA and IFX did not
differ significantly in a retrospective study of 375 patients; however, patients treated with ADA required
more dose optimisation intervention than patients on IFX.37
The following factors are believed to prevent LOR:14
l pre-medication with steroids
l concomitant immunosuppressants
l maintenance therapy as opposed to episodic treatment.
Mechanisms of LOR to anti-TNF-α agents are still unclear. The next section describes some of the possible
mechanisms in more detail.
Anti-drug antibodies
Anti-drug antibodies can be elicited by IFX or ADA during therapy as a response by the human immune
system to these foreign proteins; this is termed immunogenicity of anti-TNF-α agents. These anti-drug
antibodies bind to the anti-TNF-α agent and neutralise its action. If sufficient amounts of antibodies are
present, the individual loses response to the drug treatment. During scheduled maintenance therapy, the
incidence of anti-drug antibodies is 5–18%27,38,39 and 3–17%39 for IFX and ADA, respectively. The similar
rates for IFX and ADA might initially appear counterintuitive as ADA is a fully human recombinant protein,
whereas IFX is partly human and partly mouse protein and, therefore, ‘more’ foreign. However, ADA,
similar to IFX, is a foreign protein that will prompt a response when coming into contact with the immune
system. This indicates that the degree of ‘human-ness’ is not the main determinant of immunogenicity
(i.e. formation of antibodies to a foreign protein).39
Levels of antibodies have been found to be higher during episodic treatment, at 36–61%,39–41 than levels
found during maintenance therapy. This indicates that other factors may influence immunogenicity.
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The true incidence of antibodies in anti-TNF-α-treated patients is, therefore, unknown. The ability to mount
an immune response and measurement of that response depends on a number of factors, including
the method of measuring antibody levels and age, and also depends on concomitant treatment with
immunosuppressants.14,27,40–44 For that reason, concomitant immunosuppressants might be given to
patients to prevent or reduce the formation of antibodies. This effect was not observed in one study for
ADA,14 and Vermeire et al.45 reported that increasing anti-TNF-α above antibody-binding capacity might
have similar effects to immunosuppressants, by neutralising free antibodies. Vande Casteele et al.46 made a
similar observation for transient antibodies (antibodies detectable for a short period during a series of
follow-up test assays conducted during a course of infusions), while sustained antibodies did not disappear
after dose optimisation and were associated with LOR.
The clinical importance of antibodies can be presented as:39
l positive/negative/inconclusive
l high/low
l above/below a threshold in arbitrary units or in µg/ml
l drug concentration
l clinical effect (duration of response, need for dose intensification or switch drug)
l impact on safety (infusion reactions).
The clinical relevance of antibodies has been debated. However, numerous studies report the correlation
between presence of antibodies with low or absent drug levels and consequent response.27,38,40,43,45,47,48
This can be explained by antibodies binding to the epitope of anti-TNF-α and neutralising the drug
(i.e. making it unable to bind to TNF-α and inhibiting the working mechanism of anti-TNF-α) or by forming
immune complexes with the drug (non-neutralising antibodies), which are subsequently cleared from the
circulation (reducing the drug’s bioavailability).49
Although the importance of the neutralising antibodies has been universally acknowledged,14,34,49,50
reviewers seem to disagree in their conclusion about the importance of non-neutralising antibodies.14,34
Over 90% of antibodies to IFX and ADA are neutralising.51 In a meta-analysis, Garces et al.49 estimated
that detectable antibodies can decrease response to anti-TNF-α by as much as 80%.
An interesting additional observation was made by Steenholdt et al.,52 who showed that immunoglobulin
gamma (IgG) antibodies reacting with the fragment antigen-binding portion (see Figure 2) of IFX exist in
IFX-naive IBD patients prior to treatment. The presence of pre-existing antibodies affected response
and safety of IFX treatment in patients with CD, and the study concluded that the clinical utility of
measuring pre-treatment antibodies should be assessed.
Drug levels
Although anti-drug antibodies have been shown to reduce anti-TNF-α drug levels, there are other known
mechanisms that affect drug levels. These include dose and dosing interval, body mass index, sex,
serum albumin levels (serum albumin transports drugs and can affect the half-life of drugs), concomitant
immunosuppressants, severity of inflammation, mode of administration (intravenous vs. subcutaneous) and
drug half-life.14,44
As a consequence, drug levels vary considerably between patients and within individuals over time.34
Following administration of the anti-TNF-α agent, circulating drug concentration will be at its peak level;
the concentration just before the next round of treatment is classed as ‘trough level’. The optimal time of
testing drug levels within this cycle has been debated44 and it is largely unknown what the optimal drug
levels would be at the different time points. Although a threshold trough level is thought to be needed for
effectiveness, it is also known that supratherapeutic levels can cause infections and other adverse events.14
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Anti-tumour necrosis factor alpha and antibody level monitoring in
Crohn’s disease
One of the key studies to demonstrate and quantify the link between drug and anti-drug antibody levels,
immunosuppressant therapy and response in patients with CD on anti-TNF-α agents was the study by
Baert et al.43
Baert et al.43 was an early, and influential, study of the development of anti-drug antibodies to IFX in patients
with CD; this study stimulated numerous subsequent investigations. The study enrolled 125 consecutive
patients (38 with fistulising and 87 with luminal disease) who received 5 mg/kg of IFX at 0, 2 and 6 weeks.
Responders (89/125, 71%) were retreated with this regimen if they required restart of IFX therapy according
to clinical judgement. Mean treatment period was 10 months and median follow-up was 36 months.
Anti-drug antibodies and IFX serum levels were measured before and at 4, 8 and 12 weeks after each
infusion, using ELISA (PROMETHEUS® ELISA, Prometheus Laboratories Inc., San Diego, CA, USA). After five
infusions, 76 out of 125 (61%) patients were classified as positive for anti-drug antibodies.
When a level of 8 µg of anti-drug antibodies/ml serum was selected, it was found that concentrations of
anti-drug antibodies were > 8 µg/ml in 24 out of 56 (43%) patients taking immunosuppressants, compared
with 52 out of 69 (75%) not taking immune suppressants. The relative risk (RR) of anti-drug antibodies
concentration > 8 µg/ml in patients taking compared with those not taking suppressive therapy was 2.40
[95% confidence interval (CI) 1.65 to 3.66; p < 0.001]. Infusion reactions had occurred in 27% of patients by
the fifth infusion. The median anti-drug antibody level in patients experiencing infusion reactions was higher
than in those with no reactions (p < 0.001). Reactions were significantly more common in patients not taking
immunosuppressant therapy than in those who were taking it. When time to next infusion was taken as a
measure of response duration, it was found that response duration was reduced in those with anti-drug
antibodies levels > 8 µg/ml relative to those with levels < 8 µg/ml (median 35 days vs. 71 days; p < 0.001).
The level of IFX at 4 weeks after an infusion was correlated with the level of anti-drug antibodies prior to
the infusion (R2 = 0.34; p < 0.001) and was positively correlated with duration of response. IFX level and
anti-drug antibodies level were independent variables influencing response duration. Logistic regression
indicated that the only variable that influenced a 4-week level of IFX > 12 µg/ml was the use of
immunosuppressant therapy. IFX level was higher in those without an infusion reaction than those with one.
In summary, the results of this study suggest that production of anti-drug antibodies is common during IFX
therapy; anti-drug antibodies are associated with reduced IFX levels; duration of response is reduced by
the presence of anti-drug antibodies; and production of anti-drug antibodies may be reduced when
concomitant immunosuppressant therapy is employed.
Further evidence steadily accumulated from retrospective analyses of multiple clinical trials and case
series,38,53–55 and the observation that detectable trough levels of drug are associated with greater clinical
efficacy is now well established.44
This accumulating evidence has formed the basis of investigations into drug and anti-drug antibody
monitoring in anti-TNF-α-treated patients with CD.
Without monitoring, the options for a clinician if the anti-TNF-α agent fails are to wait and see, to intensify drug
treatment, to switch drug within its class or to switch to a different class of drugs.34 Measuring drug and
anti-drug antibodies, however, could enable clinicians and patients to make informed choices on management.
A number of studies have investigated the clinical utility of measuring drug and anti-drug antibody levels in sera
by translating the clinical management decision following a test outcome into a treatment algorithm stipulating
the management pathways for patients with a specific test outcome in clinical practice.56–59
Drug and anti-drug antibody monitoring could be undertaken in good responders (i.e. those responding to
an initial induction course of anti-TNF-α treatment), as well as in patients with LOR (i.e. those initially
INTRODUCTION
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responding to anti-TNF-α treatment but losing this response over time). The use of these technologies
provides a clinician with potentially useful information that may guide an individual patient’s future
treatment. Such information may aid in anticipating the LOR in responders or allow drug optimisation,
whereas for non-responders such analyses may help in estimating the likelihood of various candidate
reasons for LOR. In non-responders with low levels of drug and high levels of anti-drug antibodies, for
example, the loss or lack of response may be surmised to be because of rapid clearance of the drug as a
result of the action of anti-drug antibodies. On the other hand, a low level of anti-TNF-α in the absence
of anti-drug antibodies may be suggestive of non-immune mechanisms of rapid drug clearance, whereas
high levels of drug in the absence of antibodies in non-responders may be suggestive of a pathology for
the condition independent of TNF-α in a particular patient. Algorithms for future treatment based on
anti-TNF-α and anti-drug antibody estimates have been published.56–59
In theory, the application of the tests in conjunction with an appropriate algorithm for treatment based on
test results may:
l improve QoL and other outcomes (e.g. faster healing of flare-ups, reduced abdominal pain and
associated diarrhoea)
l optimise the treatment plan (facilitate adoption of the most suitable future treatment for individual
patients; this might involve a switch to an alternative anti-TNF-α or a biologic with an alternative
mechanism of action)
l minimise the risk of drug overdose and associated adverse events
l allow earlier de-escalation of therapy, leading to a reduction in the overall drug used
l help to reduce the amount of drugs used inappropriately, unnecessary hospital visits, risk of surgery
and associated costs.15
Description of technology under assessment
Intervention technologies
Various assay procedures for anti-TNF-α agents and for anti-drug antibodies have been developed in the
belief that the levels of circulating anti-TNF-α and of anti-drug antibodies can provide information useful to
clinicians in indicating potential reasons for treatment failure, and for dosage or treatment adjustment.
Commercially available ELISA kits (the LISA-TRACKER® ELISA kits, Theradiag, Marne La Vallee, France, or
Alpha Laboratories, Heriot, UK; the TNF-α-Blocker ELISA kits, Immundiagnostik AG, Bensheim, Germany;
and the Promonitor® ELISA kits, Proteomika, Progenika Biopharma, Bizkaia, Spain) are the intervention
technologies designed to measure IFX and ADA levels, and their antibodies and are investigated in
this review.
These are all particular examples of solid-phase ELISAs. They estimate the following molecules in patient
blood sera:
l IFX
l ADA
l anti-IFX antibodies
l anti-ADA antibodies.
Details of the ELISA kits available from these companies are summarised in Appendix 1.
Other ELISAs commercially available for measuring these molecules in sera include the SHIKARI® ELISA kits
(Matriks Biotechnology Co. Ltd, Ankara, Turkey). These are not included as index tests in the NICE scope.
In the UK a number of non-commercial kits are also available, but these are not the focus of this report.
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Other methodologies based on alternative principles of detection and measurement include
(1) radioimmunoassays (RIAs) (liquid-phase assays using the radioisotope 125I to label TNF); (2) cell reporter
assays based on genetically engineered cells incubated in culture medium; and (3) mobility shift assays
(liquid-phase assays using size-exclusion high-performance liquid chromatography with fluorescent dye
detection). The differences in these assays may have an effect on their individual performance, and
describing and contrasting them will help the reader to understand the abilities and limitations of
the assays.
Enzyme-linked immunosorbent assays for infliximab and adalimumab
For details of the ELISA kits, refer to Appendix 1. All three specified ELISA methods employ similar principles
in which, typically, microtitre plates with 96 wells coated with reagent receive the patient serum samples or
various standards and calibrators. Reagents are added with wash steps between additions. The final step
involves quantifying the amount of a peroxidase label in the titre well, this amount being proportional to
the amount of anti-TNF-α or anti-drug antibody in the patient’s sample or in the calibrator standard.15
The amount of peroxidase present in the well is quantified using a timed incubation with excess substrates
[hydrogen peroxide + 3,3’,5,5’-tetramethylbenzidine (3,3’,5,5’-tetramethylbiphenyl-4,4’-diamine)].
Peroxidase catalyses the following reaction:
tetramethylbenzidine + hydrogen peroxide→ chromogen + water. (1)
The incubation is stopped after an appropriate time by the addition of acid and the accumulated
chromogen quantified by measuring optical density with a spectrophotometer.
The reagents used for coating the microtitre plate wells and the reagents used in subsequent steps of the
assay procedure differ in detail according to manufacturer. The LISA-TRACKER assays for IFX and for ADA
are illustrated in Figure 3.
Serum samples from patients may contain soluble TNF-α receptors; these could compete with anti-TNF-α
for the immobilised TNF-α on the microtitre well plate and may potentially interfere with the assay.
The assay quantifies free anti-TNF-α. Samples may contain anti-TNF-α bound to antibodies to anti-TNF-α,
especially in patients who have lost a response to treatment. These anti-TNF-α–antibody complexes will be
washed away at the first wash step, leaving only free anti-TNF-α bound to immobilised TNF-α. The amount
of anti-TNF-α lost at the wash step is likely to vary between patients and is unknown; the practical
implications of this are uncertain.15
TNF-α-Blocker and Promonitor assays for anti-TNF-α drugs differ from the LISA-TRACKER assay in that the
well coat is not TNF-α, but rather a reagent (antibody or antibody fragment) able to bind specifically
to the TNF-α binding site of IFX or of ADA that is added to the microtitre well in the patient’s sample (or
calibrator). After washing, the second reagent is a peroxidase-labelled antibody able to bind the fragment
crystallising (Fc) region of the anti-TNF-α antibody (Figure 4). Thus, fewer steps and a single reagent are
used to detect well-bound anti-TNF-α drug. Table 1 summarises the information describing the
mechanisms underlying these assays.
Enzyme-linked immunosorbent assays for anti-drug antibodies
The LISA-TRACKER assays for antibodies to IFX and to ADA are illustrated in Figure 5.
This assay quantitatively estimates only free antibodies to anti-TNF-α. Therefore, anti-drug antibodies
bound to the drug are lost at the first wash. The amount of bound anti-drug antibody is likely to vary
between patients and is unknown. Whether anti-drug antibodies directed at non-idiotypic regions of the
drugs (e.g. glycoprotein moieties, variable non-idiotypic mouse regions of IFX, etc.) are detectable or
present in samples appears to be insufficiently investigated to date and is therefore uncertain. However, in
vitro tests indicate that about 90% of anti-drug antibodies bind to the TNF-binding region of anti-TNF-α
INTRODUCTION
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FIGURE 3 Diagrammatic representation of the LISA-TRACKER assay for IFX and ADA. Procedural steps C and D are
detection steps that function to detect the anti-TNF-α that is bound to the microtitre well surface via TNF-α,
ensuring a quantitative relationship between anti-TNF-α and peroxidase. Step E quantifies the amount of
peroxidase (and, therefore, anti-TNF-α) in the microtitre well (streptavidin has four very high-affinity binding sites
for biotin).
A
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FIGURE 4 Diagrammatic representation of TNF-α-Blocker and Promonitor assays for IFX and ADA. Procedural steps
C and D are detection steps that function to detect the anti-TNF-α (e.g. drugs IFX or ADA) that has been bound to
the well surface via the coating (diamond). This ensures a quantitative relationship between anti-TNF-α (IFX or
ADA) in the sample and peroxidase.
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drugs.51 These, and the other anti-drug antibodies, may hasten clearance of drug from the circulation as
well as neutralising its binding capacity.
Tumour necrosis factor alpha and Promonitor assays differ from LISA-TRACKER assays in employing a
single reagent for detecting well-bound anti-drug antibodies rather than two (biotinylated IFX or
biotinylated ADA, plus avidin-conjugated peroxidase). Table 2 summarises the information describing the
mechanisms underlying these assays.15
TABLE 1 Summary of ELISAs to be considered in this review for detection of IFX and ADA
Manufacturer and kit Microtitre plate pre-coat Detection reagent(s)
LISA-TRACKER indirect ELISA Recombinant human TNF-α Biotinylated mouse monoclonal IgG antibody
directed to IgG Fc fragment
Avidin-tagged peroxidase
TNF-α-Blocker ELISAa Monoclonal anti-TNF-α antibodyb Peroxidase-labelled antibodyc
Promonitor ELISAa Monoclonal anti-TNF-α antibodyd Peroxidase-labelled monoclonal anti-TNF-α antibodye
a Further details supplied were labelled commercial in confidence.
b Confidential information has been removed.
c Confidential information has been removed.
d Confidential information has been removed.
e Confidential information has been removed.
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FIGURE 5 Diagrammatic representation of the LISA-TRACKER assay for antibodies to IFX or to ADA. This is a bridging
assay in which antibodies to anti-TNF-α in the patient sample bridge the immobilised anti-TNF-α to the biotinylated
anti-TNF-α. Procedural steps C and D are detection steps that function to detect the sample antibodies, ensuring a
quantitative relationship between anti-TNF-α antibodies and peroxidase. Step E quantifies the amount of peroxidase
(and, therefore, anti-TNF-α antibodies). (Streptavidin has four very high-affinity binding sites for biotin.)
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Brief overview of identified assay methods
There are no gold standard assays for anti-TNF-α agents or for antibodies to anti-TNF-α agents that might
provide a robust basis for comparisons between the performances of different assays. According to US
Medical Insurance assessments ‘candidate’ assays have been insufficiently investigated to establish any as
a gold standard and, according to Steenholdt,60 the evidence is incomplete on how these different assays
may compare in practice.14,61–64
There appear to be four types of assay which differ fundamentally from each other. These are as follows.
1. ELISAs: solid-phase assays. These are available as commercial kits and several in-house methods are
mentioned in the literature. Generally, the ELISAs quantitatively measure only ‘free’ anti-TNF-α and
‘free’ anti-drug antibodies, and it is acknowledged that the level of the unmeasured ‘bound’ anti-TNF-α
and of ‘bound’ anti-drug antibody may vary considerably between patients. Thus, for some patient
samples there is an unknown and unmeasured amount of anti-TNF-α and of anti-drug antibody
present, in addition to the measured ‘free’ levels. In theory, this represents a potential deficiency in
ELISAs, although whether or not this is serious in practice is difficult to gauge, especially in the absence
of an established gold standard. This deficiency appears to have been one stimulus for the development
of methods based on alternative principles. It is possible, however, that the relative convenience and
cheapness of ELISAs means that this inability to measure total anti-TNF-α and total anti-drug antibody is
supportable in practice.
2. RIAs: liquid-phase assays. These are provided as a total service rather than as purchasable kits. They
measure total anti-TNF-α and total anti-drug antibody (probably as long as the anti-drug antibody light
chain is λ class). These RIAs use 125I-labelled human TNF-α and 125I-labelled anti-TNF-α. These are
commercially available or may be relatively easily constructed from commercially available materials;
however, in the absence of purchasable assay kits, it is unlikely that any hospital laboratory would set
up such assays for routine use. In these assays the patient’s sample is mixed with a solution containing
a fixed amount of 125I-labelled TNF-α or 125I-labelled anti-TNF-α further antibody (e.g. rabbit anti-human
immunoglobulin λ-chain), which promotes the formation of immune complexes that are pelleted by
centrifugation. The 125I in the pellet is quantified in a gamma counter. Potential disadvantages include:
(1) radiolabelled reagents do not keep indefinitely (125I decays with a half-life of 59 days); (2) the
laboratory needs to be equipped for handling hazardous (radioactive) materials; (3) some staff training
may be necessary; and (4) the laboratory requires a gamma counter (preferably automated for high
throughput). These factors obviously have cost implications for setting up RIAs.
TABLE 2 Summary of ELISAs to be considered in this review for detection of antibodies to IFX and ADA
Manufacturer and kit Microtitre plate pre-coat Detection reagent(s)
LISA-TRACKER bridge ELISA Anti-TNF-α (i.e. IFX or ADA) Biotinylated anti-TNF-α that binds to the paratope
of the anti-drug antibodies in the sample
Avidin-tagged peroxidase
TNF-α-Blocker ELISA IFXa Confidential information has
been removed
Confidential information has been removed
TNF-α-Blocker ELISA adalimumaba Confidential information has
been removed
Confidential information has been removed
Promonitor ELISAa Confidential information has
been removedb
Confidential information has been removedc
a Further details supplied were labelled commercial in confidence.
b Confidential information has been removed.
c Confidential information has been removed.
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3. Cell reporter assays: these assays utilise genetically engineered cells that respond to the presence of
anti-TNF-α agents by synthesising light-generating enzymes. The enzymes are allowed to accumulate
during an incubation period and are then supplied with appropriate substrates resulting in light
emission measured with a luminometer. Samples with anti-TNF-α will lead to light emission and samples
with antibodies to anti-TNF-α will quench light emission (for further information see Appendix 2).
4. Mobility shift assays: the mobility shift assay depends on detecting the shift in mobility of fluorescent
probes when bound to either anti-TNF-α or anti-drug antibodies (for further information, see
Appendix 2).
Timing and use of assays
The anti-TNF-α and anti-drug antibody assays are most frequently administered just before the next
administration of the anti-TNF-α agent. This is said to allow measurement of a ‘trough’ level of anti-TNF-α
and has been adopted to minimise effects from the presence of anti-TNF-α–anti-drug antibody immune
complexes in samples. For patients whose response to therapy has waned, the results of the tests are
frequently dichotomised using a cut-off assay result. Thus, on the basis of anti-TNF-α assays patients are
classified as having therapeutic levels of anti-TNF-α or subtherapeutic levels, and on the basis of anti-drug
antibody assay results they are classified as having clinically significant levels of anti-drug antibodies or
insignificant levels. Such classifications yield four categories of patient for whom different explanations of
failed response are possible. Algorithms have been developed prescribing treatment pathways and/or
further diagnostic tests (e.g. colonoscopy) based on such classification.15
Current usage of assays in the NHS
Current practice for monitoring TNF-α inhibitor antibody and drug levels in the UK is patchy because of the
lack of agreed consensus and evidence for its cost-effectiveness. In-house tests are performed in a few
laboratories in England. However, demand is low, analyses are often undertaken in batches and it can be
weeks (in some cases) before a clinician receives a result on which to act.
Although some centres have local monitoring protocols in conjunction with their link laboratory, there is,
as yet, no agreed algorithm for clinicians to refer to which allows for the translation of the results of the
tests into coherent plans for patient management according to test outcome.
However, recent emerging evidence to support anecdotal practice that such monitoring could be useful in
managing patients with TNF-α inhibitors, has encouraged a cautious increase in uptake.
It is expected that therapeutic monitoring of TNF-α inhibitors might be useful in a number of clinical
scenarios in the treatment of CD in the NHS, including for primary and LOR to anti-TNF-α therapy and in
the optimisation of dosages for those who are already responding.
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Chapter 2 Definition of decision problem
This report, undertaken for the NICE Diagnostics Assessment Programme, examines the clinicaleffectiveness and cost-effectiveness of ELISAs (LISA-TRACKER ELISA kits, TNF-α-Blocker ELISA kits and
Promonitor ELISA kits) for measurement of patient blood levels of anti-TNF-α agents (IFX and ADA; also
known as TNF-α inhibitors) and of antibodies to these agents (i.e. anti-drug antibody levels or anti-drug
antibodies) in patients with CD whose disease responds to treatment with TNF-α inhibitor or who experience
LOR during TNF-α inhibitor therapy. The report will help NICE to make recommendations about how well the
assays work and whether or not the benefits are worth the cost of the tests for use in the NHS in England.
The assessment will consider both clinical improvement in patients’ symptoms and the cost of the tests used
to measure the amount of anti-TNF-α and anti-drug antibodies in patients’ sera using evidence identified
through systematic reviews and information submitted to NICE during the evaluation process by the
companies offering the ELISA. This review was registered on PROSPERO as CRD42014015278.
The decision questions for this project are shown in Box 1.
Overall aim of the assessment
The overall aim of this report was to present the evidence on the clinical effectiveness and cost-
effectiveness of monitoring IFX and ADA and their antibodies in responders and patients with LOR when
ELISA results are used in combination with an algorithm that prescribes treatment pathways for the
management of patients with specific drug and anti-drug antibody levels.
BOX 1 Decision questions
1. Does concurrent testing of TNF-α inhibitor levels and antibodies to TNF-α inhibitors represent a clinically
effective and cost-effective use of NHS resources in patients with CD whose disease responds to treatment
with a TNF-α inhibitor? Testing will be carried out:
i. 3–4 months after start of treatment or
ii. 3–4 months and every 12 months from start of treatment.
2. Does concurrent testing of TNF-α inhibitor levels and antibodies to TNF-α inhibitors represent a clinically
effective and cost-effective use of NHS resources in patients with CD who experience LOR during
maintenance treatment with a TNF-α inhibitor?
3. Does testing of TNF-α inhibitor levels followed by reflex testing of antibodies to TNF-α inhibitors if drug level
is undetectable represent a clinically effective and cost-effective use of NHS resources in patients with CD
whose disease responds to treatment with a TNF-α inhibitor? Testing will be carried out:
i. 3–4 months after start of treatment or
ii. 3–4 months and every 12 months from start of treatment.
4. Does testing of TNF-α inhibitor levels followed by reflex testing of antibodies to TNF-α inhibitors if drug level
is undetectable represent a clinically effective and cost-effective use of NHS resources in patients with CD
who experience LOR during maintenance treatment with a TNF-α inhibitor?
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Objectives
In the current report we addressed the following objectives.
Objective A: review of comparative performance of tests
To review and critique studies of a comparison (including relative test performance) of two or more
intervention tests, or studies that compare an intervention test with a test method that can be used
to perform a linked evidence assessment and to supplement these with data submitted by the relevant
companies if of sufficient detail and quality.
To compare and contrast studies that reported a threshold analysis to determine the optimal drug level
cut-off point to predict or diagnose response.
The following objective from the protocol was moved into the introduction, as it does not address the
decision questions:
l To provide a technical description, and evaluation, of the listed intervention tests used for CD in
therapeutic monitoring of TNF-α inhibitors (IFX and ADA) and their antibodies, including what the
assays measure and the mechanisms of the assays.
Objective B: description of algorithms
To describe algorithms used in studies which include data on one or more intervention tests or on a test
that allows a linked evidence approach to be performed (i.e. algorithms used in studies identified in
objective C). The studies are required to provide an algorithm and report clinical outcomes for the
management of patients with CD following measurement of serum levels of anti-TNF-α drug and
anti-drug antibodies.
To compare the algorithms used following therapeutic drug monitoring to the algorithms specified in the
Trough level Adapted infliXImab Treatment (TAXIT) study for responders,65 and in the reporting of LOR
(algorithm adapted from the 2014 study by Scott and Lichtensteinin66).
Objective C1: review of clinical effectiveness of test with algorithm
combinations
To systematically review the literature comparing the clinical effectiveness of the intervention
assays for anti-TNF-α agents and/or for anti-drug antibodies used in conjunction with a treatment
algorithm in patients with CD treated with IFX or ADA with the clinical effectiveness of standard
care (no tests performed or test-informed algorithm used) in patients with CD treated with IFX
or ADA.
To assess and critique available evidence on the comparison of standard care with other test assays
used in conjunction with an algorithm, and on test performance compared with the study interventions
(LISA-TRACKER ELISA kits, TNF-α-Blocker ELISA kits and Promonitor ELISA kits) (see Objective A: review
of comparative performance of tests).
Objective C2: analysis of correlation between test results and clinical state
To analyse correlation studies that investigate the relationship between tests measuring anti-TNF-α and
anti-drug antibody levels and clinical outcome in terms of response in patients with CD.
This objective was added because of the paucity of management studies that address the decision
questions to generate information for economic modelling.
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Objective D: review of cost-effectiveness of test with algorithm
combinations
To assess the cost-effectiveness of employing anti-TNF-α and anti-TNF-α antibody monitoring with
LISA-TRACKER ELISA kits, TNF-α-Blocker ELISA kits and Promonitor ELISA kits in patients with CD
compared with standard care (no anti-TNF-α monitoring).
To use a linked evidence approach when necessary (see objectives C1 and C2, above) in which evidence of
clinical effectiveness is taken from studies using alternative tests and an assessment is made of the relative
performance of these tests relative to the intervention assays.
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Chapter 3 Clinical effectiveness review
Clinical effectiveness methods
Identification and selection of studies
Search strategies for clinical effectiveness
An iterative procedure was used to develop the initial MEDLINE search, with reference to our own scoping
searches and those undertaken by information specialists at NICE. Known articles were consulted and
checked for relevant terms. Additional phrases were added to find relevant articles that did not include
terms for the test name or type of test (e.g. Baert et al.43) or population (e.g. Vande Casteele et al.67)
in title, abstract or indexing. This search developed for MEDLINE was adapted as appropriate for other
databases and sources. The searches for each source are provided in Appendix 3. Searches for studies for
cost and QoL were developed separately.
The search strategy comprised the following main elements:
l searching of electronic bibliographic databases
l contact with experts in the field
l scrutiny of references of included studies
l screening of manufacturers’ and other relevant organisations’ websites for relevant publications.
The following bibliographic databases were searched from inception to the date of searching: MEDLINE;
MEDLINE In-Process & Other Non-Indexed Citations; EMBASE; The Cochrane Library (including Cochrane
Systematic Reviews, Database of Abstracts of Reviews of Effects, Cochrane Central Register of Controlled
Trials, NHS Economic Evaluation Database and HTA databases); Science Citation Index and Conference
Proceedings (Web of Science); Index to Theses; Digital Access to Research Theses-Europe; Dissertations &
Theses; National Institute for Health Research (NIHR) HTA programme; and PROSPERO (International
Prospective Register of Systematic Reviews). Searches were undertaken during the period October to
November 2014 (see Appendix 3 for exact search dates).
The following trial and patent databases were also searched: Current Controlled Trials, ClinicalTrials.gov,
UK Clinical Research Network Portfolio Database, the World Health Organization’s International Clinical
Trials Registry Platform and Espacenet (European Patent Office).
Specific conference proceedings, selected with input from clinical experts and specialist committee
members, were also checked from January 2010 to January 2015:
l European Crohn’s and Colitis Organisation
l Digestive Diseases Week (meeting of the American Gastroenterology Association)
l British Society of Gastroenterology
l United European Gastroenterology Week
l American College of Gastroenterology.
The following online resources of various health services research agencies, regulatory bodies, professional
societies and manufacturers were consulted via the internet:
l International Network of Agencies for HTA publication – www.inahta.org/
l US Food and Drug Administration medical devices – www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/Databases/default.htm
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l European Commission medical devices – http://ec.europa.eu/health/medical-devices/
l Theradiag – www.theradiag.com/en/
l Immundiagnostik AG – www.immundiagnostik.com/en
l Proteomika – www.proteomika.com/
l American College of Gastroenterology – http://gi.org/
l European Crohn’s and Colitis Organisation – www.ecco-ibd.eu
l British Society of Gastroenterology – www.bsg.org.uk
l United European Gastroenterology – www.ueg.eu/
l The American Gastroenterology Association – www.gastro.org.
The reference lists of included studies and relevant review articles were checked. Citation searches of
selected included studies were undertaken using Scopus. Identified references were downloaded in
EndNote X7 software (Thomson Reuters, CA, USA). Included papers were checked for errata using PubMed.
Inclusion and exclusion of relevant studies
During the initial inclusion/exclusion process we identified three different categories of studies which were
of interest for the review:
1. studies comparing the performance of different types of assays (assay type comparison studies
addressing objective A)
2. studies reporting an algorithm for the management of patients with drug and/or anti-drug antibody
level test results (management studies addressing objectives B and C1)
3. studies reporting the correlation of drug and/or anti-drug antibody levels with a patient’s clinical state
(response) prospectively or retrospectively (correlation studies).
The third category was included in addition to the original protocol objectives. The reason behind this was
the fact that we expected to find only a limited number of management studies to answer the decision
questions. The correlation studies were included for two purposes:
1. to provide an overview of the variation in drug-level thresholds used to predict clinical state
(for objective A – review of comparative performance of tests)
2. to pool test outcome data for responders and non-responders as an alternative to single-study data
to inform the economic model (objective C2 – analysis of correlation between test results and
clinical outcomes).
Assay-type comparison studies were considered in two phases because the work involved in objective A
(review of comparative performance of tests) was dependent on the available evidence in objective C1.
In the first phase, studies were included if they compared assay performance of two or more different test
assays (see Objective A: review of comparative performance of test assays measuring anti-tumour necrosis
factor alpha and/or anti-drug antibody levels).
Once the management studies to be included were known, the second phase included comparison studies
if they compared two or more types of intervention assay or any of the intervention assays with the assays
used in the management studies in order to inform a linked evidence approach.
See below for detailed inclusion and exclusion criteria for the different objectives.
Inclusion criteria
Objective A Studies comparing the test performance of two or more tests for IFX or ADA levels and/or
for anti-drug antibodies were identified. Studies were included if they either compared two or more
intervention tests or compared an intervention test with a test method that could be used to perform a
linked evidence assessment. All study designs were considered for inclusion.
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Objectives B and C1 Studies that satisfied the criteria outlined in Table 3 were included.
Objective C2 Correlation studies were included if they provided at least one of the following:
1. a receiver operating characteristic (ROC) threshold analysis to determine an optimal drug-level threshold
for predicting response (see Results of threshold analysis studies)
2. sufficient data to complete a 2 × 2 table of diagnostic accuracy of drug/anti-drug antibody level for
prediction of response/LOR (Table 4) [see Objective C2: studies relating test results to clinical state of
patients (correlation studies)]
Exclusion criteria
The criteria for exclusion of studies are presented in Table 5.
Objective C1 Tests that were not included under the heading of intervention but for which evidence was
available on comparative diagnostic performance compared with an intervention test, and where clinical
outcomes were also reported, were included for the purpose of performing linked evidence modelling
(these included RIAs, cell reporter assays, liquid-phase mobility shift assays and in-house ELISAs).
BOX 2 Assay methods included as interventions in the review
LISA-TRACKER assay kits (Theradiag/Alpha Laboratories)
l LISA-TRACKER Adalimumab (LTA002).
l LISA-TRACKER Infliximab (LTI002).
l LISA-TRACKER Anti-Adalimumab (LTA003).
l LISA-TRACKER Anti-Infliximab (LTI003).
l LISA-TRACKER Duo Adalimumab (LTA005).
l LISA-TRACKER Duo Infliximab (LTI005).
TABLE 3 Criteria for study inclusion
Item Criteria
Population Patients with CD (adults and children) receiving IFX or ADA. Evidence on mixed patient groups containing
CD and UC patients was included if patients with CD made up > 50% of the study population
Intervention Use of LISA-TRACKER ELISA kits, TNF-α-Blocker ELISA kits and Promonitor ELISA kits to estimate plasma
or sera levels of anti-TNF-α agents and/or of anti-drug antibodies in which test results are employed in
conjunction with a treatment algorithm (Box 2). Other assay methods were considered for a linked
evidence approach (see Box 2)
Comparator Standard care (treatment decisions made on clinical judgement without measuring levels of anti-TNF-α
and anti-drug antibodies)
Outcome Any patient outcome (e.g. CDAI score-based response rate, any measure of change in severity of CD
including physician’s global assessment; duration of response, relapse and remission; rates of
hospitalisation; rates of surgical intervention; time to surgical intervention; adverse effects of treatment;
health-related QoL; and, secondarily, if two strategies compared are found clinically equivalent: time to
result; number of inconclusive results; frequency of dose adjustment; and frequency of treatment switch)
Study design All study designs were considered for inclusion
Health-care
setting
Secondary and tertiary care
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Using the information provided by Theradiag/Alpha Laboratories,
Immundiagnostik and Proteomika
The information provided by Theradiag/Alpha Laboratories, Immundiagnostik and Proteomika (see
Appendix 4 for an itemised list of documents received) was screened for three purposes:
1. additional studies not identified by our searches
2. information for the technical description of the three intervention assays
3. information an assay comparisons.
Immundiagnostik TNF-α-Blocker ELISA kits [Immundiagnostik AG/Biohit Healthcare
(Ellesmere Port, UK)]
l Immundiagnostik TNF-α-Blocker ADA, antibodies against infliximab (e.g. Remicade) ELISA (K9650).
l Immundiagnostik TNF-α-Blocker ADA, antibodies against adalimumab (e.g. Humira) ELISA (K9652).
l Immundiagnostik TNF-α-Blocker ADA, total antibodies against infliximab (e.g. Remicade) ELISA (K9654).
l Immundiagnostik TNF-α-Blocker ADA, total antibodies against adalimumab (e.g. Humira) ELISA (K9651).
l Immundiagnostik TNF-α-Blocker monitoring, infliximab drug level (e.g. Remicade) ELISA (K9655).
l Immundiagnostik TNF-α-Blocker monitoring, adalimumab drug level (e.g. Humira) ELISA (K9657).
Promonitor ELISA kits (Proteomika)
l Promonitor-ADL ELISA (5080230000).
l Promonitor-IFX ELISA (5060230000).
l Promonitor-anti-ADL ELISA (5090230000).
l Promonitor-anti-IFX ELISA (5070230000).
BOX 2 Assay methods included as interventions in the review
TABLE 4 Criteria for inclusion of studies that provide information for a 2 × 2 table
Item Criteria
Population Patients with CD (adults and children) receiving IFX or ADA. Evidence on mixed patient groups containing
CD and UC patients was included if patients with CD made up > 50% of the study population
Intervention Any assay to measure anti-TNF-α and/or anti-drug antibody levels
Outcome 2 × 2 data of diagnostic performance of test to predict patient response/non-response and/or ROC analysis
reporting optimal drug level thresholds to predict response/non-response
Study design All study designs were considered for inclusion
TABLE 5 Criteria for exclusion of studies
Item Criteria
Population Studies with mixed patient groups containing < 50% CD patients
Intervention Studies reporting an algorithm in which patient management was not dependent on a prescriptive algorithm
Study design Narrative reviews
Systematic reviews of correlation studies without meta-analysis
Editorials/letters without original data
Non-English-language papers
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In addition, we sought detailed information from Theradiag/Alpha Laboratories, Immundiagnostik and
Proteomika by e-mail regarding mechanisms and reactants (in particular specificities and properties of
antibodies and other reagents) employed in the three-intervention ELISA.
Review strategy
The general principles recommended in the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement were used.68 Records rejected at full-text stage and reasons for exclusion
were documented. Two reviewers independently screened the titles and abstracts of all records identified by
the searches, and discrepancies were resolved through discussion. Disagreement was resolved by retrieving
the full publication and reaching consensus. Full copies of all studies deemed potentially relevant were
obtained and two reviewers independently assessed these for inclusion; any disagreements were resolved
by consensus or discussion with a third reviewer.
Data extraction strategy
Data were extracted by one reviewer, using a piloted data extraction form. Completed data extraction
forms are available in Appendix 5. A second reviewer checked the extracted data and any disagreements
were resolved by consensus or discussion with a third reviewer.
Quality assessment strategy
Objective A
For objective A, quality appraisal was completed using a modified Quality Assessment of Diagnostic
Accuracy Studies-2 (QUADAS-2) checklist.69 In the patient selection domain three questions were included,
using the standard version of the tool:
1. Was a consecutive or random sample of patients enrolled?
2. Was a case–control design avoided?
3. Did the study avoid inappropriate exclusions?
An additional question asking for the range of drug and antibody concentrations was added before a
judgement was made about applicability. The applicability question was adapted to:
4. Is there concern that the included patients or range of drug/antibody concentrations do not match the
review question?
Regarding the index test, two standard questions were included to assess risk of bias:
1. Was the threshold pre-specified?
2. Were index tests interpreted without knowledge of the reference standard?
One additional question was added:
3. Were the number of failed results and measurement repeats reported?
For the reference standard, the two standard questions were used:
1. Were the reference standard results interpreted without knowledge of the results of the index test?
2. Is the comparison test likely to correctly classify the target condition?
The best reference standard for test accuracy to use would be use of standardised spiked samples. Use of
spiked samples as a reference standard would allow the accuracy of tests to be compared with reference to
the true drug and antibody levels, and would avoid the biases associated with imperfect reference standards.
However, with spiked samples test accuracy may not be reflective of test accuracy in clinical practice.
DOI: 10.3310/hta20830 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 83
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Freeman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
27
However, when spiked samples were unavailable, one of the comparator tests used in the management
studies and considered for a linked evidence approach was used. If the reference standard was one of the
four comparator tests then it was classified as unlikely to correctly classify the target condition. This is
because, as a result of the lack of evidence, they are an imperfect reference standard. For both comparator
and index tests, judgements regarding applicability considered both the test used and the threshold applied.
For flow and timing, the following standard questions were included:
l Was there an appropriate interval between intervention test and comparison test(s)?
l Did patients receive the same reference standard?
l Were all patients included in the analysis?
An additional question was included:
l Were both intervention test and reference standard conducted on all samples?
This is to measure whether or not some patients or samples did not receive any of the index tests. This is
of particular concern if the reason for being omitted may be related to the probability of a positive or
negative result.
Objective C1: review of clinical effectiveness of test with algorithm combinations
Randomised controlled trials meeting the inclusion criteria were assessed using the Cochrane risk-of-bias
tool.70 The Downs and Black checklist71 was used to assess the quality of non-RCTs meeting the inclusion
criteria. The results of the quality assessment provide an overall description of the quality of the included
studies and a transparent method of recommendation for design of future studies. Quality assessment was
undertaken by one reviewer and checked by a second reviewer, any disagreements were resolved by a
third reviewer through discussion.
Methods of analysis/synthesis
Objective A: review of comparative performance of tests
We mapped included studies according to the comparisons they undertook. A narrative was produced to
summarise the studies that compared the performance of the intervention assays and assays suitable for a
linked evidence approach and considering the concordance between the tests. This was assessed using the
following outcomes:
1. concordance between tests (split by positive reference standard results and negative reference standard
results, or clinical outcomes when available) for therapeutic drug and detectable anti-drug for all index
tests and comparators
2. characteristics of cases in which there was disagreement and agreement between tests
3. Bland–Altman plots to show patterns of correlation.
The specific measures of concordance used were percentage agreement between the tests (split between
positive reference standard sample results and negative reference standard sample results, when available)
and Cohen’s kappa. Two main secondary outcomes were also collected. First, the characteristics of cases in
which there was disagreement and agreement between tests may provide information about the reason
for and implications of the discordant results. Second, the shape of the Bland–Altman plots shows whether
or not the difference between the two tests is dependent on absolute drug and anti-drug levels. Mean
bias and the upper and lower limits of agreement were not particularly informative here, as we are
interested in only one cut-off point not the whole range of concentrations. Pearson’s correlation coefficient
was not considered in detail, as it can have high values even when clinically meaningful differences are
present.72 When there were sufficient studies, a meta-analysis of Cohen’s kappa was considered.72
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Objective B: description of algorithms prescribing patient management
following test outcomes for drug and/or anti-drug antibody levels
Algorithms used in management studies were described narratively and compared with the algorithm
adapted from Scott and Lichtenstein66 (for LOR) and to the algorithm adapted from Vande Casteele et al.73
(for responders). Patients or decisions non-compliant with the stated algorithm were quantified.
Time of testing, sequence of testing (drug and antibodies) and sequence of analysis were also considered.
Objective C1: clinical studies evaluating drug monitoring for the
management of Crohn’s disease patients (management studies)
Depending on the available evidence, analyses were stratified according to the type of ELISA or other
assay, type of drug (IFX or ADA) and patient group (patients with LOR or responders).
Study, treatment, population and outcome characteristics were summarised and compared qualitatively
and, when possible, quantitatively in text, graphically and in evidence tables. Pooling study results by
meta-analysis was considered; however, meta-analysis was unsuitable for the data identified and we
employed a narrative synthesis using text and tables. A detailed commentary on the major methodological
problems and biases affecting the studies was also included, together with a description of how this may
have influenced individual study results.
We used a linked evidence approach.1 Evidence on outcomes reported by studies using other test methods
(RIA, liquid-phase mobility shift assay and in-house ELISAs) for patient management was linked to evidence
on comparative test performance between our intervention tests and these other methods to allow for
estimates of anticipated outcome for our intervention assays.
Time of testing, sequence of testing (drug and antibodies) and sequence of analysis were also considered.
When relevant, Kaplan–Meier plots were available, individual patient data (IPD) were reconstructed using
the method of Guyot et al.74 Parametric models were fitted to reconstructed IPD using Stata version 11
(StataCorp LP, College Station, TX, USA).
Objective C2: studies relating test results to clinical state of patients
(correlation studies)
For objective C2 we aimed to:
1. Provide an overview of meta-analyses of studies addressing the relationship between drug and/or
anti-drug antibody levels and clinical state of patients with CD by producing a narrative of identified
systematic reviews with meta-analyses, presenting the reported meta-analyses results, and undertaking
a hierarchical meta-analysis of the data presented in the systematic reviews
2. Pool test accuracy data for prediction of patients’ clinical state (response or lost response). This was
done as a potentially useful supplement to management studies for informing the economic model.
Studies that provided dichotomised test results and related these to dichotomised clinical status were identified.
In particular, studies were sought that reported on both drug and anti-drug antibody test results for individual
patients. Two-by-two data for tests were extracted, together with the type of test employed [e.g. ELISA, RIA,
homogeneous mobility shift assay (HMSA)], the anti-TNF-α drug administered, dose regimen, patient inclusion
and exclusion criteria, timing of testing, method for establishing clinical status, test cut-off point used and study
design when these were reported. The populations of interest were (1) responders and responders who lost
response; and (2) patients with LOR who continued with LOR or who regained a response.
Meta-analyses of single-test studies (i.e. measuring anti-TNF-α or anti-drug antibodies) were undertaken (1) to
provide a pooled estimate for the probability of returning a specified test result after trough anti-TNF-α testing
(useful for estimating reflex strategy test result probabilities); and (2) to provide pooled estimates for the
probability of returning a specified test results by single test (i.e. anti-TNF-α or anti-drug antibodies) that can
be compared for consistency with the corresponding probabilities from the identified patient-level studies.
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RevMan version 5.3 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark)
was used for analysis of sensitivities and specificities. Meta-analysis was undertaken in Stata version 11
using the metandi package.75,76 The prevalence of clinical status was meta-analysed using a random-effects
model with ‘MetaAnalyst’ software (Tufts University, Medford, MA, USA).
Given the prevalence (P) of the condition tested for, and the joint sensitivity (Sens) and specificity (Spec)
values from meta-analysis, the probability of returning a positive test result is:
Positive test= (P × Sens)+ ½(1− P) × (1−Spec). (2)
And the probability of returning a negative test result is:
Negative test = ½(1− P) × Spec + ½P × (1−Sens). (3)
Clinical effectiveness results
Search results
Figure 6 provides the PRISMA flow diagram for objectives A, B and C1 and 2. A total of 2428 records were
identified through electronic searches. Six additional records were identified from other sources. The
removal of duplicates left 1616 records to be screened, of which 1359 were excluded at title/abstract level,
as these were irrelevant to the decision questions. The remaining 257 records were examined for inclusion
at full text, of which 70 (reported in 68 studies) were included in the clinical effectiveness review. Table 6
summarises the 68 included studies and refers the reader to the relevant section where they are covered.
Details on the reasons for excluding studies at full text can be found in Appendix 6.
The search of ongoing trials in Clinical Trials.gov, Current Controlled Trials, the UK Clinical Research
Network Portfolio and the World Health Organization’s International Clinical Trials Registry Platform
databases (carried out between 4 and 11 November 2014) retrieved seven relevant ongoing trials (see
Appendix 7).
Of the included studies summarised in Table 6, studies comparing assay types address the performance of
the different assays for a linked evidence approach (Objective A: review of comparative performance of test
assays measuring anti-tumour necrosis factor alpha and/or anti-drug antibody levels). The management
studies address some aspects of the decision questions on the effectiveness of drug and anti-drug antibody
monitoring [Objective B: description of algorithms prescribing patient management following test outcomes
for drug and/or anti-drug antibody levels and Objective C1: clinical studies evaluating drug monitoring for
the management of Crohn’s disease patients (management studies)]. Correlation studies with a ROC
threshold analysis are summarised in Results of threshold analysis studies and correlation studies with
sufficient 2 × 2 test accuracy data to contribute to the meta-analysis are reported in C2: studies relating test
results to clinical state of patients (correlation studies). Columns are not mutually exclusive; studies feature in
more than one section.
Objective A: review of comparative performance of test assays measuring
anti-tumour necrosis factor alpha and/or anti-drug antibody levels
Aim
To compare the performance of the different index tests (three specified ELISA kits) to one another, and to
comparator tests that can be used to perform a linked evidence approach, in order to answer the question:
l Do the index tests agree with each other and with the comparator tests with regard to whether or not
therapeutic levels of drug and detectable levels of anti-drug antibodies are present and, therefore, will
using the tests lead to the same clinical decisions? Comparator tests here are tests with known links to
improving patient outcomes from prospective studies with pre-specified algorithms (management studies).
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TABLE 6 Overview of utility of included studies
Study (first author and
year of publication)
Utility of included study and reference to relevant section in report
Assay comparison:
Objective A: review
of comparative
performance of test
assays measuring
anti-TNF-α and/or
anti-drug antibody
levels
Management stipulated
by algorithm and test
outcome: Objective C1:
clinical studies
evaluating drug
monitoring for the
management of CD
patients (management
studies)
Correlation of
drug/anti-drug
antibodies and
response –
ROC: Results
of threshold
analysis studies
Correlation of
drug/anti-drug
antibodies and
response – 2 × 2:
Objective C2:
studies relating test
results to clinical
state of patients
(correlation studies)
Ainsworth et al., 200847 ✗ ✗ ✗ ✓
Baert et al., 201477 ✗ ✗ ✓ ✓
Ben-Bassat et al., 2013;78
abstract
✗ ✗ ✗ ✓
Ben-Horin et al., 201179 ✗ ✗ ✗ ✓
Ben-Horin et al., 201280 ✗ ✗ ✗ ✓
Bodini et al., 2014;81
abstract
✓ (mapping only)a ✗ ✗ ✓
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FIGURE 6 The PRISMA flow diagram describing the selection of included studies for the clinical effectiveness
review.
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TABLE 6 Overview of utility of included studies (continued )
Study (first author and
year of publication)
Utility of included study and reference to relevant section in report
Assay comparison:
Objective A: review
of comparative
performance of test
assays measuring
anti-TNF-α and/or
anti-drug antibody
levels
Management stipulated
by algorithm and test
outcome: Objective C1:
clinical studies
evaluating drug
monitoring for the
management of CD
patients (management
studies)
Correlation of
drug/anti-drug
antibodies and
response –
ROC: Results
of threshold
analysis studies
Correlation of
drug/anti-drug
antibodies and
response – 2 × 2:
Objective C2:
studies relating test
results to clinical
state of patients
(correlation studies)
Bortlik et al., 201382 ✗ ✗ ✓ ✓
Candon et al., 200683 ✗ ✗ ✗ ✓
Chiu et al., 201384 ✗ ✗ ✓ ✓
Cornillie et al., 201485 ✗ ✗ ✓ ✓
Corstjens et al., 201386 ✓ (mapping only) ✗ ✗ ✗
Daperno et al., 2013;87
abstract
✓ ✗ ✗ ✗
Dauer et al., 2013;88
abstract
✗ ✗ ✗ ✓
Egea-Pujol et al., 2013;89
abstract
✓ ✗ ✗ ✗
Eser et al., 2013;90
abstract
✓ ✗ ✗ ✗
Eser et al., 2013;91
abstract
✓ ✗ ✗ ✗
Farrell et al., 200392 ✗ ✗ ✗ ✓
Feagan et al., 2012;93
abstract
✗ ✗ ✓ ✗
Frederiksen et al., 201494 ✗ ✗ ✓ ✓
Goldberg et al., 2014;95
abstract
✗ ✗ ✓ ✗
Greathead et al., 2014;96
abstract
✓ (mapping only) ✗ ✗ ✗
Hanauer et al., 200440 ✗ ✗ ✗ ✓
Hauenstein et al., 2012;97
abstract
✓ ✗ ✗ ✗
Hibi et al., 201498 ✗ ✗ ✗ ✓
Imaeda et al., 201299 ✓ (mapping only) ✗ ✗ ✓
Imaeda et al., 2014100 ✓ (mapping only) ✗ ✓ ✓
Imaeda et al., 2014101 ✗ ✗ ✓ ✗
Karmiris et al., 200948 ✗ ✗ ✓ ✗
Kong et al., 2011;102
abstract
✗ ✗ ✗ ✓
Kopylov et al., 2012103 ✓ (mapping only) ✗ ✗ ✓
Lee et al., 201263 ✗ ✗ ✗ ✓ SR
Levesque et al., 2014104 ✗ ✗ ✓ ✗
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TABLE 6 Overview of utility of included studies (continued )
Study (first author and
year of publication)
Utility of included study and reference to relevant section in report
Assay comparison:
Objective A: review
of comparative
performance of test
assays measuring
anti-TNF-α and/or
anti-drug antibody
levels
Management stipulated
by algorithm and test
outcome: Objective C1:
clinical studies
evaluating drug
monitoring for the
management of CD
patients (management
studies)
Correlation of
drug/anti-drug
antibodies and
response –
ROC: Results
of threshold
analysis studies
Correlation of
drug/anti-drug
antibodies and
response – 2 × 2:
Objective C2:
studies relating test
results to clinical
state of patients
(correlation studies)
Marits et al., 2014105 ✗ ✗ ✓ ✗
Marzo et al., 2014;106
abstract
✗ ✗ ✗ ✓
Maser et al., 200638 ✗ ✗ ✗ ✓
Mazor et al., 2013;107
abstract
✗ ✗ ✓ ✗
Mazor et al., 2014108 ✗ ✗ ✓ ✓
McTigue et al., 2013;109
abstract
✓ (mapping only) ✗ ✗ ✗
Nagore et al., 2015 (Dr
Daniel Nagore, Progenika
Biopharma, 2015,
personal communication)
✓ ✗ ✗ ✗
Nagore et al., 2015;110
abstract
✗ ✗ ✓ ✓
Nanda et al., 2013111 ✗ ✗ ✗ ✓ SR
Pallagi-Kunstar et al.,
2014112
✗ ✗ ✓ ✗
Pariente et al., 201259 ✗ ✗ ✗ ✓
Paul et al., 2012;113
abstract
✗ ✗ ✓ ✗
Paul et al., 201358 ✗ ✗ ✓ ✗
Paul et al., 2014114 ✗ ✗ ✗ ✓ SR
Roblin et al., 2014115 ✗ ✗ ✓ ✓
Ruiz-Arguello et al.,
2013116
✓ ✗ ✗ ✗
Schatz et al., 2013117 ✓ ✗ ✗ ✗
Semmler et al., 2013;118
abstract
✓ (mapping only) ✗ ✗ ✗
Singh et al., 2014119 ✗ ✗ ✓ ✗
Steenholdt et al., 2011120 ✗ ✗ ✓ ✓
Steenholdt et al., 2013121 ✓ (mapping only) ✗ ✗ ✗
Steenholdt et al., 201352 ✗ ✗ ✗ ✓
Steenholdt et al., 2014122 ✓ ✓ ✗ ✗
Steenholdt et al., 2014123 ✓ ✓ ✗ ✓
Steenholdt et al., 2015124 ✗ ✓ ✗ ✗
continued
DOI: 10.3310/hta20830 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 83
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Freeman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
33
Rationale
In a typical linked evidence approach, test accuracy studies detect cases of disease, and are linked to
studies that show evidence of treatment effectiveness in cases detected. The test accuracy studies in this
review produce four results:
1. drug positive and anti-drug antibody positive
2. drug positive and anti-drug antibody negative
3. drug negative and anti-drug antibody positive
4. drug negative and anti-drug antibody negative.
TABLE 6 Overview of utility of included studies (continued )
Study (first author and
year of publication)
Utility of included study and reference to relevant section in report
Assay comparison:
Objective A: review
of comparative
performance of test
assays measuring
anti-TNF-α and/or
anti-drug antibody
levels
Management stipulated
by algorithm and test
outcome: Objective C1:
clinical studies
evaluating drug
monitoring for the
management of CD
patients (management
studies)
Correlation of
drug/anti-drug
antibodies and
response –
ROC: Results
of threshold
analysis studies
Correlation of
drug/anti-drug
antibodies and
response – 2 × 2:
Objective C2:
studies relating test
results to clinical
state of patients
(correlation studies)
Ungar et al., 2014;125
abstract
✓ (mapping only) ✗ ✗ ✗
Vande Casteele et al.,
2013126
✓ ✗ ✓ ✓
Vande Casteele et al.,
201267
✓ ✗ ✗ ✗
Vande Casteele et al.,
2014;127 abstract
✓ (mapping only) ✗ ✗ ✗
Vande Casteele et al.,
201573
✗ ✓ ✗ ✗
Vaughn et al., 2014128 ✗ ✓ ✗ ✗
Wang et al., 2010;129
abstract
✓ ✗ ✗ ✗
Wang et al., 2011;130
abstract
✓ ✗ ✗ ✗
Wang et al., 2012131 ✓ ✗ ✗ ✗
Ward et al., 2013;132
abstract
✗ ✗ ✓ ✗
West et al., 2008133 ✗ ✗ ✗ ✓
Yanai et al., 2012;134
abstract
✗ ✗ ✗ ✓
Yarur et al., 2013;135
abstract
✗ ✗ ✓ ✗
Total number of included
references in each
section
26 (11 mapping only) 5 24 31 and 3 SRs
✗, study did not provide data; ✓, study provided data; SR, systematic review.
a Studies comparing assays other than the intervention assays or as comparator for the linked evidence approach were
mapped for their assay type comparison but not further considered in the assessment.
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However, no trials were found that used the specified index tests to direct treatments for these four
patient groups.
The linked evidence approach we therefore used was to evaluate the evidence showing whether or not
any comparator tests (drug and anti-drug antibody tests) used in patients with CD improve outcomes
(typically a test–treat type of trial), and to assess the accuracy of the index tests versus these comparator
tests. These comparator tests form an imperfect reference standard and a simple calculation of sensitivity
and specificity of the ELISA index tests against these tests (e.g. using HMSA or RIA) as reference standards
might result in either over- or underestimation because of imperfect reference standard bias.
We took studies which investigated if testing for drug and anti-drug antibodies can improve patient
outcomes through choosing the treatment prescribed by an algorithm (i.e. in a full RCT), and linked this to
the index tests. This method may work satisfactorily if the RCT is of good quality and if there is good
evidence for high concordance between the index and (imperfect) reference or comparator tests. When there
are discordant results between tests, we do not know which is correct. Alternatively, for spiked samples,
we know which test is correct, but not whether or not this would have any impact on clinical outcomes.
Therefore, the main outcome for objective A was evaluation of the concordance between the tests. This
approach is appropriate for interpreting and synthesising data when the reference standard is imperfect.72
Results of assay type comparison studies
The search identified 25 relevant studies (reported in 26 references) that compared two or more assays to
measure anti-TNF-α and/or anti-drug antibody levels in patients with CD (Figure 7). Of these, 10 were full
texts (reported in 11 references)67,86,99,100,103,116,121–123,126,131 and the remainder were conference abstracts,
including one unpublished abstract provided by Proteomika (Dr Daniel Nagore, Progenika Biopharma,
2015, personal communication).81,87,89–91,96,97,109,117,118,125,127,129,130 Of the 25 studies, 11 were not further
considered as they compared assays other than the intervention assays or as comparators for the linked
evidence approach (see Appendix 8).81,86,96,99,100,103,109,118,121,125,127 Of the remaining 14 studies (15 references),
which undertook relevant comparisons [including one unpublished abstract provided by Proteomika
(Dr Daniel Nagore, Progenika Biopharma, 2015, personal communication)]67,87,89–91,97,116,117,122,123,126,129–131
(Figure 8), only five (six references) [including one unpublished abstract provided by Proteomika
(Dr Daniel Nagore, Progenika Biopharma, 2015, personal communication)]67,87,117,122,123 reported concordance
as numerical data or as Cohen’s kappa (see Figure 14). In addition, Proteomika provided information in the
form of a benchmark analysis which is commercial in confidence (and, therefore, redacted from the text).
Four comparator tests were identified from the literature linking use of the test to clinical outcomes: these
were the RIA,123 the Leuven in-house ELISA,73 the PROMETHEUS ELISA128 and the PROMETHEUS HMSA.128
All of the test comparisons identified in the search are detailed in Figure 7. The index tests are shown in
light green, and those tests with some literature linking use of the test to clinical outcomes are marked in
dark green.
Only those studies that compared performance between the different index tests, or between the index
and comparator tests, were considered further, as shown in Figure 8. Four comparators were identified,
with evidence linking the use of the test to clinical outcomes, as described in Objective C1: clinical studies
evaluating drug monitoring for the management of Crohn’s disease patients (management studies).
Briefly, use of the RIA was linked to outcomes in a test–treat trial123 and use of the PROMETHEUS ELISA
and HMSA were linked to outcomes in a retrospective observational cohort.128 The latter trial design is not
randomised and is also subject to biases to the extent that we considered a linked evidence approach may
be inappropriate. Nonetheless, we included these two tests in this section for comparative purposes. An
in-house ELISA from Leuven was linked to outcomes in a RCT.73
Quality appraisal
Only studies available as full texts67,122,123,126,131 included in Figure 8 were quality assessed. The results of the
quality appraisal using a tailored QUADAS-2 tool are summarised in Table 7 and Appendix 10. There was
‘high’ concern regarding patient selection across all papers, with a lack of clarity about the source of
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patients, and whether or not a consecutive series of patients was used. Some patients were selected from
a biobank on the basis of index test results,126 introducing a form of selection bias, and some were patients
from a test–treat trial, although the trial included three more patients than the comparative accuracy study
and the reason for their exclusion is unclear.122 There was also concern regarding the applicability of the
patients included in these studies to our research question, in particular one study included patients who
had UC as well as CD126 and another included patients in unspecified numbers with unspecified conditions
from departments of rheumatology and gastroenterology.67
Prometheus ELISA
Homogeneous
Mobility Shift Assay
(HMSA)
Biomonitor
Radioimmunoassay
(RIA)
Immundiagnostik
ELISA
(BioHit Healthcare)
Promonitor ELISA
(Proteomika)
LISA TRACKER ELISA
(Theradig/Alpha
Laboratories)
Leuven in-house
ELISA
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Sanquin
in-house ELISA
(and RIA for
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Eser
2013
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(i)(i*)
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(i)(i*)
Ste 2014
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(i)(i*)(a)(a*)
VC 2012
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VC 2013
(i)(i*)
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(i)(i*)VC 2012
(i)(i*)Schatz
2013
(i)(i*)
Ruiz–
Arguello
2013
(i)(i*)(a)
(a*)
Ste 2014 A
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 (i)(i *)
Ste 2014 AJG (i)
Hauenstein 2012 AJG (i)(i *)
Egea-Pujol 2013 (i)(i *)(a)(a *)
W
ang 2010 (i)(i *)
W
ang 2011 (i *)
W
ang 2012 (i *)
Data
provided by
Proteomika
(i)(i*)(a)(a*)
FIGURE 8 Comparisons that linked the index tests and comparator tests to each other. The index tests are shaded
green and comparator tests shaded blue. The comparisons are denoted (i) for IFX, (a) for ADA, (i*) for anti-drug
antibodies to IFX and (a*) for anti-drug antibodies to ADA. Studies include Daperno 2013;87 Egea-Pujol 2013;89
Eser 2013 in Gastroentrology;90 Eser 2013 in J Crohns Colitis;91 Hauenstein 2012;97 Nagore 2015 (Dr Daniel Nagore,
Progenika Biopharma, 2015, personal communication); Ruiz-Arguello 2013;116 Schatz 2013;117 Steenholdt 2014;122,123
Vande Casteele 2012;67 Vande Casteele 2013;126 Wang 2010;129 Wang 2011;130 and Wang 2012.131 AJG, American
Journal of Gastroenterology; Gastro, Gastroenterology; JCC, Journal of Crohn’s and Colitis; Ste, Steenholdt;
VC, Vande Casteele.131
TABLE 7 Results of QUADAS-269 quality appraisal of included papers for objective A
Study (first author and
year of publication)
Concerns regarding risk of bias
Concerns regarding
applicability
Patient
selection
Index
test
Reference
standard
Flow and
timing
Patient
selection
Index
test
Reference
standard
Vande Casteele et al., 201267 High Low High High High Low Low
Vande Casteele et al., 2013126 High Low High High High Low Low
Steenholdt et al., 2014122,123 High Low High High Low High Low
Wang et al., 2012131 High High Unclear High High High Low
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There was ‘low’ concern overall about the implementation of the index tests but ‘high’ concern about
applicability when the index test measured was not one of the three ELISAs specified in our research
question (i.e. they were part of a longer chain linking index tests to comparators indirectly). Risk of bias
in the reference standard was high for all studies; this is because all reference standards used were
imperfect, and it is difficult to determine their actual sensitivity and specificity for detecting therapeutic
drug levels and levels of anti-drug antibodies. One study also interpreted the reference standard with
knowledge of the index test introducing information bias.131
All studies had high risk of bias for flow and timing because either one test was performed at the time and the
others on biobanked samples122,126 or the reference test was only conducted dependent on the results of the
index test, thus introducing incorporation bias,131 and one study did not include all patients in the analysis.67
Comparisons between the index tests
Results are presented here for all included studies, as outlined in Figure 8. This includes four full papers
(five references),67,122,123,126,131 as outlined in the quality assessment in Quality appraisal, and 10 abstracts
[including one unpublished abstract provided by Proteomika (Dr Daniel Nagore, Progenika Biopharma,
2015, personal communication)].87,89–91,97,116,117,129,130
Adalimumab (Confidential information has been removed.)
One unpublished abstract that was provided by Proteomika [unpublished abstract provided by Proteomika
(Dr Daniel Nagore, Progenika Biopharma, 2015, personal communication)] compared Promonitor assays
with LISA-TRACKER assays for ADA. In this abstract, 40 samples were used from an unspecified number of
patients with IBD and an unspecified number of spiked samples. The spiked samples may be the same as
described in data provided to us from the manufacturer. For ADA, drug levels were different between the
different assays: 6.0 [standard error of mean (SEM) 0.55] for Promonitor assays and 4.9 (SEM 0.39) for
LISA-TRACKER assays. Pearson’s R2 was 0.83 and the authors concluded from the spiked samples that
LISA-TRACKER assays underestimated ADA levels. In addition, 10% of samples were above the upper limit
of quantification for LISA-TRACKER assays, and not for the Promonitor ELISA.
In summary, LISA-TRACKER assays may underestimate ADA drug levels and this underestimation will be greatest
at higher absolute drug levels. The impact this would have on performance at a set threshold is unclear.
Antibodies to ADA The same study that reported relationships between the index tests for ADA also
reported some information on antibodies to ADA [unpublished abstract provided by Proteomika (Dr Daniel
Nagore, Progenika Biopharma, 2015, personal communication)]. They reported a Cohen’s kappa of 0.8
between Promonitor and LISA-TRACKER assays for antibodies to ADA, but it is unclear how many samples
were included in this comparison. (Confidential information has been removed.)
In summary, we have one abstract giving a Cohen’s kappa of 0.8 between LISA-TRACKER assays and
Promonitor assays, in tests for antibodies to ADA, but it is not known how many samples, and of which
type, were included in this analysis.
Infliximab (Confidential information has been removed.)
There was one abstract comparing Promonitor to LISA-TRACKER assays for IFX [unpublished abstract provided
by Proteomika (Dr Daniel Nagore, Progenika Biopharma, 2015, personal communication)]. In this abstract,
69 samples from an unspecified number of patients with IBD and an unspecified number of spiked samples
were used. IFX drug levels were different between the different assays: 2.2 (SEM 0.24) for Promonitor and
3.4 (SEM 0.36) for LISA-TRACKER assays, for which the Pearson R2 was 0.98 and the authors concluded from
the spiked samples that LISA-TRACKER assays overestimated IFX levels. In addition, 23% of samples were
above the upper limit of quantification for LISA-TRACKER assays and not for the Promonitor ELISA.
In one abstract, Daperno et al.87 compared Immundiagnostik with Promonitor for IFX drug levels. In this study,
Daperno et al.87 enrolled a consecutive series of 66 patients (39 CD and 27 UC) undergoing regular IFX dosing
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by intravenous therapy. It is unclear if additional samples were included. Bland–Altman plots of IFX drug
levels showed mean bias of –1.8 µg/ml, indicating that Immundiagnostik estimates were on average lower
than those of Promonitor by 1.8 µg/ml, and upper and lower limits of agreement of –10.8 and 7.1 µg/ml,
respectively, indicating that 95% of IFX drug levels measured by Promonitor were between 10.8 µg/ml lower
and 7.1 µg/ml higher than the same sample scores using the Immundiagnostik test (Figure 9).
In summary, LISA-TRACKER assays showed most variation in results in comparison to spiked samples, with
levels of bias dependent on absolute drug levels, so performance at a set threshold cannot be inferred.
(Confidential information has been removed.)
Antibodies to infliximab (Confidential information has been removed.)
One abstract described a comparison of Promonitor and LISA-TRACKER assays for antibodies to IFX
[unpublished abstract provided by Proteomika (Dr Daniel Nagore, Progenika Biopharma, 2015, personal
communication)]. Cohen’s kappa was 1.0, indicating complete agreement between the two tests, but it is
unclear how many samples were included in this comparison. In the case of anti-drug measurements, 75%
of samples had to be retested with LISA-TRACKER assays as the original measurements were above the
upper limits of the measurement range.
One abstract, by Daperno et al.,87 compared Immundiagnostik with Promonitor for measurement of
antibodies to IFX. Daperno et al.87 enrolled a consecutive series of 66 patients (39 CD and 27 UC)
undergoing regular IFX dosing by intravenous therapy. The two tests showed identical results in just 6 out
of 63 cases included in the analysis. It is unclear what is meant in the abstract by ‘identical’ results, but the
low proportion that were identical may provide some indication that the two tests for antibodies to IFX
should not be considered equivalent.
In summary, one study found perfect agreement between Promonitor and LISA-TRACKER assays for
antibodies to IFX and another study found few (6/63, i.e. < 10%) ‘identical’ results between
Immundiagnostik and Promonitor.
Comparisons between index tests and comparator tests
Here we outline the studies linking the index tests to comparator tests, which have associated evidence
linking use of the test to changes in clinical outcomes.
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FIGURE 9 Reconstructed Bland–Altman plot comparing Promonitor IFX kits and Immundiagnostik TNF-α-Blocker
ELISA kits. Based on data from Daperno et al.87
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LISA-TRACKER assays There are no studies linking LISA-TRACKER assays to any of the comparator tests
for detecting ADA or antibodies to ADA.
There is one study by Vande Casteele et al.67 linking the LISA-TRACKER assay to the Leuven in-house ELISA
for IFX and antibodies to IFX. This same study also compares LISA-TRACKER with the Amsterdam Sanquin
in-house ELISA and RIA. These tests from the Amsterdam group are not included as comparators, but form
part of the linkage pathway between the other index tests and the comparator, Leuven in-house ELISA,
and so their relationship to LISA-TRACKER assays is also included here for interest.
Vande Casteele et al.67 used 62 plasma samples from departments of gastroenterology and rheumatology.
Of these, 36 were clinical samples from patients; the remaining 26 samples consisted of 24 spiked
samples: 10 samples spiked with IFX, 10 spiked with antibodies to IFX, one spiked with ADA, three spiked
with antibodies to ADA and two healthy control samples. The results for these different types of sample
are not fully reported separately, but parts are included. Four samples were removed as they were above
the upper limit of quantification for the LISA-TRACKER assay. In detecting IFX, the LISA-TRACKER assay
gave positive results for 11 samples that were negative when using either Amsterdam or Sanquin in-house
ELISAs. Five of these were false-positive spiked samples that did not contain IFX but did contain antibodies
to IFX (two samples) and antibodies to ADA (three samples). The remaining six samples were clinical so the
true result is not known, but the authors report high levels of antibodies in these samples. The one sample
spiked with ADA was a true negative for IFX for both LISA-TRACKER and Leuven assays, but a false
positive for the Amsterdam in-house ELISA. The Bland–Altman plots show that, although the relationship
between the Leuven and Amsterdam ELISA appears to be independent of absolute drug levels, as drug
levels increase measurements using the LISA-TRACKER assay appear to increase slower than those using
either Leuven or Amsterdam assays (Figure 10). This means that the levels of concordance between the
LISA-TRACKER assay and the other assays will be dependent upon the particular threshold used. The
Bland–Altman plot showed no pattern between the Leuven and the Amsterdam IFX tests, and from visual
inspection the bias was near zero, with upper and lower limits of agreement between –10 and 10 mg/ml.
The performance in detecting antibodies to IFX is less clear, with discordant results reported but not the
type of sample in which these results were found. The Amsterdam in-house RIA detected antibodies to IFX
in five samples when they were not detected by either of the other two assays, and both the Amsterdam
and the LISA-TRACKER assays tests detected antibodies in three samples, which tested negative using the
Leuven in-house ELISA. The thresholds used for drug and anti-drug levels, respectively, were 0.1 mg/l and
10 µg/l for LISA-TRACKER assays, 0.3 mg/l and 1 mg/l for Leuven and 0.002 mg/l and 12 arbitrary units/ml
(1 arbitrary unit/ml equals approximately 10 µg/l) for Amsterdam. This higher threshold for the Leuven
antibody ELISA may explain why fewer cases were detected.
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FIGURE 10 Reconstructed Bland–Altman plots of IFX levels (mg/l) comparing (a) Amsterdam in-house IFX ELISA and
Leuven in-house IFX ELISA; (b) Amsterdam in-house IFX ELISA and LISA-TRACKER assays premium IFX kit; and
(c) Leuven in-house IFX ELISA and LISA-TRACKER assays premium IFX kit. Based on data from Vande Casteele et al.67
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In summary, in one study, using a range of clinical and spiked samples, there is some evidence that
LISA-TRACKER assays may give false-positive results for IFX in the presence of antibodies to IFX or ADA,
whereas the Leuven and Amsterdam in-house ELISAs do not. There is also some evidence that the
Amsterdam RIA is most likely to detect antibodies, followed by LISA-TRACKER assays and then the Leuven
in-house ELISA, but whether or not these antibodies detected are true positives or false positives is unclear.
Promonitor One letter, by Ruiz-Arguello et al.,116 compared the Promonitor ELISA with the Amsterdam
Sanquin ELISA for IFX and ADA, and the Amsterdam Sanquin RIA for both anti-drug antibodies.
In addition, Vande Casteele et al.67 then linked the Amsterdam Sanquin ELISA and RIA to the Leuven
in-house ELISA, which is one of the comparator tests.
The study comparing the Promonitor assay to the Amsterdam Sanquin tests used 120 spiked samples in total,
designed to cover concentrations in the clinically meaningful range, 30 samples over the range 0.001–8 µg/ml
for IFX, 30 samples over the range 0.001–5 µg/ml for ADA and 30 samples over the range 1–5000 arbitrary
units/ml for both anti-drug antibodies to IFX and ADA.116 The study defines set cut-off points and describes
both assays as having no false-positive results for drug levels. However, no details are given of the sensitivity
of each assay at those set cut-off points or concordance between them. The analytical sensitivity, meaning
the lowest level at which the drug/antibodies are detectable, was given. Analytical sensitivity of the
Amsterdam Sanquin assay was slightly higher than that of Promonitor: 10–30 ng/ml for IFX and 2–20 ng/ml
for ADA, respectively. Bland–Altman plots of each assay in comparison with the known spiked concentrations
gave a mean bias of −0.467 ng/ml [standard deviation (SD) 1.027 ng/ml] and 0.066 ng/ml (SD 0.196 ng/ml)
for IFX and −1.140 ng/ml (SD 2.713 ng/ml) and −0.159 ng/ml (SD 0.488 ng/ml) for the Amsterdam Sanquin
and Promonitor tests for ADA, respectively. The plots are not provided, but the authors describe a systematic
overestimation of the drug levels by the Amsterdam Sanquin ELISA that increases with increased drug levels,
which would explain the greater CIs for the mean bias estimate for the Sanquin ELISA. The authors describe
this overestimation as occurring at drug levels of > 2 µg/ml. For antibodies to IFX and ADA, only correlation
coefficients and analytical sensitivity were reported. Analytical sensitivity of the Promonitor assay was higher
than that of Amsterdam Sanquin RIA, at 4 ng/ml and 20 arbitrary units/ml for IFX and 2 ng/ml and 30 arbitrary
units/ml for ADA, respectively. Therefore, there is some evidence using spiked assays that the Amsterdam
Sanquin assay may overestimate drug levels at higher concentrations, whereas the Promonitor assay may not.
In a letter of response, however, Rispens and van der Kleij136 describe an update to their testing procedure
which may have corrected the overestimation.
The second link between the Amsterdam and Leuven tests has been described in detail in LISA-TRACKER
assays. However, to recap in brief, for drug levels the Bland–Altman plot showed no pattern; therefore, the
relationship between the two tests is not dependent on threshold and from visual inspection the bias was near
zero, with upper and lower limits of agreements between –10 and 10mg/ml. For anti-drug antibodies to IFX,
the Amsterdam RIA detected more cases than the Leuven assay, with the actual veracity of these unclear.
In summary, although we have some information linking Promonitor to the Amsterdam Sanquin tests, and
further information linking these to the Leuven ELISA, it is not in a format from which we can calculate the
concordance between the tests at clinically relevant thresholds.
Immundiagnostik There are no studies linking Immundiagnostik to any of the comparator tests for ADA
or antibodies to ADA. In two abstracts, Eser et al.90,91 compared the Immundiagnostik ELISA with the
PROMETHEUS HMSA, and Schatz et al.117 compared the Immundiagnostik ELISA with the Amsterdam
Sanquin in-house tests (for IFX and antibodies to IFX), which are in turn compared with the Leuven
in-house ELISAs by Vande Casteele et al.67
The two abstracts by Eser et al.90,91 comparing Immundiagnostik ELISA with the PROMETHEUS HMSA
method used samples from 90 patients (66 CD and 24 UC). The authors report that HMSA was able to
detect anti-drug antibodies to IFX at the mid-infusion point, whereas ELISA returned inconclusive results
because of interference from IFX. However, no numerical data were presented comparing the two
methods so few, if any, conclusions can be drawn from the study.
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The study by Schatz et al.117 linking Immundiagnostik ELISA to the Amsterdam in-house tests (ELISA for drug
levels, RIA for antibody levels) compared performance of the two tests for IFX and anti-drug antibodies to
IFX. They used serum samples from 202 paediatric patients, of whom 125 had been exposed to IFX and
77 were IFX naive. Samples were considered positive for IFX if they were above the limit of detectability,
which was < 0.8 µg/ml for the Immundiagnostik ELISA and < 0.002 µg/ml for Amsterdam in-house ELISA.
Overall agreement using Cohen’s kappa was 0.792. Considering only the IFX-exposed patients, 25 were
below the lower limit of detectability for both tests, leaving 87 who tested positive for both, 11 who tested
positive only using the Amsterdam ELISA (measurements ranged from 0.1 to 2.3 µg/ml, so some of these
will be below the lower limit of detectability using the Immundiagnostik test) and two whose results were
not reported. For anti-drug antibodies to IFX, 88 samples were concordant positive, 27 samples were
concordant negative and 10 were detected only by the Amsterdam RIA and not the Immundiagnostik ELISA.
The second link between the Amsterdam and Leuven tests has been described in detail in the previous two
sections (i.e. LISA-TRACKER assays and Promonitor). For drug levels, the Bland–Altman plot showed no
pattern, so the relationship between the two tests is not dependent on threshold, and from visual
inspection the bias was near zero, with upper and lower limits of agreements between –10 and 10 mg/ml;
for anti-drug antibodies to IFX the Amsterdam RIA detected more cases than the Leuven assay, with actual
veracity of these unclear.
In summary, although there are good data linking Immundiagnostik with the Amsterdam in-house ELISA,
with agreement for 114 out of 125 samples for IFX and 115 out of 125 samples for anti-drug antibodies
to IFX, the link to the Leuven ELISA is not known in terms of agreement of the two tests at a clinically
relevant threshold.
Relationship between different comparator tests
One study, by Steenholdt et al.,122 compared the performance of the Biomonitor RIA used in the test–treat
trial with PROMETHEUS HMSA and PROMETHEUS ELISA for IFX and antibodies to IFX. Vande Casteele
et al.126 compared the Leuven in-house ELISA with PROMETHEUS HMSA. One full study, by Wang et al.,131
and four further abstracts89,97,129,130 compared the performance of HMSA with PROMETHEUS ELISA for IFX
and antibodies to IFX, Egea-Pujol et al.89 also made the same comparison for ADA and antibodies to ADA.
However, three of these abstracts (Hauenstein et al.,97 Egea-Pujol et al.89 and Wang et al.130) did not
provide data on concordance, Cohen’s kappa or numbers of false-positive, true-positive, false-negative
or true-negative test results, and will not be described further here.
The studies by Wang et al.129,131 compared the performance of HMSA and of PROMETHEUS ELISA.
Wang et al.129 described 20 patients with IBD who had relapsed from treatment with IFX. ELISA detected
IFX in 15 out of 20 patients and anti-drug antibodies to IFX in 15 out of 20 patients. HMSA detected IFX in
15 out of 20 patients and anti-drug antibodies to IFX in 18 out of 20 patients. It is not clear if the samples
that tested positive on both tests were from the same 15 patients. The focus of Wang et al.131 was to
validate the performance of HMSA rather than to compare it with ELISA. Of 100 samples from healthy
control participants, three were false-positive for antibodies to IFX for HMSA. This was to be expected as
the cut-off point was determined from the same samples as mean plus two SDs. Repeat measurements of
these three resulted in them being below the cut-off point, presumably regression to the mean. ELISA
results for the 100 healthy control participants were not reported. Out of 100 patients with IBD selected as
positive for antibodies for IFX on ELISA, five did not test positive on HMSA. The authors attribute this to
elevated levels of non-specific binding in the ELISA. As we do not have the equivalent data for ELISA
results on samples that tested positive using HMSA, it is difficult to draw any conclusions at all. The only
comparative data given constitute a plot of correlation that does not appear to show high correlation.
The studies therefore did not provide useful concordance data for evaluation.
Vande Casteele et al.126 compared the Leuven in-house ELISA to PROMETHEUS HMSA. Although the paper
does describe some discordant results, the focus of the paper is on outcomes in patients with differing
results rather than on comparisons between the two tests. HMSA appears to perform better at detecting
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antibodies to IFX in the presence of IFX; however, quantifying this is difficult, as reporting focused on other
research questions. It is described in the discussion as the HMSA having detected the median 9 weeks
earlier. However, in the absence of IFX and with the HMSA cut-off point for antibodies to IFX set at
7.95 U/ml, the Leuven in-house ELISA detected four more cases with antibodies to IFX. The authors report
that PROMETHEUS has since lowered the threshold to 3.13 U/ml.
Steenholdt et al.122 took 66 frozen patient samples (from patients with CD with LOR to IFX) from the
test–treat trial123 and reanalysed them using PROMETHEUS HMSA and PROMETHEUS ELISA. In all of these
patients, the results of RIA using the samples before freezing were available and determined the treatment
pathway at the time of the study. Threshold for positivity for IFX was unclear, but the lower limit of
quantification was clearly defined as ≥ 0.15 µg/ml, ≥ 1 µg/ml and ≥ 1.4 µg/ml for RIA, HMSA and ELISA,
respectively.122 However, in the original paper reporting the RCT,123 although the same lower limit of
quantification thresholds were given, additional cut-off points of ≥ 0.5 µg/ml and ≥ 3 µg/ml were given for
defining therapeutic drug levels for RIA and HMSA, respectively. However, no additional cut-off point was
given for ELISA. Thresholds for anti-drug antibodies to IFX were ≥ 10 arbitrary units/ml, ≥ 3.13 arbitrary
units/ml and ≥ 1.69 µg/ml for RIA, HMSA and ELISA, respectively. Using RIA, 54 out of 66 (82%) tested
positive for IFX, in comparison with 58 out of 66 (88%) for HMSA and 50 out of 66 (76%) using ELISA. The
concordance between the three tests is shown in Figure 11. In eight patients IFX was undetectable using all
three tests and in 50 patients IFX was detectable using all three tests. In four patients IFX was detected by
RIA and HMSA but not by ELISA, and in a further four patients IFX was detectable only by HMSA.
Using RIA, 18 out of 66 (27%) patients tested positive for anti-drug antibodies to IFX, in comparison with
22 out of 66 (33%) using HMSA and 6 out of 66 (9%) using ELISA. The concordance between the three
tests is shown in Figure 12. In 43 patients, anti-drug antibodies to IFX were undetectable using all three
tests, and in six patients anti-drug antibodies to IFX were detectable using all three tests. In 11 patients
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FIGURE 11 Concordance between RIA, HMSA and ELISA for detecting IFX in 66 patients with CD with LOR to IFX.
In eight patients IFX was undetectable using all three tests.
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FIGURE 12 Concordance between RIA, HMSA and ELISA for detecting anti-drug antibodies to IFX in 66 patients
with CD with LOR to IFX. In 43 patients anti-drug antibodies were not detectable in any of the tests.
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anti-drug antibodies to IFX were detected by RIA and HMSA but not by ELISA, in a further five patients
anti-drug antibodies to IFX were detectable only by HMSA and in one patient anti-drug antibodies to IFX
were detectable only by RIA.
In summary, for IFX, RIA and HMSA agreed for 62 out of 66 patients, with the remaining four patients
testing positive on HMSA but not RIA; HMSA and ELISA agreed in 58 out of 66 patients, with eight
patients testing positive on HMSA but not ELISA; and RIA and ELISA agreed on 62 out of 66 patients,
with the remaining four patients testing positive on RIA but not ELISA. The Bland–Altman plots comparing
HMSA with RIA and ELISA with RIA showed a pattern with increasing drug concentration, meaning
that these two comparisons are dependent on the absolute values for thresholds chosen (Figure 13).
The relationship between HMSA and ELISA appears to be independent of absolute drug concentrations.
In the case of anti-drug antibodies to IFX, RIA and HMSA agreed for 60 out of 66 patients, with five
patients testing positive on HMSA and not on RIA, and one testing positive on RIA and not on HMSA.
HMSA and ELISA agreed in 50 out of 66 patients, with 16 patients testing positive on HMSA but not on
ELISA; RIA and ELISA agreed in 54 out of 66 patients, with the remaining 12 patients testing positive on
RIA but not on ELISA.
Therefore, there is an indication that RIA and HMSA detect more patients with IFX than does PROMETHEUS
ELISA, and this effect is more pronounced with anti-drug antibodies to IFX. We do not know the true
measurements for these patients.
Summary
Figure 14 summarises the studies that quantify the link between the index tests and the comparator assays
using concordance data. In comparing the three index tests with one another, we have data from two
abstracts [including one unpublished abstract provided by Proteomika (Dr Daniel Nagore, Progenika
Biopharma, 2015, personal communication)].87
For anti-drug antibodies, one abstract [unpublished abstract provided by Proteomika (Dr Daniel Nagore,
Progenika Biopharma, 2015, personal communication)] describes complete agreement between
Promonitor and LISA-TRACKER assays for anti-drug antibodies to IFX and a Cohen’s kappa of 0.8 for
anti-drug antibodies to ADA, but does not report how many samples were included. It also describes the
upper limits of the measurement range for LISA-TRACKER assays as low. Daperno et al.87 compared
Immundiagnostik with Promonitor for anti-drug antibodies to IFX and found that the two tests showed
identical results in only 6 out of 63 cases in a consecutive series of 66 patients (39 with CD and 27 with
UC), but the definition of ‘identical’ was not given. It is not possible from these data to link the three index
tests as part of a linked evidence approach.
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FIGURE 13 Reconstructed Bland–Altman plots comparing PROMETHEUS ELISA, HMSA and RIA. (a) ELISA vs. HMSA;
(b) RIA vs. HMSA; and (c) RIA vs. ELISA. Based on data from Steenholdt et al.122
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For each index test we investigated all links to the comparator tests. There was one link to the Amsterdam
Sanquin tests (ELISA for IFX, RIA for anti-drug antibodies to IFX),117 which showed agreement for 114 out of
125 samples for IFX and 115 out of 125 samples for anti-drug antibodies to IFX. However, there was only
one study then linking the Amsterdam tests to the Leuven in-house ELISA,67 which reported disagreement
in at least 8 out of 62 samples, with a lack of clarity regarding the remainder of results. Similarly, there was
only one study linking LISA-TRACKER assays to the Leuven in-house ELISA67 and, although it reported
disagreement for IFX in at least 11 out of 58 samples and for anti-drug antibodies to IFX in at least 3 out of
62 samples, the results for the remainder were unclear. However, we found no concordance data linking
any of the index tests to any of the comparator tests at a clinically meaningful threshold.
In comparing the comparator tests with each other, there was one study122 that described reanalysing the
same samples previously used in a test–treat trial.123 There was agreement between PROMETHEUS ELISA
and Biomonitor RIA for IFX in 62 out of 66 samples and for anti-drug antibodies to IFX in 54 out of 66
samples; agreement between PROMETHEUS ELISA and HMSA in 58 out of 66 samples for IFX and in 49
out of 66 samples for anti-drug antibodies to IFX; and, finally, agreement between RIA and HMSA in 62
out of 66 samples for IFX and in 60 out of 66 samples for anti-drug antibodies to IFX. We found no
ongoing link to the index tests.
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FIGURE 14 Results of comparisons which linked the index tests and comparator tests to each other of studies
reporting concordance data. The index tests are shaded green and comparator tests are shaded blue. Results are
listed as either Cohen’s kappa or concordance levels displayed as a fraction for IFX (i), ADA (a), anti-drug antibodies
to IFX (i*) and anti-drug antibodies to ADA (a*). Only studies which provide concordance at set threshold or
Cohen’s kappa for the comparisons between tests are included Daperno 2013;87 Nagore 2015 (Dr Daniel Nagore,
Progenika Biopharma, 2015, personal communication); Schatz 2013;117 Steenholdt 2014;122,123 and Vande Casteele
2012.67 ADAbs, anti-drug antibodies; AJG, American Journal of Gastroenterology; Ste, Steenholdt; VC, Vande Casteele.
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Overall, there was insufficient evidence linking any of the index tests (LISA-TRACKER, Immundiagnostik or
Promonitor) to any of the comparators with links to clinical outcomes (HMSA, RIA, PROMETHEUS ELISA
or Leuven in-house ELISA).
Results of threshold analysis studies
The search identified 24 studies48,58,77,82,84,85,93–95,100,101,104,105,107,108,110,112,113,115,119,120,126,132,135 that reported a ROC
threshold analysis to determine optimal cut-off levels predictive of clinical response for IFX,58,77,82,85,93,101,104,105,
110,112,113,119,120,126 ADA48,84,94,100,107,108,115,132,135 or both.95 Table 8 summarises the studies in terms of the
threshold reported, the diagnostic performance of using the threshold, the clinical marker used for
assessment of response, the assay used and the value for the area under the curve (AUC). As the area under
a ROC curve in this case quantifies the overall ability of the test to discriminate between those individuals
who respond and those who do not respond, an AUC value > 0.5 indicates an informative test whereas an
AUC of 0.5 represents an uninformative test without discriminatory power (sensitivity + specificity = 1).
When considering the reported thresholds we need to bear in mind that response and LOR are poorly
defined and studies using different definitions will measure different outcomes, which will have implications
on the reported thresholds.
Infliximab
Studies measuring IFX used a range of assays including commercial ELISA kits, in-house or academically
developed ELISAs, HMSA and RIA. Studies generally tried to optimise diagnostic performance by finding a
cut-off point with maximum sensitivity and specificity, and maximising the AUC. However, according to the
reported performance measures, the diagnostic performance of the tests overall was only moderate. One
study aimed for high sensitivity (0.90) at a trade-off of specificity (0.37),95 whereas another favoured high
specificity (1.00) at the expense of good sensitivity (0.33).119 The reported IFX cut-off point ranged between
0.61 µg/ml101 and 4.1 µg/ml,105 and was reported to be as high as 7 µg/ml for the test with 100%
specificity requiring a minimum drug trough level of 7 µg/ml at treatment week 14 to be predictive of
good response at week 54.119 One study reported a trough difference before and after dose optimisation
as predictive of clinical outcome58 and another reported the trough level that predicts response after
reinitiation of IFX treatment.77 Although the trough levels for the HMSA and RIA were not too dissimilar,
one study reported trough levels for predicting anti-drug antibodies to IFX using HMSA that were
exceptionally high (13 µg/ml).126 There was great variation in the clinical marker used to assess clinical
response, which included mainly subjective physician’s assessment and disease activity scores as well as
laboratory markers, such as CRP and FC, and objective assessments of mucosal healing. Six studies used
a combination of different markers for the assessment.77,82,95,101,104,105
Adalimumab
Studies of ADA used mainly ELISAs, with only one study using HMSA135 and one RIA.94 One study reported
only in the form of an abstract did not specify the test type used.107 The reported thresholds for clinical
markers such as response and clinical remission ranged from 3 µg/ml95 to 6.85 µg/ml.94 However, sustained
clinical benefit, as reported by patients and defined as ‘lasting control of disease with possible dose
escalation’, was predicted with a high sensitivity of 95% by ADA levels in one study of only ≥ 0.33 µg/ml.48
One study reported the different threshold values for a test with maximum sensitivity of 14.5 µg/ml,
maximum specificity of 0.35 µg/ml and sensitivity equal to specificity of 6.85 µg/ml.94
All but one study reported AUC values considerably higher than 0.5, classing them as fair to good tests.
However, one study reported AUC values for three different time points of just over 0.5 (0.5, 0.57 and
0.58) and was unable to identify an ADA concentration associated with clinical remission (CDAI score of
< 150). This study therefore questioned the clinical utility of measuring ADA concentrations.84
Summary
The range of cut-off points illustrates that no validated threshold has been established to date. Cut-off
points strongly depend on the test assay used, the drug measured and the clinical marker investigated as
well as the method of determination of the clinical marker. It is uncertain how clinically meaningful the
CLINICAL EFFECTIVENESS REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
46
TA
B
LE
8
C
u
t-
o
ff
p
o
in
ts
fo
r
d
ru
g
le
ve
ls
fr
o
m
R
O
C
an
al
ys
es
to
p
re
d
ic
t
cl
in
ic
al
re
sp
o
n
se
St
u
d
y
(f
ir
st
au
th
o
r
an
d
ye
ar
o
f
p
u
b
lic
at
io
n
)
C
u
t-
o
ff
p
o
in
t
(µ
g
/m
l)
Pe
rf
o
rm
an
ce
m
ea
su
re
s
A
U
C
(9
5%
C
I)
C
lin
ic
al
m
ar
ke
r
D
ru
g
A
ss
ay
Se
n
si
ti
vi
ty
Sp
ec
if
ic
it
y
Po
si
ti
ve
p
re
d
ic
ti
ve
va
lu
e
N
eg
at
iv
e
p
re
d
ic
ti
ve
va
lu
e
Bo
rt
lik
et
al
.,
20
13
82
3
0.
70
0.
62
0.
41
0.
84
0.
70
(0
.5
7
to
0.
83
)
Su
st
ai
ne
d
re
sp
on
se
(n
o
tr
ea
tm
en
t
fa
ilu
re
or
dr
ug
in
to
le
ra
nc
e,
no
su
rg
er
y,
im
m
un
os
up
pr
es
sa
nt
in
tr
od
uc
tio
n,
st
er
oi
ds
or
IF
X
in
cr
ea
se
)
IF
X
C
om
m
er
ci
al
EL
IS
A
C
or
ni
lli
e
et
al
.,
20
14
85
3.
5
0.
64
0.
78
0.
56
0.
83
0.
75
Su
st
ai
ne
d
re
sp
on
se
(C
D
A
I
sc
or
e
ch
an
ge
)
IF
X
N
on
-c
om
m
er
ci
al
EL
IS
A
G
ol
db
er
g
et
al
.,
20
14
;9
5
ab
st
ra
ct
3
0.
90
0.
37
N
R
N
R
0.
75
D
is
ea
se
ac
tiv
ity
(P
hy
si
ci
an
’s
G
lo
ba
lA
ss
es
sm
en
t
an
d
C
RP
le
ve
ls
)
IF
X
C
om
m
er
ci
al
EL
IS
A
Im
ae
da
et
al
.,
20
14
10
1
0.
6
0.
73
0.
62
N
R
N
R
0.
67
(0
.6
0
to
0.
81
)
C
RP
≤
0.
3
m
g/
dl
IF
X
N
on
-c
om
m
er
ci
al
EL
IS
A
1.
0
0.
67
0.
71
N
R
N
R
0.
72
(0
.5
0
to
0.
73
)
Se
ru
m
al
bu
m
in
(≥
4.
0
m
g/
dl
)
1.
1
0.
72
0.
56
N
R
N
R
0.
63
(0
.5
5
to
0.
65
)
FC
(≤
30
0
µg
/g
)
4.
0
0.
71
0.
70
N
R
N
R
0.
63
(0
.5
6
to
0.
70
)
M
H
(R
ut
ge
er
ts
sc
or
in
g
sy
st
em
,
0
or
1)
M
ar
its
et
al
.,
20
14
10
5
4.
1
0.
87
0.
44
N
R
N
R
0.
74
(S
E
0.
03
7)
Re
m
is
si
on
(H
BI
sc
or
e
<
5
an
d
C
RP
le
ve
lo
f
<
3
m
g/
l)
IF
X
N
on
-c
om
m
er
ci
al
EL
IS
A
N
ag
or
e
et
al
.,
20
15
11
0
0.
8
0.
86
0.
75
N
R
N
R
0.
86
(0
.7
6
to
0.
96
)
A
ct
iv
e
di
se
as
e
IF
X
C
om
m
er
ci
al
EL
IS
A
(P
ro
m
on
ito
r)
Pa
lla
gi
-K
un
st
ar
et
al
.,
20
14
11
2
3.
01
N
R
N
R
N
R
N
R
N
R
D
et
ec
tin
g
an
ti-
dr
ug
an
tib
od
ie
s
IF
X
C
om
m
er
ci
al
EL
IS
A
Pa
ul
et
al
.,
20
12
;1
13
ab
st
ra
ct
2
0.
76
0.
82
N
R
N
R
0.
60
Re
m
is
si
on
(C
D
A
Is
co
re
of
<
15
0)
IF
X
C
om
m
er
ci
al
EL
IS
A
(L
IS
A
-T
RA
C
K
ER
)
Pa
ul
et
al
.,
20
13
58
0.
5
(t
ro
ug
h
af
te
r
op
tim
is
at
io
n
m
in
us
tr
ou
gh
be
fo
re
op
tim
is
at
io
n)
0.
88
0.
76
0.
78
0.
86
0.
91
(0
.8
3
to
1.
0)
M
H
(F
C
<
25
0
µg
/g
)
IF
X
C
om
m
er
ci
al
EL
IS
A
(L
IS
A
-T
RA
C
K
ER
Pr
em
iu
m
) c
on
tin
ue
d
DOI: 10.3310/hta20830 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 83
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Freeman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
47
TA
B
LE
8
C
u
t-
o
ff
p
o
in
ts
fo
r
d
ru
g
le
ve
ls
fr
o
m
R
O
C
an
al
ys
es
to
p
re
d
ic
t
cl
in
ic
al
re
sp
o
n
se
(c
o
n
ti
n
u
ed
)
St
u
d
y
(f
ir
st
au
th
o
r
an
d
ye
ar
o
f
p
u
b
lic
at
io
n
)
C
u
t-
o
ff
p
o
in
t
(µ
g
/m
l)
Pe
rf
o
rm
an
ce
m
ea
su
re
s
A
U
C
(9
5%
C
I)
C
lin
ic
al
m
ar
ke
r
D
ru
g
A
ss
ay
Se
n
si
ti
vi
ty
Sp
ec
if
ic
it
y
Po
si
ti
ve
p
re
d
ic
ti
ve
va
lu
e
N
eg
at
iv
e
p
re
d
ic
ti
ve
va
lu
e
Si
ng
h
et
al
.,
20
14
11
9
4
0.
53
0.
75
0.
76
0.
52
0.
64
(0
.5
1
to
0.
75
)
W
ee
k
14
IF
X
le
ve
ls
as
pr
ed
ic
to
r
of
w
ee
k
54
cl
in
ic
al
re
m
is
si
on
ac
co
rd
in
g
to
C
D
A
I
IF
X
C
om
m
er
ci
al
EL
IS
A
(u
p
to
Ju
ly
20
12
)
or
H
M
SA
(f
ro
m
Ju
ly
20
12
)
7
0.
33
1.
00
1.
00
0.
50
0.
67
(0
.5
8
to
0.
75
)
Ba
er
t
et
al
.,
20
14
77
2
(a
ft
er
re
-e
xp
os
ur
e
to
IF
X
)
N
R
N
R
N
R
N
R
0.
76
(0
.6
2
to
0.
90
)
Lo
ng
-t
er
m
re
sp
on
se
[c
lin
ic
al
as
se
ss
m
en
t
(H
BI
)
an
d
C
RP
le
ve
ls
(<
3
m
g/
l)]
IF
X
H
M
SA
Le
ve
sq
ue
et
al
.,
20
14
10
4
3
N
R
N
R
N
R
N
R
N
R
D
is
ea
se
ac
tiv
ity
at
w
ee
k
8
in
cr
ea
se
in
C
D
A
Is
co
re
(≥
70
po
in
ts
an
d
a
C
RP
le
ve
l
>
5
µg
/l)
IF
X
H
M
SA
V
an
de
C
as
te
el
e
et
al
.,
20
13
12
6
13
(T
L
w
ee
k
6)
0.
72
0.
81
N
R
N
R
0.
87
(S
E
0.
06
)
A
nt
i-d
ru
g
an
tib
od
y
fo
rm
at
io
n
IF
X
H
M
SA
St
ee
nh
ol
dt
et
al
.,
20
11
12
0
0.
5
0.
86
0.
85
N
R
N
R
0.
93
(0
.8
5
to
1.
0)
M
ai
nt
ai
ne
d
re
sp
on
se
(g
oo
d
re
sp
on
se
to
in
du
ct
io
n
th
er
ap
y
at
0,
2
an
d
6
w
ee
ks
fo
llo
w
ed
by
go
od
re
sp
on
se
to
m
ai
nt
en
an
ce
th
er
ap
y)
IF
X
RI
A
2.
2
(T
L
w
ee
k
14
)
0.
79
0.
94
0.
93
(S
E
0.
04
)
Fe
ag
an
et
al
.,
20
12
;9
3
ab
st
ra
ct
3
N
R
N
R
N
R
N
R
0.
74
D
is
ea
se
ac
tiv
ity
IF
X
H
PL
C
-b
as
ed
flu
id
ph
as
e
as
sa
y
C
hi
u
et
al
.,
20
13
84
N
o
A
D
A
co
nc
en
tr
at
io
n
id
en
tif
ie
d
as
so
ci
at
ed
w
ith
cl
in
ic
al
re
m
is
si
on
at
an
y
tim
e
po
in
t
so
cl
in
ic
al
ut
ili
ty
of
m
ea
su
rin
g
A
D
A
co
nc
en
tr
at
io
ns
w
as
di
ff
ic
ul
t
to
as
se
ss
N
R
N
R
N
R
N
R
W
ee
k
4,
0.
51
;
w
ee
k
24
,
0.
58
;
w
ee
k
56
,
0.
57
C
lin
ic
al
re
m
is
si
on
(C
D
A
I
sc
or
e
of
<
15
0)
A
D
A
N
on
-c
om
m
er
ci
al
EL
IS
A
CLINICAL EFFECTIVENESS REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
48
St
u
d
y
(f
ir
st
au
th
o
r
an
d
ye
ar
o
f
p
u
b
lic
at
io
n
)
C
u
t-
o
ff
p
o
in
t
(µ
g
/m
l)
Pe
rf
o
rm
an
ce
m
ea
su
re
s
A
U
C
(9
5%
C
I)
C
lin
ic
al
m
ar
ke
r
D
ru
g
A
ss
ay
Se
n
si
ti
vi
ty
Sp
ec
if
ic
it
y
Po
si
ti
ve
p
re
d
ic
ti
ve
va
lu
e
N
eg
at
iv
e
p
re
d
ic
ti
ve
va
lu
e
G
ol
db
er
g
et
al
.,
20
14
;9
5
ab
st
ra
ct
3
0.
83
0.
63
N
R
N
R
0.
8
D
is
ea
se
ac
tiv
ity
(P
hy
si
ci
an
’s
G
lo
ba
lA
ss
es
sm
en
t
an
d
C
RP
le
ve
ls
)
A
D
A
C
om
m
er
ci
al
EL
IS
A
Im
ae
da
et
al
.,
20
14
10
0
5.
9
0.
67
0.
92
N
R
N
R
0.
83
(0
.8
0
to
0.
95
)
C
RP
le
ve
lo
f
≤
0.
3
m
g/
dl
A
D
A
N
on
-c
om
m
er
ci
al
EL
IS
A
K
ar
m
iri
s
et
al
.,
20
09
48
0.
33
0.
95
N
R
0.
81
N
R
N
R
Su
st
ai
ne
d
cl
in
ic
al
be
ne
fit
(p
at
ie
nt
re
po
rt
in
g
la
st
in
g
co
nt
ro
lo
f
di
se
as
e
w
ith
po
ss
ib
le
do
se
es
ca
la
tio
n)
A
D
A
N
on
-c
om
m
er
ci
al
EL
IS
A
M
az
or
et
al
.,
20
14
10
8
5.
85
0.
68
0.
71
N
R
N
R
0.
75
(0
.6
6
to
0.
84
)
Re
m
is
si
on
ac
co
rd
in
g
to
tw
o
ph
ys
ic
ia
ns
’
as
se
ss
m
en
ts
A
D
A
N
on
-c
om
m
er
ci
al
EL
IS
A
Ro
bl
in
et
al
.,
20
14
11
5
4.
85
0.
81
0.
67
0.
84
0.
57
0.
73
C
lin
ic
al
re
m
is
si
on
(C
D
A
I
sc
or
e
of
<
15
0)
A
D
A
C
om
m
er
ci
al
EL
IS
A
(L
IS
A
-T
RA
C
K
ER
Pr
em
iu
m
)
4.
9
0.
66
0.
85
0.
88
0.
51
0.
77
M
H
(d
is
ap
pe
ar
an
ce
of
al
l
ul
ce
ra
tio
ns
on
en
do
sc
op
y)
W
ar
d
et
al
.,
20
13
;1
32
ab
st
ra
ct
4.
9
0.
83
0.
65
N
R
N
R
0.
75
Re
m
is
si
on
A
D
A
C
om
m
er
ci
al
EL
IS
A
(L
IS
A
-T
RA
C
K
ER
Pr
em
iu
m
)
Y
ar
ur
et
al
.,
20
13
;1
35
ab
st
ra
ct
5
N
R
N
R
N
R
N
R
0.
71
El
ev
at
io
n
of
C
RP
le
ve
ls
A
D
A
H
M
SA
Fr
ed
er
ik
se
n
et
al
.,
20
14
94
14
.5
1.
00
0.
12
0.
41
1.
00
0.
77
(0
.6
2
to
0.
93
)
LO
R
(P
hy
si
ci
an
’s
G
lo
ba
l
A
ss
es
sm
en
t)
A
D
A
RI
A
0.
35
0.
50
0.
96
0.
89
0.
76
6.
85
0.
69
0.
69
0.
58
0.
78
M
az
or
et
al
.,
20
13
;1
07
ab
st
ra
ct
5
N
R
N
R
N
R
N
R
0.
77
(0
.6
7
to
0.
86
)
C
lin
ic
al
re
sp
on
se
an
d
no
rm
al
C
RP
A
D
A
N
R
H
PL
C
,
hi
gh
-p
er
fo
rm
an
ce
liq
ui
d
ch
ro
m
at
og
ra
ph
y;
M
H
,
m
uc
os
al
he
al
in
g;
N
R
no
t
re
po
rt
ed
;
SE
,
st
an
da
rd
er
ro
r;
TL
,
tr
ou
gh
le
ve
l.
DOI: 10.3310/hta20830 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 83
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Freeman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
49
reported thresholds are, as the reported sensitivities and specificities have been optimised to a varying
degree across the studies, and studies use different definitions of response and LOR. An additional variable
that impacts on the threshold of anti-TNF-α drug levels (which is insufficiently depicted in Table 8 because
of poor reporting in the studies) is the time of testing and the time of clinical assessment.
Objective B: description of algorithms prescribing patient management
following test outcomes for drug and/or anti-drug antibody levels
Aim
To provide a narrative description of algorithms used in studies that report clinical outcomes for patients
whose treatment options were directed by a test-informed algorithm; and to compare these with related
algorithms identified in the literature during scoping as relevant to the NHS.66,73
Results
Studies and reviews reporting on test results and clinical status of patients have frequently proposed
test-based treatment algorithms, but most of these have never been tested or implemented in patients
with CD.44,56,57,61,64,137–139 Here we describe the test-based algorithms that have actually been implemented
in studies with patients with CD and briefly compare these with the most similar ‘precursor’ algorithms
identified during scoping as relevant to the NHS. None of the algorithms described in this section was used
in conjunction with one of the index tests.
Algorithms from management studies
No management studies of CD or IBD patients treated with ADA were found. Three IFX studies fulfilled
inclusion criteria for this objective: (1) a RCT in patients with CD with LOR to IFX;123 (2) the TAXIT RCT73 of IBD
patients responding to IFX; and (3) a retrospective observational study of IBD patients responding to IFX.128
Table 9 summarises the algorithm used by Steenholdt et al.123 Tests were done using commercially
available RIAs. Both drug and anti-drug antibody tests are dichotomised so that concurrent testing
classifies each patient into one of the four possible combinations of test results:
1. IFX negative and anti-drug antibody positive
2. IFX negative and anti-drug antibody negative
3. IFX positive and anti-drug antibody negative
4. IFX positive and anti-drug antibody positive.
An important feature is the proposal of different causes for secondary treatment failure in groups 1–3; these
proposals rest on interpretations of the supposed underlying mechanisms leading to the observed test
results. The treatment options are prescriptive for two of the groups (1 and 2), but less so for group 3
(patients with LOR who have therapeutic levels of IFX and lack detectable anti-drug antibodies). Thus, the
treatment received for group 3 requires further investigation and reflection by the treating clinician and may
or may not include relatively expensive biological agents. As most patients fall into this group, these less
prescriptive aspects add to uncertainty about treatment cost of the algorithm-based strategy and whether or
not discretion relating to cost might play a part in decision-making for group 3 (an expensive biological may
or may not be adopted because of perceived cost implications). Furthermore, treatments for this group may
be difficult to replicate between different groups of clinicians who may be subject to different health
pressures in relation to costs and/or to differing licensing regulations for biological therapies. Results for
group 4 (positive test for both IFX and anti-drug antibody) are reviewed with suspicion and require retesting
in case of error.
The TAXIT algorithm for patients responding to IFX is based on the hypothesis that an IFX trough level
between 3 and 7 µg/ml is optimum for successful maintenance of clinical response; it proposes a strategy
of prospective dose adjustment to achieve this target range; this likely requires trough tests before
each infusion.
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Figure 15 summarises the TAXIT study algorithm as described in the recently published paper.73 Patients
are categorised into four groups according to their trough IFX level: (1) undetectable, (2) low, (3) optimum
(3–7 µg/ml) or (4) high (> 7 µg/ml). Group 1 is reflex tested for anti-IFX antibodies and further divided into
two subgroups on the basis of anti-drug antibody test results: (1) in those with high anti-drug antibody
levels, IFX therapy is stopped; (2) in those with anti-drug antibodies at a lower level (< 8 µg/ml), the dose
of IFX is increased. In patients in group 2 (detectable but low trough levels of IFX; < 3 µg/ml) dosing
interval is first reduced and then, if necessary, the dose is increased, in attempt to bring IFX trough
concentrations within the ‘optimum’ range (3–7 µg/ml). In group 3, whose trough IFX levels are already in
the optimum range, dose adjustment is not necessary. In patients in group 4 (high trough levels of IFX)
dose interval is increased, followed, if required, by a dose reduction. In the trial, an ‘optimisation phase’
occurred during which the algorithm was implemented to bring patients into the optimum range, and this
preceded randomisation. Only those patients already successfully optimised were randomised; thus, if the
hypothesis is correct we would potentially expect poor generalisability with higher rates of successful
maintenance in the trial than in a broader spectrum of responders.
Vaughn et al.128 describe trough monitoring of IFX as a guide to dose adjustment in a group of retrospectively
identified IBD patients. Tests were done with a commercial ELISA for the earliest-identified patients, whereas
for those identified later the commercial HMSA method was used. Initially, dose adjustments aimed to bring
trough IFX into the detectable range, but later the target range was changed to 5–10 µg/ml. The authors
quote a typical dose adjustment for those with an undetectable trough IFX level to be an increase in dose to
7 mg/kg with a 6-week interval to the next infusion, followed by a return to 8-week infusion intervals. The
authors state that for trough levels < 5 µg/ml, the dose of IFX was increased by ‘50 or 100 mg’. For patients
with a trough level of IFX > 10 µg/ml on two testing occasions, the dose was decreased or, if the patient was
already receiving 5 mg/kg (in the full paper this is given as ‘5 mg/ml’ and is an assumed typographical error)
the infusion interval was increased. No dose adjustment was made for those in target range. This algorithm
TABLE 9 Summary of the concurrent testing-based algorithm used by Steenholdt et al.123
Cut-off point Detectable anti-IFX antibodies Undetectable anti-IFX antibodies
Subtherapeutic IFX
< 0.5 µg/ml
Group 1 Group 2
Insufficient IFX bioavailability because of the
induced immunogenicity of IFX
Insufficient IFX bioavailability because of
non-immune-mediated pharmacokinetics of IFX
↓ ↓
Change to different TNF-α-inhibitor: ADA
80mg s.c. at inclusion followed by 40mg s.c.
every other week; dose intensification allowed
Intensify IFX treatment: IFX 5 mg/kg intravenously
every 4 weeks
Therapeutic IFX
≥ 0.5 µg/ml
Group 4 Group 3
Consider:
l pharmacodynamics
l non-functional anti-IFX antibodies
l false-positive test
Pharmacodynamics: inhibition of TNF-α is
ineffective because of non-TNF-α-driven disease
↓ ↓
Repeat IFX and anti-IFX antibody analyses and
handle accordingly
If unchanged results, then act as group 3
TNF-α-inhibitors not effective, so are
discontinued. Review of clinical condition at
discretion of the investigator:
l If relapse of CD, use drug(s) with other target
(e.g. conventional immune suppressives,
glucocorticoids, and/or other biological
agents). Consider surgery if appropriate
l If no relapse, treat underlying problem
s.c., subcutaneously.
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would be somewhat difficult to implement without assuming that the authors’ preferred policy is to use
HMSA testing with a target range of 5–10 µg/ml and to manipulate dosage and dose intervals at the
clinicians’ discretion so as to bring the patient into the target range.
Comparison of algorithms that are clinically relevant to the NHS which were
identified during scoping
Scoping for this report identified two algorithms likely to be relevant for the NHS: one for patients with
LOR for use with an unspecified anti-TNF-α (based on Scott and Lichtenstein,66 who specified IFX) and one
for responders to IFX based on the public domain description of the TAXIT trial. The algorithm proposed by
Scott and Lichtenstein66 requires concurrent testing (Figure 16).
This algorithm is similar to that of Steenholdt et al.123 (see Table 9) in categorising patients with LOR into four
groups on the basis of dichotomised drug and anti-drug antibody test results. Drug trough levels are classified
as therapeutic or low rather than therapeutic or subtherapeutic as in Steenholdt et al.123 The suggested
treatments for ‘anti-drug antibody positive | drug trough level low’, ‘anti-drug antibody negative | drug
trough level therapeutic’, and ‘anti-drug antibody negative | drug trough level low’ groups are the same as
those proposed by Steenholdt et al.,123 namely treatment with an alternative anti-TNF-α drug, treatment
with a non-TNF-α drug with a different mechanism of action and escalation of drug exposure, respectively.
For the ‘anti-drug antibody positive | drug trough level therapeutic’ group, Scott and Lichtenstein66 make no
recommendations, but Steenholdt et al.123 recommend redeployment to an appropriate group after repeat
testing. This is a ‘generalised’ algorithm and therefore differs in detail from that of Steenholdt et al.123 in that
cut-off levels for drug trough levels are not specified and therapies are less prescriptive.
Scoping identified the algorithm presented by Scott and Lichtenstein (Figure 17), which is similar to that of
Steenholdt: low drug levels are termed ‘suboptimal’ and undetectable levels of anti-drug antibodies are termed
(TLI < 0.3 µg/ml) (TLI > 7 µg/ml)
Undetectable TLI
(TLI < 0.3 µg/ml)
0.3 µg/ml ≤ TLI
≤ 7 µg/ml
TLI
measurement
(1) Dose decrease
     (by 5 mg/kg)
     to 5 mg/kg
(2) Interval increase
     (by 2 weeks) 
(2) Dose increase
     (by 5 mg/kg) to
     maximum 10 mg/kg
No dose
adaptation
ATI
measurement
(1) Interval decrease
     (by 2 weeks) to
     minimum 4 weeks
High ATI level
(ATI > 8 µg/ml)
Low ATI level
(ATI < 8 µg/ml)
STOP
(1) Interval decrease
     (by 2 weeks) to 
     minimum 4 weeks
(2) Dose increase
     (by 5 mg/kg) to
     maximum 10 mg/kg
FIGURE 15 The TAXIT study algorithm presented in Vande Casteele et al.73 Reprinted from Gastroenterology,
Vol. 148, Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al., Trough
concentrations of IFX guide dosing for patients with inflammatory bowel disease, pp. 1320–9.e3, Copyright 2015
with permission from Elsevier. ATI, antibodies to IFX; TLI, trough level of IFX.
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‘low or undetectable’. In patients with ‘suboptimal drug’ and ‘low or undetectable’ anti-drug antibodies it is
recommended that adherence to treatment should be checked and that an immunosuppressant may be
added. This version of the algorithm suggests that, in the case of the patients with ‘therapeutic drug’ levels and
‘low or undetectable anti-drug antibodies’, the ‘diagnosis’ of CD is confirmed.
Patient with secondary
loss of response
Assess TNF inhibitor
and ADAb levels
Therapeutic drug
levels
Suboptimal drug
levels
Low or undetectable
ADAbs
Low or undetectable
ADAbs
Detectable ADAbs Detectable ADAbs
Confirm diagnosis/
switch to a treatment
with a different
mechanism of action
Switch to another
TNF inhibitor
Check adherence.
Increase dose or
decrease dosing
interval of current
TNF inhibitor. Add
immunomodulator
Requires further
investigation
FIGURE 17 The precursor algorithm for LOR identified in scoping (based on Scott and Lichtenstein 201466).
ADAb, anti-drug antibody.
Therapeutic
drug
levels
Therapeutic
drug
levels
Low
serum
trough
Low
serum
trough
Assess ATI, IFX
trough levels
Patient with clinical
symptoms on IFX
Alternate treatment
with different
mechanism of action
Increase dose or
decrease dose interval
of current anti-TNF
Alternate
anti-TNF
Possible with newer
assays, no clear
recommendations
Detectable
ATIs
Undetectable
ATIs
FIGURE 16 The Scott and Lichtenstein66 algorithm for patients with LOR. ATI, antibodies to IFX. Reproduced from
Current Treatment Options in Gastroenterology, Therapeutic drug monitoring of anti-TNF therapy in inflammatory
bowel disease, vol. 12, 2014, pp. 59–75, Scott FI, Lichtenstein GR66 (© Springer Science + Business Media, LLC 2014),
with permission of Springer.
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The scope precursor version of the TAXIT trial algorithm is almost identical to the public domain version
shown in Figure 18. The differences are (a) no specific trough drug levels are specified; and (b) the addition
of an immunosuppressant is recommended for the group with undetectable trough drug levels and low
anti-drug antibody levels.
Summary
Only three management studies that used a test-informed algorithm to prescribe treatment of patients
were identified.
Vaughn et al.128 recommended trough IFX testing for IBD patients to bring trough IFX into the presumed
therapeutic range (5–10 µg/ml). The algorithm was not adequately prescriptive to allow for easy replication.
The TAXIT trial algorithm for IFX responders hypothesised the therapeutic target range of 3–7 µg/ml based
on analyses using the HMSA method;140 the trial used an in-house ELISA. The algorithm prescribes dose
adjustments for patients with trough IFX levels of < 3 µg/ml and > 7 µg/ml to bring the trough drug level
to within the target range. Patients with trough IFX levels of < 0.3 µg/ml were reflex tested for anti-drug
antibody and dichotomised as above or below 8 µg/ml; the algorithm recommended cessation of IFX for
those with trough IFX levels > 8 µg/ml. The algorithm is sufficiently detailed to be replicable.
The Steenholdt et al.123 algorithm for patients with LOR to IFX employs concurrent testing for IFX and
anti-drug antibody and generates four categories of patient: (1) IFX negative and anti-drug antibody
positive; (2) IFX negative and anti-drug antibody negative; (3) IFX positive and anti-drug antibody negative;
and (4) IFX positive and anti-drug antibody positive. The trial used RIAs, and cut-off points for dichotomising
test results were based on a previous study.120 The algorithm specifies treatments for each category of
patient that are based on hypothesised mechanisms underpinning the LOR. Treatment for patients with a
positive test for drug and a negative test for anti-drug antibodies was not sufficiently prescriptive to be easily
replicated and would probably vary between clinician(s).
The precursor/scoping algorithms represent minor differences of those proposed by Steenholdt et al.123 and
the TAXIT trial73 investigators.
Patients with
response
Undetectable trough
level IFX
Trough level
IFX lower than 
target range
Trough level
IFX in target range
Trough level
IFX higher than 
target range
No dose adaption
Increase interval
(by 2 weeks)
Interval decrease
(by 2 weeks to
minimum 4 weeks)
OR
dose increase
(by 5 mg/kg to
maximum 10 mg/kg)
Anti-drug antibody
measurement
High
ADAb
level
Low
ADAb
level
IFX
discontinued
Dose increase
(by 5 mg/kg to
maximum 10 mg/kg).
Add immunosuppressant
FIGURE 18 The precursor algorithm based on the TAXIT trial algorithm for IFX responders. ADAb, anti-drug antibody.
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In addition to the cut-off levels used in the management studies, many more have been suggested by
various authors and are summarised in Table 8. This table demonstrates that cut-off levels are study
specific and are not readily generalisable.
Objective C1: clinical studies evaluating drug monitoring for the
management of Crohn’s disease patients (management studies)
Aim
The aim of this section is to assess the evidence from studies that report the clinical impact of implementing
a test-informed treatment algorithm for anti-TNF-α recipients with CD.
Results
After screening 2428 studies, we identified three which matched our inclusion criteria for management studies.
All three investigated patients treated with IFX. There were no management studies for patients treated with
ADA and none of the three studies used one of the index tests. The three studies that fulfilled our inclusion
criteria (i.e. Steenholdt et al.,123 Vaughn et al.128 and Vande Casteele et al.73) address several aspects of the
decision questions. Other studies were identified (e.g. Afif et al.,56 Pariente et al.,59 Roblin et al.57 and Paul et al.58)
that investigated the clinical utility of therapeutic drug monitoring of anti-TNF-α to predict response to a change
in treatment mainly because of LOR to anti-TNF-α. On the basis of their results, the studies retrospectively
suggested a test-informed treatment algorithm for IBD patients, but did not prospectively investigate
implementation of a test-informed algorithm strategy for patient outcomes and compare that with a strategy
that might be similar to standard care. For completeness, these studies have been summarised and their
algorithms detailed in Appendix 9. However, as the treatment change in the studies was not prescribed by a
standardised algorithm (retrospective studies) and reflected only one treatment change for all patients regardless
of test outcome (prospective studies), the studies did not satisfy our inclusion criteria and the outcomes reported
were not useful for the health economic evaluation.
Assessment of the risk of bias in the management studies
The risk-of-bias assessment, using the Cochrane risk-of-bias tool,70 for the two included RCTs73,123 is
summarised in Table 10 and Figure 19. Steenholdt et al.123 described a treatment algorithm in patients
with LOR and, more recently, provided updated longer-term data (20 weeks’ follow-up).124 The quality
assessment of the retrospective observational pilot study by Vaughn et al.128 was assessed using the Downs
and Black checklist.71 Further details on the quality assessment of these three studies are provided in
Appendix 10 and Table 10.
TABLE 10 Risk of bias by study: summary of reviewers’ judgements on each risk-of-bias item
Bias item
Study (first author and year of publication)
Steenholdt et al.
2014,123 2015124
Vande Casteele et al.,
201573
Selection bias: random sequence generation ? +
Selection bias: allocation concealment + +
Performance bias: blinding of participants/personnel – ?
Detection bias: blinding of outcome assessors ? ?
Attrition bias: incomplete outcome data + +
Reporting bias: selective reporting of the outcome, subgroups or analysis + +
Other bias: funding source, adequacy of statistical methods, type of
analysis (ITT/PP), baseline imbalance in important characteristics
– +
–, high risk of bias; +, low risk of bias; ?, unclear risk of bias; ITT, intention to treat; PP, per protocol.
DOI: 10.3310/hta20830 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 83
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Freeman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
55
0
20
40
60
80
10
0
O
th
er
 b
ia
s:
 f
u
n
d
in
g
 s
o
u
rc
e,
 a
d
eq
u
ac
y 
o
f 
st
at
is
ti
ca
l m
et
h
o
d
s
u
se
d
, t
yp
e 
o
f 
an
al
ys
is
 (
IT
T/
PP
),
 b
as
el
in
e 
im
b
al
an
ce
 in
im
p
o
rt
an
t 
ch
ar
ac
te
ri
st
ic
s
R
ep
o
rt
in
g
 b
ia
s:
 s
el
ec
ti
ve
 r
ep
o
rt
in
g
 o
f 
th
e 
o
u
tc
o
m
e,
su
b
g
ro
u
p
s 
o
r 
an
al
ys
is
A
tt
ri
ti
o
n
 b
ia
s:
 in
co
m
p
le
te
 o
u
tc
o
m
e 
d
at
a
D
et
ec
ti
o
n
 b
ia
s:
 b
lin
d
in
g
 o
f 
o
u
tc
o
m
e 
as
se
ss
o
rs
Pe
rf
o
rm
an
ce
 b
ia
s:
 b
lin
d
in
g
 o
f 
p
ar
ti
ci
p
an
ts
 a
n
d
 p
er
so
n
n
el
Se
le
ct
io
n
 b
ia
s:
 a
llo
ca
ti
o
n
 c
o
n
ce
al
m
en
t
Se
le
ct
io
n
 b
ia
s:
 r
an
d
o
m
 s
eq
u
en
ce
 g
en
er
at
io
n
Pr
o
p
o
rt
io
n
 o
f 
st
u
d
ie
s 
w
it
h
 lo
w
, h
ig
h
 o
r 
u
n
cl
ea
r 
ri
sk
 o
f 
b
ia
s 
(%
)
Risk-of-bias domain
Lo
w
 r
is
k 
o
f 
b
ia
s
U
n
cl
ea
r 
ri
sk
 o
f 
b
ia
s
H
ig
h
 r
is
k 
o
f 
b
ia
s
FI
G
U
R
E
19
R
is
k-
o
f-
b
ia
s
g
ra
p
h
ac
ro
ss
tw
o
in
cl
u
d
ed
R
C
Ts
:
re
vi
ew
er
s’
ju
d
g
em
en
ts
ab
o
u
t
ea
ch
ri
sk
-o
f-
b
ia
s
it
em
.
IT
T,
in
te
n
ti
o
n
to
tr
ea
t;
PP
,
p
er
p
ro
to
co
l.
CLINICAL EFFECTIVENESS REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
56
Randomised controlled trials
One RCT reported an adequate method for random sequence generation73 and one123,124 was judged at
unclear risk of bias because a block size of 20 for such a small study may not be ideal. Both RCTs had
adequate (low risk of bias) treatment allocation concealment, attrition bias (i.e. outcome data) and reporting
bias (i.e. complete reporting of outcomes, subgroups and analysis). Steenholdt et al.123,124 had a high risk of
performance bias, as patients were blinded to randomisation group and results of serum analyses, but the
physicians were not completely blinded because they were required to use the results of analyses of serum
IFX and IFX antibodies in the treatment of those patients who were randomised to the algorithm group. The
TAXIT study73 was considered at unclear risk of performance bias because there was insufficient information
about blinding to IFX trough and antibodies to IFX concentrations. Both studies had an unclear risk of
detection bias as no further information was provided on the blinding of outcomes assessors. Finally,
although the TAXIT study73 was considered adequate in terms of other potential bias (e.g. funding source,
statistical methods used, analysis and baseline characteristics), there was concern about potential high risk
of bias in Steenholdt et al.,123,124 as 42% of patients were not treated in accordance with the algorithm,
resulting in patients crossing over to the ‘comparator-like’ treatment. Overall, Steenholdt et al.123,124 was
rated at high risk of bias and Vande Casteele et al.73 was rated as unclear risk of bias according to the
Cochrane Handbook for Systematic Reviews of Interventions on summarising risk of bias.141
Non-randomised study
The retrospective observational pilot study by Vaughn et al.128 was of adequate quality. The hypothesis, main
outcome, characteristics of patients, interventions and main findings were all described appropriately. The
remaining reporting items were rated less favourably as (1) there was no list of principal confounders in each
group; (2) it was not possible to determine if those participants selected, invited or agreeing to take part in the
study were representative of a target population; and (3) we were unable to determine if the staff, places and
facilities where the patients were treated were representative of the treatment for the majority of patients
received. The internal validity items were, in general, of adequate quality with no data dredging, adjustments
made for different lengths of follow-up and appropriate statistical analyses, outcome measures and compliance
with the interventions; however, there was no blinding of participants or assessors of the main outcomes. The
internal validity selection bias items were rated less favourably than the other items, with concerns raised about
whether or not the recruited participants in each group might be from the same population and the same time
period, and concerns regarding method of adjustment for confounding and power.
Summary of the management studies
Overview of the included management studies
Two of the management studies included a substantial minority of UC patients along with CD patients.
Steenholdt et al.123 described management with a treatment algorithm in patients with CD with LOR and
compared this with standard dose intensification treatment in a RCT design. Vaughn et al.128 investigated
the impact of proactive drug concentration monitoring of IFX in retrospectively identified cohorts of IBD
patients who were in remission on IFX (responders); proactive drug monitoring was compared with
standard dose intensification treatment for relapse. The TAXIT study73 was a RCT comparing clinical
management with management using dose adjustment based on trough drug levels in IBD patients
previously brought to target trough level of IFX using a dose adjustment algorithm.
During the review process, Steenholdt et al. were contacted and provided further information and
clarification (Casper Steenholdt, Herlev University Hospital, 2015, personal communication). In addition,
the authors drew our attention to an extension study of the original RCT.124
The three studies were heterogeneous with regard to populations, treatment algorithms and methods of
testing for IFX and antibodies to IFX. These difference precluded meaningful pooling of study outcomes.
Table 11 summarises the major features and findings from the three studies, and is accompanied by
detailed descriptions of each of the studies.
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TABLE 11 Summary of the main features of the management studies
Feature
Management study (first author and year of publication)
Steenholdt et al., 2014123 Vande Casteele et al., 201573 Vaughn et al., 2014128
Patient population LOR to IFX Responders to IFX Responders to IFX
Type of IBD CD 68% CD; 31% UC 71.4% CD; 27% UC
Study design RCT RCT Retrospective pilot study
Setting Six Danish centres University hospital Tertiary health-care centre
Follow-up 12 weeks; 20 weeks 1 year ≈4 years
Aim of the study Assess cost-effectiveness of
AL-based treatment vs. dose
intensification (II) treatment
To compare clinical and
biological remission in ClinBD
vs. ConBD at 1 year after
randomisation
Investigate the usefulness of
proactive drug monitoring to
bring TLI target vs. no-proactive
drug monitoring
Comparisons AL vs. II ClinBD vs. ConBD Proactive drug monitoring vs.
no-proactive drug monitoring
Algorithm by drug
and antibody
levels
Yes, both IFX mainly (antibodies for those
with undetectable IFX)
IFX mainly (some reflex testing
of antibodies)
Test used RIA Leuven in-house ELISA ELISA and HMSA
Time of analysis At IFX treatment failure Before each infusion time Unclear
Drug and
antibodies: cut-off
point/target
RIA: drug ≥ 0.5 µg/l; antibodies
detectability
Target IFX: 0.3–0.7 µg/ml;
antibodies to IFX (if IFX
negative): > 8 µg/ml
Target IFX range: initially
detectable, later 5–10 µg/ml
Limit of
quantification
RIA: IFX 0.15 µg/ml;
antibodies: 10 arbitrary
units/ml
IFX 0.3 µg/ml; antibodies to IFX
1.0 µg/ml
Variable during study
Definition of
clinical response
≥ 70-point CDAI score
reduction from baseline
(luminal disease); ≥ 50%
reduction in active fistulas of
from baseline (fistulising
disease)
Symptom free or clear clinical
improvement and decrease of
disease activity but with clinical
symptoms
Unclear/physicians’ judgement
Definition of
clinical remission
CDAI score of ≤ 150 and
complete closure of all fistulas
despite gentle pressure
HBI score ≤ 4 for CD and
partial Mayo score of ≤ 2, with
no individual subscore > 1 for
UC. Biological remission = CRP
≤ 5mg/l
Lack of symptoms attributable
to underlying IBD (by treating
physicians’ documentation)
Definition of
clinical progression
Withdrawal for lack of effect
of treatment
Not given Not given
Definition of
relapse
N/A Need of IFX dose escalation or
addition of steroids, or switch
to another anti-TNF-α (on
physician’s assessment)
Not given
Major findings
Clinical response
by subgroup
II/AL at 12 weeks N/A N/A
Group 1a (n = 14;
AL n = 5, II n= 9)
ITT: 4 (44%)/2 (40%); PP: 4
(44%)/2 (40%)
N/A N/A
Group 2a (n = 3;
AL n = 1, II n= 2)
ITT: 1 (50%)/0 (0%); PP: 1
(50%)/0 (0%)
N/A N/A
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Steenholdt et al.123
Study design This was a single-blind RCT of 69 adults with CD who were previously responsive to
maintenance therapy with ‘regular’ infusions of IFX (at 5 mg/kg) (i.e. patients on maintenance IFX with
LOR). Participants were randomised to either an IFX-intensified arm (n = 36) or an algorithm arm (n = 33).
In the former, the dose frequency of 5 mg/kg IFX was increased every 4 weeks. In the latter, participants
received treatment in accordance with a defined algorithm based on serum concentrations of IFX and of
antibodies to IFX. It is unclear if the randomisation method was the most appropriate because a block size
of 20 for a small study with 69 patients may potentially threaten efficiency of allocation concealment.
Follow-up was 12 weeks. The study objective was to compare the cost of treatment and the level of
disease control of dose intensification (standard) treatment (intensification in IFX exposure) with that using
an algorithm-directed treatment strategy informed by concurrent test results. The trial was powered for
non-inferiority in disease control and was undertaken in six Danish centres.
Timing and frequency of testing Serum samples were collected at the time when IFX failure was
reported and were analysed by RIA (samples were stored for retrospective analysis by alternative assays
methods including ELISA and HMSA). The RIA cut-off points used were therapeutic IFX ≥ 0.5 µg/l and
subtherapeutic IFX < 0.5 µg/l, and the cut-off point for anti-drug antibody was the limit of quantification
(10 arbitrary units/ml). These samples were taken immediately before IFX infusion. No further tests were
undertaken during the 12 weeks’ follow-up.
Treatment algorithm According to the treatment algorithm, a patient could be categorised into one of
the four groups to receive a defined treatment, as shown in Table 9.
TABLE 11 Summary of the main features of the management studies (continued )
Feature
Management study (first author and year of publication)
Steenholdt et al., 2014123 Vande Casteele et al., 201573 Vaughn et al., 2014128
Group 3a (n = 48;
AL n = 26, II
n= 22)
ITT: 12 (55%)/16 (62%); PP:
12 (55%)/7 (54%)
N/A N/A
Group 4a (n = 4;
AL n = 1, II n = 3)
ITT: 2 (67%)/0 (0%); PP: 2
(67%)/0 (0%)
N/A N/A
Clinical response
20 weeks (all)
ITT: 56%/76%; PP: 56%/74% N/A N/A
Clinical remission II/AL at 20 weeks: ITT, 39%/
55%; PP, 39%/58%
Clinical + biological (1 year):
ConBD, 68.8%; ClinBD,
65.9%; p= 0.880
CD only: ConBD, 63%; ClinBD,
55%; p = 0.353
Not given
Probability of
remaining on IFX
N/A Not reported Proactive drug monitoring vs.
no-proactive drug monitoring:
hazard ratio of 0.3 (95% CI 0.1
to 0.6; p = 0.0006). At 5 years
in treatment: proactive drug
monitoring 86% vs. 52%
no-proactive drug monitoring
AL, algorithm; ClinBD, clinically based dosing; ConBD, concentration-based dosing; II, IFX intensification; ITT, intention to
treat; N/A, not applicable; PP, per protocol; TLI, trough level of IFX.
a Group identities of patients with lost response to IFX were based on concurrent test results as follows: group 1,
IFX negative, anti-drug antibodies positive; group 2, IFX negative, anti-drug antibodies negative; group 3, IFX positive,
anti-drug antibodies negative; and group 4, IFX positive, anti-drug antibodies positive.
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The authors suggests the following underlying mechanisms for LOR:
l group 1 – insufficient bioavailability of IFX because of immunogenicity of IFX
l group 2 – insufficient bioavailability of IFX because of non-immune-mediated pharmacokinetics
l group 3 – inhibition of TNF-α ineffective because of non-TNF-α-driven disease
l group 4 – patients are classified with group 3 if test results are replicated.
Patient characteristics and concurrent treatments Participants could receive concomitant therapy with
thiopurines, methotrexate or antibiotics, or stable doses of topical agents, loperamide, oral hydrocortisone or
budesonide. Participants were followed up every 4 weeks. Mean age was 37 years (range 19–81 years) and
the majority were female (61%). The mean duration of disease was slightly greater in the IFX-intensified arm
than in the algorithm arm [10 years (range 1–35 years) vs. 7 years (range 1–27 years)]. Around one-quarter
(26%) of the participants gave a history of smoking and 30% had undergone previous surgery, whereas
around 20% of patients had received anti-TNF-α therapy previously. Mean treatment duration at anti-TNF-α
failure was 657 days (range 97–3313 days). Mean CRP level was 9 mg/ml (range 2–22mg/ml).
Primary and other outcomes The dual primary outcome consisted of mean cost of treatment over
12 weeks and the proportion of patients with ‘clinical response’ at 12 weeks. Clinical response was
defined as ‘> 70 point reduction in CDAI score from baseline in luminal disease and a reduction in active
fistulas of > 50% from baseline in fistulising disease’.123 The study objective of estimating ‘disease control’
in each arm was undertaken using the proportion of patients with the primary outcome of clinical
response. Other secondary outcomes included (1) the proportion with remission, defined as an absolute
CDAI score of < 150 and complete closure of all fistulas despite gentle pressure [at baseline the mean
CDAI score was 296 (range 221–526) and 301 (range 230–487) in algorithm and control arms,
respectively; three and four patients in each arm had fistulising disease]; and (2) the proportion with a
CDAI score of 100 response (a reduction of CDAI score from baseline of ≥ 100). Mean decrease in CDAI
and PDAI scores and mean increase in IBDQ scores were also reported, together with changes in
laboratory measures (white blood cell count, haemoglobin level and albumin level).
Intention-to-treat and per-protocol populations and handling of withdrawals Outcome analyses
were reported for intention-to-treat (ITT) and for per-protocol (PP) populations. All 36 patients in the dose
intensification arm received allocated treatment; there were eight withdrawals for lack of effect or severe
infusion reaction.
In the intervention arm, patients in group 1 received ADA therapy during the study in accordance with
local guidelines at the participating centres. Some used ADA in the dosing registered by European
Medicines Agency (80 mg at week 0 followed by 40 mg every other week), whereas others used a more
intensive regimen (160 mg at week 0, 80 mg at week 2, 40 mg at week 4 and then 40 mg every other
week). Dose optimisation of ADA was allowed (Dr C Steenholdt, Herlev University Hospital, Denmark,
25 January 2015, personal communication).
In the algorithm arm, 14 out of 33 patients did not receive treatment allocated in accordance with the
local algorithm, leaving a PP population of 19. Most of these 14 non-PP patients continued to receive IFX.
Of these, IFX was continued in 12 patients (nine patients in group 3 and one in group 4). The IFX regimen
administered was as follows (with all patients receiving 5 mg/kg): IFX q8 regimen (two infusions during the
trial, i.e. weeks 0 and 8), n = 5; IFX q4 regimen (four infusions during the trial, i.e. weeks 0, 4, 8 and 12),
n = 2; IFX q4 regimen but not throughout the entire trial (three infusions during the trial), n = 1; IFX q4
regimen but not throughout the entire trial (two infusions during the trial), n = 2; and IFX q4 regimen but
not throughout the entire trial (one infusion during the trial), n = 2.
The remaining two patients were switched to ADA because of misinterpretation of test results. Both
patients were in group 3. The applied ADA regimen was ADA induction (160 mg–80 mg–40 mg) followed
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by 40 mg every other week for one patient and ADA induction (80 mg–40 mg) followed by 40 mg every
other week for the other patient (Dr Casper Steenholdt, Herlev University Hospital, Denmark,
25 January 2015, personal communication).
There were two withdrawals in the algorithm arm and eight in the dose-intensified arms. Patients who
dropped out were also included in the statistical analyses at subsequent study visits using the last
observations carried forward for efficacy (response and remission), CDAI, PDAI, biochemical variables and
safety, and by using the actual direct medical costs related to CD. There remains some ambiguity because
it is unclear if the eight patients who withdrew from dose intensification contributed to medical costs
carried forward (but for treatment which they did not receive) or if post-withdrawal drug costs were zero.
Test results according to intention-to-treat and per-protocol populations In the algorithm arm,
concurrent testing categorised the 33 patients to the four groups as follows: 26 to group 3, five to group 1
and one to each of groups 2 and 4. Similar results (not known to the treating physicians) were found for the
dose-intensified arm. The test results are summarised in Table 12.
The 14 patients not treated PP in the algorithm arm were in group 3 (13 patients) or group 4 (one patient).
This left the distribution of groups in the PP population as shown in Table 13.
These test results imply that LOR is most commonly associated with therapeutic drug levels in the absence
of detectable anti-drug antibodies (group 3 represents 70% of 69 patients). The authors’ mechanistic
interpretation is that ‘inhibition of TNF-α is ineffective due to non-TNF-α-driven disease. TNFα inhibitors not
TABLE 12 Proportion of patients according to concurrent testing (ITT population)
Grouping in algorithm
Arm
All (N= 69),
n (%)
Algorithm (N= 33),
n (%)
IFX intensified (N= 36),
n (%)
Group 1: subtherapeutic IFX and anti-drug antibody
positive
5 (15) 9 (25) 14 (20)
Group 2: subtherapeutic IFX and anti-drug antibody
undetectable
1 (3) 2 (6) 3 (4)
Group 3: therapeutic IFX and anti-drug antibody
undetectable
26 (79) 22 (61) 48 (70)
Group 4: therapeutic IFX and anti-drug antibody
positive
1 (3) 3 (8) 4 (6)
TABLE 13 Proportion of patients in each algorithm group (PP population)
Grouping in algorithm
Arm
All (N= 55),
n (%)
Algorithm (N= 19),
n (%)
IFX intensified (N= 36),
n (%)
Group 1: subtherapeutic IFX and anti-drug antibody
positive
5 (26) 9 (25) 14 (26)
Group 2: subtherapeutic IFX and anti-drug antibody
undetectable
1 (5) 2 (6) 3 (5)
Group 3: therapeutic IFX and anti-drug antibody
undetectable
13 (68) 22 (61) 35 (64)
Group 4: therapeutic IFX and anti-drug antibody
positive
0 (0) 3 (8) 3 (5)
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effective and is discontinued’.123 The algorithm treatment for this group is subject to discretion and
requires further investigation and reflection by clinicians.
Primary outcome results For the ITT population, the rate of clinical response was similar in the algorithm
arm (18/33; 58%) and the dose intensification arm (19/36; 53%) (RR 1.09, 95% CI 0.713 to 1.673;
p = 0.810). For the PP population the rates were again similar in the dose intensification arm (19/36; 53%)
and in the algorithm arm (9/19; 47%) (RR 0.898, 95% CI 0.510 to 1.580; p = 0.781).
Table 14 summarises the rates of clinical response in ITT and PP populations according to test-defined
subgroups. Group 3 (i.e. therapeutic IFX levels with undetectable anti-IFX antibodies) contributed the
majority of the patients (ITT, 66.7%; PP, 63.6%) and also most of the clinical responses (ITT, 75.6%;
PP, 67.9%), and thereby greatly influences the overall comparison between arms.
More than half (55%) of group 3 patients in the dose intensification arm had regained response at
12 weeks. This appears surprising if symptoms are driven by a non-TNF-α mechanism; however,
explanations other than intensified IFX may explain regain of response, including changes in or improved
effectiveness of concomitant therapies and the natural relapse–remission cycling characteristic of CD in
these relatively small patient groups.
A quite high response at 12 weeks was found for group 3 algorithm patients (16/26; 62%); of these
26 group 3 patients, around half received IFX; again, various IFX-independent explanations for regain of
response include changes in or improved effectiveness of concomitant therapies, or introduction of
alternative therapies and the natural relapse–remission cycling characteristic of CD.
For the ITT population, the coprimary outcome measure of mean cost was lower in the algorithm arm
(€6038, SD €4146) than in the dose intensification arm (€9178, SD €2058) (mean difference –€3141,
TABLE 14 Clinical response according to test-defined subgroups
Subgroup Population
Arm, n/N (%)
Algorithm vs. IFX-intensified
arm, RR (95% CI); p-valueIFX intensified Algorithm
Group 1: subtherapeutic IFX and
anti-drug antibody positive
ITT 4/9 (44) 2/5 (40) 0.900 (0.246 to 3.297); 1.00
Insufficient IFX bioavailability because of
the induced immunogenicity of IFX
PP 4/9 (44) 2/5 (40) 0.900 (0.246 to 3.297); 1.00
Group 2: subtherapeutic IFX and
anti-drug antibody undetectable
ITT 1/2 (50) 0/1 (0) NC
Insufficient IFX bioavailability because of
non-immune-mediated pharmacokinetics
PP 1/2 (50) 0/1 (0) NC
Group 3: therapeutic IFX and
anti-drug antibody undetectable
ITT 12/22 (55) 16/26 (62) 1.128 (0.693 to 1.837); 0.770
Inhibition of TNF-α ineffective because
of non-TNF-α-driven disease
PP 12/22 (55) 7/13 (54) 0.987 (0.525 to 1.856); 1.00
Group 4: therapeutic IFX and
anti-drug antibody positive
ITT 2/3 (67) 0/1 (0) NC
Pharmacodynamics or non-functional
anti-IFX antibodies or false-positive test
PP 2/3 (67) 0/0 (0) NC
All four subgroups ITT 19/36 (53) 18/33 (58) 1.09 (0.713 to 1.673); 0.810
PP 19/36 (53) 9/19 (47) 0.898 (0.510 to 1.580); 0.781
NC, not calculated.
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95% CI –€4617 to –€1373; p < 0.001). For the PP population, mean costs were €4062 (SD €2763) in the
algorithm arm compared with €9178 (SD €2058) in the dose intensification arm (mean difference –€5116,
95% CI –€6482 to –€3561; p < 0.001). Table 15 summarises the mean cost in ITT and PP populations
according to test-defined subgroups.
As for response, the coprimary outcome of mean cost was predominantly contributed by group 3 patients.
The total cost of 12 weeks of treatment for the 36 dose-intensified patients was €330,408, of which group
3 patients contributed 65.9% (€217,756). The corresponding total cost for 33 algorithm patients was
€199,252, of which 74.7% (€148,928) was contributed by group 3 patients. The total 12-week cost for
19 PP algorithm group 3 patients was €48,488, so that the non-PP algorithm group 3 patients (n = 13) cost
€100,440, at a mean cost per patient of €7726.
Remission According to ITT and PP analysis, clinical remission was achieved by more patients in the
IFX-intensified arm than in the algorithm arm [ITT: 14/36 (39%) vs. 10/33 (30%); PP: 14/36 (39%) vs. 4/19
(21%)]; the difference did not reach statistical significance [ITT: RR 0.779, 95% CI 0.403 to 1.507;
p = 0.613; PP: RR 0.541, 95% CI 0.207 to 1.417; p = 0.234 (RR is for algorithm vs. dose intensification)].
Extension study Clinical outcome findings to 20 weeks and mean cost to 52 weeks have been
published.124 Of 69 patients included in the trial, 45 (17 in the algorithm arm; 28 in the IFX-intensified arm)
completed 12 weeks of PP treatment and 29 patients (16 in the algorithm arm; 13 in the IFX-intensified
arm) completed 20 weeks of PP treatment. Results at 20 weeks were reported for the following
populations: ITT (n = 69); PP at 12 weeks (n = 55); completed PP at 12 weeks (n = 45; i.e. 55 minus
10 withdrawals); and completed PP at 20 weeks (n = 29). Table 16 summarises the results.
TABLE 15 Mean cost according to test-defined subgroups
Subgroup Population
Arm (€), mean (SD) Algorithm vs. IFX
intensification (€), mean
difference (95% CI); p-valueIFX intensified Algorithm
Group 1: subtherapeutic IFX and
anti-drug antibody positive
ITT 8299 (1796) 6837 (990) –1462 (–2819 to 712); 0.090
Insufficient IFX bioavailability because of
the induced immunogenicity of IFX
PP 8299 (1796) 6837 (990) –1462 (–2819 to 712); 0.090
Group 2: subtherapeutic IFX and
anti-drug antibody undetectable
ITT 8666 (1111) 9814 (N/A) 1148 (N/A); N/A
Insufficient IFX bioavailability because of
non-immune-mediated pharmacokinetics
PP 8666 (1111) 9814 (N/A) 1148 (N/A); N/A
Group 3: therapeutic IFX and
anti-drug antibody undetectable
ITT 9898 (1901) 5728 (4606) –4169 (–5968 to –1788); 0.001
Inhibition of TNF-α ineffective because
of non-TNF-α-driven disease
PP 9898 (1901) 2552 (1639) –7349 (–8557 to –6032); < 0.001
Group 4: therapeutic IFX and
anti-drug antibody positive
ITT 6883 (2309) 6003 (N/A) –880 (N/A); N/A
Pharmacodynamics or non-functional
anti-IFX antibodies or false-positive test
PP 6883 (2309) N/A (N/A) N/A; N/A
All four subgroups ITT 9178 (2058) 6038 (4146) –3141 (–4617 to –1373); < 0.001
PP 9178 (2058) 4062 (2763) –5116 (–6482 to –3561); < 0.001
N/A, not applicable.
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None of the differences between dose-intensified and algorithm groups reached statistical significance.
According to ITT analyses in this and the original study, of the 33 patients in the algorithm arm, 18 patients
showed response at 12 weeks, and this number increased to 25 by week 20. Of the 36 patients in the
dose-intensified arm, 19 patients showed response at week 12, increasing to 20 at week 20. Among
dose-intensified patients, 14 out of 36 were in remission at both 12 and 20 weeks, whereas in the
algorithm arm the proportion increased from 10 out of 33 at week 12 to 18 out of 33 by week 20. These
results imply quite large clinical improvement between weeks 12 and 20 in the algorithm arm and relatively
stable clinical status in the dose-intensified arm.
In this extension study, cost results were reported in 2012 US dollars (US$) rather than euros, as in the earlier
report. This made it problematic to compare cost over the first 12 weeks with those subsequently accumulated
to week 20 or 52. According to ITT analysis, mean costs related to CD at 20 weeks were US$11,940 and
US$17,236 in the algorithm and dose-intensified arms, respectively (mean difference –US$5296, 95% CI –
US$8453 to – US$1566; p= 0.005). At 52 weeks (ITT analysis), the corresponding values were US$22,066
and US$29,072 (mean difference – US$7006, 95% CI – US$12,848 to – US$874; p = 0.022).
Summary and conclusions One published study described the implementation of an algorithm in
patients with CD with LOR. The authors concluded that the treatment of LOR to IFX using an algorithm
based on concurrent IFX plus anti-drug antibody measurements significantly reduces average treatment
costs per patient compared with routine IFX dose escalation and without any apparent negative effect on
clinical control of disease. These conclusions are supported by the available data. However, a number of
weaknesses in the study should be borne in mind: the population was small; withdrawals accounted for
> 20% of patients in the IFX-intensified arm; follow-up was short; and a large proportion of patients in the
algorithm arm did not receive the algorithm-recommended treatment (42%), raising the question of
whether or not the efficacy of the algorithm has, in fact, been tested.
In addition, little information was provided on the components contributing to the coprimary outcome of
mean cost. Test costs were not reported and it was unclear if or how these were incorporated into the
cost analysis; nearly all patients fell into a single algorithm group, which, unfortunately, was the one in
which treatments were least well described and largely depended on clinicians’ judgement and reflection,
which is unlikely to be replicable between clinicians (note that further details of treatments were provided
in the extension study124).
TABLE 16 Clinical response and remission at 20 weeks (Steenholdt et al. 2015124)
Population
Arm, n/N (%)
Algorithm vs. IFX-intensified
arm, RR (95% CI); p-valueIFX intensified Algorithm arm
Response
ITT (n= 69) 20/36 (56) 25/33 (76) 1.4 (1.0 to 1.9); 0.128
PP (n= 55) 20/36 (56) 14/19 (74) 1.3 (0.9 to 2.0); 0.248
Completed PP to 12 weeks (n= 45) 15/28 (54) 12/17 (71) 1.3 (0.08 to 2.1); 0.351
Completed PP to 20 weeks (n= 29) 10/13 (77) 11/16 (69) 0.9 (0.6 to 1.4); 0.697
Remission
ITT (n= 69) 14/36 (39) 18/33 (55) 1.4 (0.8 to 2.4); 0.232
PP (n= 55) 14/36 (39) 11/19 (58) 1.5 (0.9 to 2.6); 0.256
Completed PP to 12 weeks (n= 45) 10/28 (36) 10/17 (59) 1.7 (0.9 to 3.1); 0.216
Completed PP to 20 weeks (n= 29) 7/13 (54) 9/16 (54) 1.1 (0.5 to 2.0); 1.000
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Vande Casteele et al.: Trough level Adapted infliXImab Treatment study73
Study design This RCT73 included 251 patients with IBD (173 with CD; 78 with UC) with stable response to
IFX therapy who were randomised (1 : 1) to two different treatment strategies: (1) clinically based dosing
(n= 123); or (2) IFX trough concentration-based dosing (n= 128) that targeted an IFX trough level of 3–7 µg/ml.
Prior to randomisation, a consecutive cohort of 275 IBD patients (186 with CD; 89 with UC) were screened and
subjected to an optimisation phase using an algorithm for dose adjustment to identify patients whose trough
IFX levels could be successfully brought to the target range. All randomised patients entered with trough IFX
levels within the target range. For patients randomised to the clinically based dosing arm, subsequent IFX dosing
was in accordance with clinical symptoms and CRP levels (recorded at each infusion) and followed standard
clinical criteria. For those randomised to the trough concentration-based dosing arm, IFX dosing continued in
accordance with the algorithm. Patients were followed for 52 weeks post randomisation.
Of the 275 consecutive patients, 12 were excluded because of loss to follow-up, or ineligibility, or because
their trough IFX levels were undetectable and antibodies to IFX were detected at > 8 µg/ml (n = 6).
The remaining 263 proceeded to optimisation. For 12 patients, the optimisation algorithm failed to bring
trough IFX levels into the target range; the remaining 251 were randomised to continued dosing based on
trough IFX levels or to the clinically based dosing strategy.
Specified primary and secondary outcomes The primary outcome was the rate of clinical plus biological
remission 1 year after randomisation (clinical remission required a HBI score of ≤ 4 for CD and partial Mayo
score of ≤ 2 for UC; biological remission required a CRP concentration of ≤ 5 mg/l). Early terminations
were considered failures for the primary end point [criteria for termination included safety and failure of
IFX therapy defined as persisting clinical symptoms (HBI score of > 4 or partial Mayo score of > 2) on
two consecutive visits (including unscheduled visits) and active inflammation based on increased CRP
concentration OR endoscopic activity].
Secondary outcomes included durable remission, relapse, trough IFX levels in target range, anti-drug
antibody positivity, European Quality of Life-5 Dimensions (EQ-5D) QoL score and total cost of treatment.
In the recently accepted paper, an objective was also to compare cost-effectiveness and safety of trough
level-based dosing to clinically based dosing of IFX.73
Optimisation phase During optimisation patients were first categorised into one of four categories on
the basis of trough IFX levels: (1) trough IFX levels > 7 µg/ml; (2) trough IFX levels in the target range
(3–7 µg/ml); (3) trough IFX levels < 3 µg/ml; or (4) trough IFX levels undetectable and anti-drug antibodies
< 8 µg/ml (patients with undetectable trough IFX levels but anti-drug antibodies > 8 µg/ml were excluded
at screening). In each category, dose was adjusted in accordance with the algorithm shown in Figure 15.
Of 72 patients with trough IFX levels < 3 µg/ml (categories 3 and 4), dose escalation brought 69 to a target
trough level of IFX. In total, 115 category 2 patients were in range and were randomised, and in 67 out of
72 category 1 patients dose was de-escalated to achieve the target range. A total of 251 patients were
randomised: 128 to trough IFX level-monitored dosing and 123 to clinically based dosing.
Infliximab and antibody measurement The trough IFX and anti-drug antibody levels were measured
using an in-house developed ELISA (Leuven in-house ELISA). The trough IFX level was measured using
direct ELISA and anti-drug antibody levels using bridging ELISA. The lowest quantification value for IFX and
anti-drug antibody limit for the test was 0.3 and 1.0 µg/ml, respectively.
Patient characteristics The authors reported baseline characteristics and results according to two phases:
optimisation phase and maintenance phase (i.e. post randomisation).
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Optimisation phase (n = 263): the mean age of patients was 41.0 years (range 30–48.5 years) and, 77.2%
of patients were in remission, mean CRP level was 1.7 mg/l and the mean IFX trough level was 4.6 µg/ml
(2.5–7.7 µg/ml). Around 5% of patients were receiving immunosuppressant.
Maintenance phase (n = 251): about 55% of patients were female; most patients (69%) were diagnosed
with CD, approximately 30% had previously undergone surgery, median duration of disease was
12.5 years (range 6.3–19.9 years), median duration of disease at first IFX exposure was 5.8 years (range
1.7–13.5 years), median time since first IFX was 4.6 years (range 2.1–7.5 years), 82.5% of patients were in
remission (CD, 79.8%; UC, 88.5%) and mean CRP and mean IFX trough concentration were 1.4 mg/l
(range 0.6–4.2 mg/l) and 4.9 µg/ml (range 3.9–8.5 µg/ml), respectively.
Results: optimisation phase The results for patients with CD are summarised in Table 17.
Of 178 patients with CD entering optimisation, 131 were in clinical remission (HBI ≤ 4). After optimisation,
138 out of 173 were in remission (ITT: RR 1.053, 95% CI 0.936 to 1.186).
Of 44 patients with CD in the dose escalation group entering optimisation, 43 achieved target trough IFX
levels. Of these, 28 were in clinical remission at entry, rising to 38 in clinical remission after optimisation
[reported PP, odds ratio (OR) 4.1, 95% CI 1.3 to 12.5; RR 1.297, 95% CI 1.008 to 1.669; p = 0.020].
These patients also showed a significant decrease in mean CRP concentration at the end of optimisation
(from 4.3 mg/l to 3.2 mg/l; p < 0.001). The corresponding results for UC patients did not reach statistical
significance (p = 1.0 and p = 0.16, respectively). Among patients with CD who underwent dose reduction
during optimisation (PP, n = 51), the proportion in remission decreased from 80.4% to 69.4% (PP: RR 0.854,
95% CI 0.678 to 1.074).
No statistically significant changes in clinical remission or in mean CRP concentration by the end of
optimisation were observed for CD or UC patients who achieved target trough IFX levels (p = 0.3 and
p = 1.0, respectively, for clinical remission and p = 0.56 and p = 0.86, respectively, for CRP levels).
In the dose escalation group, an average of 2.1 optimisations were required to reach target trough IFX
levels, and at the end of optimisation the median infusion interval was 6 weeks (range 4–8 weeks).
In the dose reduction group, a mean of 1.4 optimisations was required and the median infusion interval
was 8 weeks (range 6–12 weeks).
Results: maintenance phase 52 week primary outcome Almost 90% of patients completed the
maintenance phase. The reasons for not completing were, in the clinically based and concentration-based
dosing arms respectively, discontinuation because of active disease (4 and 4), serious adverse event (1 and 1),
TABLE 17 Remission rates for patients with CD; comparison of after optimisation vs. before optimisation
Patient group
Clinical remission, n/N (%)
Statistic (after vs. before) (95% CI)After optimisation Before optimisation
All patients with CDa 138/173 (79.8) 131/178 (73.6) RR 1.053 (0.936 to 1.186)
Patients with CD dose escalatedb 38/43 (88.4) 28/43 (65.1) OR 4.071 (1.324 to 12.524); RR 1.297
(1.008 to 1.669)
Patients with CD dose reducedb 35/51 (69.4) 41/51 (80.4) OR 0.534 (0.215 to 1.325); RR 0.854
(0.678 to 1.074)
OR, odds ratio.
a ITT analysis.
b PP analysis, numbers of patients estimated from reported percentages.
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lost to follow-up (2 and 1), pregnancy (3 and 1), inability to maintain the target trough level (0 and 1) and
other reasons (2 and 1).
Similar primary outcome rates were observed in both randomised arms [88/128 (68.8%) in the
concentration-based dosing arm and 81/123 (66%) in the clinically based dosing arm (p = 0.686)].
Corresponding results for CD and UC patients separately were 63% versus 55% (p = 0.353) and 88%
versus 84% (p = 0.748), respectively.
The results did not change when analysis was restricted to those in remission at the start of maintenance.
Results: maintenance phase secondary outcomes There was little difference between groups in the
probability of maintaining durable remission (26% and 27% in the concentration-based dosing arm and
the clinically based dosing arm, respectively; p = 0.88).
A higher proportion of patients in the concentration-based dosing arm than in the clinically based dosing
arm (74% vs. 57%) had IFX trough concentrations between 3 and 7 µg/ml (p < 0.001), whereas the risk of
patients in the clinically based arm having undetectable trough levels of IFX was significantly greater (RR 3.7,
95% CI 1.7 to 8.0; p < 0.001). None of the patients in the concentration-based dosing arm was positive for
anti-drug antibodies, but three patients in the clinically based arm were (p = 0.116).
No deaths occurred in any group, but two patients in the clinically based dosing arm required hospital
admission: one because of acute appendicitis and another because of ileostomy complications. There were
12 discontinuations in the clinically based dosing arm and 13 in the concentration-based dosing arm.
More patients in the clinically based arm (n = 21, 17%) than in the concentration-based dosing group
(n = 9, 7%) relapsed and needed rescue therapy (RR 2.4, 95% CI 1.2 to 5.1; p = 0.018). Relapse was
defined as ‘the need for IFX dose escalation (interval decrease and/or dose increase), the addition of
steroids or switch to another anti-TNFα and was based on the physician’s global assessment’.73 Among
those relapsing and requiring rescue therapy, relatively more (9/21, 43%) in the clinically based arm than
in the concentration-based arm (2/9, 22%) had trough IFX levels of < 3 µg/ml.
Relapse free-survival time was longer in the concentration-based dosing arm than in the clinically based
dosing arm (Figure 20).
Authors’ conclusions The authors concluded that optimisation of IFX dose to achieve the target trough
levels of 3–7 µg/ml is more efficient and is cost-effective relative to clinically based adjustment. Therefore,
the authors recommended using dose-to-target optimisation of IFX to achieve the target trough IFX levels
and to re-evaluate the level after 6 months. It should be borne in mind that both arms received target dose
optimisation prior to randomisation and, therefore, even the comparator group, which received a clinically
guided dosing regimen, had already received a phase of trough level monitoring and dose adjustment.
Vaughn et al.128
Study design and conduct The aim was to investigate the usefulness of proactive therapeutic
concentration monitoring and titration of IFX to a target concentration.128 This was a retrospective
observational pilot study of patients with IBD in clinical remission receiving IFX at tertiary health-care
centres; patients were identified from records and classified into those who received proactive drug
monitoring and those who did not (control group); patients who did not achieve remission were excluded.
For both proactive drug monitoring and control groups, clinical remission was defined as ‘lack of
symptoms attributable to underlying IBD based on the treating gastroenterologist’s documentation’.128
The IFX and antibodies to IFX concentrations were measured initially using solid-phase ELISA (PROMETHEUS
Laboratories) and later with the HMSA (PROMETHEUS laboratories). The latter test could detect IFX
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concentrations as low as 1 µg/ml, compared with 1.4 µg/ml for ELISA. In the proactive drug monitoring
group, serum trough IFX levels were used to guide dose modifications to achieve target drug levels. Initially
the target was detectable IFX; later the target was changed to an IFX concentration between 5 and 10 µg/ml.
Typical changes in dose administration in the proactive drug monitoring group were as follows:
l For patients with undetectable trough drug levels, the dose of IFX infusion was increased to 7.5 mg/kg.
The next infusion was given after 6 weeks, and after which IFX was given every 8 weeks.
l For patients with detectable trough drug levels < 5 µg/ml, the dose of IFX was increased by 50 or 100 mg.
l In patients with trough drug levels of > 10 µg/ml on at least two occasions, the dose was reduced.
However, in those patients who were already receiving 5 mg/kg IFX, instead of dose modification, the
treatment interval was increased.
l In patients who had trough levels in the range 5–10 µg/ml, no changes were made.
(Trough concentration was defined as ‘IFX concentration measured at any time up to 7 days before the
next infusion’.128)
Reactive testing was done in both groups whenever there was LOR or if there was a concern that the
patient was experiencing side effects as a result of antibody formation. For patients in the control group
with LOR, the dose of IFX was increased at the treating physician’s discretion in accordance with a
standard of care guideline (typically to 10 mg/kg, but the dose did not reach > 10 mg/kg every 4 weeks).
Patient populations There were 48 IBD patients in the proactive drug monitoring group and 78 in the
control group. They were followed from the start of maintenance therapy until August 2013 or until their
last documented clinical encounter. Proactive drug monitoring was initiated at some time during patients’
maintenance and was adopted as a strategy ‘starting in 2009’. The determining difference between
groups was that testing was performed only reactively in the control group, but both reactively and
proactively in the proactive drug monitoring group to determine any dose changes judged necessary to
reach target trough concentration; furthermore, when the dose was escalated in the control group, IFX
exposure was probably doubled (e.g. to 10 mg/kg), but dose escalations in the proactive drug monitoring
group were of much smaller magnitude (e.g. by 50–100 mg; for a 70-kg individual this raises the dose
from 5 mg/kg to between 5.7 and 6.4 mg/kg). Dose de-escalation (to < 5 mg/kg) occurred only in the
proactive drug monitoring group.
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FIGURE 20 Kaplan–Meier analysis of time to relapse during maintenance phase. IPD reconstructed using the
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Two patients were ‘IBD unclassified’, 90 (69%) were diagnosed as having CD and 34 (29%) were
diagnosed as having UC. Almost 70% were male. Median age at IFX initiation was 34.9 years in the
proactive drug monitoring arm and 35 years in the control arm [interquartile range (IQR) 26.2–49.7 years].
The median age at diagnosis was 23.5 and 25 years in the proactive drug monitoring and control arms,
respectively; 30% of patients had undergone IBD surgery previously (40% of the proactive drug
monitoring group, but only 25% of the control group); 10% of patients were current users of tobacco,
25% were former users and 56% had never used tobacco; and 52 patients (41%) received combination
therapy (44% and 40% of the proactive drug monitoring and control group, respectively). The median
duration of IFX before proactive drug monitoring was 43 weeks (IQR 32–72 weeks).
The main reported outcomes comparing the proactive drug monitoring and control groups were the time
remaining on IFX (Kaplan–Meier analysis) and the reasons for stopping IFX. Further details about dose
changes and trough levels in the proactive drug monitoring group were also provided.
Outcomes: time remaining on infliximab Patients identified as belonging to the proactive drug
monitoring group remained on IFX treatment longer than those identified as belonging to the control
group. At 5 years (260 weeks) the probabilities of remaining on treatment were 86% and 52%,
respectively. Figure 21 shows the reconstructed Kaplan–Meier comparison between groups. Beyond
5 years there are very few patients at risk; the median duration of IFX treatment before proactive drug
monitoring implementation was reported to be 43 weeks (IQR 32–72 weeks). In multiple Cox regression
analysis, the probability of patients remaining on IFX therapy was found to be significantly related only to
proactive drug monitoring of IFX.
The authors also reported on the subgroup of patients that started maintenance IFX after 1 January 2009.
As the implementation of proactive drug monitoring was reported to be from 2009, this subgroup would
appear to be the more relevant population. Figure 22 shows the reconstructed Kaplan–Meier comparison
between the proactive drug monitoring and control subgroups. The reported hazard ratio was 0.3
(95% CI 0.1 to 0.7; p = 0.003). The reconstructed hazard ratio was similar, at 0.24 (95% CI 0.12 to 0.51); it
is possible that the authors stratified their analysis by baseline variables (e.g. monotherapy or combination
therapy, previous surgery, etc.). Parametric modelling based on reconstructed IPD is provided in Appendix 11.
Wilcoxon rank-sum test p = 0.0006
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Outcomes: reasons for stopping infliximab The reasons for stopping IFX are summarised in Table 18;
the most frequent causes for the control group were recurrence of IBD symptoms and acute infusions
reactions. Adverse events and high antibody levels were the main causes for the proactive drug
monitoring group.
Outcomes: proactive drug monitoring group trough levels and dose changes For the proactive drug
monitoring group, the authors reported data concerning proactive tests undertaken; all reactive tests were
omitted. Of initial proactive tests (n = 48), 37 used ELISA and 11 used HMSA methodology. Of subsequent
proactive tests (n = 40), seven used ELISA and 33 used HMSA.
Median trough IFX at initial testing was 5 µg/ml (IQR 2.8–9.9 µg/ml), whereas the median subsequent
trough level was 7.6 µg/ml (IQR 4.3–12.3 µg/ml).
Dosing adjustment after the initial proactive test was implemented in 17 patients (35%) as follows: dose
escalation in 12 patients (71%), dose reduction in three patients (18%) and termination of therapy in two
patients (12%). Dosing adjustment in subsequent proactive tests involved 10 patients (25%); these adjustments
were described as eight patients (80%) who received dose escalation and two (20%) a dose decrease.
Following proactive drug monitoring, the median dose increment was 100 mg (range 50–250 mg) and the
median duration of IFX therapy was 144 weeks (range 36–685 weeks).
A trough level of IFX ≥ 5 µg/ml (lower end of the later target range) was reportedly achieved in 75% of
patients (36/48). Of those in who reached this level of IFX, none developed antibodies to IFX or an immune
reaction. In one patient, IFX was stopped after colectomy, which was undertaken for flat low-grade dysplasia.
Authors’ conclusions The authors concluded that proactive trough concentration monitoring of IFX
frequently identified patients with low or undetectable trough concentrations and resulted in a greater
probability of remaining on IFX. In this study the treatment algorithm was ill-defined and test methods
were adjusted during the study. The retrospective observational design means that the selection of patient
groups was at risk of bias.
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Summary of major findings from three management studies
Three disparate studies were identified that implemented a test-informed algorithm and reported clinical
outcomes. One examined patients with CD only, and the other two examined both CD and UC patients.
Two were RCTs and the other was a retrospective observational study. None employed designated
intervention tests (LISA-TRACKER assays, TNF-α-Blocker or Promonitor ELISA).
The Steenholdt et al. RCT123 used concurrent RIA testing prior to implementation of a treatment algorithm
for patients with CD with LOR to IFX; the comparator group received IFX intensification. At 12 weeks after
randomisation there was no clinical benefit from the test algorithm strategy relative to dose intensification.
For 64% of patients in the algorithm arm (those with therapeutic IFX but no anti-drug antibodies) the
algorithm recommended cessation of IFX therapy. That cessation of IFX therapy was not associated with
reduced disease control suggests IFX may not be useful for most patients with CD with LOR; however, the
criteria for LOR may have been imprecise so that patients appeared to regain response 12 weeks later.
Weaknesses of the study include short duration, small size, a large number of withdrawals, the fact that
many participants did not receive algorithm-prescribed treatments, and unclear or high risk of bias in
several risk-of-bias domains. The authors reported cost savings for the test algorithm group relative to the
dose escalation group that are probably attributable to less use of IFX in the algorithm arm. Further studies
are required to test the reliability of findings.
The TAXIT RCT (Vande Casteele et al.73) used a test algorithm for IFX responders to optimise the trough IFX
level to a set target range. Tests employed in-house ELISAs. Trough optimisation with dose adjustments did
not change the proportion of patients with CD in clinical remission (RR for after vs. before optimisation:
1.053, 95% CI 0.936 to 1.186). After trough level optimisation, patients were randomised to continued
trough test monitoring or to clinical monitoring. For the primary outcome (rate of clinical plus biological
remission at 52 weeks) there was no difference between groups for patients with CD (54.9% vs. 62.6%;
p = 0.353). Time to relapse for CD plus UC patients was superior with test monitoring than with clinical
monitoring (p = 0.018). Total cost post randomisation (CD plus UC patients) was slightly lower with test
monitoring (€20,723 vs. €21,023). The risk of bias was low for most risk-of-bias domains.
The retrospective observational study of Vaughn et al.128 compared proactive trough concentration
monitoring with dosing based on clinical judgement (test results did not influence treatment). Among
TABLE 18 Reasons for stopping IFX therapy
Reason for stopping
Group (n)
Proactive drug monitoring No proactive drug monitoring
Recurrent IBD symptoms 0 15
Adverse events
Pneumonia 0 1
Drug-induced lupus 1 0
Psoriasis 1 0
High antibody concentration 1 0
Infusion reactions
Acute 0 6
Delayed 1 0
Other unrelated to IFXa 1 2
a Includes: unable to afford copayment, surgery for adhesive small bowl obstruction, and proactive drug monitoring group
trough levels and dose changes colectomy for flat low-grade dysplasia.
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clinically managed patients, dose escalations were likely to involve a doubling of IFX exposure, whereas in
the trough monitoring group some dose changes were dose reductions, and dose escalations were
considerably more moderate than in the clinically managed group. The authors’ major finding was that
relative to clinical monitoring, trough monitoring was associated with far superior retention on IFX treatment
(hazard ratio 0.3, 95% CI 0.1 to 0.7; p = 0.003). The observational design of the study and the retrospective
identification of participants based on medical records mean that the study was at considerable risk of bias.
Limitations of the review of management studies
The most important limitation of this review was that the relevant management studies did not directly
address our research questions; a further difficulty was the very limited supply of studies. Three
management studies73,123,128 were found in which patients treated with IFX were investigated, but no
corresponding studies were found for ADA. The timing of testing specified in the research questions did
not correspond with that used in any of the studies. Furthermore, two of the three available studies
investigated a mixture of CD and UC patients, and only one study (Steenholdt et al.123) reported the impact
of treatment algorithm in clinical outcomes for patients exclusively diagnosed with CD. In this study there
were few patients and follow-up was short; therefore, the power to detect differences in clinical outcome
between randomised groups over a clinically meaningful period was limited. However, this study provided
some evidence that, at least in the short term, a dose escalation strategy for LOR to IFX may be more
costly than the alternative strategy proposed in the authors’ treatment algorithm. Further investigation is
required to establish that cost savings are not associated with deterioration in disease control. The TAXIT
RCT investigated IBD patients with stable response to IFX.73 Patients in both randomised groups were
optimised to a target trough level of IFX; therefore, a comparator group in which from outset ‘treatment
decisions made on clinical judgement without measuring levels of TNF[-]α inhibitor and antibodies to
TNF[-]α inhibitors’73 did not exist. The pilot study of Vaughn et al.128 was a retrospective observational study
and, therefore, findings should be viewed with considerable caution. This review of management studies
clearly highlights gaps in the evidence and indicates that further studies are needed.
Evidence taken forward to the economic evaluation
Data from the three management studies73,123,128 have been taken forward for economic evaluation. The
two RCTs, one for responders and the other for IFX recipients with LOR, have informed model structure
and provided information for the base-case economic analysis. The study by Vaughn et al.,128 which reports
substantial clinical advantage for a test algorithm strategy in terms of retention in IFX treatment, has been
used in economic evaluation sensitivity analysis.
Objective C2: studies relating test results to clinical state of patients
(correlation studies)
Search results
The search identified three systematic reviews with meta-analytic pooling of results from multiple
studies32,63,111,114 and 31 primary studies38,40,47,52,59,77–85,88,92,94,98–100,102,103,106,108,110,115,120,123,126,133,134 that reported
the relationship between test outcomes and clinical status of patients in sufficient detail to allow us to
extract 2 × 2 data of diagnostic performance when using a drug and/or anti-drug antibody test to
diagnose/predict response or LOR. The systematic reviews are summarised in Published meta-analyses of
studies relating test results to clinical state of patients and the primary studies are analysed in Analysis of
correlation studies of anti-tumour necrosis factor alpha/anti-drug antibodies level and response.
Published meta-analyses of studies relating test results to clinical state of patients
Aim
To present an overview of meta-analyses of studies addressing the relationship between drug and/or
anti-drug antibody levels and clinical state of patients with CD.
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Rationale
Anti-TNF-α drug and anti-drug antibody levels can be used to aid the management of patients with CD on
anti-TNF-α drugs if test results are used to predict response or LOR and prompt appropriate action. How
good the tests are will therefore depend not only on the choice of treatment (change) following the test
results (prescribed by the algorithms discussed in Objective B: description of algorithms prescribing patient
management following test outcomes for drug and/or anti-drug antibody levels) but also on the diagnostic
performance of the test to predict response or lack of response correctly. We therefore reviewed systematic
reviews that carried out meta-analyses of studies addressing the relationship between drug and/or anti-drug
antibody levels and clinical state of patients with CD to assess the diagnostic performance of the various
assays in predicting response and LOR. It should be kept in mind that the definitions of response and
remission are not standardised, and that the standard the tests are measured against is clinical assessment,
which is far from perfect.
Results
The literature search yielded several reviews that addressed the relationship between test results and
the clinical state of patients with IBD.36,44,49,61–63,111,114,139 Of these, four were systematic reviews that
meta-analysed pooled results from multiple studies.49,63,111,114 One meta-analysis encompassed several
inflammatory conditions in addition to IBD and is not considered further here.49 The three remaining
meta-analyses considered anti-drug antibodies, and one also examined drug trough level tests.114 Although
many of the primary studies included in the meta-analyses presented data in terms of diagnostic or
predictive tests (e.g. sensitivity, specificity and other test accuracy measures), the meta-analyses addressed
the risk of a particular test result (e.g. negative) in patients with a particular clinical state (e.g. LOR and
calculated a RR of a negative test result in LOR relative to state no LOR or, conversely, RR of LOR in
patients with negative test relative to those with a positive test). Viewing the tests as diagnostic/predictive
permits hierarchical (bivariate) meta-analysis that incorporates covariance between sensitivity and specificity
estimates. The RR statistic does not formally allow for covariance between estimated associations. Each of
the meta-analyses is considered in turn.
Nanda et al.111 The authors estimated the pooled RR of LOR to IFX in patients with a positive test for
anti-drug antibodies relative to those with a negative test for anti-drug antibodies (a greater risk of LOR in
patients who were antibody positive than in patients who were antibody negative generates a RR of > 1.0).
Eleven studies were included,40,47,55,59,79,83,92,99,103,120,142 one with only UC patients, three studies with mixed
IBD populations (one of which reported results separately by UC and CD) and seven studies of CD patients.
The comparative numbers of events and patients were reported. The pooled estimate (Figure 23a; RR 3.16,
95% CI 2.00 to 4.98; I2 = 70.1%) indicated that the risk of LOR was about threefold higher in those with a
positive anti-drug antibodies test than in those with a negative test.
When viewed as a predictive/diagnostic test143 the same data can be analysed to estimate the sensitivity
and specificity, and meta-analysed to generate a pooled joint sensitivity–specificity value (and other test
accuracy parameters).144 In this case, a positive test for anti-drug antibodies is viewed as predictive/
diagnostic of LOR. Figure 23b indicates marked heterogeneity among the studies and the trade-off
between sensitivity and specificity in the different studies. Figure 23c and d summarises the summary
receiver operating characteristic (sROC) meta-analysis results. The meta-analysis test accuracy results are
summarised in Table 19. The large RCT-based study by Hanauer et al.40 was identified as both influential
and an outlier; including or excluding this study made little difference to the summary test accuracy
estimates, but substantially decreased the 95% CI around the prediction region in sROC space (see Figure 23c).
This study differed from the others in having the lowest ratio of positive to negative test results, probably
resulting from the number of tests classified as inconclusive.
The implication of these test accuracy results was explored in terms of predictive values as suggested in the
Cochrane Handbook for Systematic Reviews of Interventions.141 As predictive values are influenced by
prevalence of the target condition, we determined a pooled random-effects estimate of prevalence (LOR)
among the studies (34.7%, 95% CI 25.1% to 44.4%). The point estimates for positive predictive values
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(PPVs) and negative predictive values (NPVs) at this prevalence were 65% and 84%, respectively. The
influence of prevalence on these values is illustrated in Figure 24 across the range of prevalence of the
included studies and the 95% CI around the pooled prevalence.
The meta-analysis results indicate that the anti-drug antibody test has only moderate accuracy performance
in predicting/detecting LOR to IFX.
Lee et al.63 The authors estimated the pooled RR of remission in patients with a positive test for anti-drug
antibodies to IFX relative to those with a negative test for anti-drug antibodies (a RR of < 1.0 indicates
that anti-drug antibodies are associated with lower risk of remission, consistent with the hypothesis
that anti-drug antibodies reduce response to IFX therapy) based on nine studies.38,40,47,55,83,92,142,145,146
Comparative numbers of events and patients were reported. The fixed- and random-effects RRs are 0.90
(95% CI 0.79 to 1.02) and 0.96 (95% CI 0.77 to 1.19), respectively. Statistical heterogeneity unexplained
by chance was 37% (I2-statistic). When the presence of antibodies to IFX is considered as predictor of, or
diagnostic of, a lack of remission, then meta-analysis yielded low joint sensitivity specificity values of 0.42
and 0.69, respectively (Figure 25).
The results indicate that presence of anti-drug antibodies does not strongly increase the risk of lack of
remission and that a positive test for the presence of anti-drug antibodies has poor discriminatory power
for predicting/diagnosing a lack of remission.
TABLE 19 Test accuracy parameters generated by hierarchical MA144
Studies
included Estimate Sensitivity Specificity
Diagnostic
OR
Likelihood ratio
positive
Likelihood ratio
negative
Excludes outlier Point
estimate
0.72 0.79 9.87 3.49 0.35
95% CI 0.64 to 0.78 0.64 to 0.89 4.07 to 23.92 1.85 to 6.60 0.26 to 0.48
All studies Point
estimate
0.70 0.81 9.81 3.63 0.37
95% CI 0.55 to 0.82 0.67 to 0.89 4.09 to 23.54 2.04 to 6.45 0.24 to 0.58
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FIGURE 24 Positive predictive values and NPVs, according to prevalence of LOR at the sROC, model estimates of
sensitivity and specificity, as prevalence increases PPV increases and NPV decreases. Data points are PPV and NPV at
sROC sensitivity and specificity and pooled prevalence. Dashed vertical lines are pooled prevalence and 95% CI.
Thick curves are PPV and NPV for hierarchical model sensitivity and specificity at the pooled prevalence and 95% CI.
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Lee et al.63 also reported a meta-analysis examining the association between the development of anti-drug
antibodies and the use of immunosuppressant therapies. Eleven studies were included38,40,43,45,53–55,142,146–148
and the authors generated a fixed-effects RR (antibodies present with suppressants vs. antibodies present
with no suppressants) of 0.50 (95% CI 0.42 to 0.59; I2 = 43.4%), indicating a 50% reduction in risk
of developing anti-drug antibodies when suppressants are administered. The results of fixed- and
random-effects meta-analyses are illustrated in Figure 26.
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FIGURE 25 Meta-analysis of data based on that from Lee et al.63 (a) Fixed-effects meta-analysis of the RR of
remission (presence of antibodies to IFX vs. absence of antibodies to IFX); and (b) sROC bivariate meta-analysis of
sensitivity specificity pairs (hollow symbols) with pooled point estimate square solid symbol. ATI, antibodies to IFX;
HSROC, hierarchical summary receiver operating characteristic; M–H, Mantel–Haenszel.
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Paul et al.114 The authors estimated the pooled ratio for the odds of a lack of response in association with
a negative test for ADA (i.e. subtherapeutic) compared with the odds of a lack of response in those with a
positive test for ADA (an OR of > 1.0 indicates that subtherapeutic ADA levels are associated with lack of
clinical response). The comparative numbers of events and patients were not reported and it was difficult
to verify the included data from the references provided. The pooled OR differed between three studies of
adults with CD (pooled OR 7.5, 95% CI 3.58 to 13.90) and two studies of children with CD (pooled OR
1.59, 95% CI 1.00 to 2.54). The overall pooled OR was 2.60 (95% CI 1.79 to 3.77).
The reported ORs are equivalent to the diagnostic odds ratio (DOR) of a diagnostic test in which
subtherapeutic drug levels are the test for lack of clinical response. As such, they are modest relative to the
DOR value of 9.6 (odds pooled sensitivity/odds pooled specificity) for studies included in the Nanda et al.111
review using the test for antibodies to IFX as predictor of lack of response.
The authors also estimated the pooled ratio for the odds of lack of response in association with a negative
test for anti-drug antibodies to ADA compared with the odds of lack of response in those with a positive
test for anti-drug antibodies (an OR of > 1.0 indicates that the presence of anti-drug antibodies is
associated with lack of clinical response). The reported OR of 10.15 (95% CI 3.90 to 26.40) is equivalent
to the DOR for presence of antibodies (to ADA) as a predictor for the lack of clinical response. This value is
similar to the DOR for antibodies to IFX as a predictor for the lack of response [using the pooled sensitivity
specificity pair (0.72 and 0.79) derived from the studies in the Nanda et al.111 review, which provides a
DOR of 9.67 [(0.72/0.28)/(0.21/0.79)].
Summary
When viewed as predictive tests for lack of response and or lack of remission, the published meta-analyses
indicate modest accuracy of tests for trough drug levels or for presence of anti-drug antibodies. Typically,
the predictive values indicate substantial proportions of false-positive and false-negative test results.
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FIGURE 26 The RR of anti-drug antibodies with immunosuppressants vs. without suppressants. Data based on
Lee et al.63 ATI, antibodies to IFX; D+ L, DerSimonian–Laird; M–H, Mantel–Haenszel.
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Analysis of correlation studies of anti-tumour necrosis factor alpha/anti-drug
antibodies level and response
Aim
To pool test outcome data from correlation studies for responders and patients with LOR as an alternative
to single-study data to inform the economic model.
Rationale
No published and tested multivariable prognostic models were found that incorporated test results with
other variables to predict clinical status. The majority of the identified studies of tests for anti-TNF-α and
anti-drug antibody levels were classified as correlation studies (see Table 3). These reported correlations or
associations between test results and other patient-dependent variables. Only one published management
study123 used test results to guide treatment options according to an algorithm; thus, most of the evidence
about tests does not directly address the clinical effectiveness decision questions. Some of the studies
dichotomised test and related test results to clinical status; they can provide probabilities that a patient will
return a particular type of test result and the probability that the test outcome is associated with response
or lack of response; information that may be useful for economic modelling.
The decision questions identify two testing strategies, concurrent and reflex:
1. In concurrent testing, levels of anti-TNF-α drug and anti-drug antibodies are measured at the same
time. When tests are dichotomised using cut-off points, four patient categories are generated:
i. anti-drug antibodies positive and anti-TNF-α negative
ii. anti-drug antibodies positive and anti-TNF-α positive
iii. anti-drug antibodies negative and anti-TNF-α negative
iv. anti-drug antibodies negative and anti-TNF-α positive.
2. In reflex testing, tests for anti-TNF-α levels precede subsequent testing for anti-drug antibodies,
and anti-drug antibodies tests are carried out only in those with subtherapeutic levels of anti-TNF-α.
When tests are dichotomised using cut-off points, three patient categories are generated:
i. anti-TNF-α positive
ii. anti-TNF-α negative and anti-drug antibodies positive
iii. anti-TNF-α negative and anti-drug antibodies negative.
Test result probabilities by patient category can be obtained from studies that reported both drug and
anti-drug antibody test results for each patient. Very few such studies were found. For reflex testing, test
result probabilities for the first test may also be obtained from studies in which test results are reported by
group rather than by individual; when several such studies are available, the option of meta-analysis of
multiple studies offers greater power. Studies that undertook both anti-TNF-α and anti-drug antibody tests
but did not provide test results for each patient (but only by group) were not useful for obtaining estimates
of concurrent testing probabilities because contingency probabilities could not be calculated (e.g. the
probability that an individual with a negative drug test was either negative or positive for the anti-drug
antibody test). However, these may be meta-analysed to provide a comparison (by a single test result) with
the few available patient-level studies in order to gauge consistency of test results from patient-level
studies with those across multiple studies.
Results
The studies identified as correlation (n = 136) adopted several perspectives in reporting test results. Most
commonly, the association of test results with another variable, usually correlation of drug levels and
anti-drug antibodies levels, was assessed and correlation reported as Pearson’s correlation coefficient or
Spearman’s rank correlation coefficient. Other associations investigated were between anti-drug antibodies
and/or anti-TNF-α levels and measures of serum CRP concentration, or of FC, or estimates of clinical status.
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Those that dichotomised test results and related these to dichotomised clinical state (e.g. response or lack
of response) were considered potentially useful for the decision questions. Data from this type of study can
be represented in a 2 × 2 diagram similar to that shown in Table 20.
Those studies from which the values for a, b, c and d could be obtained were taken further (n = 31)
and those (n = 105) that had insufficient data were excluded (see Appendix 6). Some viewed test results
as diagnostic or predictive of the clinical state of interest and test accuracy parameters were reported
(e.g. sensitivity, specificity or ROC plots). Other studies considered the risk of a particular test result
(e.g. positive) in patients with a particular clinical state (e.g. state A) and calculated a RR of a positive test
result in state A relative to state B {[a/(a + d)]/[b/(b + c)]} or, conversely, RR of state A in patients with a
positive test relative to those with a negative test {[a/(a + b)]/[d/(d + c)]}.
The 31 studies38,40,47,52,59,77–85,88,92,94,98–100,102,103,106,108,110,115,120,123,126,133,134 taken forward for meta-analysis (see
Table 53, Appendix 12) were heterogeneous in terms of populations, treatments, tests used, completeness
of reporting, test cut-off points used for dichotomising test results, definitions of clinical response and the
time from treatment initiation to that at which clinical status was assessed. Most studies were retrospective
and used convenience sample populations when data from medical records about clinical state were
available and serum samples had been collected and stored for future assay. The most common threats to
validity of study findings in this collection of studies are selection bias, lack of power and the use of
subjective measures to establish clinical status.
Concurrent testing: test result probabilities Three studies reported both drug and antibody test results
for the same individuals in relation to clinical status.99,100,123 These allowed calculation of the number of
patients in each of the two dichotomised clinical states distributed to each of the four possible combinations
of test result (i.e. drug positive and antibody positive; drug positive and antibody negative; drug negative and
antibody positive; and drug negative and antibody positive).99,100,123 The results summarised in Tables 21–23
indicate the probability of LOR according each possible test result category for the three studies.
Reflex testing: test result probabilities The test results for studies that reported both drug and antibody
test results for the same individuals in relation to clinical status can be condensed to provide test results for
three groups of patients: (1) anti-TNF-α positive; (2) anti-TNF-α negative and anti-drug antibodies positive;
and (3) anti-TNF-α negative and anti-drug antibodies negative. The results summarised in Tables 24–26
indicate the probability of LOR according to each possible test result category.
Meta-analytic test result probabilities: trough infliximab levels Meta-analysis results for single-test
studies using trough IFX levels as a test for LOR in responders and failure to regain response in patients
with LOR are summarised in Appendix 12, Infliximab trough level tests for loss of response or lack of
regaining response. For responders the probability of returning a positive test result (i.e. IFX undetectable)
was 0.367 at the pooled prevalence (the range based on 95% CI for prevalence was 0.340 to 0.385; this
does not take into account uncertainty in the summary point estimate); for a negative test result the
probability was 0.632 (the range based on 95% CI for prevalence was 0.615 to 0.659; this does not take
into account uncertainty in the summary point estimate). The probability of a positive test reduced to
TABLE 20 Illustration of 2 × 2 table data from correlation studies
Test result Clinical state A Clinical state B Total
Test positive (a) TP (b) FP a+ b
Test negative (d) FN (c) TN d+ c
Total a + d b+ c a+ b + c + d
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
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TABLE 21 Concurrent testing for responders receiving ADA
Study: Imaeda et al.,
2014100 ADAbs positive ADAbs negative Total
Population and anti-TNF-α
therapy; tests
Anti-TNF-α negative LOR = 8 LOR = 2 LOR = 10 Responders on ADA maintenance;
ELISA; prevalence of LOR = 37.5%
RESP = 0 RESP= 2 RESP = 2
Anti-TNF-α positive LOR = 2 LOR = 3 LOR = 5
RESP = 4 RESP= 19 RESP = 23
Total LOR = 10 LOR = 5 LOR = 15
RESP = 4 RESP= 21 RESP = 25
ADAb, anti-drug antibody; RESP, responders.
Note
The probabilities of a patient returning each of the four possible test result combinations were ADAbs positive and
anti-TNF-α negative = 0.200; ADAbs positive and anti-TNF-α positive = 0.150; ADAbs negative and anti-TNF-α
negative= 0.10; and ADAbs negative and anti-TNF-α positive = 0.550.
The probabilities of losing response according to category of test result were 1.00, 0.333, 0.500 and 0.136, respectively.
TABLE 23 Concurrent testing for patients with LOR receiving IFX
Study: Steenholdt et al.,
2014123 ADAbs positive ADAbs negative Total
Population and anti-TNF-α
therapy; tests
Anti-TNF-α negative NOR = 8 NOR = 2 NOR = 10 Failure on IFX, continued failure
or gain of response at 12 weeks;
RIA; prevalence of NOR = 44.9%RESP= 6 RESP= 1 RESP= 7
Anti-TNF-α positive NOR = 1 NOR = 20 NOR = 21
RESP= 3 RESP= 28 RESP= 31
Total NOR = 9 NOR = 22 NOR = 31
RESP= 9 RESP= 29 RESP= 38
ADAb, anti-drug antibody; NOR, no regain of response; RESP, responders.
Note
The probabilities of a patient returning each of the four possible test result combinations were ADAbs positive and
anti-TNF-α negative = 0.203; ADAbs positive and anti-TNF-α positive = 0.058; ADAbs positive and anti-TNF-α
negative= 0.0.043; and ADAbs negative and anti-TNF-α positive = 0.696.
The probabilities of failing to gain a response according to category of test result were 0.571, 0.250, 0.667 and 0.417,
respectively.
TABLE 22 Concurrent testing for responders receiving IFX
Study: Imaeda et al., 201299 ADAbs positive ADAbs negative Total
Population and anti-TNF-α
therapy; tests
Anti-TNF-α negative LOR = 9 LOR = 0 LOR = 9 Responders on IFX maintenance;
ELISA; prevalence of LOR = 29.3%
RESP = 1 RESP= 7 RESP = 8
Anti-TNF-α positive LOR = 3 LOR = 5 LOR = 8
RESP = 3 RESP= 30 RESP = 33
Total LOR = 12 LOR = 5 LOR = 17
RESP = 4 RESP= 37 RESP = 41
ADAb, anti-drug antibody; RESP, responders.
Note
The probabilities of a patient returning each of the four possible test result combinations were ADAbs positive and
anti-TNF-α negative = 0.172; ADAbs positive and anti-TNF-α positive = 0.103; ADAbs negative and anti-TNF-α
negative= 0.121; and ADAbs negative and anti-TNF-α positive = 0.603.
The probabilities of losing response according to category of test result were 0.900, 0.500, 0.000 and 0.143, respectively.
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TABLE 24 Reflex testing for responders receiving ADA
Study: Imaeda et al.,
2014100 ADAbs positive ADAbs negative Total
Population and anti-TNF-α
therapy; tests
Anti-TNF-α negative LOR= 8 LOR = 2 LOR = 10 Responders on ADA maintenance;
ELISA; prevalence of LOR = 37.5%
RESP= 0 RESP= 2 RESP = 2
Anti-TNF-α positive LOR= 5 – LOR = 5
RESP= 23 – RESP = 23
Total LOR= 13 LOR = 2 LOR = 15
RESP= 23 RESP= 2 RESP = 25
ADAb, anti-drug antibody; RESP, responders.
Note
The probabilities of a patient returning each of the three possible test result combinations were anti-TNF-α positive = 0.700;
anti-TNF-α negative and ADAbs positive = 0.200; and anti-TNF-α negative and ADAbs negative = 0.100.
The probabilities of losing response according to category of test result were 0.179, 1.00 and 0.500, respectively.
TABLE 25 Reflex testing for responders receiving IFX
Study: Imaeda et al., 201299 ADAbs positive ADAbs negative Total
Population and anti-TNF-α
therapy; tests
Anti-TNF-α negative LOR = 9 LOR = 0 LOR= 9 Responders on IFX maintenance;
ELISA; prevalence of LOR = 29.3%
RESP= 1 RESP= 7 RESP= 8
Anti-TNF-α positive LOR = 8 – LOR= 8
RESP= 33 – RESP= 33
Total LOR = 17 LOR = 0 LOR= 17
RESP= 34 RESP= 7 RESP= 41
ADAb, anti-drug antibody; RESP, responders.
Note
The probabilities of a patient returning each of the three possible test result combinations were anti-TNF-α positive = 0.707;
anti-TNF-α negative and ADAbs positive = 0.172; and anti-TNF-α negative and ADAbs negative = 0121.
The probabilities of losing response according to category of test result were 0.195, 0.00 and 0.900, respectively.
TABLE 26 Reflex testing for patients with LOR receiving IFX
Study: Steenholdt et al.,
2014123 ADAbs positive ADAbs negative Total
Population and anti-TNF-α
therapy; tests
Anti-TNF-α negative NOR = 8 NOR = 2 NOR = 10 Failure on IFX, continued failure or
gain of response at 12 weeks;
RIA; prevalence of NOR = 44.9%RESP= 6 RESP= 1 RESP = 7
Anti-TNF-α positive RESP= 31 – NOR = 21
NOR = 21 – RESP = 31
Total NOR = 29 NOR = 2 NOR = 31
RESP= 37 RESP= 1 RESP = 38
ADAb, anti-drug antibody; NOR, no regain of response; RESP, responders.
Note
The probability of a patient returning each of the three possible test result combinations was: anti-TNF-α positive = 0.754;
anti-TNF-α negative and ADAbs positive = 0.203; and anti-TNF-α negative and ADAbs negative = 0.044.
The probabilities of not gaining response according to category of test result were 0.404, 0.667 and 0.571, respectively.
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0.271 when prevalence was set to that of the single available patient-level study of Imaeda et al.,100 which
returned a similar positive test probability of 0.293 (95% CI 0.181 to 0.427).
Only two studies were available for patients with LOR so that a meaningful pooled estimate could not
be undertaken.
Meta-analytic test result probabilities: antibodies to infliximab Meta-analysis results for single-test
studies using antibodies to IFX as a test for LOR in responders and failure to regain response in patients
with LOR are summarised in Appendix 12, Antibodies to infliximab tests for loss of response or lack of
regaining response. The probability of returning a positive test result (i.e. anti-IFX antibodies undetectable)
was 0.345 at the pooled prevalence (the range based on 95% CI for prevalence was 0.324 to 0.365); and
for a negative test result the probability was 0.655 (the range based on 95% CI for prevalence was 0.635
to 0.686); these do not take into account uncertainty in the summary point estimate. The probability of a
positive test reduced to 0.274 when prevalence was set to that of the single available patient-level study of
Imaeda et al.,100 which returned a similar positive test probability of 0.276 (95% CI 0.167 to 0.409).
Seven heterogeneous studies47,59,77,79,83,123,126 were available for patients with LOR (see Table 53, Appendix 12).
The probability of returning a positive test result (i.e. anti-IFX antibodies present) was 0.387 at the pooled
prevalence (the range based on 95% CI for prevalence was 0.331 to 0.442; this does not take into account
uncertainty in the summary point estimate); for a negative test result the probability was 0.613 (the range
based on 95% CI for prevalence was 0.558 to 0.669; this does not take into account uncertainty in the
summary point estimate). The probability of a positive test increased to 0.425 when prevalence was set to
that of the single available patient-level study of Steenholdt et al.,123 which returned a much lower positive
test probability of 0.261 (95% CI 0.163 to 0.381).
Meta-analytic test result probabilities: trough ADA levels Meta-analysis results for single-test studies
using trough ADA levels as a test for LOR in responders and failure to regain response in patients with LOR
are summarised in Appendix 12, Adalimumab trough level test for loss of response or lack of regaining
response. The probability of returning a positive test result (i.e. ADA undetectable) was 0.444 at the
pooled prevalence (the range based on 95% CI for prevalence was 0.389 to 0.499; this does not take into
account uncertainty in the summary point estimate). The probability of a positive test reduced to 0.390
when prevalence was set to that of the single available patient-level study of Imaeda et al.,99 which
returned a lower positive test probability of 0.300 (95% CI 0.166 to 0.465).
A single study related trough ADA levels to clinical outcome for patients with LOR. No patient-level dual
test studies were available for a comparison of test probabilities.
Meta-analytic test result probabilities: anti-ADA antibody levels Meta-analysis results for single-test
studies using trough anti-ADA antibody levels as a test for LOR in responders are summarised in Appendix 12,
Antibodies to adalimumab as test for loss of response or lack of regaining response.
The probability of returning a positive test result (i.e. anti-ADA antibodies present) was 0.253 at the pooled
prevalence. The probability of a positive test reduced to 0.230 when prevalence was set to that of the
single available patient-level study of Imaeda et al.,99 which returned a higher positive test probability of
0.350 (95% CI 0.206 to 0.517).
Summary
Available evidence Only three studies were found that reported the results of both drug and anti-drug
antibody tests for individual patients (one for IFX-treated responders, one for IFX-treated patients with LOR
and one for responders treated with ADA). These studies allowed estimation of the proportion of patients
who would enter each of the treatment categories following from concurrent or reflex testing strategies.
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Representativeness of available evidence As only a single patient-level study was available for each of
the different CD patient populations, the test results from these studies were compared with test results
from the meta-analysis of multiple single-test studies. In view of the considerable uncertainties, partly
because of the small number of studies and their small size, the meta-analysis test results were sufficiently
similar to those of the three patient-level studies to conclude that the three patient-level studies were
reasonably representative for the patient populations of interest.
Accuracy of tests as predictors of clinical condition The test accuracy of drug level tests and anti-drug
antibody level tests as predictors of clinical status was moderate (see Appendix 12). PPVs and NPVs across
clinical prevalence ranges indicated that 20–30% of positive and negative test results were incorrect at
plausible prevalence settings for clinical status (see Appendix 12, Predictive values for drug and anti-drug
antibodies tests for LOR or failure to regain response).
Evidence taken forward to the economic evaluation
The only correlation studies that provided input for economic evaluation were the concurrent testing study
by Imaeda et al.99 of patients treated with IFX and that of Steenholdt et al.123 of patients with LOR to
maintenance IFX. As the Steenholdt et al.123 study coupled testing results with prospective implementation
of a treatment algorithm, it was used in the base-case economic analysis. Data from the Imaeda et al.
study99 were used in a sensitivity analysis in the cost-effectiveness comparison of testing strategies with
standard care. The reason for the lack of usefulness of most of the correlation studies was that very few
reported extractable data for concurrent or reflex testing.
Summary of clinical effectiveness findings
Assays based on different principles have been developed to measure anti-TNF-α agents and antibodies to
anti-TNF-αs in blood samples. There is little consensus about the most appropriate assay to use in clinical
practice and no gold standard is established against which assay performance can be assessed. Studies
have examined the predictive ability of tests to discriminate clinical condition of IBD patients; meta-analysis
of such studies has indicated that the tests have only moderate predictive utility. Irrespective of imperfect
test accuracy, when tests are used in tandem with an appropriate treatment algorithm, they may deliver
equal or better patient outcomes than a standard care strategy undertaken without testing. No RCT was
found that tested this possibility for patients with CD responding to anti-TNF-α agents. The TAXIT trial
described outcomes when a test algorithm strategy based on trough IFX levels was implemented for IBD
patients responding to IFX, but a standard care comparator population was not available because all
randomised TAXIT study patients received test-directed optimisation of IFX dosing. A single retrospective
case series of IBD patients responding to IFX reported better retention in IFX treatment for those whose
dose changes were based on prospective testing than for those whose dose was not based on prospective
testing. However, this study design was at appreciable risk of bias, particularly with respect to selection
bias. One randomised study compared a test algorithm strategy with an intensified dose strategy in
patients with CD who had lost response to IFX. No difference in clinical outcome was observed, but cost
savings were reported for the test algorithm strategy. The study was of short duration (data at 12 and
20 weeks only) and was small (69 patients); about half of the intervention patients received treatment
that did not conform to the algorithm and a substantial proportion received unspecified therapy decided
according to clinical judgement. The generalisability of findings and the longer-term implications of the
study are difficult to gauge.
The available evidence provides a limited platform for deciding if testing for anti-TNF-α agents and/or
antibodies to anti-TNF-α drugs provides a clinical advantage over standard anti-TNF-α strategies
used for responders or for patients with LOR. Ongoing trials may deliver more relevant data to inform
a decision.
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The main points of the clinical effectiveness can be summarised:
l ELISAs are susceptible to interference to a greater extent than other assays such as RIA and HMSA.
l There is uncertainty about which assay is optimal for drug monitoring, as well as when and how often
assessments should take place and whether levels of drug, anti-drug antibodies or both should
be determined.
l The clinical significance of measuring accurate and very low levels of drug/anti-drug antibodies is not known.
l Transient anti-drug antibodies might be the result of the drug masking anti-drug antibodies from
detection by forming complexes, particularly after dose intensification.
l The evidence on concordance between the three intervention assays is contradictory. Overall, there is
insufficient evidence to make claims about the comparative performance between the three
intervention assays or in relationship to other assays for a linked evidence approach.
l The available evidence, although scarce, showed varying degree of disagreement between assays.
l Studies determined their own cut-off values, which vary greatly between studies. This reflects the fact
that cut-off points are study specific and not readily generalisable.
l Two RCTs, with evidence on the clinical utility of testing and test-informed algorithm that are
sufficiently prescriptive, were identified: one for patients with LOR and one for responders.
l The algorithms in the RCTs are slightly different from the ones presented to us in the NICE scope for
this work, reflecting the influence of the variation in clinical judgement.
l The RCTs recruited different patients groups (LOR/responders), used different tests and different testing
strategies addressing different aspects of the decision questions [concurrent testing for patients with
LOR and reflex testing (dose optimisation) for responder].
l Drug monitoring might be cost saving without loss of effectiveness mainly because of reduced
administration of IFX in patients who do not require IFX (drug positive and anti-drug antibody negative)
according to one RCT.
l Drug optimisation during the induction phase in responders might lead to an increase in clinical
remission and savings in drug costs according to one RCT.
l Trough level-based dosing during maintenance may increase the probability of remaining on IFX
treatment according to one observational study.
l Problems with the RCTs included:
¢ mixed patient populations
¢ short follow-up
¢ small patient numbers
¢ no evidence on ADA
¢ timing of testing did not correspond with decision questions.
l Meta-analyses of correlation studies showed that the diagnostic performance of the assays is only
moderate when measured against clinical assessment.
l Single patient-level study outcomes in correlation studies were sufficiently similar to meta-analyses of
multiple single-test studies to use outcomes as estimates of proportions of patients entering each
treatment category for concurrent and reflex testing.
The clinical effectiveness review provided information that was useful for the modelling in the following ways:
the three management studies73,123,128 both informed the structure of the economic model and provided some
of the required data to populate it. The model structure was also informed by clinical expert advice about the
relevant patient treatment pathways that addressed the decision problem. This extended the model to a time
horizon well beyond the data from the two RCT management studies and necessitated considerable data input
from studies not included in the clinical effectiveness review. A single correlation study delivered some input for
the economic evaluation; however, the usefulness of the correlation studies for economic analysis was limited
because concurrent or reflex testing results were rarely reported (most studies correlated clinical status only with
either test results for anti-TNF-α or results for antibodies to anti-TNF-α). Although the correlation studies provide
some indication of the test accuracy of currently used tests, this is irrelevant for the economic decision because
any deficiency in test accuracy is subsumed within the combined test + algorithm intervention.
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Chapter 4 Cost-effectiveness review and health
economic modelling
Systematic review of existing cost-effectiveness evidence
This chapter will explore and review all published studies on the cost-effectiveness of LISA-TRACKER ELISA
kits, TNF-α-Blocker ELISA kits and Promonitor ELISA kits for measuring levels of TNF-α inhibitors and of
anti-drug antibodies in detail.
Aim
To review all cost-effectiveness studies including any existing models and to identify any suitable data such
as resource use, costs, utilities and transition probabilities to help inform our economic model for the
evaluation of the cost-effectiveness of LISA-TRACKER ELISA kits, TNF-α-Blocker ELISA kits and Promonitor
ELISA kits for measuring levels of TNF-α inhibitors and of anti-drug antibodies in detail.
Methods
Search strategy
A comprehensive search of the literature for published economic evaluations (including any existing
models), cost studies and QoL (utility) studies was performed. The systematic search included searching the
following electronic databases during December 2014 (from 12 to 17 December 2014):
l MEDLINE (via Ovid) (1946 to Week 3 November 2014)
l MEDLINE In-Process Citations and Daily Update (via Ovid) (11 December 2014)
l EMBASE (via Ovid) (1947 to 15 December 2014)
l NHS Economic Evaluation Database (The Cochrane Library)
l Science Citation Index (Web of Knowledge) (1970–present)
l Cost-effectiveness Analysis Registry
l EconPapers (Research Papers in Economics)
l School of Health and Related Research Health Utilities Database.
The search included terms for CD, anti-TNF-α drugs and the different assay kits, combined with economic
and QoL terms. The search was limited to studies published in the English language. The search strategy
developed was based on the clinical effectiveness review, with input from a health economist. Details of
the full search strategies are provided in Appendix 3.
Inclusion criteria
Only studies meeting the following inclusion criteria were included in the review:
l study type – fully published economic evaluations (including economic models)
l population – people with CD
l intervention – anti-TNF-α drugs (ADA and IFX) and antibody drug testing (LISA-TRACKER ELISA kits,
TNF-α-Blocker ELISA kits and Promonitor ELISA kits) for any dosage or treatment regimen
l comparator – standard care treatment: anti-TNF-α drugs (ADA and IFX) for any dosage or treatment
regimen
l outcomes – cost-effectiveness or cost–utility studies reporting outcomes as clinical effectiveness
measures or utility measures [utility, EQ-5D, Short Form questionnaire-6 Dimensions score or
quality-adjusted life-years (QALYs)].
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Exclusion criteria
Studies meeting the following exclusion criteria were excluded from the review:
l non-English-language publications
l studies in the health areas where these anti-TNF-α drugs have also been used, such as UC, rheumatoid
arthritis, psoriasis and tuberculosis.
Assessment of eligibility and data extraction
All retrieved records (citations and abstracts) were collected in a specialist database (EndNote) and
duplicate records were identified and removed. Two reviewers independently reviewed titles and abstracts
to identify potentially relevant papers for inclusion. Any discrepancies were resolved by discussion. See
Appendix 13 for the table of full-text studies excluded with reasons.
Data extraction was carried out in two stages by one reviewer using standardised data extraction sheets
(see Appendix 14) and was then checked by a second reviewer. Stage 1 considered all eligible studies
(fully published economic evaluations including any economic models) and stage 2 considered studies
assessed for usefulness for populating the economic model. Data extracted during stage 1 included
the following:
l study details – author names, source of publication, language and publication type
l baseline characteristics – population, intervention, comparators, outcomes and type of economic evaluation
l methods – target population and subgroups, setting and location, study perspective, time horizon,
discount rate, measurement of effectiveness, measurement and valuation preference-based outcomes,
resource use and costs, currency, price date and conversion, model type, assumptions and analytical
methods
l results – study parameters, incremental costs and outcomes and characterising uncertainty
l discussion – study findings, limitations, generalisability and conclusions
l other – sources of funding, conflicts of interest and comments.
Quality assessment
The quality of full economic evaluation studies that were identified was assessed using the Consolidated
Health Economic Evaluation Reporting Standards (CHEERS) checklist (see Appendix 15) by one reviewer and
cross-checked by a second reviewer. The CHEERS checklist comprises six dimensions: title and abstract,
introduction, methods, results, discussion and other. Under these dimensions, a series of questions check
whether or not the criteria have been clearly reported. Any studies containing an economic model were further
assessed using the framework for the quality assessment of decision-analytic modelling by Philips et al.149
(see Appendix 15). The Philips checklist contains two main dimensions: structure of the model and data used
to parameterise the model. Under these dimensions several questions assess whether or not the criteria has
been clearly reported.
Data synthesis
Information extracted from the included studies were summarised and tabulated. Findings from individual
studies were compared narratively.
Results
In developing the economic model, we have consulted the previous technology appraisal guideline
and HTA report by Dretzke et al.5 even though this work did not include any assay kits for measuring
levels of TNF-α inhibitors and of anti-drug antibodies. The aim of this diagnostic assessment review, as
specified by NICE, was to build upon this previous work. The next section contains a summary of this
previous HTA report and then the results of the cost-effectiveness review including quality assessment will
be outlined.
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Summary of the Health Technology Assessment report by Dretzke et al.5
The main aim of this HTA report was to assess the cost-effectiveness of anti-TNF-α drugs in the
management of adult patients with moderate to severe CD in the UK NHS. The authors described
induction therapy as the use of anti-TNF-α therapy with the aim of achieving remission (a repeated
reinduction treatment was considered, rather than a one-off induction therapy) and maintenance therapy
as the use of anti-TNF-α therapy to maintain remission in patients who have responded (and continue to
respond) to anti-TNF-α therapy when in relapse. Response by the authors was defined as remission
within 8 weeks.
The authors developed a Markov model from a NHS and Personal Social Services (PSS) perspective to
estimate the incremental cost per QALY gained for both ADA and IFX (anti-TNF-α therapy) compared with
standard care. Mortality was not included in the model, as the authors found no difference in the mortality
rates that were reported in the clinical trials reviewed and, therefore, felt that a lifetime horizon would not
improve the precision of the cost-effectiveness estimate. Instead, the time horizon for the model was
1 year and the cycle duration was 4 weeks. The model for both induction and maintenance therapy
started with a cohort of patients in the standard care refractory relapse health state. The model had four
main health states and at any time, and on any given treatment, a patient was in remission, in relapse,
undergoing surgery or in post-surgery remission.
Transition probabilities for the standard care health states were based on Silverstein et al.150 Transition
probabilities for both the induction and maintenance model were assigned a treatment effect by using
relapse to remission probabilities from RCT evidence; however, for the maintenance model there was a
lower remission to relapse rate.
The majority of utility values for the model were based on the study by Gregor et al.,20 which used the
time-trade off measure to estimate the health-related QoL in CD. A utility value for surgery was not
available in the published literature; therefore, it was assumed that the average utility value for surgery
would be equivalent to EQ-5D health state 22222, with a utility weight of 0.516.
The direct costs to the NHS were the sum of the anti-TNF-α costs and type-specific health-state costs. The
costs of anti-TNF-α therapy, both induction and maintenance, were derived from the BNF (2007/8),151,152
and administration costs were also included for IFX. Type-specific health-state costs included costs for
surgery, which were modelled as the cost of inpatient IBD interventions, and post-surgery remission costs,
which were based on outpatient surgical gastrointestinal follow-up. Moderate and severe relapse costs
were modelled as the cost of IBD outpatient major and intermediate interventions. Relapse costs were
based on a gastrointestinal admission to hospital. Remission costs were modelled using literature. The
majority of health-state unit costs were obtained from the NHS reference cost database (NHS Reference
Costs 2005 to 2006153).
Incremental cost-effectiveness ratios (ICERs) and cost-effectiveness acceptability curves were presented.
One-way sensitivity analyses and probabilistic sensitivity analyses (PSAs) using 10,000 simulations were
conducted to characterise uncertainty in the model.
For induction therapy for severe CD, both ADA and IFX dominated standard care (i.e. they were cheaper
and more effective). For maintenance therapy for severe CD, neither drug was cost-effective (well above
NICE thresholds). For moderate CD, for maintenance therapy for both drugs and induction therapy
for IFX, these were not cost-effective (well above NICE thresholds); however, for induction therapy, ADA
dominated standard care.
Sensitivity analysis showed that, in patients with severe disease, IFX induction treatment was cost-effective
relative to maintenance treatment and standard care in > 99% of cases at all points up to £100,000 per
QALY. Likewise, ADA induction treatment was found to be cost-effective relative to maintenance
treatment and standard care for thresholds up to £100,000 per QALY.
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The key limitations of this model was a short time frame (1-year time horizon); the exclusion of death from the
model; no randomised controlled data available for maintenance therapy; and the use of Silverstein et al.150
data for transition probabilities, which inherently had their own problem (i.e. surgery rates were higher and
relapse rates much lower than in routine practice).
Search results for objective D
The literature search identified 2466 records through electronic database searches and other sources.
After removing duplicates, 1527 records were screened for inclusion. On the basis of a title and abstract
sift only, 1518 records were excluded. The remaining nine records were subjected to full-text screening.
A further five articles5,26,154–156 were excluded at the full-text stage, as these studies did not use assay kits
to measure levels of TNF-α inhibitors and anti-drug antibodies. The literature search identified four
studies73,123,124,157 of the cost-effectiveness of different assay kits for measuring levels of TNF-α inhibitors
and of anti-drug antibodies (Figure 27).
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FIGURE 27 The PRISMA flow diagram of cost-effectiveness studies.
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Overview of included studies
The literature search identified four studies73,123,124,157 that met our inclusion criteria (studies looking at
the cost-effectiveness of different assay kits for measuring levels of TNF-α inhibitors and of anti-drug
antibodies) and were reviewed. In the following sections we present an overview of the included studies by
population (responders and those showing LOR) of interest.
Vande Casteele et al.73
Vande Casteele et al.73 aimed to determine whether or not concentration-based IFX dosing was more
cost-effective than clinically based IFX dosing. These authors conducted a RCT and assigned people with
moderate to severe CD or UC to receive concentration-based or clinically based IFX dosing. Included
patients were those who were treated with maintenance IFX therapy for at least 14 weeks and who had a
stable clinical response. These authors defined clinical response as being ‘symptom-free (full responder)
or having clinical improvement with an obvious decrease of disease activity but with clinical symptoms
still present (partial responder)’.73 Patients eligible for the study were dose optimised until IFX trough
concentrations between 3 and 7 µg/ml were reached. At the assessment of each trough concentration
using an in-house-developed ELISA, the dosing regimen was changed to reflect the proposed treatment
algorithm, until patients had a trough concentration between 3 and 7 µg/ml. Briefly, depending on IFX
trough concentration, patients received an increase dose of IFX treatment, no dose adaptation or a
decrease in IFX treatment. The study was prospective and was undertaken at a tertiary referral centre in
Belgium. The study was conducted from the perspective of the third-party payer and the time horizon
was 1 year. The EQ-5D was used to calculate QALYs, and any differences in baseline utility scores were
adjusted for by the use of a multiple regression approach. Resource use and costs were not reported in
detail, apart from the drug costs per patient per year. All costs were expressed in euros in 2012 prices.
The base-case results were expressed as an ICER based on the outcome of cost per QALY gained.
Uncertainty in incremental QALYs and costs was determined by non-parametric bootstrapping consisting
of 1000 iterations and plotted onto a cost-effectiveness plane. The base-case results demonstrated that
concentration-based dosing was slightly less effective (0.8227 vs. 0.8421) and less costly (€20,700 vs.
€21,000) than clinically based dosing, but overall differences were small.
Steenholdt et al.123
Steenholdt et al.123 assessed the cost-effectiveness of receiving treatment based on serum concentrations of IFX
and IFX antibodies at the time of IFX treatment failure in accordance with the algorithm (for further details of
the algorithm, see Chapter 3, Objective B: description of algorithms prescribing patient management following
test outcomes for drug and/or anti-drug antibody levels) compared with receiving IFX at an increased dose
frequency of 5 mg/kg every 4 weeks. The study included patients who experienced failure of IFX treatment
while on maintenance treatment. Failure of IFX treatment was defined in the study as recurrence of active
disease with a CDAI score of ≥ 220 and/or a minimum of one draining fistula. Serum IFX and IFX antibodies
were analysed using RIA. Samples were stored and further analysed using ELISA and HMSA after study
completion. The study was a single-blind RCT set in six Danish hospitals. Study perspective was not clearly
stated. Cost-effectiveness was assessed at 12 weeks, with visits scheduled at 0, 4, 8 and 12 weeks. Clinical
effectiveness was based on clinical response rates, which is regaining response or continuing to lose response
to IFX therapy. Resource use and costs were based on IFX doses and all inpatient and outpatient contacts in
hospitals, which also included diagnostic and treatment procedures that were recorded in the National Patient
Registry database. Costs were reported in Danish krone and converted to euros in 2012 prices. The base-case
results were expressed as cost per ITT and PP population. Costs were compared using arithmetic means and
were assessed by non-parametric bootstrapping. One-way sensitivity analyses of key primary and secondary
end points were conducted. The base-case results showed that costs were significantly lower in the algorithm
group than in the IFX intensification group in both the ITT and PP population.
Steenholdt et al.124
In follow-up to their study published in 2014,123 Steenholdt et al.124 extended the time horizon to 1 year to
assess the long-term costs and clinical outcomes of treatment of CD in patients with LOR to IFX maintenance
therapy using a proposed algorithm compared with intensified IFX treatment. Serum IFX and IFX antibodies
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were analysed using RIA, and were further analysed using ELISA and HMSA after study completion. IFX levels
were classified as therapeutic or subtherapeutic (≥ 0.5 µg/ml and < 0.5 µg/ml, respectively); IFX antibodies were
classified as detectable or undetectable. Costs were assessed at the 20-week scheduled trial visit and again at
1 year. Clinical outcomes were assessed after 20 weeks. Costs were reported in Danish krone and converted to
US dollars in 2012 prices. The base-case results were expressed as cost per ITT population, cost PP population,
cost PP population completion at end of trial week 12 and cost PP population completion at end of follow-up
week 20. Sensitivity analyses on inclusion of estimated costs for administering biologic agents, use of
actual IFX dosing and a reduction in the price of biologic agents of 3.5% and 7% were conducted to determine
the robustness of the base-case results. At the 20-week follow-up, the costs were significantly lower in the
algorithm group than in the IFX intensification group, and this differential was maintained throughout the
1-year study period. The base-case results, in terms of ITT for patients randomised to the algorithm group,
showed costs of approximately US$11,900 for one patient at the 20-week follow-up, compared with
US$22,100 at the 1-year follow-up. Among patients randomised to the IFX intensification group, the
corresponding costs were US$17,200 and US$29,100, respectively. In terms of PP, among those randomised
to the algorithm and the IFX groups, costs at the 20-week follow-up were approximately US$8700 and
US$17,200, respectively, whereas at the 1-year follow-up the costs were approximately US$15,700 and
US$29,100, respectively. The results from the sensitivity analyses were similar to the base-case results.
Velayos et al.157
Velayos et al.157 used a decision-analytical model to assess the cost-effectiveness of a testing-based strategy
with an empiric dose escalation strategy for patients with moderate to severe CD who become unresponsive
to therapy with IFX. These authors used the algorithm proposed by Afif et al.56 to form the basis of the
testing-based strategy, whereas the empiric dose escalation strategy was informed by the consensus
statement from the World Congress of Gastroenterology.157 The study was conducted from the perspective
of the third-party payer and a time horizon of 1 year, with a 4-week cycle length. Outcomes were reported
as QALYs. QALYs gained were derived based on utility values obtained from the study undertaken by
Gregor et al.20 Briefly, utility scores for 180 individuals with CD were obtained using various elicitation
methods (standard gamble, time trade-off or visual analogue scale). Gregor et al.20 suggested that the
standard gamble technique reflected the true value for health states related to patients with CD. Resource
use and costs included the cost of interventions – IFX, ADA, certolizumab pegol, natalizumab and surgery –
and the cost of diagnostics – anti-IFX antibody/serum IFX measurement, computerised tomography
enterography and colonoscopy. Costs were expressed in US dollars, but the price year was not reported.
The base-case results were expressed as an ICER based on the outcome of cost per QALY gained. Extensive
one-way sensitivity analyses were conducted and populated with data to run the model probabilistically to
represent the uncertainty in key model input parameters. The base-case results demonstrated that the
testing strategy was cheaper and marginally more effective, thus dominating the empiric strategy. Results
from the sensitivity analyses showed that empiric strategy was less expensive when the cost of surgery was
fivefold more than in the base case. In addition, reducing the utility value for the health state of the
‘mild/minimal inflammation with symptoms’ from 0.80 to 0.70 resulted in marginally greater QALYs in the
empiric group than in the testing-based group. Furthermore, increasing the cost for testing 25-fold resulted
in the testing-based strategy being more expensive than the empiric strategy. Results from the PSA showed
that the testing-based strategy has approximately 69% probability of being cost-effective compared with
empiric dose escalation at a willingness-to-pay of US$50,000 per QALY.
Comparison of the included studies
All four studies included in this review have been summarised in Table 27. Three studies were based on
RCTs73,123,124 and only one study157 presented an economic model. Of the RCTs, two123,124 were conducted
in Denmark and one73 was conducted in Belgium. All four studies73,123,124,157 conducted cost-effectiveness
analyses: Vande Casteele et al.73 compared concentration-based with clinician-based dosing; Steenholdt
et al.123,124 compared IFX treatment failure using a treatment algorithm compared with IFX dose increasing;
and Velayos et al.157 compared a testing-based strategy with an empiric dose escalation strategy. All
studies73,123,124,157 clearly stated the type of assay used to analyse serum levels and antibodies to anti-TNF-αs.
Two studies123,124 used RIA in the base case, one study73 used an assay developed in house and the
remaining study157 used a PROMETHEUS ELISA.
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The patient populations for three studies73,123,124 included eligible patients with moderate to severe CD,
whereas the study by Vande Casteele et al.73 included patients with UC. The study perspective was not
reported in two studies,123,124 whereas the other two studies73,157 conducted the analysis from a third-party
payer perspective. The time horizon varied from 12 weeks to 1 year. Steenholdt et al.123 based their
analysis on a 12-week horizon, whereas the other three studies73,124,157 used a 1-year time horizon to
estimate the cost-effectiveness of the different strategies.
In two studies,73,157 outcomes were reported as cost per QALYs gained. Vande Casteele et al.73 used the
EQ-5D measure to estimate QALYs, whereas Velayos et al.157 did not explicitly report how the QALYs were
estimated, except to say that they were obtained from a secondary source.20 The two studies by Steenholdt
et al.123,124 reported outcomes in terms of cost per ITT and cost PP population.
Three studies123,124,157 provided quite a comprehensive breakdown of resource use and costs, whereas the
study by Vande Casteele et al.73 did not elaborate on resource use, apart from the drug costs. Three
studies73,123,124 reported costs in 2012 prices, whereas Velayos et al.157 did not report the price year explicitly;
however, we assumed that costs are most likely to be in 2012 prices, as the study was published in 2013.
No studies conducted discounting for either costs or benefits as the time horizon for these studies was
≤ 1 year.
The results and conclusions reported differed between studies, Vande Casteele et al.73 demonstrated that
concentration-based dosing was slightly less effective and less costly than clinically based dosing, but
overall differences were small. Steenholdt et al.123 showed that the intervention based on the algorithm
achieved similar clinical and life quality outcomes to dose intensification, but at a lower cost at 12 weeks.
These results were maintained at both 20 weeks and 1 year.124 Velayos et al.157 showed that the testing
strategy was cheaper and more effective than the empiric strategy.
All four studies73,123,124,157 conducted sensitivity analyses to deal with uncertainty around key parameters.
The sensitivity analyses ranged from the most simplistic one-way sensitivity analyses123,124 to the more
sophisticated probabilistic analyses.157
Quality assessment
We present, in Appendix 15, a summary of the reporting quality of the studies included in the current
review against the CHEERS checklist.158 Using a 25-point CHEERS checklist, one article73 did not identify
the study as an economic evaluation in the title. All studies provided background information to the study
and clearly outlined the objectives of the study. Two studies73,157 reported the viewpoint of the economic
analysis. All studies described the comparators fully and reported the time horizon. However, because of
the short time horizon, no studies conducted discounting of costs and benefits. In addition, the choice of
health outcomes was well reported by all four studies;73,123,124,157 however, only one study73 reported how
these health states were valued. Resource use and costs were well reported in three studies123,124,157 apart
from that by Vande Casteele et al.,73 who described only the drug costs. The majority of the studies73,123,124
conducted an economic analysis alongside a RCT, whereas one study157 developed an economic model.
In terms of analytical methods, study parameters, incremental costs and outcomes and uncertainty were
well reported by all four studies. Limitations were provided by all four studies and generalisability was only
partially reported by three studies.123,124,157
From the studies identified, one157 conducted a model-based economic analysis to determine whether or
not a testing-based strategy was more cost-effective than an empiric dose escalation strategy. We present,
in Appendix 15, a summary of the reporting quality of this study against Philips’s checklist.149 In general,
Velayos et al.157 conformed to best practice for reporting model-based economic evaluations in terms of
clearly stating the decision problem, adequately outlining the objectives, clearly stating the viewpoint of
the analysis and describing the model structure, which represented the clinical pathway that patients with
CD may follow. Time horizon and cycle length were stated and justified. In terms of the data required to
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populate the model, Velayos et al.157 adequately provided references, but they were unclear on the choices
made between data sources and the quality of information used in the model. In addition, it was unclear
whether or not any expert opinion had been used when choosing baseline information for the model. The
other limitations identified were the lack of explanation of pre-model analysis (e.g. calculation of transition
probabilities, and methods and assumptions used to extrapolate short-term results into final outcomes) and
the omission of half-cycle correction.
Discussion and conclusion
The evidence available on the cost-effectiveness of LISA-TRACKER ELISA kits, TNF-α-Blocker ELISA kits and
Promonitor ELISA kits for measuring levels of TNF-α inhibitors and of anti-drug antibodies appears to be
limited. We identified four cost-effectiveness analyses,73,123,124,157 which comprised three economic analyses
conducted alongside clinical trials and one model-based economic analysis.
The majority of the populations included in these studies had moderate to severe CD and were considered
responders to IFX maintenance treatment. Studies (n = 2) mainly used RIA kits to analyse serum levels and
antibodies to anti-TNF-αs. We appraised these analyses against frameworks for best practice for reporting
economic evaluation and economic modelling. In general, all studies provided background information on
the decision problem, clearly outlined the objectives of the study, adequately described and justified the
choice of comparators and reported the time horizon. In addition, Velayos et al.157 clearly stated the
viewpoint of their model-based economic analysis and outlined the model structure. These studies all provide
useful information in this developing area, but are subject to limitations. First, the definition for responder
was not clear and it varied between studies. In addition, the definition of patients with moderate to severe
CD varied across studies. Second, owing to the small sample sizes, the studies may not be reflective. Third,
the short time horizon may not capture the longer-term costs and benefits of the use of testing to monitor
serum anti-TNF-α levels and antibodies to anti-TNF-αs. Fourth, the method used to choose between data
sources and the quality of information used in the model was unclear. Of the two studies73,157 that reported
their outcomes in terms of cost per QALY, only one157 reported the generic preference-based measure used
to estimate QALYs. This highlights a lack of transparency of the information used in the model. Other
concerns relate to the lack of justification for the 4-week cycle length and the lack of transparency on how
transition probabilities were obtained and derived in the modelling study by Velayos et al.157 and, in the case
of the study conducted by Vande Casteele et al.,73 the lack of detail on the resource use and costs.
In summary, all of these studies indicated that a testing strategy might be less costly than alternatives with
variable small effects on effectiveness, some indicating small reduced benefits and some small increased
benefits. Use of standard checklists suggested that all the studies are subject to some limitations.
In Developing the model structure, we outline the development of economic models to determine the
cost-effectiveness of various assays to inform on the treatment algorithm for patients who are considered
responders and patients with LOR.
Considerations of using the former Health Technology Assessment
model by Dretzke et al.5 to inform the current model structure
The previous HTA model5 used natural history data, which are now outdated. The current model for the
standard care arm is restricted to starting with IFX (through lack of data for ADA) but otherwise adopts
the general approach used in the HTA model but using updated natural history data (for surgery, for
maintenance of response, for dose escalation and for other minor parameters, together with more recent
clinical expert advice). Clearly the HTA model structure is not easily transferable to the current intervention
arm, as the latter requires considerable added complexity because it is based on drug and anti-drug
antibody testing; however, this arm conforms to the HTA approach and is designed for comparison with
standard care on IFX.
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Health economic methods
Objective
To assess the cost-effectiveness of employing anti-TNF-α and anti-TNF-α antibody monitoring with
LISA-TRACKER ELISA kits, TNF-α-Blocker ELISA kits and Promonitor ELISA kits in patients with CD
compared with standard care.
Standard care for patients during maintenance of disease (responders) is shown in Figure 28.
Standard care of patients with CD may vary across hospitals in the UK. Based on expert clinical input, we
assumed that patients categorised as responders will continue to receive IFX maintenance therapy every
8 weeks until they lose response. Patients who lose response will receive an increased dose of IFX. Patients will
either respond to this increased dose or continue to exhibit LOR, in which case they will receive another agent
in addition to their current treatment. Patients who receive another agent may regain response or continue to
exhibit LOR, in which case their anti-TNF-α treatment will be changed. Patients who do not respond a new a
anti-TNF-α treatment will be considered for surgery. We have assumed that patients who respond to treatment
will remain on that treatment until they lose response. We assume that patients who are in the post-surgery
health state might receive various treatments (anti-TNF-α, a combination of anti-TNF-α and immunosuppressant
or no treatment). Patients who experience LOR post surgery are expected to follow the standard care treatment
pathway as for responders entering the model who subsequently lose response, that is they will receive an
increased dose of IFX and follow the same treatment regime until they require repeat surgery.
Developing the model structure
We developed a Markov model using TreeAge Pro 2013 software program (TreeAge Software, Williamstown,
MA, USA). The model was developed with clinical input, and represents the clinical pathway patients would
undergo while being treated for moderate to severe CD. The illustrative model structures for responders and for
those who lose response are shown in Figures 29 and 30, respectively. More detailed decision trees on the
Patients on IFX
Respond Do not respond 
Respond Do not respond 
Respond Do not respond 
Respond Do not respond 
Increase dose
Add another agent
Switch anti-TNF-α
Surgery
FIGURE 28 Standard care pathway for patients on maintenance therapy.
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Dead
Loss of response to
anti-TNF-α
Post surgery
Regain response
Responder
Loss of response
(discontinuation of
anti-TNF-α)
FIGURE 29 Illustrative structure for responders.
Post surgery
Dead
Regain responseLoss of response to
anti-TNF-α
Loss of response
(discontinuation of
anti-TNF-α)
FIGURE 30 Illustrative structure for LOR.
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patient pathways can be found in Appendix 16. In the models, we compared concurrent and reflex testing
conducted every 3 months with standard care for responders and those who experience LOR:
l standard care
l concurrent testing – testing for TNF-α inhibitor levels and antibodies to TNF-α inhibitors
l reflex testing – testing for TNF-α inhibitor levels followed by testing of antibodies to TNF-α inhibitors
depending on the drug test level.
The NICE guidance on model-based economic analyses suggests adopting a time horizon long enough to
capture the costs and effects of an intervention; normally a lifetime horizon because chronic conditions
may reduce life expectancy.5 To our knowledge, no clinical trials have provided evidence of significant
difference between testing and standard regimens in CD mortality.5 Hence, we assumed a 10-year time
horizon with 4-week cycle lengths to be appropriate to capture all benefits of testing and treatment.
Table 28 shows the health states required for the responder and LOR models.
In the following sections we discuss the testing strategies (concurrent and reflex testing) to be compared in
both models (responders and patients with LOR).
Concurrent testing
In the concurrent testing strategy, patients undergo tests for serum anti-TNF-α levels and antibodies to
anti-TNF-α simultaneously, and once the test results are available follow the proposed algorithm. Patients are
classified, on the basis of their test results, into one of four groups: drug absent and antibodies present, drug
absent and antibodies absent, drug present and antibodies present, or drug present and antibodies absent.
Alternatively, patients may be categorised according to levels of drug regardless of antibody levels (e.g. as in
the TAXIT trial73). Details of test results and proposed algorithms from Steenholdt et al.123 for patients with LOR
and from Vande Casteele et al.73 for responders are presented in Chapter 3, Objective B: description of
algorithms prescribing patient management following test outcomes for drug and/or anti-drug antibody levels.
Responder
Based on the results from concurrent testing in the responder group, various treatment options may be
adopted depending on the treatment algorithm used. In the model the treatment options are based on those
used in the TAXIT study,73 the only clinical study of an implemented and defined algorithm for responders:
1. if drug is absent and antibodies are present in a concentration > 8 mg/ml, patients receive a switch in
TNF-α inhibitor
TABLE 28 Definition of health states included in the Markov model
Health state Definition
Responder Maintenance treatment when the patient has supportable active symptoms of abdominal pain,
diarrhoea, rectal bleeding or weight loss
LOR Recurrence of active symptoms while on treatment with maintenance regimen, after having
responded to treatment
LOR (no anti-TNF-α)a Recurrence of active symptoms having discontinued anti-TNF-α treatment with maintenance
regimen, but receiving best supportive care
Regain response Maintenance treatment when the patient has no active symptoms having previously lost response
Post surgery Medication/no medication after inpatient surgical procedure
Dead By definition
a Patients who have discontinued anti-TNF-α treatment, but are receiving best supportive care.
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2. if drug is absent and antibodies are present in a concentration < 8 mg/ml, patients receive an increased
dosage of current treatment (i.e. IFX dose to 10 mg/kg every 8 weeks)
3. if the drug is present (there is no need to measure antibodies), and depending on the trough levels,
patients would have either a decrease in the dosing interval (if trough level below the target range), no
dose adaptation (if trough level is within the target range) or an increase the dosing intervals (if trough
level is above the target range).
Following adoption of these algorithm treatments, patients may remain responders, lose response (move to
the LOR health state) or die.
Loss of response
After LOR to anti-TNF-α, testing and algorithm treatments are based on those used by Steenholdt et al.123
in patients who lost response to anti-TNF-α (IFX); this is the only clinical study of implementation of an
algorithm for patients with lost response:
1. Drug absent and antibodies present – patients would receive a switch in TNF-α inhibitor.
2. Drug absent and no antibodies – patients would receive an increase dosage of current treatment.
3. Drug present and antibodies present – we have assumed that patients will either have symptoms not
requiring surgery and discontinue anti-TNF-α treatment or have active symptoms that require surgery.
Patients in the former group would discontinue maintenance treatment and move to the LOR health
state (discontinuation of anti-TNF-α) and receive best supportive care. Patients who develop active
symptoms that require surgery move to the post-surgery health state or could die.
4. Drug present and no antibodies – the pathway for patients with drug and antibodies present is identical
to the pathway for patients with drug present without antibodies.
As a result of the treatment algorithm, patients may remain with LOR, regain response or could die.
Loss of response health state (discontinuation of anti-tumour necrosis factor alpha)
Patients who occupy this health state are those who have discontinued anti-TNF-α maintenance treatment
and are receiving best supportive care. As in the LOR health state (see Concurrent testing), we have
assumed that patients who remain in this health state have symptoms of CD that do not require surgery.
Patients who develop active symptoms that require surgery move to the post-surgery health state or
could die.
Regain response health state
Patients who move to the ‘regain response’ health state are tested for drugs and antibodies concurrently.
Here we have assumed that they would follow the same treatment algorithm as a patient who was classed
as a responder (see the TAXIT study73 algorithm in Chapter 3, Objective B: description of algorithms
prescribing patient management following test outcomes for drug and/or anti-drug antibody levels). As a
result of the treatment algorithm, patients can remain in the regain response health state, lose response
(move to the LOR health state) or could die.
Post-surgery (remission) health state
For patients who move to the post-surgery health state, treatment options are an anti-TNF-α, an
immunosuppressant, a combination of an anti-TNF-α and an immunosuppressant or no treatment. Patients
who are receiving an anti-TNF-α or a combination of anti-TNF-α and an immunosuppressant can regain
response or lose response. For patients who regain response or who lose response, we have assumed that
the pathway is similar to patients in the regain response health state (see Concurrent testing, Regain
response health state) or the LOR health state (see Concurrent testing, Loss of response), respectively.
Patients who are receiving immunosuppressants or no treatment could remain in the post-surgery health
state until further surgery is required or die.
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Reflex testing
In the reflex testing strategy, patients would receive a test to analyse serum anti-TNF-α levels. As a result
of testing, two test outcomes are likely: drug absent or drug present. Based on the drug result, patients
would undergo further testing for the presence or absence of antibodies. In this section we outline the
health states and the pathways for patients undergoing reflex testing for both responder and LOR models.
No study was identified that tested an algorithm for reflex testing. The algorithm followed in the model
was therefore based on that of the TAXIT73 trial for responders and the Steenholdt et al.123 algorithm for
patients with LOR using concurrent testing. Further details of test results and proposed algorithms are
presented in Chapter 3, Objective B: description of algorithms prescribing patient management following
test outcomes for drug and/or anti-drug antibody levels.
Responder
Based on the results from reflex testing in the responder group, various treatment options are available:
1. If drug is absent, test for antibodies – patients with antibodies present would receive a switch in TNF-α
inhibitor. Patients with no antibodies would receive an increase dosage of current treatment (i.e. IFX
dose to 10 mg/kg every 8 weeks).
2. If drug is absent and there are no antibodies – patients would receive an increase dosage of current
treatment (i.e. IFX dose to 5 mg/kg every 4 weeks).
3. If the drug is present and depending on the trough levels – patients would have a decrease in the
dosing interval (if trough level below the target range), no dose adaptation (if trough level is within the
target range) or an increase in the dosing intervals (if trough level is above the target range).
As a result of the treatment algorithm, patients could remain responders, lose response (move to the LOR
health state) or could die.
Loss of response
1. Drug absent and antibodies present: patients would receive a switch in TNF-α inhibitor.
2. Drug absent and no antibodies: patients would receive an increased dosage of current treatment.
3. Drug present and antibodies present: we have assumed that some patients will have symptoms not
requiring surgery and discontinue anti-TNF-α treatment or have active symptoms that require surgery.
Patients in the former would discontinue maintenance treatment and move to the LOR health state
(discontinuation of anti-TNF-α) and receive best supportive care. Patients who develop active symptoms
that require surgery move to the post-surgery health state or could die.
As a result of the treatment algorithm, patients could remain in the LOR state, regain response or die.
Loss of response health state (discontinuation of anti-tumour necrosis factor alpha)
Patients who occupy this health state are those who have discontinued anti-TNF-α maintenance treatment
and who are receiving best supportive care. As in the LOR health state (see Reflex testing, Loss of
response), we have assumed that patients who remain in this health state have symptoms of CD that do
not require surgery. Patients who develop active symptoms that require surgery move to the post-surgery
health state or could die.
Regain response health state
Those patients who move to the regain response health state would receive reflex testing for drug levels
and, if required, testing for antibodies to anti-TNF-α. We have assumed that they would follow the same
treatment algorithm for patients categorised as responders (see TAXIT study73 algorithm in Chapter 3,
Objective B: description of algorithms prescribing patient management following test outcomes for drug
and/or anti-drug antibody levels). As a result of the treatment algorithm, patients can remain in the regain
response health state, lose response (move to the LOR health state) or could die.
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Post-surgery (remission) health state
For patients who move to the post-surgery health state, the treatment options are to receive an anti-TNF-α,
immunosuppressant, a combination of anti-TNF-α and an immunosuppressant or no treatment. Patients
who are receiving an anti-TNF-α or a combination of anti-TNF-α and an immunosuppressant can regain or
lose response and follow the same pathways as outlined in Reflex testing, Regain response health state
and Reflex testing, Loss of response. For patients who are receiving immunosuppressants or no treatment,
the modelled options are to remain in the post-surgery health state until further surgery is required or
to die.
Model assumptions
A number of assumptions were required to develop a workable model structure to enable the analyses to
be undertaken. These assumptions are:
1. In our base case, the model starts with a hypothetical cohort of 30-year-olds with moderate to
severe CD.
2. Patients were assumed to have received intravenous infusions of 5 mg/kg IFX at weeks 0, 2 and 6.
Here we assumed that patients weighed > 70 kg.
3. Patients who regained response have the same utility as those who are considered to be responders.
4. We have assumed that patients with CD are not at increased risk of dying from the disease, and that
there is no difference in mortality between testing and standard care. However, in the case of patients
who have undergone surgery, the model assumes an increased risk of 0.0015 of dying as a result of
the procedure.
5. Treatment effects for patients receiving dose escalation (from 5 mg/kg to 10 mg/kg IFX) and a
decreased interval (from 8 weeks to 6 weeks) are the same.
6. Patients who are categorised as responders and who have trough concentration within the range that
the treatment algorithm suggests receive no dose adaptation.
7. In the base case we have assumed transition probabilities to be the same as standard care and used
those derived from Juillerat et al.159
8. Patients who remain in the LOR health state (discontinuation of anti-TNF-α) have symptoms of CD that
in time may require surgery. Patients will receive best supportive care until the development of active
symptoms necessitating surgery.
Data required for the model
The model was populated with clinical information from the current clinical effectiveness review and
supplemented with information from secondary sources. Information required to parameterise the model
included proportions, transition probabilities, resource use and costs, and utilities.
Proportions
The proportions of patients required to populate various model decision tree branches were obtained
from secondary sources [e.g. management studies described in Chapter 3, Objective C1: clinical studies
evaluating drug monitoring for the management of Crohn’s disease patients (management studies)] and,
when such data were lacking, from clinical input. Proportions that were estimated included partitioning of
patients by presence or absence of IFX and of antibodies to IFX in responders and in those with LOR;
partitioning of responders according to defined IFX trough levels; and partitioning by treatment options
following surgery.
Table 29 summarises the partitioning of IFX responders based on the study of Imaeda et al.,99 discussed in
Chapter 3, Analysis of correlation studies of tumour necrosis factor alpha/anti-drug antibodies level and
response, that used concurrent monitoring for the absence or presence of IFX and antibodies to IFX.
The proportions of IFX responders with various trough levels of IFX were based on Vande Casteele et al.73
(discussed in Chapter 3, Vande Casteele et al.: Trough level Adapted infliXImab Treatment study73). These
authors screened a cohort of patients with IBD who were receiving maintenance IFX treatment, and further
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categorised patients by drug concentration based on test result. Drug levels < 3 µg/ml were considered
below the target range, levels between 3 and 7 µg/ml were considered within range and those > 7 µg/ml
were above target range. Table 30 shows the proportions of responders with different trough drug levels
and the proportions of responders derived from this study.
The partitioning of IFX patients with LOR according to concurrent test monitoring of IFX and antibodies to
IFX was based on information obtained from Steenholdt et al.123 Table 31 summarises these proportions.
Patients who have undergone surgery may receive post-operative treatment to maintain remission.
These options include an anti-TNF-α, an immunosuppressant, a combination of an anti-TNF-α and an
immunosuppressant or no treatment. Table 32 shows these proportions based on the study of
van der Have et al.160
TABLE 29 Proportions derived based on concurrent testing of patients responding to IFX
Result Proportion Source
IFX absent and antibodies to IFX present 0.17241 Imaeda et al.99
IFX absent and antibodies to IFX absent 0.12069
IFX present 0.7069
TABLE 30 Proportions according to IFX trough levels of patients responding to IFX
Trough level Threshold (µg/ml) Proportion Source
1 < 3 0.2310 Vande Casteele et al.73
2 3–7 0.4821
3 > 7 0.2869
TABLE 31 Proportions based on concurrent testing of patients with LOR to IFX
Result Proportion Source
IFX absent and antibodies to IFX present 0.1515 Steenholdt et al.123
IFX absent and antibodies to IFX absent 0.0303
IFX present and antibodies to IFX present 0.0303
IFX present and antibodies to IFX absent 0.7879
TABLE 32 Treatment following surgery
Result Proportion Source
Anti-TNF-α 0.1250 van der Have et al.160
Immunosuppressant 0.5000
Combination of anti-TNF-α and immunosuppressant 0.1250
No treatment 0.2500
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Table 33 summarises the proportions of IFX responders based on the study by Imaeda et al.,99 in which
reflex testing was used to test for the absence or presence of IFX. In patients in whom IFX was present,
we used the proportions according to IFX trough levels based on the Vande Casteele et al.73 study, as
shown in Table 30.
The partitioning of IFX patients with LOR according to reflex test monitoring of IFX was based on
information obtained from Steenholdt et al.123 Table 34 summarises these proportions.
Time-to-event transition probabilities
Table 35 summarises the transition probabilities for time-to-event outcomes used in the models.
Transition probabilities from time-to-event studies
The transition probabilities provided in Table 35 are mainly derived from analyses of various time-to-event
studies judged to provide relevant information consistent with the model structure. Further details
regarding the derivation of, and justification for, these are provided in Appendix 17.
Resource use and costs
The resource use and costs included were those directly incurred by the NHS. The costs of reagents for
monitoring trough concentration of anti-TNFs and of antibody-measuring kits, treatment for CD and
laparoscopic ileocolic resection were all included in the analysis. Resource use and costs associated with
occupying all health states except dead were also included. Unit costs are presented in Table 36. The
majority of the cost information used in the analyses was obtained from secondary sources.
The costs of monitoring kits for IFX and for antibodies to IFX were obtained from Theradiag/Alpha
Laboratories. In Appendix 18, we present a breakdown of the resource use and costs associated with
monitoring kits for IFX and antibodies to IFX. In the models, we used a cost of £39.58 per person for
concurrent testing for IFX and antibodies to IFX. In the case of reflex testing, we used a cost of £43.48 for
patients in whom testing for IFX was followed by testing for antibodies because the results of the former
were negative. For patients in whom a test for IFX was positive, no subsequent antibodies monitoring test
was undertaken and, hence, we used a cost of £21.74.
The costs of maintenance treatment were obtained from the BNF (2013/14).166 The costs of treatment
associated with the induction phase (weeks 0–6) were not included. IFX treatment costs comprised its
acquisition and administration costs. In the base case, we assumed that patients receiving maintenance
therapy have received infusions of IFX 5 mg/kg every 8 weeks and that patients weighed, on average,
70 kg. For IFX maintenance, we derived a cost of £1966.41 (assuming four 100-mg vials at £419.62 plus
administration costs of £287.93 per infusion) every 8 weeks. For patients switching to ADA, we derived a
cost of £704.28 (2 × £352.14, assuming 40 mg of ADA is required every 2 weeks) per 4-week cycle. We
assumed that patients would self-administer ADA; hence, no administration costs were included.
The estimated costs of management (outpatient visits to consultants and further investigations) associated
with occupying all health states except the dead state were obtained from NHS Reference Costs 2013 to
2014167 and in consultation with a clinical expert. These health-state costs include outpatient visits,
colonoscopy and magnetic resonance imaging. In Table 36, we present the unit costs per year associated
with each health state.
TABLE 33 Proportions derived based on reflex testing of patients responding to IFX
Result Proportion Source
IFX absent 0.2931 Imaeda et al.99
IFX present 0.7069
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TABLE 35 Summary of parametric models used for estimating transition probabilities for time-to-event outcomes
Transition
Transition
probabilities (95% CI) Source Comments/assumptions
Standard care
1. IFX maintenance to LOR 0.008075
(0.007179 to 0.009084)
Juillerat et al.159 Observed data to 10 years,
patients with CD only
2. IFX maintenance to LOR after IFX
escalation
0.017415
(0.014443 to 0.020991)
Ma et al.161 Time to LOR after dose escalation.
Observed data to > 6 years
3. ADA after IFX, failure to LOR 0.058553
(0.052622 to 0.065129)
Sandborn et al.;162
Karmiris et al.48
RCT of ADA for CD (Sandborn
et al.162) and prospective study of
168 patients (Karmiris et al.48)
All
4. Time to surgery 0.002591
(0.002279 to 0.002945)
Nguyen et al.163 Large study with 7 years of data;
surgery incidence similar to small
UK study
5. Time to recurrent surgery 0.003122
(0.002398 to 0.004065)
Nguyen et al.163 As 4 above
6. Time to post-surgical relapse on
no therapy
0.049792
(0.042951 to 0.057538)
Gordon et al.164 Limited data
7. Time to post-surgical relapse on
immunosuppressant
0.029714
(0.024975 to 0.035022)
Gordon et al.164 Limited data
8. Time to post-surgical relapse on
anti-TNF-α
0.020784
(0.0143 to 0.030162)
Baert et al.77 Limited data, assumes applicability
of study population
9. Time to post-surgical relapse on
anti-TNF-α and immunosuppressant
As 8 above Lack of data Assumed as anti-TNF-α alone
Intervention arm: test algorithm strategy
10. IFX maintenance to LOR
(dose-escalation group)
As 1 above Juillerat et al.159 No evidence for advantage
relative to standard care
11. IFX maintenance to LOR
(dose-unchanged group)
As 1 above Juillerat et al.159 No evidence for difference
according to trough group
12. IFX maintenance to LOR
(dose-decreased group)
As 1 above Juillerat et al.159 No evidence for difference
according to trough group
13. Regained response on ADA to
LOR (group 1, IFX negative/
antibodies to IFX positive)
As 3 above As 3 above As 3 above
14. Regained response on
intensified IFX to LOR (group 2, IFX
negative/antibodies to IFX negative)
As 2 above As 2 above As 2 above
15. Regained response on
un-prescribed treatment for LOR
(group 3 or 4 IFX positive/antibodies
to IFX positive or negative) to LOR
0.086173
(0.04727 to 0.140943)
Rutgeerts et al.165 Constant hazard for loss of
regained response based on
placebo group from the 1999
Rutgeerts et al.165 RCT
TABLE 34 Proportions based on reflex testing of patients with for LOR to IFX
Result Proportion Source
IFX absent and antibodies present 0.2029 Steenholdt et al.123
IFX and antibodies absent 0.0435
IFX present 0.7536
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TABLE 36 Resource use and costs and utilities used in the models
Variable
Base-case
value
Range for
sensitivity
analysis Distribution Reference(s)
Resource use and costs
Monitoring IFX £21.74 Fixed NICE (Sarah Bond, NICE, 2014,
personal communication)
Monitoring antibodies to IFX (reflex
testing)
£41.98 Fixed
Monitoring IFX and antibodies to IFX
(concurrent testing)
£38.83 Fixed
Maintenance IFXa £1966.41 Fixed BNF 2013/14166
Maintenance ADAb £352.14 Fixed BNF 2013/14166
Azathioprinec £8.40 Fixed BNF 2013/14166 and expert
opinion
Mercaptopurined £100.94 Fixed
Prednisolonee £14.25 Fixed
Nutritional therapy (Modulen)f £15.06 Fixed
Laparoscopic ileocolic resectiong £6908 Fixed NHS Reference Costs 2013 to
2014167 and expert opinion
Responderh £725.69 Fixed
LORh £1241.38 Fixed
Regain responseh £725.69 Fixed
Post surgeryh £790.69 Fixed
Utility values
Responder 0.77 0.70–0.84 Beta(117.04,
34.96)
Velayos et al.157
LOR 0.62 0.59–0.66 Beta(465, 750) Derived from Gregor et al.20
Regain response 0.77 0.70–0.84 Beta(117.04,
34.96)
Assumption
Surgery 0.60 0.46–0.73 Beta(28.8, 19.2) Marchetti et al.168
Post surgery 0.86 0.82–0.90 Beta(301, 49) Velayos et al.157
Dead 0 Fixed By definition
Other
Mortality (age-specific death rates) Life tables Fixed Office for National Statistics,
2014169
Mortality associated with surgical
procedure
0.0015 Fixed Velayos et al.157
Discount rate per annum (costs and
QALYs)
3.5% Fixed
a Patients receiving 5 mg/kg IFX during maintenance therapy every 8 weeks. See Appendix 18, Table 63 for details.
b Patients receiving of ADA during maintenance therapy every 40 mg/kg every 2 weeks. See Appendix 18, Table 63
for details.
c Cost based on a 50-mg (56-tablet) pack and recommended dosage of 2.5 mg/kg per day.
d Cost based on a 50-mg (25-tablet) pack and recommended dosage of 1.25 mg/kg per day.
e Cost based on a 20-mg/100-ml single dose and recommended dosage of 30 mg in week 1, then 5mg each week for
the next 3 weeks.
f Cost based on 400 g of Modulen®; IBD (Nestlé, York, UK).
g Patients undergoing a laparoscopic ileocolic procedure. Detail resources used are provided in Appendix 18, Table 63.
h Unit cost (per year) associated with occupying this health state. Please see Appendix 18, Table 64 for further details on
resource use.
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Costs obtained from published sources were adjusted to 2013/14 prices using the Hospital and
Community Health Service Pay and Price Index170 and future costs were discounted at a rate of 3.5%
per annum, as recommended by NICE.
Outcomes
The outcome measure used in our analyses was the number of QALYs gained. To calculate the estimated
QALYs associated with the health states described in the model, we obtained utility weights from
published literature157 reported in our review of cost-effectiveness, and combined these utility values with
data on life expectancy from the Office for National Statistics.169 Utility values reported in Velayos et al.157
were obtained from the study undertaken by Gregor et al.,20 who compared various elicitation techniques
(standard gamble, time trade-off and visual analogue scale) in 180 consecutive CD patients. These authors
suggested that the standard gamble technique reflected the true value for health states related to patients
with CD, and these values may be the most appropriate for an economic analysis. Table 36 shows the
utility weights used in the model. In each cycle of the model, patients will incur a utility pay-off depending
on the health state being occupied. In the model, we applied a utility weight of 0.77 for individuals
categorised as responders or as having regained response. For those considered to have lost response, we
assigned a utility value of 0.62. Those who had undergone a surgical procedure and who remained in the
post-surgery health state were assigned a utility weight of 0.86.
Analysis
The model was constructed to assess the cost-effectiveness of concurrent testing, reflex testing and no
testing of blood levels of anti-TNF-α agents and of antibodies to these agents in patients with severe CD.
The model estimated the mean costs and effects associated with each testing strategy, and was simulated
over a 10-year time horizon with 4-weekly cycle lengths. The starting point for the responder population
was a hypothetical cohort of patients aged 30 years whose disease responds to a maintenance course of
TNF-α inhibitor therapy. This age was chosen because the onset for CD is likely to occur from the late
teens to age 30 years.171 We define a maintenance course as 5 mg/kg intravenous IFX every 8 weeks.
The analysis was undertaken from a NHS perspective in an outpatient care setting, and outcomes were
reported as ICERs, expressed in terms of cost per cost per QALY gained.
Sensitivity analysis
In addition to our base-case analysis, we have undertaken a number of sensitivity analyses. These analyses
are summarised below:
1. undertake concurrent testing and reflex testing every 12 months in the responder and LOR models
2. estimate the mean costs and effects associated with each strategy using a 1-year time horizon with
4-week cycle lengths
3. in the responders model – three possible modes of one-off testing:
i. one-off testing at 3 months followed by yearly retesting
ii. one-off testing at 3 months and one retest for those who regained response
iii. one-off testing at 3 months and no retesting for responders/regained response.
4. in the LOR model – 3-monthly testing for patients with LOR; no testing for patients who have
regained response
5. no regain of response following best supportive care (responders)
6. no regain of response following best supportive care (LOR).
Probabilistic sensitivity analyses
Probabilistic sensitivity analyses were undertaken to determine the joint uncertainty in key model input
parameters of test results and expected QALYs. The PSA was undertaken based on the outcome of cost
per QALY only. In PSA, each model parameter is assigned a distribution reflecting the amount and pattern
of its variation, and cost-effectiveness results are calculated by simultaneously selecting random values
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from each distribution. The distributions used in the PSA are presented in Table 36. We have calculated
probabilities that each strategy is the most cost-effective, at a willingness to pay of £20,000/QALY.
Results of base-case analyses and sensitivity analyses
Here we present the results of the base-case analyses based on the simplifying assumptions made in the
model. In the base case, using a hypothetical cohort of adults aged 30 years with severe CD, the results of
concurrent testing, reflex testing and no testing (standard practice), in terms of QALYs gained, are presented
in Table 37. At the 10-year time horizon, in the standard practice cohort, reflex testing resulted in a mean
gain of 6.2761 QALYs, with a corresponding mean cost of £138,700. The concurrent testing cohort gained
6.2637 QALYs, with a mean cost of £139,800. The no-testing cohort gained 6.5084 QALYs, with a mean
cost of £150,500. These results show that the reflex testing strategy was less costly and produced more
QALYs than the concurrent testing strategy, hence dominating the concurrent testing. The no-testing
strategy was the most costly and effective strategy with an ICER of approximately £50,800 per QALY.
Table 38 presents the results of the analyses based on an outcome of cost per QALY in the LOR model
with testing (concurrent and reflex) undertaken every 3 months. The results show that at the 10-year time
horizon the concurrent testing strategy resulted in 6.1807 QALYs, with a corresponding mean cost of
approximately £129,400. Reflex testing produced marginally more QALYs at an incremental cost of
approximately £94,700 per QALY. The no-testing strategy has a mean cost of approximately £215,800 and
costs approximately £84,800 more than reflex testing, with a total effectiveness of 6.4961 QALYs. This
result indicates that, in this LOR model, the no-testing strategy is less cost-effective than either reflex or
concurrent testing. (Each additional QALY gained by adopting the no-testing strategy compared with reflex
testing costs £284,100 in a cohort of patients with LOR.)
Results of sensitivity analyses
We undertook a number of one-way sensitivity analyses to determine the impact on the results of
changing key model input parameters (Table 39).
First, in the responder model, we changed the testing strategy from 3 months to annual testing.
The results showed that concurrent testing was the cheapest strategy, with a mean cost of approximately
£114,000 and generating 6.2201 QALYs. In the reflex testing arm, this strategy was marginally more
expensive and provided more QALYs, with an ICER of approximately £12,500 per QALY. As expected,
TABLE 37 Base-case results for the analysis cost per QALY (2013/14 prices)
Strategy
Mean cost per
strategy (£)
Difference in
costs (£)
Effectiveness
(QALYs)
Incremental
QALYs ICER (£)
Reflex testing 138,700 – 6.2761 – –
Concurrent
testing
139,800 1100 6.2637 –0.0124 Dominated
No testing 150,500 11,800 6.5084 0.2323 50,800
TABLE 38 Base-case results for the analysis cost per QALY (2013/14 prices) (LOR model)
Strategy
Mean cost per
strategy (£)
Difference in
costs (£)
Effectiveness
(QALYs)
Incremental
QALYs ICER (£)
Concurrent
testing
129,400 – 6.1807 – –
Reflex testing 131,000 1600 6.1976 0.0169 94,700
No testing 215,800 84,800 6.4961 0.2985 284,100
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TABLE 39 Univariate sensitivity analyses
Parameter varied
Mean cost per
strategy (£)
Difference in
costs (£)
Effectiveness
(QALYs)
Incremental
QALYs ICER (£)
Base case
Reflex testing 138,700 – 6.2761 – –
Concurrent testing 139,800 1100 6.2637 –0.0124 Dominated
No testing 150,500 11,800 6.5084 0.2323 50,800
Annual testing in responder model
Concurrent testing 114,000 – 6.2201 – –
Reflex testing 114,100 100 6.2281 0.0080 12,500
No testing 150,500 36,400 6.5084 0.2803 129,900
Annual testing in LOR model
Concurrent testing 106,900 – 6.1406 – –
Reflex testing 108,100 1200 6.1532 0.0126 95,200
No testing 215,800 107,700 6.4961 0.3429 314,100
1-year time horizon in responder model
No testing 14,900 – 0.7686 – –
Concurrent testing 18,500 3600 0.7549 –0.0137 Dominated
Reflex testing 19,200 4300 0.7543 –0.0143 Dominated
1-year time horizon in LOR model
Concurrent testing 12,000 – 0.6870 – –
Reflex testing 12,500 500 0.6915 0.0045 111,100
No testing 23,500 11,000 0.7560 0.0645 170,500
One-off testing at 3 months followed by yearly retesting
Reflex testing 113,400 – 6.2290 – –
Concurrent testing 113,800 800 6.2244 –0.0046 Dominated
No testing 150,500 37,100 6.5084 0.2794 132,800
One-off testing at 3 months and one retest for those who regained response
Concurrent testing 102,000 – 6.2255 – –
Reflex testing 103,000 1000 6.2390 0.0135 74,100
No testing 150,500 47,500 6.5084 0.2694 176,300
One-off testing at 3 months and no retesting for responders/regained response
Concurrent testing 102,000 – 6.2255 – –
Reflex testing 102,900 900 6.2390 0.0135 66,700
No testing 150,500 47,600 6.5084 0.2694 176,700
In the LOR model: 3-monthly testing for patients with LOR; no testing for patients who have regained response
Concurrent testing 96,200 - 6.1453 – –
Reflex testing 97,700 1500 6.1630 0.0177 84,700
No testing 215,800 118,100 6.4961 0.3331 354,500
continued
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the mean cost and effectiveness of the no-testing strategy remained unchanged. A no-testing strategy
compared with a reflex testing strategy had a reported ICER of £129,900 per QALY.
Second, changing the 3-month testing to annual testing in the LOR model resulted in both concurrent and
reflex testing being cheaper than the no-testing strategy.
Third, on changing the model time horizon from 10 years to 1 year with 3-month cycles, we found that
the no-testing strategy dominated both testing strategies. In the LOR model, the no-testing strategy was
the most expensive and most effective strategy, with a mean cost of approximately £23,500 and
corresponding QALYs of 0.7560.
Finally, changing the testing regime in the responder model to one-off testing at 3 months followed by
yearly testing (for those responding to treatment), at 3 months followed by one retest for those who
regained response, and at 3 months and no retesting for responders or those who regained response
showed that no testing was more expensive than testing and was more effective. Similar results were
shown obtained for the one-off testing in the LOR model, and assuming that patients could not regain
response following best supportive care.
In further sensitivity analyses, we varied key model input parameters to determine which inputs influence
the ICER. Figures 31 and 32 show the percentage change in the cost per QALY as a result of increasing or
decreasing these inputs by 10% of the base-case value. The results showed that the model is stable to
most of these changes, but is sensitive to a 10% increase in the utility value for patients who regain
response in both reflex and concurrent testing.
Results of probabilistic sensitivity analysis and cost-effectiveness
acceptability curves
Figure 33 shows the Monte Carlo simulation for the responder model. The scatterplot illustrates the
uncertainty in the expected costs and QALYs based on concurrent and reflex testing compared with no
testing. Scatterplots of the 10,000 runs of the Monte Carlo simulations show considerable uncertainty
around additional expected costs and QALYs.
The results for the responder model are presented in the form of cost-effectiveness acceptability curves in
Figure 34. Cost-effectiveness acceptability curves give the probability that a strategy is cost-effective at
various values of willingness to pay for a QALY. The willingness-to-pay threshold used by NICE is between
£20,000 and £30,000 per QALY. From the information and assumptions used in the model, the results in
Figure 34 show that, at £20,000 per QALY, the no-testing strategy is 92% likely to be cost-effective
compared with concurrent and reflex testing.
TABLE 39 Univariate sensitivity analyses (continued )
Parameter varied
Mean cost per
strategy (£)
Difference in
costs (£)
Effectiveness
(QALYs)
Incremental
QALYs ICER (£)
No regain of response following best supportive care (responders)
Reflex testing 87,900 – 5.7853 – –
Concurrent testing 89,900 2000 5.7838 –0.0015 Dominated
No testing 150,500 62,600 6.5084 0.7231 86,600
No regain of response following best supportive care (LOR)
Concurrent testing 54,000 – 5.4649 – –
Reflex testing 57,700 3700 5.4992 0.0343 107,900
No testing 215,700 158,000 6.4961 0.9969 158,500
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Cost of concurrent testing
Cost of IFX
Cost of dose escalation
Cost of surgery
Utility for responder
Utility for regain response
Utility for LOR
Utility for surgery
Utility for post surgery
ICER (£000, cost per QALY)
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FIGURE 31 Tornado diagram comparing no testing with reflex testing.
ICER (£000, cost per QALY)
Cost of concurrent testing
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Cost of surgery
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Utility for regain response
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Utility for surgery
Utility for post surgery
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FIGURE 32 Tornado diagram comparing no testing with concurrent testing.
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Summary of cost-effectiveness
In summary, a de novo Markov model was built in TreeAge Pro 2013 to evaluate the cost-effectiveness of
test algorithm-based treatment strategies compared with standard care. Two test strategies were assessed:
concurrent testing of drugs and of antibodies to the drugs, and sequential or reflex testing (i.e. a drug test
first, and then an anti-drug antibody test depending on the results of the drug test). The model structure
was informed by studies from the clinical effectiveness review, additional published studies and analysis,
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and expert clinical advice. The model had a 4-week cycle and a 10-year time horizon and adopted NHS
and PSS perspectives. Costs were adjusted to 2013/14 prices and annually discounted at 3.5%. The
starting point was a hypothetical cohort of patients aged 30 years. Outcomes are reported as ICERs,
expressed in terms of cost per QALY gained. A linked evidence approach was necessary. In this approach,
evidence from studies using tests other than the designated intervention tests was employed as a proxy for
intervention test evidence. A number of sensitivity analyses were undertaken, including a shortened 1-year
time horizon with 4-week cycle lengths, altered transition probabilities for LOR, altering the proportions
of patients in the different testing results categories and an arbitrary 10% change in the main input
parameters. PSA was also undertaken (10,000 model runs).
Two management studies, both RCTs of reasonable quality, have used treatment algorithms similar to
those suggested in the NICE scope. The economic modelling has been built around the algorithms used in
these studies. Expert opinion was sought regarding the complex patient pathways followed by patients
with CD and the treatment pathways dictated by the algorithms. Populating the model with information
from the two management studies was problematic because the studies were of small size and short
duration, and reported outcomes that were not directly relevant to an economic model; in addition, one
study lacked an appropriate standard care arm for economic modelling and neither reported outcomes
according to testing results. Many external sources of data were required to populate the model and
refining data inputs from these sources is currently still in progress.
Base-case deterministic and probabilistic model results and sensitivity analysis results have been presented.
The results require scrutiny using further investigations for model data inputs and sensitivity analyses,
particularly with regard to frequency of testing, so as to test their robustness and to identify the main
drivers of the ICER. However, we conclude that QALY gains are likely to very similar in both arms
(concurrent/reflex) whereas the cost of the testing strategy (concurrent/reflex) appears to be more than
twice the cost of standard care.
DOI: 10.3310/hta20830 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 83
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Freeman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
113

Chapter 5 Discussion
I t has been proposed that measuring levels of anti-TNF-α drug and antibodies raised against the drugduring an immune response can aid the management of patients with CD who are on maintenance
therapy. This implies that patients have responded to induction therapy of anti-TNF-α with a reduction in
symptoms and receive scheduled regular treatments. The main reason for drug monitoring in CD is to keep
patients symptom free for as long as possible and avoid surgery by (1) optimising the dose and preventing
LOR in patients who respond to drug treatment and (2) treating LOR with the most appropriate change
in treatment in patients who have lost response during maintenance therapy. In this assessment we
investigated to what extent drug and anti-drug antibody measurements obtained using three different
types of commercially available ELISA kits can meet this aim of improved outcomes and if this approach is
cost-effective. The kits under assessment were LISA-TRACKER ELISA kits, TNF-α-Blocker ELISA kits and
Promonitor ELISA kits.
Decision problem and objectives
Our overall objective was to undertake a clinical effectiveness and cost-effectiveness analysis of testing
anti-TNF-α levels and antibodies to anti-TNF-α in patients with CD who either are responding to anti-TNF-α
treatment or have lost response to treatment during maintenance therapy. Testing strategies considered in
this review were concurrent testing of drug and anti-drug antibody levels and antibody testing conditional
on the absence of anti-TNF-α. We aimed to systematically review the evidence on the clinical effectiveness
of monitoring anti-TNF-α drugs and their antibodies in responders and patients with LOR when ELISA
results are used in combination with an algorithm that prescribes treatment pathways for the management
of patients with specific drug and anti-drug antibody levels. We also aimed to identify evidence relevant to
the costs of using these ELISAs and develop a cost-effectiveness model.
Summary of methods and findings
Clinical effectiveness
We searched a number of databases including MEDLINE, EMBASE, The Cochrane Library and the Science
Citation Index. We mapped the included studies according to the focus of the studies as management
studies (reporting clinical outcomes following drug and anti-drug antibody testing and change in patient
management according to a prescriptive algorithm for the management of CD patients), assay-type
comparison studies (comparing any of the three intervention ELISAs with each other or with assays used in
a linked evidence approach) and correlation studies (reporting the relationship between test outcome and
clinical status of tested patients). Management studies were assessed for their clinical outcome data in
relationship to assay type, test outcomes and algorithm followed. Four different test outcomes are possible
when administering dichotomised testing for drug and anti-drug antibody levels. These are drug present
and antibodies absent; drug absent and antibodies absent; drug present and antibodies present; and drug
absent and antibodies present. The proportion of patients falling into these four categories according to
testing and their clinical outcome data in terms of response and non-response following prescribed
treatment changes were taken forward to the modelling. Another testing strategy categorises patients into
groups according to several levels of anti-TNF-α and prescribes appropriate treatment accordingly.
Assay-type comparison studies were assessed for concordance statistics reported for relevant comparisons
between assay types used in management studies and the three intervention assay kits. Our aim was to
evaluate the generalisability of clinical outcome data from studies using non-intervention assays to the
three intervention assays of interest in a linked evidence approach.
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Correlation studies were assessed for sufficient data on the diagnostic performance of tests in predicting
response/LOR in the two different patient groups and meta-analysed in order to use alternative data to the
data from single management studies in the modelling.
We found 2428 records, of which 62 studies were included; an additional six studies were identified
through other sources, making a total of 68 included studies. Of these studies, three were management
studies measuring levels of IFX using RIA in patients with LOR, a commercial ELISA and HMSA in responders
and an in-house ELISA in responders. The three studies used different algorithms for the management of
patients with certain test outcomes and only two of the three studies measured antibodies in addition to IFX
levels. All of the studies were small in size and none was long enough to fully assess the effect of following
a treatment algorithm for the management of patients undergoing anti-TNF-α therapy for CD. Furthermore,
the cut-off points of drug and anti-drug antibody levels used to determine therapeutic levels were not
comparable in these studies. The sample collection times and analysis times were different, as were the
definitions used for clinical response, remission, progression and relapse. Steenholdt et al.123,124 was the only
RCT that compared drug monitoring and treatment change according to an algorithm with standard care
(dose intensification) in patients with LOR. The primary outcome of this study was cost, and the authors
concluded that combined measurement of drug and anti-drug antibodies reduces average treatment costs
per patients compared with routine IFX dose escalation and without any apparent negative effect on clinical
efficacy. However, dose escalation was the most expensive treatment option in the standard care arm
and might not be representative for UK clinical practice. Two studies investigated dose optimisation in
responders: a 52-week RCT (TAXIT)73 indicated no benefit in clinical remission from test-directed dose
optimisation (RR after compared with before optimisation 1.053, 95% CI 0.936 to 1.186), and no
difference at 1 year between clinically based dosing and test-based dosing in clinical and biological
remission (p = 0.686); the small retrospective observational study of Vaughn et al.128 reported superior
retention in IFX treatment, implying clinical benefit from test monitoring, but this study was judged to be at
considerable risk of selection bias.
The links from the assays used in the management studies to the intervention assays of interest were weak
and were complicated by the fact that none of the assays can be classed as a gold standard; this limits the
comparative data that are useful for a linked evidence approach using concordance data and/or Cohen’s
kappa. The only direct link that was found was a study67 comparing the performance of LISA-TRACKER
assays with that of the Leuven in-house ELISA used in the TAXIT trial investigating the clinical effectiveness
of dose adjustment in responders to IFX.73 It reported disagreement for IFX level measurements in at least
11 out of 58 samples and for anti-drug antibodies to IFX in at least 3 out of 62 samples; the results for the
remainder were unclear.67 Overall, there were no concordance data linking any of the index tests to any of
the comparator tests at a clinically meaningful threshold. From these data, it cannot be assessed which
assay is more accurate or to what extent the results from the management studies are relevant to the
intervention assays.
Meta-analyses of correlation studies indicated moderate test accuracy; PPV and NPV estimates derived from
meta-analyses indicated that between 20% and 30% of positive and negative test results are likely to
be inaccurate.
Cost-effectiveness
A comprehensive search of the literature for published economic evaluations, utility studies and cost
studies was performed.
Four studies reported information on the cost-effectiveness of kits available for measuring levels of TNF-α
inhibitors and of anti-drug antibodies in patients with severe CD. Of these, one study157 used a decision-
analytic model to assess the cost-effectiveness of using test-based strategy compared with dose escalation
in patients who have lost responsiveness to IFX. This review highlights that there is a paucity of economic
evidence in this area.
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The economic evidence was critically appraised against frameworks for best practice for reporting an
economic evaluation. In terms of the quality of the reporting standards, most studies performed well
against the CHEERS checklist. These studies provided useful information, but were subject to limitations.
First, the title of one study73 failed to state that an economic evaluation was conducted. Second, resource
use and costs reported in Vande Casteele et al.73 were not comprehensive, including only costs related
to drug treatment. In the case of the study157 that conducted a model-based economic evaluation, the
authors have adequately reported information on the decision problem, the structure of the model and
its assumptions, time horizon and cycle lengths, and resource use and costs. However, the study had
limitations: first, that there was lack of clarity regarding the methods used to extrapolate short-term results
into final outcomes; and, second, it was unclear if the model was developed with any clinical input. Finally,
these authors did not undertake half-cycle correction or justify its omission.
A de novo Markov model was built in TreeAge Pro 2013 to evaluate the cost-effectiveness of test
algorithm-based treatment strategies compared with standard care. Two test strategies were assessed:
(1) concurrent testing of drugs and antibodies to the drugs, and (2) sequential or reflex testing (i.e. a drug
test first, and then an anti-drug antibody test depending on the results of the drug test). The model
structure was informed by studies from the clinical effectiveness review, additional published studies and
expert clinical advice. The model had a 4-week cycle and a 10-year time horizon, and adopted NHS and
PSS perspectives. Costs were adjusted to 2013/14 prices and annually discounted at 3.5%. The starting
point was a hypothetical cohort of patients aged 30 years. Outcomes are reported as ICERs, expressed in
terms of cost per QALY gained. A linked evidence approach was necessary. In this approach, evidence
from studies using tests other than the designated intervention tests was employed as a proxy for
intervention test evidence. A number of sensitivity analyses were undertaken, including a shortened 1-year
time horizon with 4-week cycle lengths, altered transition probabilities for LOR and altering the proportions
of patients in the different testing results categories. PSA was also undertaken (10,000 model runs).
In the base case, results show that standard practice was less costly and produced more QALYs; hence,
dominating both the reflex testing and the concurrent testing strategy.
The results based on the outcome cost per QALY showed that reflex testing dominated the concurrent
testing strategy at the 10-year time horizon. Standard practice was more costly and produced more QALYs
than the other strategies. No testing resulted in 6.5084 QALYs, with a corresponding mean cost of
£150,500. Reflex testing resulted in 6.2761 QALYs, with a mean cost of £138,700. Concurrent testing
generated 6.2637 QALYs, with a mean cost of £139,800.
Sensitivity analyses indicated that change in testing frequency from 3-monthly to annually or reducing the
time horizon to 1 year changed the most cost-effective option to a concurrent testing strategy. The PSA
indicated a 92% likelihood that the no-testing strategy was cost-effective at a willingness to pay of
£20,000 per QALY.
The no-testing strategy dominated both of the other testing strategies when making changes to the model
time horizon in the responder model.
Varying key model input parameters by an arbitrary 10% showed that the no-testing strategy continued to
dominate the testing strategies in most cases.
Strengths and limitations
We undertook extensive systematic searches for relevant evidence and screened more than 30,000 titles.
We used a recently developed method for analysis of published time-to-event data and undertook a new
meta-analysis of test accuracy studies. In undertaking a linked evidence approach, and as far as evidence
would allow, we rigorously examined the probable equivalence of assay methods specified as interventions
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compared with those used in the identified studies which investigated a test–treatment algorithm strategy.
A particular strength of this work was the consideration of the additional objective (objective C2: analysis
of studies relating test results to clinical state of patients) to include correlation studies. Correlation studies
that reported both drug and anti-drug antibody test results for each patient provided test result probabilities
by patient category (response and LOR). This was used in the economic model as an alternative to the
probabilities reported by the management studies. Correlation studies reporting test results by group rather
than by individual were used to provide a pooled estimate for the probability of returning a specified test
result after trough anti-TNF-α testing (useful for estimating reflex strategy test result probabilities). This
information was used when no evidence from management studies was available.
One of the main problems with this work is that the underlying evidence base for a ‘linked evidence’
approach is of concern. No test algorithm studies employed the specified intervention tests. The only
comparative evidence of monitoring drug and anti-drug antibody levels and standard care for the
economic evaluation comes from studies using other assays than the three intervention assays under
assessment, even though a formal link between those assays and the intervention assays could not be
established. All of the economic modelling depends on the reasonable assumption that the commercial
ELISA kits with RIA and the Leuven in-house ELISA are equivalent. However, the technical description of
the assays, the differing drug thresholds used and the data from assay type comparison studies seem to
suggest otherwise. Furthermore, there was insufficient evidence to link any of the index tests to any of the
comparator tests with links to clinical outcomes. We looked for concordance data or Cohen’s kappa at set
thresholds to determine how much different tests agreed and to use these data to undertake a sensitivity
analysis. Unfortunately, the study by Steenholdt et al.122 did not use any of the index tests and the link
based on concordance data could not be established. We therefore remain uncertain to what extent the
outcomes of the assessment apply to the three assay kits under evaluation, and the cost-effectiveness
estimates that we have presented may not be reflective of the cost-effectiveness of LISA-TRACKER ELISA
kits, TNF-α-Blocker ELISA kits and Promonitor ELISA kits.
Furthermore, most of the available evidence about tests and algorithms for prescribing treatment in
accordance with test results does not directly address the clinical effectiveness decision questions. The
majority of evidence in the form of correlation studies does not generally present clinical decision-making
following test outcome; and studies that do present clinical decision-making generally did not act on a
prescriptive algorithm. Although a number of algorithms have been suggested, only two have been tested
in RCTs. Steenholdt et al.123 tested a prescriptive algorithm for the clinical management of patients with
LOR following combined drug and anti-drug antibody testing. This is representative of our concurrent
testing strategy. However, no RCT presenting and evaluating an algorithm for reflex testing was identified.
We therefore needed to assume that the Steenholdt algorithm can be adapted and the same treatment
options are applicable for the three possible test outcomes following reflex testing (drug absent and
antibody present; drug absent and antibody absent; drug present). As the drug-positive and anti-drug
antibodies-positive group is treated identically to the drug-positive and anti-drug antibodies-negative group
in the RCT by Steenholdt et al.123 (using combined drug and anti-drug antibodies testing), the model
structure of the strategies of reflex testing and concurrent testing are identical.
It seems unlikely that reflex testing could be clinically feasible, as the delay in treatment because of
conditional testing of antibodies on absence of drug could be up to 4 weeks. The evidence for responders
comes from Vande Casteele et al.73 In this RCT, reflex testing of drug and anti-drug antibodies was
intended to aid drug optimisation with the aim to save drug costs and avoid adverse events in patients
with high drug levels by decreasing the dose and to avoid LOR in patients with low drug levels by
increasing the dose. Dose optimisation appears to be the most useful approach in responders, for whom
the dichotomisation of drug present or absent is not applicable. In that respect, only one of the decision
questions prescribed by the NICE scope was directly addressed by the RCTs.
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There are many possible test algorithm strategies in the literature reflecting individual groups’ views, but
the only currently relevant ones are those that have been implemented prospectively with patients and
compared with standard care, and then only if relevant outcomes were reported. A concern for the validity
of this review is the evidence on the lack of adherence to a pre-specified algorithm for the management of
tested patients. A number of studies show that the main reasons (generally > 50%) for initiating testing
are LOR, partial response or a flare.56,95,172–174 Other reasons for testing include routine monitoring and
adverse events. Although this finding is reasonably constant across studies, the consideration of test results
in clinical decision-making in the absence of a prescriptive treatment algorithm varied widely. Although
one study reported that drug levels but not the presence of antibodies influenced treatment decisions,95
another study reported that more patients with positive anti-drug antibody tests than with negative ones
received a treatment change.175 There is also evidence that test results affected treatment decisions in only
73% of patients tested56 and that an appropriate treatment change of switching anti-TNF-α agents in
patients with a positive anti-drug antibody test and dose increase in patients with subtherapeutic IFX levels
occurred in only 57% and 21% of patients, respectively.173
The rather sporadic consideration of test results in clinical decision-making seems to suggest that an
algorithm is needed to standardise the response to test outcomes. The study by Steenholdt et al.123
revealed, however, that the algorithm for prescribing treatment in this study was not followed in 42% of
patients in the algorithm group tested for drug and anti-drug antibodies. This questions the validity of the
comparative evidence, the usefulness of the algorithm and, therefore, the usefulness of testing anti-TNF-α
drug and anti-drug antibodies if no standardised treatment approach can be achieved.
In the course of the review it became apparent that the management of patients with CD varies widely
between hospitals and between treating clinicians, and that elements of the NICE guidance are possibly
out of date. The overall aim to avoid surgery, the heterogeneity of disease symptoms, the relapsing and
remitting disease pattern and, possibly, the personal preferences of clinicians and individual patients mean
that it is difficult to establish a standardised pathway for patients with CD. This is reflected in the different
algorithms identified but also in the different treatment options specified for patients with a certain test
outcome, and reflects the common opinion that a personalised approach to optimal anti-TNF-α treatment
can be successful only if multiple factors rather than just a single test result are considered in the
management of patients.30
This presented a considerable challenge for the modelling. Although the published algorithms tended to
present several treatment options for patients with a certain test outcome, reflecting the individual
difference in disease status, previous medication and duration of disease, our model was required to be
prescriptive, restricting treatment options to one or two possible treatments with little consideration of
patient variability. It is therefore questionable to what extent the model results can predict or reflect clinical
practice. A further complication was the fact that the algorithms were not developed for UK practice. The
change to other non-TNF-α biologics, namely vedolizumab, could not be chosen as an option in our model
as suggested in the Steenholdt algorithm. For this reason the proportion receiving surgery might be slightly
overestimated in the model. However, clinicians advised us that patients might be referred to clinical trials
of vedolizumab so could still be receiving this treatment option. Approval of vedolizumab for the treatment
of CD in the UK would therefore change the model outcome.
When considering using ELISAs or other assays to predict clinical outcomes (e.g. response) of patients with
CD on anti-TNF-α treatment, it is important not to forget that the tests are not perfect. Evaluation of the
predictive performance of the assays appears to show that a considerable number of patients will have a
false-positive or false-negative result and might receive the wrong treatment if prescribed by an algorithm
considering only test outcomes. Unfortunately, because of a lack of outcome data, we were unable to
model patients as true positives/true negatives/false positives/false negatives according to test outcome.
Therefore, in our model the test is not treated strictly as a diagnostic test but rather as an intervention of
combined test and algorithm, and the test result is not considered as a separate entity. This of course begs
the question of test accuracy.
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Furthermore, there is no reference standard for the assessment of response in CD patients. This means
that studies use different definitions for response, remission and relapse. As these definitions were used for
patient selection and for classification of outcomes in primary studies, we need to be cautious about the
generalisability of outcomes. Finally, we had to deal with tests that lack a validated threshold for drug
levels for the classification of response, which has large implications for the generalisability of study
outcomes. Appropriate test thresholds are strongly dependent on assay type and time of testing, the drug
measured and whether or not anti-drug antibodies are measured, and the type of clinical marker used to
evaluate response (CRP level, serum albumin, FC or endoscopic scoring of mucosal healing). Although we
are aware that the various assays do not measure the precise levels of drug and anti-drug antibody
because of the difficulties of interference and drug–antibody complexes, the uncertainties around the test
threshold and definitions of response question the value of knowing precise measurements of drug and
anti-drug antibody levels in patients.
The included studies recruited only adult patients with CD, and the applicability of outcomes to children
therefore remains unknown. However, in an abstract, Turon et al.176 reported that measurements of IFX
levels in paediatric IBD patients were informative and may improve safety and clinical symptoms in this
patient group, in which 47% of tests resulted in some form of modification of management.
Evidence was also lacking on the clinical effectiveness of monitoring patients on ADA. Although both ADA
and IFX are anti-TNF-α agents, they are different molecules and are administered via different routes and
at different doses using different schedules. It is, therefore, a further big assumption to treat outcomes of
monitoring patients on IFX as equivalent to outcomes for patients on ADA. For these reasons the economic
modelling was limited to IFX-treated patients.
The impact of immunosuppressants on patient outcome was not formally assessed in this review, as it was
outside the scope. However, the evidence suggests that immunosuppressants generally improve patient
outcome. The role that immunosuppressants might play in the monitoring of drug levels and anti-drug
antibody levels is an area for future research. Evidence is also emerging that FC can be used to monitor
patients with CD, as it is a good marker for IBD activity and predicts relapse in time before symptoms
return, thereby providing the clinician time to optimise therapy.177 Future research is needed into how this
marker and anti-TNF-α monitoring might complement each other in the management of CD patients.
Finally, although this review was restricted to the population of patients with CD, a substantial number of
studies included in the review recruited patients with IBD. We remain uncertain about the impact of patient
mix on the reported outcomes. Even though IFX and ADA have recently been approved by NICE for the
treatment of UC (positive NICE technology appraisal published in December 2014178), outcomes from this
assessment should not be readily transferred to UC patients; for example, Bar-yoseph et al.179 reported that
IFX is more immunogenic and reaches lower trough levels in patients with UC than in those with CD. This
seems to suggest that there are may be differences in the response to IFX between the two patient groups
that may be of importance for the cost-effectiveness of monitoring anti-TNF-α agents in UC patients.
Overall, owing to the paucity of evidence, and especially the lack of comparative studies, it is difficult to
draw firm conclusions regarding the clinical effectiveness of testing strategies.
One of the strengths of the work includes the building of a de novo Markov model for the cost-effectiveness
assessment. However, populating the economic model with outcome and test data from the management
studies was problematic because of the small population size and short duration of these studies, and
difficulties in allocating outcomes to categories of patients returning different defined test results. Inputs for
the economic model need to be drawn from disparate studies so our conclusions need to be tested with
data from further research. The appropriateness of evidence sourced from other studies may be questioned
because of differences in populations and because of incomplete or ambiguous information regarding
trough drug and anti-drug antibody levels. Several studies sourced for model inputs included a proportion of
patients with a UC diagnosis; the impact of this on model input is difficult to gauge.
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Although data are available about duration of anti-TNF-α therapies, few studies report reasons for
stopping these therapies; some patients may stop because of sustained remission and it was not possible
to model this change in treatment satisfactorily because of lack of relevant data for the population groups
explored in the model. For the same reasons it was not possible to model in the long term patients who
are reintroduced to anti-TNF-α treatment, for example the substantial proportion of patients who fail on
IFX and are then switched to receive a variety of non-anti-TNF-α therapies that may or may not improve
their clinical status, but who in the longer term are given an anti-TNF-α again.
All the studies used for modelling included mixed patient populations, a substantial proportion of whom
were already being treated with immunosuppressants and had previously been exposed to steroids. Steroids
are used intermittently for flare, and information on frequency and duration of use is missing. The goal of
treatment with immunosuppressants added to anti-TNF-α therapy is to restore a better response to anti-TNF-α.
The clinical effects of these agents are subsumed within the analysis of time to anti-TNF-α cessation.
Information about the timing and frequency of addition of immunosuppressants and the duration of their use
is inadequate. Therefore, it was difficult to model the addition of immunosuppressants and use of steroids for
patients on anti-TNF-α, and clinical expert opinion was sought regarding the proportion of time over 10 years
patients treated with anti-TNF-α agents would spend using steroid and immunosuppressants. These data were
assumed to apply for both testing and standard care arms of the model and were used for costing purposes.
We were not able to include adverse events occurring as a result of drug treatments in the models. In
addition, we have not included any health states or costs for patients who may have complications
following surgery. As a result, this may underestimate the costs.
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Chapter 6 Conclusions
The systematic review evidence gives some indication that the use of testing for IFX could becost-effective, but the RCTs on which this finding is based are small and lack validity. The tests
themselves appear to generate substantial rates of false positives and false negatives. Base-case
deterministic and probabilistic model results for IFX have been presented. These indicate that very similar
QALY gains are likely in both arms. No testing appears to be the most cost-effective option. This finding
was robust when investigated in various sensitivity analyses. Conclusions for ADA cannot be drawn from
the current evidence.
Recommendations for further research
We are aware that more comparative evidence is becoming available with the publication of the
Trial Assigning Individualized Options for Treatment (Rx) (ClinicalTrials.gov identification number
NCT01442025).180,181 This trial will provide further insight into the effectiveness of sustaining therapeutic
IFX trough levels by measuring drug levels followed by dose increase if criteria are met in CD patients.
Furthermore, the Personalised anti-TNF therapy in Crohn’s disease (UK Clinical Research Network
identification number 14175) study is expected to report the most comprehensive data relating test
outcomes to patient status in the second half of 2015.
However, there are many shortcomings in the current evidence base. Future research should address the
following questions:
1. How does measuring anti-TNF-α drug and their antibodies by ELISA kits vary from using RIA and
other methods?
2. What are the clinically significant differences in the performance of ELISAs, RIA and HMSA?
3. What are the best criteria for estimating response, non-response and LOR, and at what time should an
assessment take place?
4. What is the most widely acceptable algorithm in the UK?
5. What are the barriers of following an algorithm for clinical management according to anti-TNF-α and
anti-drug antibody levels?
6. What is the best time point of measuring drug and antibody, and how frequently should
measurements be taken in responders and in patients with LOR?
7. What is the validated drug threshold that predicts clinical outcome?
8. What is the clinical effectiveness and cost-effectiveness of monitoring patients with CD on ADA and
for paediatric patients with CD?
9. What is the relevance of cotreatment with immunosuppressants in the monitoring of anti-TNF-α
agents and their antibodies?
10. Is there a benefit of measuring total drug/antibodies over free drug/antibody only?
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Appendix 1 Details of manufacturers’
enzyme-linked immunosorbent assay kits
Sections of this appendix have been reproduced with permission from NICE.15
These details are taken from the NICE final scope for this diagnostic assessment and are based on
information supplied to NICE by the kit manufacturers.
LISA-TRACKER enzyme-linked immunosorbent assay kits
(Theradiag/Alpha Laboratories)
LISA-TRACKER assay kits are ELISAs for the quantitative determination of TNF-α inhibitor levels and antibodies
against TNF-α inhibitor. There are six LISA-TRACKER ELISA kits relevant to this assessment (Table 40): two of
these kits measure the levels of free anti-drug antibodies; two kits measure the levels of free TNF-α inhibitor;
and two kits measure the levels of both free anti-drug antibodies and TNF-α inhibitor.
The LISA-TRACKER ELISA kits consist of pre-coated strips of microtitre plate (96 wells), reagents, wash
buffer, standards and controls. The assays can be run simultaneously or individually on any manual or
automated standard ELISA-based processor platform. The assay procedure is similar for all the assays, but
the reagents used are dependent on whether the ELISA is detecting levels of TNF-α inhibitor or levels of
anti-drug antibody in the patient’s serum.
Detecting levels of tumour necrosis factor alpha inhibitor
Patient samples, the standards and controls are added to the pre-coated microtitre plate. The TNF-α
inhibitor (ADA or IFX) present in the patient samples, standards and controls binds to the coated wells
during the first incubation step and any unbound substances are removed in a subsequent washing step.
The secondary reagent is then added and binds to the TNF-α inhibitor attached to the coated plate. Any
unbound reagent is removed by a second wash step before peroxidase-labelled streptavidin is added to the
TABLE 40 LISA-TRACKER ELISA kits
Name (code) Detects
Microtitre plate
pre-coat Secondary reagent Incubation times
LISA-TRACKER Adalimumab (LTA002) Free ADA TNF-α Biotinylated
anti-human IgG
antibody
1 hour; 1 hour;
30 minutes; and
15 minutesLISA-TRACKER Infliximab (LTI002) Free IFX TNF-α
LISA-TRACKER anti-Adalimumab
(LTA003)
Free anti-ADA
antibodies
ADA Biotinylated ADA 1 hour; 1 hour;
30 minutes; and
15 minutes
LISA-TRACKER anti-Infliximab (LTI003) Free anti-IFX
antibodies
IFX Biotinylated IFX
LISA-TRACKER Duo Adalimumab
(LTA005)
As above; the Duo Adalimumab kit consists of a LISA-TRACKER Adalimumab kit
and a LISA-TRACKER anti-Adalimumab kit
LISA-TRACKER Duo Infliximab
(LTI005)
As above; the Duo Infliximab kit consists of a LISA-TRACKER Infliximab kit and a
LISA-TRACKER anti-Infliximab kit
Note
There are two additional LISA-TRACKER ELISA kits that are available in some European countries, but not in the UK. The
LISA-TRACKER Premium Adalimumab and the LISA-TRACKER Premium Infliximab assays both measure three parameters:
TNF-α inhibitor, TNF-α levels and anti-drug antibody levels.
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plate. Streptavidin binds to the biotin-labelled antibody complex and any unbound streptavidin is removed
by a final wash step. Finally, a chromogenic substrate solution is added and colour develops in proportion
to the amount of TNF-α inhibitor present in the patient sample. The colour change reaction is stopped
by the addition of an acid solution and the optical density is read by a spectrophotometer. A range of
calibration is determined based on the optical density of the standards and this is used to define the
quantity of drug in each sample. The limits of detection are presented in Table 41.
Detecting levels of antibodies to tumour necrosis factor alpha inhibitor
Patient samples, the standards and the controls are added to the pre-coated microtitre plate. The free
anti-IFX antibodies or free anti-ADA antibodies present in the patient samples, standards and controls bind
to the coated wells during the first incubation step, and any unbound substances are removed in a
subsequent washing step. The secondary reagent is then added, which binds to the anti-drug antibodies
attached to the coated plate. Any unbound reagent is removed by a second wash step before peroxidase-
labelled streptavidin is added to the plate. Streptavidin binds to the biotin-labelled complex and any
unbound streptavidin is removed by a final wash step. Finally, a chromogenic substrate solution is added
and colour develops in proportion to the amount of anti-drug antibodies present in the patient sample.
The colour change reaction is stopped by the addition of an acid solution and the optical density is read by
a spectrophotometer. A range of calibration is determined based on the optical density of the standards
and this is used to define the quantity of antibodies to TNF-α inhibitor in each patient sample. The limits of
detection and assay ranges are presented in Table 41.
Tumour necrosis factor alpha-Blocker enzyme-linked
immunosorbent assay kits (Immundiagnostik AG)
There are six Immundiagnostik ELISA kits relevant to this assessment, which are distributed in the UK by
BioHit Healthcare Ltd (Table 42): two of these kits measure the levels of free anti-drug antibodies; two kits
measure the levels of total anti-drug antibodies (free antibodies and antibodies already bound to the drug);
and two kits measure the levels of free TNF-α inhibitor.
The kits consist of strips of pre-coated microtitre plate (96 wells), reagents, buffers, standards (drug-level
ELISAs only) and controls. The ELISAs can be performed manually or run on an automated ELISA processor.
The two ELISAs that measure free IFX or ADA (K9655 and K9657) follow a standard ELISA procedure for
detecting levels of TNF-α inhibitor, as described in Chapter 1, Intervention technologies, except that the
secondary reagent is directly labelled with peroxidase and, therefore, there is no biotin–streptavidin binding
step. The two ELISAs that measure free anti-ADA antibodies or free anti-IFX antibodies (K9650 and K9652)
follow a standard ELISA procedure for detecting levels of antibodies to TNF-α inhibitor, as described in
Chapter 1, Intervention technologies, except that the secondary reagent is directly labelled with peroxidase
and, therefore, there is no biotin–streptavidin binding step. Furthermore, standards are not used in the
anti-drug antibody ELISAs; therefore, the results are interpreted semiquantitatively using a cut-off control.
Details on the interpretation of results, limits of detection and assay measurement ranges are presented in
Table 43.
TABLE 41 Interpretation of results, limits of detection and assay ranges for LISA-TRACKER assays
Name (code) Results interpretation
Limit of
detection Assay range
LISA-TRACKER Adalimumab (LTA002) Quantitative. Generation of standard curve
and determination of drug level in µg/ml
0.1 µg/ml 0.1–8 µg/ml
LISA-TRACKER Infliximab (LTI002) 0.1 µg/ml 0.1–8 µg/ml
LISA-TRACKER anti-Adalimumab (LTA003) Quantitative. Generation of standard curve
and determination of ADAb level in ng/ml
10 ng/ml 10–160 ng/ml
LISA-TRACKER anti-Infliximab (LTI003) 10 ng/ml 10–200 ng/ml
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The TOTAL anti-drug antibody ELISA kits (K9654 and K9651) enables the measurement of anti-drug
antibodies in the presence of TNF-α inhibitor. During sample preparation, immune complexes between
anti-drug antibodies and ADA or IFX are dissociated using an acidic buffer. Biotinylated and peroxidase-
labelled ADA or IFX are added to the sample and form complexes with the anti-drug antibodies. The
complexes bind via biotin to the streptavidin-coated plate. Following a wash step, a chromogenic substrate
is added, the colour change reaction is stopped by the addition of an acid solution and the optical density
is read by a spectrophotometer.
TABLE 42 Immundiagnostik ELISA kits
Name (code) Detects
Microtitre plate
pre-coat
Secondary
reagent Incubation times
Immundiagnostik TNF-α-Blocker
monitoring, infliximab drug level
(e.g. Remicade) ELISA (K9655)
Free IFX Monoclonal
anti-IFX antibody
Peroxidase-labelled
antibody
1 hour; 1 hour;
and 10–20 minutes
Immundiagnostik TNF-α-Blocker
monitoring, adalimumab drug level
(e.g. Humira) ELISA (K9657)
Free ADA Monoclonal
anti-ADA
antibody
Peroxidase-labelled
antibody
Immundiagnostik TNF-α-Blocker ADA,
antibodies against infliximab
(e.g. Remicade) ELISA (K9650)
Free anti-IFX
antibodies
IFX F(ab)2
fragments
Peroxidase-labelled
IFX
2 × 15 minutes;
16–20 hours;
1 hour; and
10–20 minutes
Immundiagnostik TNF-α-Blocker ADA,
antibodies against adalimumab
(e.g. Humira) ELISA (K9652)
Free anti-ADA
antibodies
ADA F(ab)2
fragments
Peroxidase-labelled
ADA
16–20 hours;
1 hour; and
10–20 minutes
Immundiagnostik TNF-α-Blocker ADA,
TOTAL antibodies against infliximab
(e.g. Remicade®) ELISA (K9654)
Total anti-IFX
antibodies
Streptavidin N/A 20 minutes;
1 hour; 1.5 hours;
and 10–20 minutes
Immundiagnostik TNF-α-Blocker ADA,
TOTAL antibodies against adalimumab
(e.g. Humira) ELISA (K9651)
Total anti-ADA
antibodies
Streptavidin N/A
N/A, not applicable.
TABLE 43 Interpretation of results, limits of detection and assay ranges for the Immundiagnostik ELISAs
Name (code) Results interpretation
Limit of
blank Assay range
Immundiagnostik TNF-α-Blocker monitoring,
infliximab drug level (e.g. Remicade) ELISA (K9655)
Quantitative. Generation
of standard curve and
determination of drug level
in µg/ml
2.0 ng/ml 0.4–45 µg/ml
Immundiagnostik TNF-α-Blocker monitoring,
adalimumab drug level (e.g. Humira) ELISA (K9657)
2.3 ng/ml 0.4–45 µg/ml
Immundiagnostik TNF-α-Blocker ADA, antibodies
against infliximab (e.g. Remicade) ELISA (K9650)
Semiquantitative. Evaluated by
a cut-off control (10 arbitrary
units/ml) to give a positive or
negative result
5.787 arbitrary
units/ml
N/A
Immundiagnostik TNF-α-Blocker ADA, antibodies
against adalimumab (e.g. Humira) ELISA (K9652)
N/A N/A
Immundiagnostik TNF-α-Blocker ADA, TOTAL
antibodies against infliximab (e.g. Remicade) ELISA
(K9654)
Semiquantitative. Evaluated by
a cut-off control (10 arbitrary
units/ml) to give a positive or
negative result
2.653 arbitrary
units/ml
N/A
Immundiagnostik TNF-α-Blocker ADA, TOTAL
antibodies against adalimumab (e.g. Humira) ELISA
(K9651)
2.765 arbitrary
units/ml
N/A
N/A, not applicable.
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Promonitor enzyme-linked immunosorbent assay kits
(Proteomika)
There are four Promonitor ELISA kits relevant to this assessment (Table 44): two of these kits measure the
levels of free anti-drug antibodies; and two kits measure the levels of free TNF-α inhibitor.
The kits consist of strips of pre-coated microtitre plate (96 wells), reagents, buffers, standards, controls and
ELISA cover films. The IFX ELISA and ADL ELISA follow a standard ELISA procedure for detecting levels of
TNF-α inhibitor, as described in Chapter 1, Intervention technologies, except that the secondary reagent is
directly labelled with peroxidase and, therefore, there is no biotin–streptavidin binding step. The anti-IFX
ELISA and the anti-ADL ELISA follow a standard ELISA procedure for detecting levels of antibodies to TNF-α
inhibitor, as described in Chapter 1, Intervention technologies, except that the secondary reagent is directly
labelled with peroxidase and, therefore, there is no biotin–streptavidin binding step. The ELISAs can be
performed manually or run on an automated ELISA processor. Details on the interpretation of results,
the assay ranges and limits of quantification are presented in Table 45.
TABLE 44 Promonitor ELISA kits
Name (code) Detects
Microtitre plate
pre-coat Secondary reagent Incubation times
Promonitor ADL ELISA
(5080230000)
Free ADA Anti-ADA human
monoclonal antibody
Peroxidase-labelled
anti-ADA monoclonal
antibody
1 hour; 1 hour;
and 25–35 minutes
Promonitor IFX ELISA
(5060230000)
Free IFX Anti-TNF-α human
monoclonal antibody
bound to human
recombinant TNF-α
Peroxidase-labelled
anti-IFX monoclonal
antibody
1 hour; 1 hour;
and 10–20 minutes
Promonitor anti-ADL
ELISA (5090230000)
Free anti-ADA
antibodies
ADA Peroxidase-labelled
ADA
1 hour; 1 hour;
and 25–35 minutes
Promonitor anti-IFX
ELISA (5070230000)
Free anti-IFX
antibodies
IFX Peroxidase-labelled
IFX
1 hour; 1 hour;
and 25–35 minutes
TABLE 45 Limits of quantification and assay ranges for Promonitor ELISAs
Name Results interpretation
Limit of
quantification Assay range
Promonitor ADL ELISA Semiquantitative. Evaluated using a
cut-off value (0.024 µg/ml for ADA
and 0.035 µg/ml for IFX) to give a
positive or negative result
2.9 ng/ml 0.024–12 µg/ml
Promonitor IFX ELISA Quantitative. Generation of standard
curve and determination of drug
level in µg/ml
1.7 ng/ml 0.035–14.4 µg/ml
Promonitor anti-ADL
ELISA
Semiquantitative. Evaluated using a
cut-off value (10 arbitrary units/ml for
anti-ADA antibodies and 5 arbitrary
units/ml for anti-IFX antibodies) to
give a positive or negative result
3.7 arbitrary units/ml 3.5–2000 arbitrary units/ml
Promonitor ADLanti-IFX
ELISA
Quantitative. Generation of standard
curve and determination of anti-drug
antibody level in arbitrary units/ml
2 arbitrary units/ml 2–1440 arbitrary units/ml
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Appendix 2 Cell reporter assays and mobility
shift assays
Cell reporter assays
The reporter cells are genetically engineered to contain genes for two light-producing enzyme luciferases
(one from the firefly which can generate red light and one from the sea pansy which can generate blue
light). The firefly gene is under the control of a TNF-α signalling pathway so that when the cells are incubated
in the presence of TNF-α they synthesise the enzyme. After a standard incubation time, appropriate
substrates for the enzyme are added and the emitted red light measured with a luminometer. If anti-TNF-α is
present, then the TNF-α response is partially quenched and the quenching estimated. If anti-drug antibodies
are present, quenching by anti-TNF-α is reduced and this can be measured. The sea pansy gene is expressed
during incubation, after which appropriate substrates are added and the blue light emitted measured in the
luminometer. The usefulness of the blue light measure is that it allows ‘normalisation’ of the red light
emission, as interfering agents in patient blood samples equally affect both firefly and sea pansy systems.
Requirements in addition to appropriate cell reporter cultures and reagents include a luminometer (although
these are not necessarily routinely available) and equipment for culture of growth-arrested genetically
engineered cells under controlled conditions (oxygen, carbon dioxide and humidity). These assays appear to
be available as a service and commercial kits are not available.
Mobility shift assays
The mobility shift is exploited using size-exclusion high-performance liquid chromatography (SE-HPLC).
The mobility shift assay is a liquid-phase assay based on SE-HPLC, which separates free probe (small size)
from probe in an immune complex (large size). The probe for the assay of antibodies to an anti-TNF-α drug
(e.g. antibodies to IFX) is a fluorescent dye-labelled anti-TNF-α drug (e.g. IFX); the probe for the assay of
anti-TNF-α drug is fluorescent dye-labelled TNF-α.
The anti-drug antibody assays (e.g. assays for antibodies to IFX) use fluorescent dye-labelled anti-TNF-α
(D*) as the probe; in the presence of antibodies to the anti-TNF-α drug (e.g. antibodies to IFX) some D*
form immune complexes with these (D*–anti-drug antibody complexes) and will exhibit a mobility shift on
the SE-HPLC column relative to the D* which remains free. The amount of D* shifted to greater mobility is
proportional to the amount of anti-drug antibody present. The amount of dye (*) present in the eluent
stream coming from the high-performance liquid chromatography (HPLC) column at different mobilities is
measured with a fluorimeter (Figure 35).
The anti-TNF-α drug assay (e.g. assay for IFX) uses fluorescent dye-labelled TNF-α (TNF-α*) as the probe; in
the presence of anti-TNF-α drug (e.g. IFX) some TNF-α* form immune complexes with the anti-TNF-α and
these have greater mobility on the SE-HPLC than the free TNF-α*. The amount of TNF-α* shifted to greater
mobility is proportional to the amount of anti-TNF-α drug present. The amount of dye (*) present in the
eluent stream coming from the HPLC column at different mobilities is measured with a fluorimeter.
In measuring anti-drug antibody, the patient sample is subjected to an acid step which ‘unbinds’ bound
anti-TNF-α and anti-drug antibody so that all anti-TNF-α and anti-drug antibody are ‘free’; after
neutralisation the sample is incubated with fluorescent dye-labelled anti-TNF-α drug (D*) as described
above. Some D* will form immune complexes with the sample anti-drug antibodies (D*–anti-drug
antibody complexes) and these have a different mobility on SE-HPLC than D*; thus, the mobility of some
of the D* is shifted and the proportion of D* shifted is dependent on the level of anti-drug antibody in the
sample. This assay is theoretically a candidate for a gold standard. It is more likely to measure all classes of
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anti-drug antibodies and also total anti-drug antibody than the ELISAs, and is probably less prone to
interference from serum components in samples. It does not use hazardous materials. This assay appears
to be available only as a service and may not be practicable for use in UK patients. Setting up mobility shift
assays in a hospital laboratory and constructing requisite reagents would be a major and expensive
undertaking.
Probe no
sample
Probe +
sample 1
Probe +
sample 2Mobility shift
sample 2Mobility shift
sample 1
FIGURE 35 Illustration of chromatograms obtained after size exclusion of probe-labelled samples using HPLC.
The vertical axis represents the fluorescence signal.
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Appendix 3 Search strategies
Clinical effectiveness: database searches
MEDLINE(R) (via Ovid)
Exact database searched: 1946 to October week 2 2014.
Date searched: 22 October 2014.
Search strategy
1 adalimumab.mp. 3597
2 ADA.tw. 7105
3 infliximab.mp. 8842
4 IFX.tw. 326
5 ((anti-TNF* or antiTNF* or TNF*) adj2 inhibitor*).mp. 2577
6 anti* tumo?r* necrosis* factor*.mp. 3007
7 Tumor Necrosis Factor-alpha/ and Antibodies, Monoclonal/ 7682
8 anti* drug* antibod*.tw. 186
9 ADAb.tw. 19
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 24,181
11 lisa* tracker*.mp. 1
12 (immundiagnostik* or immunodiagnostik* or immunediagnostik*).mp. 159
13 (proteomika* or promonitor*).mp. 13
14 exp Enzyme-Linked Immunosorbent Assay/ 129,174
15 enzyme* link* immunoassay*.mp. 2873
16 enzyme* link* immuno* assay*.mp. 158,537
17 ELISA*.mp. 113,426
18 11 or 12 or 13 or 14 or 15 or 16 or 17 205,224
19 *Radioimmunoassay/ 7091
20 (radioimmuno* or radio immuno* or radio-immuno*).mp. 101,819
21 RIA.tw. 17,353
22 reporter* gene* assay*.mp. 3663
23 RGA.tw. 336
24 semi* fluid* phase* enzyme* immuno*.mp. 0
25 EIA.tw. 8288
26 ((homogenous* or homogeneous*) adj1 mobilit* shift* assay*).mp. 4
27 HMSA.tw. 62
28 (Biomonitor* or iLite).tw. 4102
29 (Matriks* Biotek* or Shikari*).mp. 2
30 (Prometheus* or Anser IFX or Anser ADA).mp. 258
31 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 124,775
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32 ((monitor* or pharmacokinetic* or measur* or level* or concentration*) adj3 (adalimumab or ADA or
infliximab or IFX or Anti-TNF* or Anti-Tumour Necrosis Factor*)).mp.
1087
33 Inflammatory Bowel Diseases/ 14,444
34 Crohn Disease/ 31,596
35 crohn*.tw. 32,370
36 inflammator* bowel* disease*.tw. 26,840
37 IBD.tw. 11,936
38 33 or 34 or 35 or 36 or 37 58,401
39 (((monitor* or pharmacokinetic* or measur* or level* or concentration*) adj3 (adalimumab or infliximab
or Anti-TNF* or AntiTNF* or Anti-Tumour Necrosis Factor*)) and (correlat* or associat* or test
performance)).mp.
218
40 10 and 18 and 38 93
41 10 and 31 and 38 19
42 32 and 38 157
43 39 or 40 or 41 or 42 367
44 Animals/ not Humans/ 3,983,380
45 43 not 44 349
MEDLINE(R) In-Process & Other Non-Indexed Citations (via Ovid)
Exact database searched: 21 October 2014.
Date searched: 22 October 2014.
Search strategy
1 adalimumab.mp. 469
2 ADA.tw. 426
3 infliximab.mp. 814
4 IFX.tw. 69
5 ((anti-TNF* or antiTNF* or TNF*) adj2 inhibitor*).mp. 308
6 anti* tumo?r* necrosis* factor*.mp. 323
7 anti* drug* antibod*.tw. 39
8 ADAb.tw. 1
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 1824
10 lisa* tracker*.mp. 0
11 (immundiagnostik* or immunodiagnostik* or immunediagnostik*).mp. 2
12 (proteomika* or promonitor*).mp. 0
13 enzyme* link* immunoassay*.mp. 133
14 enzyme* link* immuno* assay*.mp. 3996
15 ELISA*.mp. 8044
16 10 or 11 or 12 or 13 or 14 or 15 10,101
17 (radioimmuno* or radio immuno* or radio-immuno*).mp. 1176
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18 RIA.tw. 386
19 reporter* gene* assay*.mp. 240
20 RGA.tw. 47
21 semi* fluid* phase* enzyme* immuno*.mp. 0
22 EIA.tw. 357
23 ((homogenous* or homogeneous*) adj1 mobilit* shift* assay*).mp. 0
24 HMSA.tw. 5
25 (Biomonitor* or iLite).tw. 343
26 (Matriks* Biotek* or Shikari*).mp. 1
27 (Prometheus* or Anser IFX or Anser ADA).mp. 23
28 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 2386
29 ((monitor* or pharmacokinetic* or measur* or level* or concentration*) adj3 (adalimumab or ADA or
infliximab or IFX or Anti-TNF* or Anti-Tumour Necrosis Factor*)).mp.
112
30 crohn*.tw. 2478
31 inflammator* bowel* disease*.tw. 2627
32 IBD.tw. 1480
33 30 or 31 or 32 4400
34 (((monitor* or pharmacokinetic* or measur* or level* or concentration*) adj3 (adalimumab or infliximab
or Anti-TNF* or AntiTNF* or Anti-Tumour Necrosis Factor*)) and (correlat* or associat* or test
performance)).mp.
30
35 9 and 16 and 33 15
36 9 and 28 and 33 0
37 29 and 33 35
38 34 or 35 or 36 or 37 57
EMBASE Classic and EMBASE
Exact database searched: 1947 to 2014 week 42.
Date searched: 22 October 2014.
Search strategy
1 adalimumab.tw. 7379
2 *adalimumab/ 3997
3 ADA.tw. 10,848
4 infliximab.tw. 13,600
5 *infliximab/ 8056
6 IFX.tw. 1722
7 ((anti-TNF* or antiTNF* or TNF*) adj2 inhibitor*).tw. 4663
8 anti* tumo?r* necrosis* factor*.tw. 4171
9 *tumor necrosis factor alpha inhibitor/ 1283
10 anti* drug* antibod*.tw. 469
11 ADAb.tw. 44
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12 *drug antibody/ 1528
13 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 35,630
14 lisa* tracker*.tw. 11
15 (immundiagnostik* or immunodiagnostik* or immunediagnostik*).tw. 74
16 (proteomika* or promonitor*).tw. 27
17 *enzyme linked immunosorbent assay/ 14,622
18 enzyme* link* immunoassay*.tw. 3275
19 enzyme* link* immuno* assay*.tw. 71,923
20 ELISA*.tw. 166,866
21 14 or 15 or 16 or 17 or 18 or 19 or 20 207,373
22 *radioimmunoassay/ 17,240
23 (radioimmuno* or radio immuno* or radio-immuno*).tw. 74,895
24 RIA.tw. 20,769
25 reporter* gene* assay*.tw. 4396
26 RGA.tw. 400
27 semi* fluid* phase* enzyme* immuno*.tw. 1
28 EIA.tw. 10,836
29 ((homogenous* or homogeneous*) adj1 mobilit* shift* assay*).tw. 39
30 HMSA.tw. 98
31 (Biomonitor* or iLite).tw. 5664
32 (Matriks* Biotek* or Shikari*).tw. 13
33 (Prometheus* or Anser IFX or Anser ADA).tw. 568
34 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 113,752
35 ((monitor* or pharmacokinetic* or measur* or level* or concentration*) adj3 (adalimumab or ADA or
infliximab or IFX or Anti-TNF* or Anti-Tumour Necrosis Factor*)).tw.
2016
36 *crohn disease/ 34,280
37 crohn*.tw. 50,039
38 inflammator* bowel* disease*.tw. 41,418
39 IBD.tw. 23,266
40 36 or 37 or 38 or 39 82,551
41 (((monitor* or pharmacokinetic* or measur* or level* or concentration*) adj3 (adalimumab or infliximab
or Anti-TNF* or AntiTNF* or Anti-Tumour Necrosis Factor*)) and (correlat* or associat* or test
performance)).tw.
544
42 13 and 21 and 40 278
43 13 and 34 and 40 109
44 35 and 40 507
45 41 or 42 or 43 or 44 938
46 nonhuman/ not human/ 3,490,973
47 45 not 46 917
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The Cochrane Library (via Wiley Online Library)
Date searched: 22 October 2014.
Search strategy
#1 adalimumab:ti,ab,kw 451
#2 ADA:ti,ab 237
#3 infliximab:ti,ab,kw 767
#4 IFX:ti,ab 39
#5 ((anti-TNF* or antiTNF* or TNF*) near/2 inhibitor*):ti,ab,kw 106
#6 (anti* next tumo*r* next necrosis* next factor*):ti,ab,kw 256
#7 MeSH descriptor: [Tumor Necrosis Factor-alpha] this term only 2408
#8 MeSH descriptor: [Antibodies, Monoclonal] this term only 3978
#9 #7 and #8 409
#10 (anti* next drug* next antibod*):ti,ab,kw 19
#11 (ADAb):ti,ab,kw 0
#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 6714
#13 (lisa* next tracker*):ti,ab,kw 0
#14 (immundiagnostik* or immunodiagnostik* or immunediagnostik*):ti,ab,kw 0
#15 (proteomika* or promonitor*):ti,ab,kw 0
#16 MeSH descriptor: [Enzyme-Linked Immunosorbent Assay] explode all trees 2122
#17 (enzyme* next link* next immunoassay*):ti,ab,kw 84
#18 ELISA*:ti,ab,kw 2534
#19 #13 or #14 or #15 or #16 or #17 or #18 3958
#20 MeSH descriptor: [Radioimmunoassay] explode all trees 1176
#21 (radioimmuno* or radio next immuno* or radio-immuno*):ti,ab,kw 2761
#22 RIA:ti,ab 570
#23 (reporter* next gene* next assay*):ti,ab,kw 11
#24 RGA:ti,ab 8
#25 (semi* next fluid* next phase* next enzyme* next immuno*):ti,ab,kw 0
#26 EIA:ti,ab 339
#27 ((homogenous* or homogeneous*) near/1 (mobilit* next shift* next assay*)):ti,ab,kw 1
#28 HMSA:ti,ab 1
#29 (Biomonitor* or iLite):ti,ab,kw 14
#30 (Matriks* next Biotek* or Shikari*):ti,ab,kw 0
#31 (Prometheus* or Anser next IFX or Anser next ADA):ti,ab,kw 23
#32 #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 3651
#33 ((monitor* or pharmacokinetic* or measur* or level* or concentration*) near/3 (adalimumab or ADA or
infliximab or IFX or Anti-TNF* or Anti-Tumour next Necrosis next Factor*)):ti,ab,kw
83
#34 MeSH descriptor: [Inflammatory Bowel Diseases] this term only 273
#35 MeSH descriptor: [Crohn Disease] this term only 997
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#36 crohn*:ti,ab,kw 1512
#37 (inflammator* next bowel* next disease*):ti,ab,kw 798
#38 IBD:ti,ab 271
#39 #34 or #35 or #36 or #37 or #38 2037
#40 (((monitor* or pharmacokinetic* or measur* or level* or concentration*) near/3 (adalimumab or
infliximab or Anti-TNF* or AntiTNF* or Anti-Tumour next Necrosis next Factor*)) and (correlat* or
associat* or test next performance)):ti,ab,kw
33
#41 #12 and #19 and #39 8
#42 #12 and #32 and #39 1
#43 #33 and #39 18
#44 #40 or #41 or #42 or #43 49
All results (49)
l Cochrane reviews (0).
l Other reviews (1).
l Trials (47).
l Methods studies (0).
l Technology assessments (1).
l Economic evaluations (0).
l Cochrane Groups (0).
Science Citation Index and Conference Proceedings – Science (Web of Science)
Date searched: 22 October 2014.
Search strategy
#40 #39 OR #38 OR #37 OR #36 806
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#39 #35 AND #32 324
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#38 #35 AND #31 AND #9 26
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#37 #35 AND #16 AND #9 128
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#36 TS=(((monitor* or pharmacokinetic* or measur* or level* or concentration*) near/3 (adalimumab or
ADA or infliximab or IFX or Anti-TNF* or (“Anti-Tumour Necrosis” near/1 Factor*))) and (correlat* or
associat* or “test performance”))
539
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#35 #34 OR #33 80,743
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#34 TS=(((inflammator* near/1 bowel*) near/1 disease*) or IBD) 53,142
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#33 TS=crohn* 50,398
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
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#32 TS=((monitor* or pharmacokinetic* or measur* or level* or concentration*) near/3 (adalimumab or
ADA or infliximab or IFX or Anti-TNF* or (“Anti-Tumour Necrosis” near/1 Factor*)))
1366
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#31 #30 OR #29 OR #28 OR #27 OR #26 OR #25 OR #24 OR #23 OR #22 OR #21 OR #20 OR #19 OR #18
OR #17
79,288
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#30 TS=(Prometheus* or “Anser IFX” or “Anser ADA”) 713
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#29 TS=((Matriks* near/1 Biotek*) or Shikari*) 10
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#28 TS=(Biomonitor* or iLite) 8841
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#27 TS=HMSA 107
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#26 TS=((homogenous* or homogeneous*) near/1 (mobilit* near/1 (shift* near/1 assay*))) 11
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#25 TS=EIA 8832
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#24 TS=((semi* near/1 fluid*) near/3 (enzyme* near/1 immuno*)) 1
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#23 TS=((semi* near/1 fluid*) near/2 (enzyme* near/1 immuno*)) 0
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#22 TS=(semi* near/1 fluid* near/1 phase* near/1 enzyme* near/1 immuno*) 0
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#21 TS=(((semi* near/1 fluid*) near/1 phase*) near/1 (enzyme* near/1 immuno*)) 0
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#20 TS=RGA 1230
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#19 TS=(reporter* near/1 gene* near/1 assay*) 4518
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#18 TS=RIA 12,773
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#17 TS=(radioimmuno* or (radio near/1 immuno*) or radio-immuno*) 46,937
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#16 #15 OR #14 OR #13 OR #12 OR #11 OR #10 146,389
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#15 TS=ELISA* 113,120
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#14 TS=((enzyme* near/1 link*) near/1 (immuno* near/1 assay)) 60,666
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
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#13 TS=((enzyme* near/1 link*) near/1 immunoassay*) 2850
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#12 TS=(proteomika* or promonitor*) 1
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#11 TS=(immundiagnostik* or immunodiagnostik* or immunediagnostik*) 9
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#10 TS=(lisa* near/1 tracker*) 0
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#9 #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1 32,262
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#8 TS=ADAb 35
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#7 TS=((anti* near/1 drug*) near/1 antibod*) 2534
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#6 TS=((anti* near/1 tumo$r*) near/1 (necrosis* near/1 factor*)) 4072
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#5 TS=((anti-TNF* or antiTNF* or TNF*) near/2 inhibitor*) 4065
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#4 TS=IFX 373
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#3 TS=infliximab 13,729
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#2 TS=ADA 8006
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
#1 TS=adalimumab 4973
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
Index to Theses
Date searched: 22 October 2014.
Search strategy
((adalimumab or infliximab or AntiTNF* or Anti-TNF* or “Anti TNF” or “Anti TNFa” or “Anti TNFalpha” or
(TNF* w/2 inhibitor*) or (Anti-Tum*r w/2 Necrosis) or (“anti drug” w/2 antibod*) or ADAb) AND (crohn*
or “inflammatory bowel disease” or IBD))
Fourteen documents retrieved.
(((adalimumab or infliximab or AntiTNF* or Anti-TNF* or “Anti TNF” or “Anti TNFa” or “Anti TNFalpha” or
(TNF* w/2 inhibitor*) or (Anti-Tum*r w/2 Necrosis) or “anti drug antibody” or “anti drug antibodies”
or “anti-drug antibody” or “anti-drug antibodies” or ADAb) w/10 (monitor or monitoring or monitors or
monitored or pharmacokinetic or pharmacokinetics or measure or measures or measurement or measuring
or level or levels or concentration or concentrations)) AND ((correlate* or correlation* or associate* or
association* or “test performance”)))
Four documents retrieved.
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Digital Access to Research Theses – Europe
Date searched: 28 October 2014.
Search strategy
(adalimumab or infliximab or AntiTNF* or Anti-TNF* or “Anti TNF” or “Anti TNFa” or “Anti TNFalpha” or
(TNF* and inhibitor*) or (Anti-Tum*r and Necrosis) or (“anti drug” and antibod*) or ADAb) and (crohn* or
“inflammatory bowel disease” or “inflammatory bowel diseases” or IBD)
One hundred and thirteen documents retrieved.
Dissertations and Theses
Date searched: 29 October 2014.
Search strategy
all(((adalimumab or infliximab or AntiTNF* or Anti-TNF* or “Anti TNF” or “Anti TNFa” or “Anti TNFalpha”
or (TNF* n/2 inhibitor*) or (Anti-Tum*r n/2 Necrosis) or (“anti drug” n/2 antibod*) or ADAb) AND (crohn*
or “inflammatory bowel disease” or “inflammatory bowel diseases” or IBD)))
Twenty-one documents retrieved.
all(((adalimumab or infliximab or AntiTNF* or Anti-TNF* or “Anti TNF” or “Anti TNFa” or “Anti TNFalpha”
or (TNF* n/2 inhibitor*) or (Anti-Tum*r n/2 Necrosis) or “anti drug antibody” or “anti drug antibodies”
or “anti-drug antibody” or “anti-drug antibodies” or ADAb) n/10 (monitor or monitoring or monitors or
monitored or pharmacokinetic or pharmacokinetics or measure or measures or measurement or measuring
or level or levels or concentration or concentrations)) and (correlate* or correlation* or associate* or
association* or “test performance”))
Fifteen documents retrieved.
National Institute for Health Research Health Technology
Assessment programme
Date searched: 29 October 2014.
Search strategy
adalimumab
Sixteen documents retrieved.
infliximab
Twenty-three documents retrieved.
TNF
Seventeen documents retrieved.
PROSPERO
Date searched: 29 October 2014.
Search strategy
adalimumab in All fields
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OR
infliximab in All fields
OR
TNF* inhibitor* in All fields
OR
AntiTNF* in All fields
OR
Anti-TNF* in All fields
Twenty-nine records retrieved.
ClinicalTrials.gov
Date searched: 4 November 2014.
Search strategy
Search Terms (any field): adalimumab OR infliximab OR (TNF AND (anti OR inhibitor OR blocker)) OR “anti
drug antibody” OR “anti drug antibodies” OR ADAb
AND
Condition: crohn OR “inflammatory bowel disease” OR “inflammatory bowel diseases”
AND
Title: monitor OR pharmacokinetic OR measure OR measuring OR level OR concentration OR assay
Fourteen studies retrieved.
Current Controlled Trials
Date searched: 4 November 2014.
Search strategy
(adalimumab OR infliximab OR TNF* OR AntiTNF* OR Anti-TNF* OR anti drug antibod* OR ADAb) AND
(crohn* OR inflammatory bowel disease*) AND (monitor* OR pharmacokinetic* OR measure* OR
measuring OR level* OR concentration* OR assay*)
Thirty studies retrieved.
UK Clinical Research Network Portfolio Database
Date searched: 4 November 2014.
Search strategy
Specialty: Gastroenterology
Research Summary: adalimumab infliximab TNF AntiTNF Anti-TNF ADAb
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‘Any’ selected (combines terms with Boolean OR)
Four studies retrieved.
World Health Organization’s International Clinical Trials Registry Platform
Date searched: 10 November 2014.
Advanced search
In Title: adalimumab OR infliximab OR AntiTNF* OR Anti-TNF* OR TNF inhibitor* OR TNF-α inhibitor* OR
TNF alpha inhibitor* OR TNFalpha inhibitor* OR anti drug antibody OR anti drug antibodies OR ADAb
AND
In Condition: Crohn* OR inflammatory bowel disease*
AND
In Intervention: monitor* OR pharmacokinetic* OR measure* OR measuring OR level* OR concentration*
OR assay*
Thirty-nine trials found.
Espacenet (European Patent Office)
Date searched: 10 November 2014.
Advanced search
Applicant(s): Theradiag – 1 result “Methods for detecting antibodies” (relevant)
Applicant(s): Immundiagnostik – 27 results (sifted online, none relevant)
Checked how known Theradiag patent found above is classified and combined the following two most
relevant classification numbers:
G01N2333/525 Assays involving biological materials from specific organisms or of a specific nature -
Tumor necrosis factor (TNF)
G01N2800/52 Detection or diagnosis of diseases - Predicting or monitoring the response to
treatment; Prognosis
Advanced search
Cooperative Patent Classification: G01N2333/525 AND G01N2800/52 – 27 results (browsed for
manufacturer’s name, found relevant Proteomika patent)
Sifted online and used ‘Also published as’ to find English language versions
Clinical effectiveness: conference proceedings
Date searched: 22 January 2015.
Specifically looked for studies with clinical outcomes and based on the use of an algorithm
(i.e. ‘management’ studies).
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European Crohn’s and Colitis Organisation
Abstracts published in Journal of Crohn’s and Colitis
2011–2014 Indexed in EMBASE. Checked and the search of EMBASE has picked them up.
2015 searchable via website
Sifted 2015 online. Five potentially relevant abstracts saved.
Digestive Diseases Week (meeting of the American Gastroenterology Association)
www.ddw.org
Abstracts in Gastroenterology
2009–2014 Indexed in EMBASE. Checked and the search of EMBASE has picked them up.
Note: Promonitor have sent two abstracts submitted to Digestive Diseases Week May 2015.
British Society of Gastroenterology
Abstracts in Gut.
Indexed in EMBASE (2011, 2012 and 2014). Checked and the search of EMBASE has picked these years up.
Checked 2010 and 2013 via organisation’s website: www.bsg.org.uk/education/meeting/index.html
Searches
infliximab
adalimumab
TNF
Sifted online. Two potentially relevant abstracts saved.
United European Gastroenterology Week
Searched 2013 and 2014 in United European Gastroenterology journal, available via PubMed Central. Not
indexed in EMBASE.
Checked via PubMed.
Search Query Items found
#4 Search ((#2 or #3)) AND #1 13 – sifted online, none with algorithms
#3 Search (inflammatory bowel disease*) OR IBD 36,891
#2 Search crohn* 42,212
#1 Search “United European Gastroenterol J”[Journal] 149
Previous years not available.
American College of Gastroenterology
Meeting abstracts in American Journal of Gastroenterology.
2010–13 indexed in EMBASE. Checked and the search of EMBASE has picked them up.
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2014 conference website says ‘All abstracts submitted will be published in a supplement to the October
2014 issue of The American Journal of Gastroenterology.’ Check via journal website: www.nature.com/ajg/
journal/v109/n2s/pdf/ajg2014281a.pdf
Searches
infliximab
adalimumab
TNF
2014 sifted online – no ‘management’ studies with clinical outcomes based on use of an algorithm.
Clinical effectiveness: websites
Searched on 2 February 2015.
European Crohn’s and Colitis Organisation
URL: www.ecco-ibd.eu
Browsed consensus statements for Crohn’s Disease, Publications and Research Projects.
No additional ‘management’ studies identified.
The American Gastroenterology Association
URL: www.gastro.org
Browsed: ‘Technical Reviews’.
Browsed: Research > Research Resource Library > Immunology, Microbiology and IBD.
No additional ‘management’ studies identified.
British Society of Gastroenterology
URL: www.bsg.org.uk
Browsed: ‘Research’ and ‘Clinical’ sections.
No additional ‘management’ studies identified.
United European Gastroenterology
URL: www.ueg.eu
Browsed: ‘Research’ section.
No additional ‘management’ studies identified.
American College of Gastroenterology
URL: http://gi.org
Browsed: ‘Research and Awards’ and ‘Clinical Guidelines’ sections.
No additional ‘management’ studies identified.
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International Network of Agencies for Health Technology Assessment
publication
URL: www.inahta.org
Searched within publications for:
infliximab
adalimumab
TNF
No additional ‘management’ studies identified.
US Food and Drug Administration medical devices
URL: www.fda.gov/MedicalDevices/ProductsandMedicalProcedures
Searched for:
infliximab
adalimumab
TNF
Filtered by topic to limit to ‘Medical Devices’.
No additional ‘management’ studies identified.
European Commission medical devices
URL: http://ec.europa.eu/growth/sectors/medical-devices
Searches
infliximab
adalimumab
TNF
No additional ‘management’ studies identified.
Theradiag
URL: www.theradiag.com/en
Browsed Theranostics > LISA-TRACKER
Saved and sifted list of publications for LISA-TRACKER assays. No additional ‘management’
studies identified.
Immundiagnostik
URL: www.immundiagnostik.com/en
Browsed website.
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No specific lists of publications, but manuals for relevant assays contain references. The manuals have
been sent with other information from manufacturer and references already sifted.
Proteomika
URL: www.proteomika.com
Browsed website.
Brochure has a list of references. Sifted. No additional ‘management’ studies identified.
Cost-effectiveness: searches for published cost-effectiveness studies
MEDLINE(R) (via Ovid)
Exact database searched: 1946 to October week 3 2014.
Date searched: 12 December 2014.
Search strategy
1 adalimumab.mp. 3662
2 ADA.tw. 7143
3 infliximab.mp. 8957
4 IFX.tw. 335
5 ((anti-TNF* or antiTNF* or TNF*) adj2 inhibitor*).mp. 2630
6 anti* tumo?r* necrosis* factor*.mp. 3048
7 Tumor Necrosis Factor-alpha/ and Antibodies, Monoclonal/ 7737
8 anti* drug* antibod*.tw. 188
9 adalimumab.mp. 3662
10 ADA.tw. 7143
11 infliximab.mp. 8957
12 IFX.tw. 335
13 ((anti-TNF* or antiTNF* or TNF*) adj2 inhibitor*).mp. 2630
14 anti* tumo?r* necrosis* factor*.mp. 3048
15 Tumor Necrosis Factor-alpha/ and Antibodies, Monoclonal/ 7737
16 anti* drug* antibod*.tw. 188
17 ADAb.tw. 19
18 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 24,434
19 lisa* tracker*.mp. 1
20 (immundiagnostik* or immunodiagnostik* or immunediagnostik*).mp. 159
21 (proteomika* or promonitor*).mp. 13
22 exp Enzyme-Linked Immunosorbent Assay/ 129,940
23 enzyme* link* immunoassay*.mp. 2879
24 enzyme* link* immuno* assay*.mp. 159,574
25 ELISA*.mp. 114,330
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26 19 or 20 or 21 or 22 or 23 or 24 or 25 206,726
27 *Radioimmunoassay/ 7654
28 (radioimmuno* or radio immuno* or radio-immuno*).mp. 102,645
29 RIA.tw. 17,539
30 reporter* gene* assay*.mp. 3695
31 RGA.tw. 337
32 semi* fluid* phase* enzyme* immuno*.mp. 0
33 EIA.tw. 8313
34 ((homogenous* or homogeneous*) adj1 mobilit* shift* assay*).mp. 4
35 HMSA.tw. 62
36 (Biomonitor* or iLite).tw. 4140
37 (Matriks* Biotek* or Shikari*).mp. 2
38 (Prometheus* or Anser IFX or Anser ADA).mp. 260
39 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 125,716
40 Inflammatory Bowel Diseases/ 14,609
41 Crohn Disease/ 31,828
42 crohn*.tw. 32,634
43 inflammator* bowel* disease*.tw. 27,171
44 IBD.tw. 12,128
45 40 or 41 or 42 or 43 or 44 58,950
46 18 and 45 3875
47 26 and 45 1771
48 39 and 45 278
49 exp Economics/ 513,380
50 exp “Costs and Cost Analysis”/ 190,833
51 Health Status/ 63,445
52 exp “Quality of Life”/ 126,611
53 exp Quality-Adjusted Life Years/ 7642
54 (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).tw. 461,021
55 (health state* or health status).tw. 40,275
56 (qaly* or utilit* or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or SF36 or SF-6D or SF-6D or SF6D
or HUI).tw.
138,384
57 (markov or time trade off or TTO or standard gamble or hrql or hrqol or disabilit* or disutilit*).tw. 129,972
58 (quality adj2 life).tw. 148,233
59 (decision adj2 model).tw. 3980
60 (visual analog* scale* or discrete choice experiment* or health* year* equivalen* or (willing* adj2
pay)).tw.
31,394
61 (“resource use’ or resource utili?ation).tw. 9307
62 (well-being or wellbeing).tw. 44,692
63 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 1,298,647
64 46 and 63 458
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65 47 and 63 71
66 48 and 63 9
67 64 or 65 or 66 526
68 limit 67 to english language 479
MEDLINE(R) In-Process & Other Non-Indexed Citations (via Ovid)
Exact database searched: 11 December 2014.
Date searched: 16 December 2014.
Search strategy
1 adalimumab.mp. 502
2 ADA.tw. 461
3 infliximab.mp. 868
4 IFX.tw. 76
5 ((anti-TNF* or antiTNF* or TNF*) adj2 inhibitor*).mp. 330
6 anti* tumo?r* necrosis* factor*.mp. 355
7 anti* drug* antibod*.tw. 45
8 ADAb.tw. 2
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 1949
10 lisa* tracker*.mp. 0
11 (immundiagnostik* or immunodiagnostik* or immunediagnostik*).mp. 3
12 (proteomika* or promonitor*).mp. 2
13 enzyme* link* immunoassay*.mp. 142
14 enzyme* link* immuno* assay*.mp. 4191
15 ELISA*.mp. 8507
16 10 or 11 or 12 or 13 or 14 or 15 10,654
17 (radioimmuno* or radio immuno* or radio-immuno*).mp. 1197
18 RIA.tw. 401
19 reporter* gene* assay*.mp. 250
20 RGA.tw. 49
21 semi* fluid* phase* enzyme* immuno*.mp. 0
22 EIA.tw. 379
23 ((homogenous* or homogeneous*) adj1 mobilit* shift* assay*).mp. 1
24 HMSA.tw. 6
25 (Biomonitor* or iLite).tw. 390
26 (Matriks* Biotek* or Shikari*).mp. 1
27 (Prometheus* or Anser IFX or Anser ADA).mp. 23
28 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 2503
29 crohn*.tw. 2585
30 inflammator* bowel* disease*.tw. 2745
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31 IBD.tw. 1547
32 29 or 30 or 31 4595
33 9 and 32 466
34 16 and 32 110
35 28 and 32 6
36 (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).tw. 54,972
37 (health state* or health status).tw. 3544
38 (qaly* or utilit* or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or SF36 or SF-6D or SF-6D or SF6D
or HUI).tw.
15,909
39 (markov or time trade off or TTO or standard gamble or hrql or hrqol or disabilit* or disutilit*).tw. 13,731
40 (quality adj2 life).tw. 17,497
41 (decision adj2 model).tw. 400
42 (visual analog* scale* or discrete choice experiment* or health* year* equivalen* or (willing* adj2
pay)).tw.
3999
43 (“resource use” or resource utili?ation).tw. 992
44 (well-being or wellbeing).tw. 4897
45 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 101,172
46 33 and 45 63
47 34 and 45 9
48 35 and 45 1
49 46 or 47 or 48 73
50 limit 49 to english language 71
EMBASE Classic and EMBASE (via Ovid)
Exact database searched: 1947 to 15 December 2014.
Date searched: 16 December 2014.
Search strategy
1 adalimumab.tw. 7509
2 *adalimumab/ 4043
3 ADA.tw. 10,949
4 infliximab.tw. 13,814
5 *infliximab/ 8148
6 IFX.tw. 1753
7 ((anti-TNF* or antiTNF* or TNF*) adj2 inhibitor*).tw. 4742
8 anti* tumo?r* necrosis* factor*.tw. 4224
9 *tumor necrosis factor alpha inhibitor/ 1298
10 anti* drug* antibod*.tw. 477
11 ADAb.tw. 45
12 *drug antibody/ 1542
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13 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 36,094
14 lisa* tracker*.tw. 11
15 (immundiagnostik* or immunodiagnostik* or immunediagnostik*).tw. 76
16 (proteomika* or promonitor*).tw. 27
17 *enzyme linked immunosorbent assay/ 14,705
18 enzyme* link* immunoassay*.tw. 3301
19 enzyme* link* immuno* assay*.tw. 72,608
20 ELISA*.tw. 169,424
21 14 or 15 or 16 or 17 or 18 or 19 or 20 210,314
22 *radioimmunoassay/ 17,241
23 (radioimmuno* or radio immuno* or radio-immuno*).tw. 75,063
24 RIA.tw. 20,852
25 reporter* gene* assay*.tw. 4446
26 RGA.tw. 401
27 semi* fluid* phase* enzyme* immuno*.tw. 1
28 EIA.tw. 10,934
29 ((homogenous* or homogeneous*) adj1 mobilit* shift* assay*).tw. 40
30 HMSA.tw. 99
31 (Biomonitor* or iLite).tw. 5679
32 (Matriks* Biotek* or Shikari*).tw. 14
33 (Prometheus* or Anser IFX or Anser ADA).tw. 568
34 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 114,144
35 *crohn disease/ 34,603
36 crohn*.tw. 50,590
37 inflammator* bowel* disease*.tw. 42,049
38 35 or 36 or 37 79,897
39 13 and 38 6882
40 21 and 38 2411
41 34 and 38 394
42 exp *health economics/ 200,481
43 exp health status/ 150,318
44 exp “quality of life”/ 283,712
45 exp quality adjusted life year/ 13,007
46 (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).tw. 656,408
47 (health state* or health status).tw. 51,749
48 (qaly* or utilit* or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or SF36 or SF-6D or SF6D or SF-6D
or HUI).tw.
195,997
49 (markov or time trade off or TTO or standard gamble or hrql or hrqol or disabilit* or disutilit*).tw. 189,075
50 (quality adj2 life).tw. 233,390
51 (decision adj2 model).tw. 5912
52 (visual analog* scale* or discrete choice experiment* or health* year* equivalen*).tw. 42,481
DOI: 10.3310/hta20830 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 83
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Freeman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
165
53 (“resource use” or resource utili?ation).tw. 15,005
54 (willing* adj2 pay).tw. 4494
55 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 1,506,135
56 39 and 55 969
57 40 and 55 143
58 41 and 55 33
59 56 or 57 or 58 1106
60 limit 59 to english language 1045
NHS Economic Evaluation Database (via The Cochrane Library)
Date searched: 17 December 2014.
Search strategy
#1 adalimumab:ti,ab,kw 522
#2 ADA:ti,ab 295
#3 infliximab:ti,ab,kw 824
#4 IFX:ti,ab 56
#5 ((anti-TNF* or antiTNF* or TNF*) near/2 inhibitor*):ti,ab,kw 129
#6 (anti* next tumo*r* next necrosis* next factor*):ti,ab,kw 264
#7 MeSH descriptor: [Tumor Necrosis Factor-alpha] this term only 2420
#8 MeSH descriptor: [Antibodies, Monoclonal] this term only 3989
#9 #7 and #8 411
#10 (anti* next drug* next antibod*):ti,ab,kw 22
#11 (ADAb):ti,ab,kw 0
#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 6872
#13 (lisa* next tracker*):ti,ab,kw 0
#14 (immundiagnostik* or immunodiagnostik* or immunediagnostik*):ti,ab,kw 0
#15 (proteomika* or promonitor*):ti,ab,kw 0
#16 MeSH descriptor: [Enzyme-Linked Immunosorbent Assay] explode all trees 2128
#17 (enzyme* next link* next immunoassay*):ti,ab,kw 88
#18 ELISA*:ti,ab,kw 2609
#19 #13 or #14 or #15 or #16 or #17 or #18 4037
#20 MeSH descriptor: [Radioimmunoassay] explode all trees 1176
#21 (radioimmuno* or radio next immuno* or radio-immuno*):ti,ab,kw 2769
#22 RIA:ti,ab 572
#23 (reporter* next gene* next assay*):ti,ab,kw 11
#24 RGA:ti,ab 8
#25 (semi* next fluid* next phase* next enzyme* next immuno*):ti,ab,kw 0
#26 EIA:ti,ab 342
#27 ((homogenous* or homogeneous*) near/1 (mobilit* next shift* next assay*)):ti,ab,kw 1
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#28 HMSA:ti,ab 1
#29 (Biomonitor* or iLite):ti,ab,kw 15
#30 (Matriks* next Biotek* or Shikari*):ti,ab,kw 0
#31 (Prometheus* or Anser next IFX or Anser next ADA):ti,ab,kw 24
#32 #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 3665
#33 ((monitor* or pharmacokinetic* or measur* or level* or concentration*) near/3 (adalimumab or ADA or
infliximab or IFX or Anti-TNF* or Anti-Tumour next Necrosis next Factor*)):ti,ab,kw
90
#34 MeSH descriptor: [Inflammatory Bowel Diseases] this term only 277
#35 MeSH descriptor: [Crohn Disease] this term only 1006
#36 crohn*:ti,ab,kw 1556
#37 (inflammator* next bowel* next disease*):ti,ab,kw 843
#38 IBD:ti,ab 304
#39 #34 or #35 or #36 or #37 or #38 2123
#40 #12 and #39 344
#41 #19 and #39 31
#42 #32 and #3 9
#43 #40 or #41 or #42 373
All results (373)
l Economic evaluations (30)
Science Citation Index 1970 – present (via Web of Knowledge)
Date searched: 17 December 2014.
Search strategy
#42 (#41) AND LANGUAGE: (English) 784
Indexes=SCI-EXPANDED Timespan=All years
#41 #40 AND #39 820
Indexes=SCI-EXPANDED Timespan=All years
#40 TS=(“quality of life” or QoL or hrql or hrqol or (“quality adjusted life” NEAR/1 year*) or QALY*
or cost* or economic* or pharmacoeconomic* or pharmaco-economic* or euro-qol or utilit* or
disutilit* or euroqol or “euro qol” or EQ5D or EQ-5D or SF-36 or SF36 or SF-6D or SF6D or HUI or
(time NEAR/1 trade*) or TTO or “standard gamble” or markov or (decision NEAR/2 model*) or (visual
NEAR/1 analog*) or “discrete choice” or ((health* NEAR/1 year*) NEAR/1 equivalen*) or (health
NEAR/1 stat*) or “willingness to pay” or “resource use” or (resource NEAR/1 utili?ation) or wellbeing
or well-being)
1,328,585
Indexes=SCI-EXPANDED Timespan=All years
#39 #38 OR #37 OR #36 8339
Indexes=SCI-EXPANDED Timespan=All years
#38 #34 AND #31 246
Indexes=SCI-EXPANDED Timespan=All years
#37 #34 AND #16 1971
Indexes=SCI-EXPANDED Timespan=All years
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#36 #34 AND #9 6311
Indexes=SCI-EXPANDED Timespan=All years
#35 TS=(((monitor* or pharmacokinetic* or measur* or level* or concentration*) near/3 (adalimumab or
ADA or infliximab or IFX or Anti-TNF* or ("Anti-Tumour Necrosis” near/1 Factor*))) and (correlat* or
associat* or “test performance"))
560
Indexes=SCI-EXPANDED Timespan=All years
#34 #33 OR #32 80,169
Indexes=SCI-EXPANDED Timespan=All years
#33 TS=(((inflammator* near/1 bowel*) near/1 disease*) or IBD) 52,825
Indexes=SCI-EXPANDED Timespan=All years
#32 TS=crohn* 50,019
Indexes=SCI-EXPANDED Timespan=All years
#31 #30 OR #29 OR #28 OR #27 OR #26 OR #25 OR #24 OR #23 OR #22 OR #21 OR #20 OR #19 OR
#18 OR #17
77,531
Indexes=SCI-EXPANDED Timespan=All years
#30 TS=(Prometheus* or “Anser IFX” or “Anser ADA”) 588
Indexes=SCI-EXPANDED Timespan=All years
#29 TS=((Matriks* near/1 Biotek*) or Shikari*) 11
Indexes=SCI-EXPANDED Timespan=All years
#28 TS=(Biomonitor* or iLite) 8544
Indexes=SCI-EXPANDED Timespan=All years
#27 TS=HMSA 102
Indexes=SCI-EXPANDED Timespan=All years
#26 TS=((homogenous* or homogeneous*) near/1 (mobilit* near/1 (shift* near/1 assay*))) 13
Indexes=SCI-EXPANDED Timespan=All years
#25 TS=EIA 8367
Indexes=SCI-EXPANDED Timespan=All years
#24 TS=((semi* near/1 fluid*) near/3 (enzyme* near/1 immuno*)) 1
Indexes=SCI-EXPANDED Timespan=All years
#23 TS=((semi* near/1 fluid*) near/2 (enzyme* near/1 immuno*)) 0
Indexes=SCI-EXPANDED Timespan=All years
#22 TS=(semi* near/1 fluid* near/1 phase* near/1 enzyme* near/1 immuno*) 0
Indexes=SCI-EXPANDED Timespan=All years
#21 TS=(((semi* near/1 fluid*) near/1 phase*) near/1 (enzyme* near/1 immuno*)) 0
Indexes=SCI-EXPANDED Timespan=All years
#20 TS=RGA 962
Indexes=SCI-EXPANDED Timespan=All years
#19 TS=(reporter* near/1 gene* near/1 assay*) 4550
Indexes=SCI-EXPANDED Timespan=All years
#18 TS=RIA 12,369
Indexes=SCI-EXPANDED Timespan=All years
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#17 TS=(radioimmuno* or (radio near/1 immuno*) or radio-immuno*) 46,687
Indexes=SCI-EXPANDED Timespan=All years
#16 #15 OR #14 OR #13 OR #12 OR #11 OR #10 145,530
Indexes=SCI-EXPANDED Timespan=All years
#15 TS=ELISA* 112,098
Indexes=SCI-EXPANDED Timespan=All years
#14 TS=((enzyme* near/1 link*) near/1 (immuno* near/1 assay)) 60,765
Indexes=SCI-EXPANDED Timespan=All years
#13 TS=((enzyme* near/1 link*) near/1 immunoassay*) 2846
Indexes=SCI-EXPANDED Timespan=All years
#12 TS=(proteomika* or promonitor*) 1
Indexes=SCI-EXPANDED Timespan=All years
#11 TS=(immundiagnostik* or immunodiagnostik* or immunediagnostik*) 10
Indexes=SCI-EXPANDED Timespan=All years
#10 TS=(lisa* near/1 tracker*) 1
Indexes=SCI-EXPANDED Timespan=All years
#9 #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1 31,622
Indexes=SCI-EXPANDED Timespan=All years
#8 TS=ADAb 31
Indexes=SCI-EXPANDED Timespan=All years
#7 TS=((anti* near/1 drug*) near/1 antibod*) 2570
Indexes=SCI-EXPANDED Timespan=All years
#6 TS=((anti* near/1 tumo$r*) near/1 (necrosis* near/1 factor*)) 4119
Indexes=SCI-EXPANDED Timespan=All years
#5 TS=((anti-TNF* or antiTNF* or TNF*) near/2 inhibitor*) 4113
Indexes=SCI-EXPANDED Timespan=All years
#4 TS=IFX 381
Indexes=SCI-EXPANDED Timespan=All years
#3 TS=infliximab 13,827
Indexes=SCI-EXPANDED Timespan=All years
#2 TS=ADA 7173
Indexes=SCI-EXPANDED Timespan=All years
#1 TS=adalimumab 5046
Indexes=SCI-EXPANDED Timespan=All years
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Cost-effectiveness Analysis Registry
Date searched: 17 December 2014.
Search strategy
Search for: Articles
Full Search Contents: crohn
Total: 24
Search for: Articles
Full Search Contents: inflammatory bowel disease
Total: 6
Total with duplicates from search above removed: 5
Total: 29
EconPapers (research papers in economics)
Date searched: 17 December 2014.
Search strategy
crohn* OR inflammatory bowel disease* among working papers and articles and books & chapters and
software and authors (25)
School of Health and Related Research Health Utilities Database
Date searched: 17 December 2014.
Search strategy
crohn* in Any field
OR
inflammatory bowel disease* in Any field
Total: 1.
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Appendix 4 Information provided by Theradiag/
Alpha Laboratories, Proteomika and Immundiagnostik
Information from Theradiag/Alpha Laboratories
The submission consists of:
l request for information
l technologies scoping reports
¢ in response to an enquiry from NHS Greater Glasgow and Cycle (Number 18 October 2013)
¢ background
¢ method
¢ finding
¢ summary.
Full text of abstracts:
l Unsworth 2013 – Measurement of infliximab and anti-infliximab antibodies analytical aspects and
clinical implications
l Swart 2013 – Acceptance and adjustment in a districts general cohort of IBD patients: finding
and implications
l Ward 2013 – Clinical utility of measuring adalimumab trough levels and antibodies to adalimumab in
patients with IBD.
Full papers
Lists of full papers included related to Alpha Laboratories (1) in manufacturer’s submission are:
1. Nanda 2013 Am J Gastro – Impact of antibodies to infliximab on clinical outcomes and TRI in IBD
meta-analysis
2. Paul 2013 Inflamm Bowel Dis – Pharmacokinetic of adalimumab SR and meta-analysis
3. Paul 2013 Inflamm Bowel Dis – Drug monitoring of IFX
4. Steenholdt 2013 Gut – IBD economic
5. Velayos 2013 Clin Gastro Hepato – testing more cost-effective than empiric dose escalation
6. Ben Horin 2014 Nature IBD review – Anti-TNF tailoring in IBD
7. Vande Casteele 2014 Curr Gastro Rep – IBD reviews
8. Roblin 2014 AJG – Algorithm adalimumab IBD
9. Roblin 2014 CGH – Association between pharmacokinetics of adalimumab and mucosal healing
10. Roblin 2014 IBD – Pharmacokinetics of adalimumab in IBD – meta-analysis
11. Ruemmele 2014 J Crohn Colitis – consensus paediatric CD.
Presentation
The submission consists of presentation hand-outs on ‘Monitoring antiTNF α drugs in chronic inflammatory
disease-impact on tailoring therapies’.
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LISA-TRACKER assays information
Detailed information about LISA-TRACKER assays from the company websites in two different languages,
that is English and French:
(a) LISA-TRACKER Duo Infliximab (French)
(b) LISA-TRACKER Duo Infliximab (English)
(c) LISA-TRACKER anti-Infliximab (French)
(d) LISA-TRACKER anti-Infliximab (English)
(e) LISA-TRACKER Infliximab (French)
(f) LISA-TRACKER Infliximab (English)
(g) LISA-TRACKER Duo Adalimumab (French)
(h) LISA-TRACKER Duo Adalimumab (English)
(i) LISA-TRACKER anti-Adalimumab (French)
(j) LISA-TRACKER anti-Adalimumab (English)
(k) LISA-TRACKER Adalimumab (French)
(l) LISA-TRACKER Adalimumab (English).
Information from Proteomika
This submission consists of the following.
Annex 1
Lists of promonitor peer-reviewed articles (indexed in PubMed) (n = 8):
1. Chen DY, Chen YM, Tsai WC, Tseng JC, Chen YH, Hsieh CW, et al. Significant associations of anti-drug
antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept
treatment in rheumatoid arthritis. Ann Rheum Dis 2014;74:e16.
2. Llinares-Tello F, Rosas J, de la Torre I, Valor L, Barber X, Senabre JM. Comparative study of both versions
of an immunoassay commercialised for therapeutic drug monitoring of adalimumab in rheumatoid
arthritis. Reumatol Clin 2014;10:105–8.
3. Llinares-Tello F, Rosas-Gómez de Salazar J, Senabre-Gallego JM, Santos-Soler G, Santos-Ramírez C,
Salas-Heredia E, et al. Practical application of acid dissociation in monitoring patients treated with
adalimumab. Rheumatol Int 2014;34:1701–8.
4. Llinares-Tello F, de Salazar JR, Gallego JM, Soler GS, Ramírez CS, Heredia ES, et al. Analytical and
clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and
adalimumab. Clin Chem Lab Med 2012;50:1845–7.
5. Mazilu D, Opris¸ D, Gainaru C, Iliuta M, Apetrei N, Luca G, et al. Monitoring drug and anti-drug levels:
a rational approach in rheumatoid arthritis patients treated with biologic agents who experience
inadequate response while being on a stable biologic treatment. Biomed Res Int 2014;2014:702701.
6. Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, et al. Influence of
immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis.
Rheumatology 2011;50:1445–52.
7. Plasencia C, Pascual-Salcedo D, Nuño L, Bonilla G, Villalba A, Peiteado D, et al. Influence of
immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximab.
Ann Rheum Dis 2012;71:1955–60.
8. Ruiz-Argüello B, del Agua AR, Torres N, Monasterio A, Martínez A, Nagore D. Comparison study of two
commercially available methods for the determination of infliximab, adalimumab, etanercept and
anti-drug antibody levels. Clin Chem Lab Med 2013;51:e287–9.
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Annex 2
Lists of promonitor abstracts presented at international congresses in 2014 (n = 34):
1. Barrios Y, Matheu V, Franco A, Delgado E, Bustabad S. Immunogenicity Analysis of Two Anti-TNF
Infliximab vs Etanercept) Therapies in Rheumatologic Patients. Proceedings of the American Academy
of Allergy, Asthma & Immunology, 2014 Annual Meeting, 28 February–4 March, San Diego, CA,
abstract no. 639. ABS 5.2.0 DTD Abstracts AB185.
2. Daperno M, Lavagna A, Fracchia M, Guiotto C, Germano L, Rigazio C, et al. Infliximab Trough Levels
(IFX-Tl) are Higher in Patients with Inflammatory Bowel Disease (IBD) Treated with Immunosuppressives:
Clinical Correlations of IFX-LT and Antibodies to Infliximab (ATI) in IBD. Proceedings of the American
Gastroenterological Association (AGA), 2013, abstract no. Tu1173.
3. Daperno M, Frigerio F, Guiotto C, Germano L, Ercole E, Arico S, et al. Identical Diagnostic Performance
of Two Commercially Available Tests for Infliximab Trough Levels (ifx-tl) and Antibodies to Infliximab
(ati) Titration in Inflammatory Bowel Disease (IBD): Promonitor and Immunodiagnostik Tests.
Proceedings of the American Gastroenterological Association (AGA), 2013, abstract no. Tu1168.
4. Daperno M, Frigerio F, Guiotto C, Germano L, Ercole E, Arico S, et al. Evaluation of the Diagnostic
Performance of Two Commercially Available Tests for Infliximab Trough Levels (IFX-TL) and Antibodies
to Infliximab (ATI) Titration in Inflammatory Bowel Disease (IBD). Proceedings of the European Crohn’s
and Colitis Organisation (ECCO), Poster presentations: Clinical: Therapy and observation, 2013,
abstract no. P508.
5. Daperno M, Frigerio F, Guiotto C, Laura G, Ercole E, Lavagna A, et al. Comparison of the Performance
of Two Commercially Available Tests for Determination of Infliximab Trough Levels (IFX-TL) and
Antibodies to Infliximab (ATI), Promonitor and Immundiagnostik, in Inflammatory Bowel Disease.
Proceedings of Digestive and Liver Disease 45S, 19th National Congress, 2013, abstract no. P.03.13.
6. Daperno M, Lavagna A, Fracchia M, Guiotto C, Germano L, Rigazio C, et al. Clinical Correlations of
Infliximab Trough Levels (IFX-TL) and Antibodies to Infliximab (ATI) in Inflammatory Bowel Disease.
Proceedings of the European Crohn’s and Colitis Organisation (ECCO), Poster presentations: Clinical:
Therapy and observation, 2013, abstract no. P569.
7. Diana M, Iliuta M, Gainaru C, Luca G, Apetrei N, Gudu T, et al. Correlation between Serum Rituximab
Level and Clinical Response in Rheumatoid Arthritis Patients Treated with B Cell Depletion Therapy.
Proceedings of the European League Against Rheumatism (EULAR), 2014 Annual meeting, Paris,
France, abstract no. FRI0026.
8. Hernández Flórez D, Valor L, Nieto JC, Martínez L, de la Torre I, del Rio T, et al. Infliximab levels and
anti-infliximab antibodies comparison between two comercial elisa versions in patients with ankylosing
spondylitis. Ann Rheum Dis 2014;73(Suppl. 2):715–16, abstract no. SAT0340.
9. Hernández D, de la Torre I, Martínez L, Nieto J, Llinares F, Rosas J, et al. Establishing cut-off of
infliximab and anti-infliximab antibody levels using a commercial ELISA in patients with rheumatoid
arthritis. Ann Rheum Dis 2013;72(Suppl. 3);237, abstract no. THU0215.
10. Hernández MV, Palasti S, Inciarte J, Cabrera-Villalba S, Ruiz-Esquide V, Ramírez J, et al. Analysis of the
immunogenicity induced by tumor necrosis factor antagonists in patients with chronic inflammatory
arthropathies. Ann Rheum Dis 2013;72(Suppl. 3):429, abstract no. FRI0171.
11. Inciarte-Mundo J, Hernández MV, Cabrera S, Ruiz-Esquide V, Ramirez J, Cañete J, et al.
Immunogenicity Induced by Tumor Necrosis Factor Antagonists in Chronic Inflammatory Arthropathies:
Retrospective Study in Clinical Practice Conditions. Proceedings of the American College of
Rheumatology (ACR), 2013 ACR/ARHP Annual Meeting, abstract no. 1444.
12. Inciarte-Mundo J, Ramírez García J, Estrada P, García M, Gozález A, Saura C, et al. Drug serum levels
of tnf antagonists do not correlate with subclinical synovitis by ultrasound in patients with rheumatoid
arthritis and psoriatic arthritis in clinical remission or low disease activity. Ann Rheum Dis
2014;73(Suppl. 2):934–5, abstract no. AB0388.
13. Jauregui-Amezaga A, Ordas I, Gallego M, Ramirez A, Pino S, Masamunt MC, et al. [Impacto de la
medición de niveles de anti-TNF y título de anticuerpos contra el fármaco en el manejo de la
enfermedad inflamatoria intestinal.] XVI Reunión Anual de la Asociación Española de Gastroenterología,
2013, abstract no. 93, poster no. 50.
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14. Jauregui-Amezaga A, Ordas I, Gallego M, Ramirez A, Pino S, Masamunt MC, et al. Impact of Serum
Drug Level and Human Anti-drug Antibody Measurement on Management of Biologic Drugs in
Inflammatory Bowel Disease. Proceedings of the European Crohn’s and Colitis Organisation (ECCO),
Poster presentations: Clinical: Therapy and observation, 2013, abstract no. P481.
15. Juan G, Alvariño A, Oltra L, Maroto N, Cano N, Ferrer I, et al. Utility of ‘Trough Levels’ Determination
and Anti-infliximab Antibodies in Patients with Inflammatory Bowel Disease. Estimation of Individual
Pharmacokinetic Parameters (PK) through Population Pharmacokinetic Model. Proceedings of the
European Crohn’s and Colitis Organisation (ECCO), Poster presentations: Clinical: Therapy &
observation, 2014, abstract no. P302.
16. Llinares-Tello F, Rosas J, de la Torre I, Valor L, Senabre JM, Barber X, et al. Comparative study of
both versions of an immunoassay commercialized for therapeutic drug monitoring of adalimumab.
Ann Rheum Dis 2013;72(Suppl. 3):A234, abstract no. THU0207.
17. Llinares-Tello F, Rosas J, Senabre-Gallego JM, Molina J, Salas E, Santos-Soler G, et al. Usefulness of the
acid dissociation in inmunogenicity detection in patients in treatment with anti-TNF drugs. Ann Rheum
Dis 2014;73(Suppl. 2):237–8, abstract no. THU0166.
18. Martínez L, Hernández D, Valor L, Carreño L, de la Torre I. Human Anti-chimeric Antibodies (HACAs)
in a Cohort of Rheumatoid Arthritis (RA) Patients Treated with the anti-TNF-alpha Agent Infliximab
(IFX): Disease Activity and IFX Levels. Proceedings of the 8th International Congress on Autoimmunity,
9–13 May 2012, Granada, Spain, abstract no. 609.
19. Nuño L, Pascual-Salcedo D, Balsa A, Moral R, Lopez MT, Ruiz A, et al. Clinical significance of the
presence of anti-infliximab antibodies. Ann Rheum Dis 2010;69(Suppl. 3):55, abstract no. OP0017.
20. Opris D, Diana M, Gainaru C, Iliuta M, Groseanu L, Saulescu I, et al. Serum drug level and anti-citrullinated
peptide antibodies as biomarkers that predict eular response in rheumatoid arthritis – a new step to
personalized medicine. Ann Rheum Dis 2014;73:946–7, abstract no. AB0422.
21. Pascual-Salcedo D, Plasencia C, Nuño L, Ramiro S, Bonilla G, Nagore D, et al. Immunogenicity
influences the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Ann Rheum Dis
2011;70(Suppl. 3):412, abstract no. FRI0207.
22. Pascual-Salcedo D, Bonilla MG, Nuño L, Ruiz A, Martín-Mola E, Balsa A. Influence of immunogenicity
on the efficacy of long-term treatment with infliximab. Am Coll Rheumatol 2011; abstract no. 2636.
23. Pascual-Salcedo D, Plasencia C, Diez J, Rojo L, Bonilla G, Ramiro S, et al. The development of
antibodies against a first anti-TNF influences the clinical outcome of the therapy in rheumatic patients
after switching to a second TNF inhibitor. Int Congress Autoimmun 2012; abstract no. 1590.
24. Pascual-Salcedo D, Plasencia C, Gonzalez del Valle L, López T, Arribas F, Villalba A, et al. Therapeutic
drug monitoring (TDM) in rheumatic day clinic enables to reduce pharmaceutical cost maintaining
clinical efficacy. Ann Rheum Dis 2013;72:227, abstract no. THU0189.
25. Plasencia C, Pascual-Salcedo D, Bonilla MG, Nuño L, Moral R, Ruiz del Agua A, et al. Influence
of immunogenicity on the efficacy of long-term treatment with infliximab in spondyloarthritis.
Ann Rheum Dis 2011;70(Suppl. 3):82, abstract no. OP0045.
26. Plasencia C, Pascual-Salcedo D, Garcia-Carazo S, Bonilla G, Lojo L, Nuño L, et al. The immunogenicity
to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF in
spondyloarthritis patients. Am Coll Rheumatol 2012; abstract no. 546.
27. Rosas-Gomez de Salazar J, Llinares-Tello F, Senabre-Gallego JM, Santos-Soler G, Santos-Ramirez C,
Salas-Heredia E, et al. Evaluation of anti-tumor necrosis factor levels and anti-tumor necrosis factor
antibodies in rheumatic diseases treated with infliximab and adalimumab; preliminary results from a
local registry. Am Coll Rheumatol 2011; abstract no. 2211.
28. Rosas J, Llinares F, Santos-Ramírez C, Senabre JM, Santos-Soler G, Barber X, et al. Evaluation of
anti-TNF levels and anti-TNF antibodies in rheumatic diseases treated with adalimumab, etanercept
and infliximab; results from a local registry. Int Congress Autoimmun 2012; abstract no. 1568.
29. Rosas J, Llinares F, de la Torre I, Valor L, Barber X, Santos-Ramírez C, et al. Clinical usefulness of serum
level of adalimumab, in patients with rheumatoid arthritis. Ann Rheum Dis 2013;72(Suppl. 3):233,
abstract no. THU0206.
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30. Rosas J, Llinares-Tello F, Martín S, Senabre JM, Salas E, Oliver S, et al. Evaluation of serum level of
golimumab and antibodies anti-golimumab in patients with rheumatic diseases: results from a local
registry. Ann Rheum Dis 2014;73(Suppl. 2), abstract no. AB0389.
31. Ruiz del Agua A, Pascual-Salcedo D, Balsa A, Ramos I, Novalbos L, Ramiro S, et al. Monitoring of
anti-TNF biological treatments. J Transl Med 2010;8(Suppl. 1):P32.
32. Sanmartí R, Inciarte J, Estrada P, García M, González A, Narvaez J, et al. Immunogenicity of anti-TNF
antagonists in patients with rheumatoid arthritis or polyarticular psoriatic arthritis in clinical remission or
low disease activity: the inmunoremar study. Ann Rheum Dis 2014;73(Suppl. 2): abstract no. FRI0265.
33. Sarmiento Guevara M, Diaz Torne C, Ortiz MA, Torres N, Nagore D, Diaz López C, et al. Association of
rituximab levels to clinical response and B cell recovery in rheumatoid arthritis patients. Ann Rheum Dis
2013;72(Suppl. 3):623, abstract no. SAT0125.
34. Valor L, Hernández D, de la Torre I, Llinares F, Rosas J, Yagüe J, et al. Infliximab and adalimumab levels
and anti-drug antibodies detection in patients with rheumatoid arthritis (RA): an interlaboratory
comparison using a commercial ELISA assay. Ann Rheum Dis 2014;73(Suppl. 2): abstract no. AB0396.
Full paper
Rosas 2014 Clinical and Experimental Rheumatology
Clinical relevance of monitoring serum levels of adalimumab in patients with rheumatoid arthritis in
daily practice.
Presentation
Topic (confidential information has been removed).
Report
Progenika Biopharma reports on ‘method-comparison study between Promonitor-ELISA and iLITE™ kits for
the measurement of infliximab and anti-infliximab antibodies in IBD and RA patients’ (dated on 25 June 2012).
Technical specification
Information on Technical specification from Proteomika:
i. Promonitor ADL
ii. Promonitor Anti-ADL
iii. Promonitor Anti-IFX
iv. Promonitor IFX.
Request for information
Responses from Proteomika SLU to request for information.
Full texts of Proteomika’s abstracts
ACR 2014 (n = 5):
1. Ghia ACR 2014–2436 – Analytical and clinical evaluation of an immunoassay for estimating
immunogenicity of infliximab and etanercept in Indian population.
2. Inciarte-Mundo ACR 2014–2926 – Calprotectin serum levels reflect residual inflammatory activity in
patients with rheumatoid arthritis and psoriatic arthritis on clinical remission or low disease activity
undergoing TNF-antagonist therapy.
3. Llinares-Tello ACR 2014–1519 – Implementation of an acid dissociation procedure for immunogenicity
detection in patients treated with anti-TNF drugs.
4. Opris ACR 2014–1539 – Relation between number of previous anti TNF agents and clinical response in
rheumatoid arthritis patients treated with rituximab.
5. Rosas ACR 2014–1531 – Cut off level of adalimumab and prevalence of antibodies anti-adalimumab in
patients with ankylosing spondylitis: results from local registry.
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Information pack and technical specification
Information pack and technical specification about the products:
i. Promonitor-IFX
ii. Promonitor-anti-IFX
iii. Promonitor-anti-ADL
iv. Promonitor-ADL.
Further information from Proteomika
i. Promonitor-IFX (5060230000).
ii. Promonitor-ADL (5080230000).
iii. Promonitor-anti-IFX (5070230000).
iv. Promonitor-anti-ADL (5090230000).
Information from Immundiagnostik/BioHit
This submission contains evidence which includes full texts (n = 2), abstracts (n = 4), poster (n = 5) and
letters to the editor (n = 2):
i. Bender 2006 (Rheumatol Int) – Immunogenicity, efficacy and adverse events of adalimumab in RA
patients (full text).
ii. Kopylov 2012 (Inflamm Bowel Dis) – Clinical utility of anti-human lamda chain-based enzyme linked
immunosorbet assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies
(full text).
iii. Daperno 2013 (poster) – Identical diagnostic performance of two commercially available tests for
infliximab trough levels (IFX-TL) and antibodies to infliximab (ATI) titration in inflammatory bowel
disease (IBD): promonitor and immundiagnostik test.
iv. Semmler 2013 (poster) – Development of a new immunoassay for the accurate determination of
anti-infliximab antibodies in inflammatory bowel disease (IBD).
v. Guidi 2013 (poster) – Assessment of loss of response to infliximab therapy in inflammatory bowel
disease using antibodies to infliximab and trough levels.
vi. Perry 2013 (poster) – Infliximab is stable in whole blood clotted samples for 7 days at room temperature.
vii. Development of a new immunoassay (2014) (poster).
viii. Eser 2012 (abstract) – Detection of anti-infliximab antibodies in patients with IBD in the presence of
infliximab by homogeneous liquid-phase anti infliximab mobility shift assay.
ix. Jahnel 2014 (abstract) – Formation of antibodies against infliximab in paediatric Crohn’s disease.
x. Ussia 2014 (abstract) – A prospective assessment of anti-drug antibody response over time by a new
ELISA in patients with IBD treated with infliximab.
xi. Schatz 2012 (abstract) – Comparison of different tests for determination of infliximab levels and
antibodies against infliximab in paediatric IBD patients.
xii. Fritzsche 2012 (letter) – Infliximab and adalimumab use during breastfeeding.
xiii. Kong 2013 (letter) – Low trough serum infliximab and antibodies to infliximab in smoker.
Immundiagnostik TNF-alpha blocker ELISAs (provided via e-mail
after discussion)
Data on assays regarding the limit of blank.
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Manual
There is a manual that provides information on technology in two different versions (i.e. English version
and German version).
i. TNF-α Blocker adalimumab, total antibodies against adalimumab (e.g. Humira®) (German and
English version).
ii. TNF-α Blocker adalimumab, antibodies against adalimumab (e.g. Humira®) (German and English version).
iii. TNF-α Blocker adalimumab, total antibodies against infliximab (e.g. Remicade®) (German and
English version).
iv. TNF-α Blocker adalimumab, antibodies against infliximab (e.g. Remicade®) (German and English version).
v. TNF-α Blocker monitoring adalimumab drug level (e.g. Humira®) (German and English version).
vi. TNF-α Blocker monitoring infliximab drug level (e.g. Remicade®) (German and English version).
Request for information.
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Appendix 5 Data extraction sheets
Data extraction form anti-tumour necrosis factor alpha drug
monitoring: comparison of assay types
Name of first reviewer: Sian Taylor-Phillips.
Name of second reviewer: Martin Connock.
Study details
Study ID (EndNote ref.)
First author surname
Year of publication
Country
Study design
Publication (full/abstract)
Study setting
Number of centres (by arm)
Duration of study
Follow-up period
Funding
Competing interests
Aim of the study
Inclusion/exclusion criteria for patients
Test comparison
Tests Name Details
Intervention test
Comparison test 1
Comparison test 2
Comparison test 3
Details of any repeat measurements (to check reliability, performance across different laboratories)
Drug type tested
IFX
Anti-IFX
ADA
Anti-ADA
Selection and storage of patients/plasma samples
Description of method of selection
Description of method and duration of storage
Number of clinical samples
Number of calibrator samples (spiked) for anti-TNF
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Selection and storage of patients/plasma samples
Number of calibrator samples (spiked) for antibodies
Number of blank (control) samples
Total number of plasma samples
Results of comparison
Name of test
Threshold for drug
Number positive for drug
Threshold for antibodies
Number positive for antibodies
Details of correlation/overlap between the tests
Other information
Results of comparison of drug levels
Name of tests to be compared
Total number concordant/all tested
Number of positive cases concordant/all positive cases
Number of negative cases concordant/all negative cases
Correlation of drug measurement
Regression method
Linearity test/cusum test?
R2 (95% CI)
Slope (95% CI)
Intercept (95% CI)
From Bland–Altman plot for drug measurement
Percentage bias (95% CI)
Upper limit of agreement
Lower limit of agreement
Details of outliers
Visually is there a pattern between the mean value and the difference?
Results of comparison for antibody levels
Name of tests to be compared
Total number concordant/all tested
Number of positive cases concordant/all positive cases
Number of negative cases concordant/all negative cases
Correlation of antibody measurement
Regression method
Linearity test/cusum test?
R2 (95% CI)
Slope (95% CI)
Intercept (95% CI)
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From Bland–Altman plot for antibody measurement
Percentage bias (95% CI)
Upper limit of agreement
Lower limit of agreement
Details of outliers
Visually is there a pattern between the mean value and the difference?
Authors’ conclusion
Reviewer’s conclusion
Data extraction form for anti-tumour necrosis factor alpha
drug monitoring: management studies
Name of first reviewer: Deepson S Shyangdan.
Name of second reviewer: Martin Connock.
Study details
Study identification number 123
First author surname Steenholdt
Year of publication 2014
Country Denmark
Study design Randomised controlled, single-blind trial
Publication (full/abstract) Full
Study setting Not clear (but looking at authors’ affiliation, it appears that the participating
centres were university hospitals)
Number of centres (by arm) Six Danish centres
Duration of study 12 weeks
Follow-up period At weeks 0, 4, 8 and 12
Funding Aase and Ejnar Danielsen’s Foundation, Beckett Foundation, Danish
Biotechnology Program, Danish Colitis-Crohn Society, Danish Medical Association
Research Foundation, Frode V Nyegaard and Wife’s Foundation, Health Science
Research Foundation of Region of Copenhagen, Herlev Hospital Research
Council, Lundbeck Foundation, P Carl Petersen’s Foundation, Ole Ostergaard
Thomsen’s Research Foundation and Jorn Brynskov’s Research Foundation
Aim of the study
To investigate the cost-effectiveness of interventions defined by an algorithm designed to identify specific reasons for
therapeutic failure
Inclusion/exclusion criteria for patients
Inclusion criteria Adult patients diagnosed with CD and a previous beneficial clinical response
to standard IFX maintenance therapy with regular infusions of 5 mg/kg. At
inclusion, all patients had secondary IFX treatment failure on IFX maintenance
therapy defined as recurrence of active disease with a CDAI score of ≥ 220 and/
or presence of at least one draining perianal fistula
Exclusion criteria Any contraindication to continued IFX, short bowel syndrome, recent history of
abdominal surgery or of a severe medical condition, pregnancy, or alcohol or
drug abuse
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Study design
n screened 95
n excluded (ineligible) 26
Randomisation / blinding Randomised to algorithm or IFX intensification groups using block randomisation
(block size= 20) using sequentially numbered opaque envelopes
Patients blinded to randomisation group and results of serum analyses.
Physicians were blinded to IFX and IFX Ab test results in the intensification arm
only
n randomised 36 to dose intensification, 33 to algorithm treatments
n non-participants 14 not treated according to algorithm protocol (n = 7 continued IFX no
assessment; n= 5 continued IFX no inflammation; and n= 2 misinterpreted
analyses)
Item IFX-intensified arm Algorithm arm All
n study sample at baseline randomised
(if applicable)
N/A N/A N/A
Withdrawals 8 (n= 7 lack of effect;
n = 1 severe infusion
reaction)
2 (lack of effect) 10
Lost to follow-up/dropouts (sample
attrition)
Unclear Unclear Unclear
Study flow (CONSORT diagram)
Available in paper
Treatment algorithm for patients randomised to algorithm arm
Detectable anti-IFX antibodies Undetectable anti-IFX antibodies
Subtherapeutic
IFX < 0.5 µg/ml
Group 1 Group 2
Insufficient IFX bioavailability due to induced
immunogenicity of IFX
Insufficient IFX bioavailability due to non-immune-
mediated pharmacokinetics of IFX
Change to different TNF-α-inhibitor: ADA 80mg
s.c. at inclusion followed by 40mg s.c. every
other week: dose intensification allowed
Intensify IFX treatment: IFX 5mg/kg i.v. every 4 weeks
Therapeutic IFX
≥ 0.5 µg/ml
Group 4 Group 3
Consider: Pharmacodynamics: inhibition of TNF-α is
ineffective as a result of non-TNF-α-driven disease
Pharmacodynamics
Non-functional anti-IFX antibodies
False-positive test
Repeat IFX and anti-IFX antibody analyses
and handle accordingly. If unchanged results,
then act as group 3
TNF-α-inhibitors not effective discontinued.
Review of clinical condition at discretion of the
investigator: if relapse of CD, use drug(s) with
other target, for example conventional immune
suppressives, glucocorticoids, and/or other
biological agents. Consider surgery if appropriate.
If no relapse, treat underlying problem
i.v., intravenously; s.c., subcutaneously.
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Participants (characteristics and numbers)
Item Intensification arm Algorithm arm All
Total number of participants at
baseline (% CD), all patients CD
36 33 69
n (%) followed up Unclear Unclear Unclear
n (%) included in analysis 36 ITT (100); 36 PP
(100)
33 ITT (100); 19 PP (58) 69 ITT (100); 55 PP (80)
Patient group (responders/secondary
LOR)
Secondary LOR Secondary LOR Secondary LOR
Age (years), mean (range) 37 (19–63) 36 (19–81) 37 (19–81)
Sex (women), n (%) 20 (61) 22 (61) 42 (61)
Diagnostic criteria for CD CDAI, presence of
fistulas
CDAI, presence of
fistulas
CDAI, presence of
fistulas
Children, n (%) None None None
CDAI score, mean (range) 301 (230–487) 296 (221–526) 299 (221–526)
n (%) patients in remission All patients at inclusion had recurrence of active disease
n (%) patients with active CD
CD classification (Vienna/Montreal) Not clear Not clear Not clear
Disease duration (years), mean (range) 10 (1–35) 7 (1–27) 9 (1–35)
Smoking, n (%) 12 (33) 6 (18) 18 (26)
Previous surgery, n (%) 10 (28) 10 (30) 20 (29)
Concomitant treatment (specify), n (%)
Immunosuppressants 14 (39) 13 (39) 27 (39)
Systemic corticosteroids or budesonide 1 (3) 1 (3) 2
Treatment duration at anti-TNF failure
(days)
635 (range 97–1913) 681 (range 126–3313) 657 (range 97–3313)
Previous anti-TNF therapy 6 (17) 8 (24) 14 (20)
CRP (mg/ml) 6 (range 1–28) 9 (range 3–21) 9 (range 2–22)
Calprotectin (µg/g) NR NR NR
Treatment
Item IFX-intensified arm Algorithm arm
Anti-TNF drug (name) IFX IFX
Anti-TNF dose IFX at an increased dose frequency of 5 mg/kg every
4 weeks
IFX or other based on
the algorithm
Duration of treatment Not clear, planned 12 weeks Not clear planned
12 weeks
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Intervention test assay (please specify):
Manufacturer RIA (probably Biomonitor A/S, Copenhagen, Denmark)
Post hoc paper ELISA and HMSA (Prometheus Laboratories, San Diego, CA, USA)
Assay type RIA liquid-phase assays; assay for antibodies detects those with lambda chains
(not kappa)
Assay name Not specified
Time of anti-TNF/antibody
measurement
Serum samples for IFX and IFX Ab testing were collected at the time of
reported IFX treatment failure. Samples were sent for immediate analysis
by radioimmunoassay
Frequency of anti-TNF/antibody
measurement
One test time only
Threshold of IFX/ADA (therapeutic/
subtherapeutic) (µg/ml)
l RIA: therapeutic ≥ 0.5 µg/l; subtherapeutic < 0.5 µg/l
Post hoc
l ELISA: 1.4 µg/ml for IFX
l HMSA: therapeutic ≥3 µg/l; subtherapeutic <3 µg/l
Limit of quantification of anti-TNF
antibodies [U/ml (arbitrary units/ml)] for
antibodies detectable/
non-detectable
l RIA: LOQ 10 arbitrary units/ml
Post hoc
l ELISA: 1.69 µg/ml for IFX Abs
l HMSA: LOQ 3.13 U/ml
Outcomes reported
Item
Primary outcome(s) (a) Mean cost of treatment over 12 weeks
(b) Proportion of patients with ‘clinical response’ at 12 weeks. Clinical response
was defined as:
> 70-point reduction in CDAI score from baseline in luminal disease and a
reduction in active fistulas of > 50% from baseline in fistulising disease
Secondary study outcomes CDAI 100 response; clinical remission; CDAI decrease; PDAI decrease; IBDQ
increase; CRP change; white blood cells change; haemoglobin change; albumin
change
Timing of assessments (including
information on parallel or sequential)
Weeks 0, 4, 8 and 12
Time to test result Not clear; the paper states that:
. . . serum samples for IFX and IFX Ab testing were collected at the time of
reported IFX treatment failure. Samples were sent for immediate analysis
by RIA
Number of inconclusive results, n (%) None (note that in group 4 of intervention arm, tests should be repeated to
confirm first test result)
Frequency of dose adjustment, n (%) NR
Frequency of treatment switch, n (%) NR
Measure of disease activity (e.g. CDAI,
others?)
CDAI; Short IBDQ; PDAI; number of draining fistulas
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Item Algorithm arm Intensification arm Comparison
(A) Rates of response (coprimary
outcome). Note that all patients
started with secondary LOR
ITT: 19/33 (58%) ITT: 19/36 (53%) ITT: RR 1.09, 95% CI
0.713 to 1.673;
p= 0.810;
difference = 5%
(–19% to 28%)
PP: 9/19 (47%) PP: 19/36 (53%) PP: RR 0.898, 95% CI
0.510 to 1.580;
p= 0.781;
difference = –5%
(–33% to 22%)
(B) Rates of CDAI 100 response ITT: 16/33 (49%) ITT: 17/36 (47%) ITT: RR 1.027, 95% CI
0.627 to 1.681; p= 1.0
PP: 8/19 (42%) PP: 17/36 (47%) PP: RR 0.892, 95% CI
0.475 to 1.675;
p= 0.781
(C) Clinical remission ITT: 10/33 (30%) ITT: 14/36 (39%) ITT: RR 0.779, 95% CI
0.403 to 1.507;
p= 0.613
PP: 4/19 (29%) PP: 14/36 (39%) PP: RR 0.541, 95% CI
0.207 to 1.417;
p= 0.234
Clinical response by subgroups,
n (%) Algorithm arm Intensification arm Comparison
Group 1 (n= 14; algorithm arm: n = 5;
IFX-intensified arm: n= 9)
ITT: 2/5 (40) ITT: 4/9 (44) ITT: RR 0.90, 95% CI
0.246 to 3.297; p= 1.00
(Subtherapeutic IFX + detectable
anti-IFX Abs + insufficient IFX
bioavailability due to induce
immunogenicity of IFX)
PP: 2/5 (40) PP: 4/9 (44) PP: RR 0.90, 95% CI
0.246 to 3.297; p= 1.00
Group 2 (n= 3: algorithm arm, n= 1;
IFX-intensified arm, n= 2)
ITT: 0/1 (0) ITT: 1/2 (50) ITT: not calculable
(Subtherapeutic IFX + undetectable
anti-IFX Abs + insufficient IFX
bioavailability due to non-immune-
mediated pharmacokinetics)
PP: 0/1 (0) PP: 1/2 (50) PP: not calculable
Group 3 (n= 48: algorithm arm,
n= 26; IFX-intensified arm, n=22)
ITT: 16/26 (62) ITT: 12/22 (55) ITT: RR 1.128, 95% CI
0.693 to 1.837;
p= 0.770
(Therapeutic IFX + undetectable anti-
IFX Abs + inhibition of TNF-alpha
ineffective due to non-TNF drive
disease)
PP: 7/13 (54) PP: 12/22 (55) PP: RR 0.987, 95% CI
0.525 to 1.856; p= 1.00
Group 4 in algorithm (n= 4: algorithm
arm, n= 1; IFX-intensified arm, n= 3)
ITT: 0/1 (0) ITT: 2/3 (67) ITT: not calculable
(Therapeutic IFX + detectable anti-IFX
Abs + pharmacodynamics or
non-functional anti-IFX Abs or FP test)
PP: 0/0 PP: 2/3 (67) PP: not calculable
Describe definition of progression:
Patients who withdrew because of lack of effect of study treatment were classified as having no response and no remission
at subsequent study visits
Describe definition of remission:
An absolute CDAI score of ≤ 150 and complete closure of all fistulas despite gentle pressure
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Definition of clinical response:
≥ 70-point reduction in CDAI from baseline in luminal disease and a reduction in active fistulas of ≥ 50% from baseline in
fistulising disease
Duration of: Algorithm arm Intensification arm Comparison
Response NR NR NR
Relapse NR NR NR
Remission NR NR NR
Rates of hospitalisation, n (%) NR NR NR
Rates of surgical intervention, n (%) NR NR NR
Time to surgical intervention, yes/no NR NR NR
Health-related QoL, yes/no Yes Yes Yes
Length of follow-up reported, yes/no Yes; 12 weeks Yes; 12 weeks Yes; 12 weeks
Proportion progressing to surgery,
n (%)
NR NR NR
Time to surgical intervention NR NR NR
Incidence of adverse effects of treatment
Item Algorithm arm IFX-intensified arm p-value
NR NR NR
Dose changes
Item Algorithm arm IFX-intensified arm p-value
Number of patients outside
therapeutic range (subtherapeutic IFX)
Group 1: 5 Group 1: 9 Group 1: 14
Group 2: 1 Group 2: 2 Group 2: 3
Group 3: 0 Group 3: 0 Group 3: 0
Group 4: 0 Group 4: 0 Group 4: 0
Mean anti-TNF (mg/m2/week) (SD) NR
Number of patients dose increased Unclear treatments for group 3 of algorithm arm; all patients were increased in
the dose intensification arm
Number of patients dose reduced Unclear, group 3 of algorithm arm should have stopped IFX but many did not
Health-related QoL
Item
Algorithm arm, mean
(standard error)
IFX-intensified arm,
mean (standard error) Mean difference
PDAI score decrease from baseline ITT: 2.4 (0.8) ITT: 1.5 (0.7) 0.9 (95% CI −1.4 to 3.2);
p= 0.421
PP: 1.4 (0.5) PP: 1.5 (0.7) −0.1 (95% CI −2.1 to
1.9); p= 0.911
IBDQ score increase from baseline ITT: 8.8 (1.7) ITT: 8.8 (1.9) 0 (95% CI −5.1 to 5.2);
p= 0.996
PP: 5.4 (2.0) PP: 8.8 (1.9) −3.4 (95% CI −9.6 to
2.7); p= 0.264
Author’s conclusion
Treatment of secondary IFX failure using an algorithm based on combined IFX and IFX antibody measurements significantly
reduces average treatment costs per patient compared with routine IFX dose escalation and without any apparent negative
effect on clinical efficacy
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Reviewer’s conclusion
The primary outcome measure of the trial concerns costs rather than a clinical outcome. However, results on clinical
response rate, defined as patients with ‘≥ 70-point reduction in CDAI from baseline in luminal disease and a reduction in
active fistulas of ≥ 50% from baseline in fistulising disease’ were reported. The trial included patients with secondary loss
to response with IFX and they were randomised into two groups; that is, IFX-intensified arm in which IFX treatment was
intensified and an algorithm arm in which patients would receive interventions based on the serum IFX and IFX antibody
levels using the proposed algorithm. In terms of clinical response rate, the study found no significant difference between
the two groups. The clinical response rate was numerically found to very slightly favour the algorithm arm using the ITT
population (58% vs. 53%), whereas the IFX-intensified arm was found to be very slightly numerically superior using the PP
population (53% vs. 47%), in both cases the difference was not statistically significant. The study was underpowered to
detect clinical differences between groups
CONSORT, Consolidated Standards of Reporting Trials; FP, false positive; LOQ, limit of quantification; N/A, not applicable;
NR, not reported.
Name of first reviewer: Martin Connock.
Name of second reviewer: Paul Sutcliffe.
Study details
Study identification number 73
First author surname Vande Casteele
Year of publication 2015
Country Belgium
Study design RCT
Publication (full/abstract) Full
Study setting Tertiary referral centre
Number of centres (by arm) One
Duration of study 52 weeks from randomisation
Follow-up period As above
Funding Belgian Research Foundation
Aim of the study
To determine whether or not dosing based on therapeutic drug monitoring increases the rate of remission and whether or
not continued concentration-based dosing is superior to clinically based dosing of IFX for maintaining remission in patients
with CD and UC
Inclusion/exclusion criteria for patients
Inclusion criteria l Moderate to severe CD or UC confirmed by endoscopy and histology
l Aged ≥ 18 years
l On IFX at least 14 weeks
l Clinically stable
Exclusion criteria Non-standard higher dosing regimen for secondary LOR to IFX therapy at time
of screening; ATI > 8 µg/ml equivalents
Study flow (CONSORT diagram)
Available in paper
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Item Clinical dosing arm
Concentration
dosing arm All
n screened Optimisation preceded randomisation 275
n excluded (ineligible) Unclear Unclear 24
n included for optimisation 263
n randomised 123 128 251
n of non-participants at study entry
(those refused, etc.)
6 of 263 withdrew consent during ‘optimisation’ before randomisation;
6 further either developed LOR or could not be optimised
n study sample at baseline randomised 123 128 251
Discontinued post randomisation 12 13 25
Lost to follow-up post randomisation 2 2 4
Participants (characteristics and numbers) randomised phase
Total number of participants at baseline
(% CD)
123 (66.7) 128 (71.1) 251
n (%) followed up 121 (100) 126 (100) 247
n (%) included in analysis primary
outcome (remission at week 52)
123 (100) 128 (100) 251 (ITT)
Patient group (responders/secondary LOR) Responders Responders Responders
Age (years), median (IQR) 42.0 (32.0–48.0) 41.0 (30.0–50.3) 41.0 (30.5–49.0)
Sex (women), n (%) 51 (41.5) 62 (48.4) 113 (45.0)
Diagnostic criteria for CD IBD confirmed by endoscopy and histology
Children, n (%) None None None
CD activity; CRP (mg/l) 1.3 (IQR 0.6–4.5) 1.5 (IQR 0.7–4.0) 1.4 (IQR 0.6–4.2)
n (%) patients in remission
(for CD HBI ≤ 4)
At randomisation (after dose optimisation): IBD 101 (82.1) and 106 (82.8),
for CD 63/82 (76.8) and 75/91 (82.4), in clinical and concentration arms,
respectively
CD classification (Vienna/Montreal) Unclear Unclear Unclear
Disease duration (years), median (IQR) 12.5 (7.1–19.3) 12.0 (5.6–20.8) 12.5 (6.3–19.9)
Smoking, n (%) 38 (30.9) 26 (20.3) 64 (25.5)
Previous surgery, n (%) 70/178 CD (39.3) All 76/263 (28.9)
Concomitant treatment (specify), n (%)
Immunosuppressants 7 (5.7) 6 (4.7) 13 (5.2)
Systemic corticosteroids or budesonide NR NR NR
Treatment duration at anti-TNF failure
(days)
N/A N/A N/A
Previous anti-TNF therapy, n (%) NR NR NR
CRP (mg/ml), median (IQR) 1.3 (0.6–4.5) 1.5 (0.7–4.0) 1.4 (0.6–4.2)
Calprotectin (µg/g) NR NR NR
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Treatment
Item Clinical dosing arm
Concentration
dosing arm
Anti-TNF drug (name) IFX IFX
Anti-TNF dose Various based on clinical decisions
(CRP and symptoms)
Various based on
trough IFX testing
Duration of treatment Patients entered on IFX
Intervention test assay (please specify): ELISA
Technical aspect of test assay:
Manufacturer Non-commercial ELISA ‘in-house’ (Leuven University)
Time of anti-TNF, antibody measurement Repeated trough IFX testing during dose optimisation phase. After
randomisation testing was done before each infusion in the concentration
dosing arm
Assay type ELISA
Assay name In-house Leuven
Type of ELISA (bridging/ capture) Capture ELISA to measure IFX concentrations
Bridging ELISA to measure IFX Abs
Anti-TNF-α detection: limit of detection In-house ELISA; reference provided to previous study
Lower limit of detection 0.3 µg/ml IFX
Antibody detection: limit of detection In-house ELISA; reference provided to previous study
Lower limit of detection 1.0 µg/ml IFX
Outcomes reported
Item
Primary outcome(s) Proportion with clinical (HBI ≤ 4 for CD, Mayo ≤ 2 UC) and biological
(CRP ≤ 5m/l) at 52 weeks post randomisation
Secondary study outcomes Durable remission (as primary but throughout 52 weeks); relapse (need for
dose escalation or addition of steroids or switch treatment), EQ-5D; costs of
treatment
Timing of assessments (including
information on parallel or sequential)
Probably at each infusion, or every 8 weeks
Time to test result NR
Number of inconclusive results, n (%) Authors used defined cut-off points, inconclusive results= 0%
Frequency of dose adjustment, n (%) Unclear; both groups received dose adjustments, if required, during
optimisation phase so as to bring drug trough levels with target range
(3–7 µg/ml). 115 no adjustment, 76 dose escalated, 72 dose reduction
(CD plus UC). Post-randomisation dose adjustments unclear
Frequency of treatment switch, n (%)
Measure of disease activity (e.g. CDAI,
others?)
For CD: HBI; CRP level; relapse, see below
Rates of remission (clinical), optimisation
phase
Before 131/178 CD (73.6%)
After 138/173 CD (79.8%) by ITT 138/178 (77.5%)
After randomisation at week 52: clinical
and biological remission
Clinical-based CD 54.9%; trough-based CD 62.6%; p= 0.353 (at start of
randomisation NR)
Durable remission (clinical and biological
through 52 weeks)
CD + UC: clinically based 27%; concentration based 26%; p = 0.880
Relapse (need for dose escalation or
addition of steroids or switch in
treatment)
Clinically based, 21 (17%); concentration based, 9 (7%) (RR 2.4, 95% CI
1.2 to 5.1; p= 0.018). Time-to-relapse log-rank test, p = 0.017
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Describe definition of response:
Clinical response = being:
. . . symptom-free (full responder) or having clinical improvement with an obvious decrease of disease activity but with
clinical symptoms still present (partial responder)
Describe definition of progression:
Relapse defined as the need for dose escalation or addition of steroids or switch treatment
Describe definition of remission:
Clinical remission for patients with CD= HBI score of ≤ 4 corresponds to remission. Biological remission = CRP
concentration of ≤ 5mg/l
Rates of hospitalisation, n (%) Two out of 263 hospitalised: one for appendectomy and one for ileostomy
complications; both patients were in the clinically based dosing group
Rates of surgical intervention, n (%) NR/unclear
Time to surgical intervention, yes/no NR
Health-related QoL, yes/no Yes
Length of follow-up reported, yes/no Yes; 52 weeks
Proportion progressing to surgery, n (%) NR/unclear
Time to surgical intervention Unclear
Incidence of adverse effects of treatment (post-randomisation phase)
Item
Clinically based dosing
(N=123), n (%)
Concentration-based dosing
(N=128), n (%)
Adverse event
Pharyngitis 20 (16.3) 25 (19.5)
Upper respiratory tract infection 55 (44.7) 59 (46.1)
Pneumonia 3 (2.4) 6 (4.7)
Aphthous stomatitis 1 (0.8) 3 (2.3)
Headache 4 (3.3) 3 (2.3)
Arthralgia 37 (30.1) 33 (25.8)
Infusion reaction 6 (9.4) 3 (2.3)
Acute reaction 6 (9.4) 1 (0.8)
Delayed hypersensitivity 0 (0) 2 (1.6)
Serious adverse event 0 (0) 1 (0.8)
Dose monitoring
Item (please define if necessary)
Time of anti-TNF/antibody measurement See above
Frequency of anti-TNF/antibody
measurement
See above
Assay type See above
Assay name See above
Threshold of IFX/ADA (therapeutic/
subtherapeutic) (µg/ml)
Trough level defined groups at start of optimisation:
1. IFX < 0.3 µg/ml ADAb < 8 µg/ml
2. IFX < 3 µg/ml
3. IFX 3–7 µg/ml
4. IFX > 7 µg/ml
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Dose monitoring
Item (please define if necessary)
Limit of quantification of anti-TNF
antibodies
1.0 µg/ml (see above)
Algorithm specified for management,
yes/no (specify)
Yes
Algorithm provided Yes
Number of patients outside therapeutic
range
Of 263 entering optimisation phase, 12 were not optimised (withdrew,
lost response or failed to get to target range)
Mean anti-TNF (mg/m2 per week) (SD) NR
Optimisation phase CD for supp; table 1
Number of patients dose increased IBD 76 (28.9%), CD 44/178
Number of patients dose reduced IBD 72 (27.4%), CD 52/178
Number of patients no change IBD 115 (43.7%), CD 82/178
During randomised phase
Number of patients dose increased Unclear
Number of patients dose reduced Unclear
Number of patients no change Unclear
Health-related QoL
Item Concentration based Clinically based
EQ-5D completed Unclear Unclear
Author’s conclusion
Targeting patients’ IFX TCs to 3–7 µg/ml results in a more efficient use of the drug. After dose optimisation, continued
concentration-based dosing was not superior to clinically
Reviewer’s conclusion
Small gains in reduced drug costs with dose optimisation, unclear if cost of testing will offset these; no clinical benefit
demonstrated for testing strategy other than more relapse (probably requiring dose escalation) occurred in the clinically
based dosing group
ATI, antibodies to IFX; CONSORT, Consolidated Standards of Reporting Trials; N/A, not applicable; NR, not reported.
Name of first reviewer: Deepson S Shyangdan.
Name of second reviewer: Martin Connock.
Study details
Study identification number 128
First author surname Vaughn
Year of publication 2014
Country USA
Study design Retrospective observational study (pilot study) with treatment algorithm
Publication (full/abstract) Full
Study setting Beth-Israel Deaconess Medical Center (Boston, MA, USA)
Number of centres (by arm) One
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Study details
Duration of study Probably start of 2009 to August 2013
Follow-up period Variable according to analysis subgroups
Funding Unclear/NIHR training grant
Aim of the study
To describe the outcomes of proactive TCM of IFX-treated patients in clinical remission on IFX using dose adjustment based
on testing to bring IFX into target range. Outcomes include initial and subsequent IFX trough levels, dosing changes
including dose escalation and de-escalation, and outcomes of patients on IFX monotherapy. The secondary aims were to
assess if proactive TCM was associated with a longer duration of IFX compared to a control group (i.e. that did not receive
proactive TCM) and to assess reasons for cessation of IFX
Inclusion/exclusion criteria for patients
Inclusion criteria Patients receiving IFX for IBD at the Beth-Israel Deaconess Medical Center
(Boston, MA, USA). For a patient to be considered as having had proactive
TCM of IFX, the patient must have had an IFX trough concentration while
in clinical remission and testing not done for a reactive purpose (i.e. for
symptoms concerning for IBD or concern for and IFX-mediated side effect)
Exclusion criteria Patients were excluded if:
1. the IFX infusions were not administered at the hospital’s
infusion centre
2. the IFX concentration was drawn from cord blood
3. there was no follow-up visit after the IFX concentration was drawn
4. the IFX concentration was not documented in a gastroenterology
clinic note
5. patient failed to receive at least one maintenance infusion of IFX
Study flow (CONSORT diagram)
Available in paper
Item Proactive TCM group Control group
n screened 88 identified from
Prometheus Laboratories data
84 identified from infusion centre
n excluded (ineligible) 14 did not meet inclusion
criteria; 22 did not reach
clinical remission; four
patients did not have level
when in remission or level
was not a trough
10 did not reach clinical remission
n enrolled/included (eligible) 48 included as ‘proactive TCM
of IFX’
74+ 4 from PROMETHEUS record= 78
n non-participants at study entry (those
refused, etc.)
N/A N/A
n study sample at baseline randomised (if
applicable)
N/A N/A
Withdrawals N/A N/A
Lost to follow-up/drop outs (sample attrition) N/A N/A
Participants (characteristics and numbers)
Item TCM group Control (non-TCM) group
Total number of participants at baseline
(% CD)
48 (38/48; 79%) 78 (45/78; 67%)
n (%) followed up 48 78
n (%) included in analysis 48 78
Patient group (responders/secondary LOR) Responders (in remission) Responders (in remission)
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Study flow (CONSORT diagram)
Participants (characteristics and numbers)
Age, median (range), years 35 (29–42.5) at start of IFX
therapy
34.9 (26.2–49.7) at start of IFX therapy
Sex (women), n (%) 15 (31) 33 (42)
Diagnostic criteria for CD NR NR
Children, n (%) None None
CDAI score, mean (SD) NR NR
n (%) patients in remission All patients in remission All patients in remission
n (%) patients with active CD
CD classification (Vienna/Montreal) NR NR
Disease duration (years) Not clear Not clear
Smoking, n (%) – tobacco status Current: 5 (10) Current: 7 (9)
Former: 12 (25) Former: 14 (18)
Never: 31 (56) Never: 57 (73)
Previous surgery, n (%) 19 (40) 19 (25)
Concomitant treatment (‘combination
therapy’), n (%)
21 (44) 31 (40)
Treatment duration at anti-TNF failure
(weeks)
Not clear Not clear
Line of therapy NR NR
Previous anti-TNF therapy, n (%) IFX (100%) IFX (100%)
CRP (mg/ml) NR
Calprotectin (µg/g) NR
Treatment
Item
Anti-TNF drug (name) IFX
Anti-TNF dose Various
Duration of treatment Various time-to-treatment cessation = primary outcome
Intervention test assay (please specify):
ELISA and HMSA – the authors report that:
. . . the period of the study overlapped with the use of 2 methods of IFX and ATI detection. Initially, testing was
performed through solid-phase ELISA and the testing was changed to a non-radiolabeled liquid-phase mobility
shift assay
Technical aspect of test assay:
Manufacturer Prometheus Laboratories (San Diego, CA, USA) (they performed the
assays)
Time of anti-TNF, antibody measurement Various
Assay type/name ELISA or HMSA
Type of ELISA (bridging/ capture) NR
Anti-TNF-α detection: ELISA, HMSA details NR
Antibody detection: ELISA, HMSA details NR
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Outcomes reported
Item
Primary outcome(s) Primary outcome applied for the proactive TCM group only: initial and
subsequent IFX trough levels, dosing changes including dose escalation
and de-escalation, and outcomes of patients on IFX monotherapy
Secondary study outcomes Time-to-IFX treatment cessation TCM vs. control group
Timing of assessments (including information
on parallel or sequential)
Unclear
Time to test result NR
Number of inconclusive results, n (%) NR
Frequency of dose adjustment, n (%) TCM group: first trough test: dose escalated 12/48; dose decreased 3/48;
dose stopped 2/48; and dose unchanged 31/48
Subsequent trough tests: dose escalated 8/40; dose decreased 2/40; and
dose unchanged 30/40
Frequency of treatment switch, n (%) N/A
Measure of disease activity (e.g. CDAI,
others?)
Physicians’ judgement of remission assessed on medical notes; cessation of
treatment
Rates of:
Response, yes/no Time-to-event analysis of time to IFX treatment cessation. Others: no
Relapse, yes/no
Remission, yes/no
Describe definition of progression:
Equivalent to IFX treatment cessation
Describe definition of remission:
Physicians’ judgement based on medical notes (clinical remission defined as ‘lack of symptoms attributable to underlying
IBD based on the treating gastroenterologist’s documentation’)
Duration of:
Response Time-to-event analysis of time to IFX treatment cessation
Relapse
Remission
Rates of hospitalisation, n (%) NR
Rates of surgical intervention, n (%) NR
Health-related QoL, yes/no No
Length of follow-up reported, yes/no Various; follow-up to IFX cessation in Kaplan–Meier analysis
Incidence of adverse effects of treatment (reasons for stopping IFX)
Item TCM group No-TCM group
Recurrent IBD symptoms 0 15
Adverse events
Pneumonia 0 1
Drug-induced lupus 1 0
Psoriasis 1 0
High antibody concentration 1 0
Infusion reactions
Acute 0 6
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Incidence of adverse effects of treatment (reasons for stopping IFX)
Item TCM group No-TCM group
Delayed 1 0
Other (unrelated to IFX) 1 2
Dose monitoring
Item (please define if necessary)
Time of anti-TNF/antibody measurement Various
Frequency of anti-TNF/antibody measurement Unclear
Threshold of IFX/ADA (therapeutic/
subtherapeutic) (µg/ml)
Initially undetectable IFX was defined as subtherapeutic, later the target
range of 5–10 µg/ml was used as the therapeutic range, dose adjustments
(in the TCM group) were made to bring patients into this range
Limit of quantification of anti-TNF antibodies
[U/ml (arbitrary unit/ml)] for Ab detectable/
non-detectable
HMSA for IFX IFX 1 µg/ml; ELISA 1.4 µg/ml
Algorithm specified for management, yes/no
(specify)
Yes. Algorithm resulted in dose increases of typically 50–100mg (for a
70-kg patient receiving 5 mg/kg (total 350 mg); this represents an increase
of between 14% and 28%
Algorithm provided Yes, provided in narrative description, but ill defined
Number of patients outside therapeutic
range
In TCM arm at first trough test 35% needed dose adjustment
Mean anti-TNF (mg/m2/week) (SD) Unclear
Number of patients dose increased See above
Number of patients dose reduced See above
Health-related QoL
Item NR
Author’s conclusion
Proactive TCM of IFX frequently identified patients with low or undetectable trough concentrations and resulted in a
greater probability of remaining on IFX
Reviewer’s conclusion
The distinction between proactive and non-proactive groups is that in the latter testing was done reactively for symptom
worsening; this implies that identification of this group will tend to select ill patients (select patients with worsening
symptoms), whereas in the proactive group tests were not done in response to symptoms and therefore those identified
are probably less likely to be ill patients than in the control group. Patients that did not reach remission were excluded;
this resulted in 22 exclusions from 88 in the TCM group, but only 10 from 84 in the control group
The part of the study comparing TCM with no TCM provided time-to-event outcomes for retention in IFX treatment; in the
main other outcomes referred to the TCM only. For time-to-event data extraction using the method of Guyot please refer
to appropriate data extraction files
ATI, antibodies to IFX; CONSORT, Consolidated Standards of Reporting Trials; N/A, not applicable; NR, not reported;
TCM, trough concentration monitoring.
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Appendix 6 Excluded studies with reason
Full text exclusions with reason
TABLE 46 Full-text exclusions from the review with reason for exclusion
Reference Reason for exclusion
Afif W, Loftus EV Jr, Faubion WA, Kane SV, Bruining DH, Hanson KA, et al. Clinical utility of
measuring infliximab and human anti-chimeric antibody concentrations in patients with
inflammatory bowel disease. Am J Gastroenterol 2010;105:1133–9
C insufficient data
M no algorithm
specified/acted on
Baert F, Noman M, Vermeire S, Van Assche G, D’Haens G, Carbonez A, et al. Influence of
immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med
2003;348:601–8
C insufficient data
Balzola F, Bernstein C, Ho GT, Lees C. Clinical utility of measuring infliximab and human
antichimeric antibody concentrations in patients with inflammatory bowel disease:
commentary. Inflamm Bowel Dis Monitor 2010;11:85–6
Commentary no original
data
Balzola F, Cullen G, Ho GT, Russell RK. Clinical utility of newly developed immunoassays for
serum concentrations of adalimumab and anti-adalimumab antibodies in patients with
Crohn’s disease. Inflamm Bowel Dis Monitor 2013;14:19
Commentary no original
data
Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s
disease. Aliment Pharmacol Ther 2011;33:987–95
Review without
meta-analysis
Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose
intensification in Crohn’s disease: a systematic review. Am J Gastroenterol 2011;106:674–84
SR without meta-analysis
Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in
Crohn’s disease: a critical systematic review. Inflamm Bowel Dis 2009;15:1264–75
Review without
meta-analysis
Chaparro M, Guerra I, Munoz-Linares P, Gisbert JP. Systematic review: antibodies and
anti-TNF-alpha levels in inflammatory bowel disease. Aliment Pharmacol Ther
2012;35:971–86
SR without meta-analysis
Colombel JF, Feagan BG, Sandborn WJ, Van Assche G, Robinson AM. Therapeutic drug
monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012;18:349–58
Review without
meta-analysis
Ebert EC, Das KM, Mehta V, Rezac C. Non-response to infliximab may be due to innate
neutralizing anti-tumour necrosis factor-alpha antibodies. Clin Exp Immunol
2008;154:325–31
Measurement of antibodies
to TNF-α, not to anti-TNF-α
drugs
Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in
immune-mediated inflammatory diseases: a systematic review of the literature with a
meta-analysis. Ann Rheum Dis 2013;72:1947–55
> 50% RA patients
Hamalainen A, Sipponen T, Kolho KL. Serum infliximab concentrations in pediatric
inflammatory bowel disease. Scand J Gastroenterol 2013;48:35–41
C insufficient data
Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Motegi K, et al. Retrieval of serum
infliximab level by shortening the maintenance infusion interval is correlated with clinical
efficacy in Crohn’s disease. Inflamm Bowel Dis 2012;18:1480–7
C insufficient data
Khanna R, Sattin BD, Afif W, Benchimol EI, Bernard EJ, Bitton A, et al. Review article:
a clinician’s guide for therapeutic drug monitoring of infliximab in inflammatory bowel
disease. Aliment Pharmacol Ther 2013;38:447–59
SR without meta-analysis
Lazebnik LB, Sagynbaeva VE. [Level of adalimumab and its antibody titers define the
effectiveness of the biological (anticytokine) therapy in Crohn’s disease.] Eksp Klin
Gastroenterol 2013;7:18–22
Non-English
Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory
bowel disease and factors implicated in treatment response. Therap Adva Gastroenterol
2013;6:269–93
SR without meta-analysis
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TABLE 46 Full-text exclusions from the review with reason for exclusion (continued )
Reference Reason for exclusion
Malickova K, Duricova D, Bortlik M, Machkova N, Janatkova I, Lukas M. [Serum infliximab
trough levels and induction of antibodies to infliximab during the biological treatment of
patients with inflammatory bowel diseases.] Alergie 2011;13:216–22
Non-English
Rivero Marcotegui A, Ibanez Bosch R, Zuniga Vera A, Arin Letamendia A, Burusco Paternain
MJ. [Clinical usefulness in measuring infliximab and human anti-chimeric antibodies.]
Rev Labor Clin 2014;7:68–72
> 50% RA patients
Roblin X, Rinaudo M, Del Tedesco E, Phelip JM, Genin C, Peyrin-Biroulet L, et al.
Development of an algorithm incorporating pharmacokinetics of adalimumab in
inflammatory bowel diseases. Am J Gastroenterol 2014;109:1250–6
C insufficient data
M no algorithm specified/
acted on
Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and
safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain
remission in Crohn’s disease. Gastroenterology 1999;117:761–9
C insufficient data
Sono K, Yamada A, Yoshimatsu Y, Takada N, Suzuki Y. Factors associated with the loss of
response to infliximab in patients with Crohn’s disease. Cytokine 2012;59:410–16
C insufficient data
Steenholdt C, Svenson M, Bendtzen K, Thomsen OO, Brynskov J, Ainsworth MA. Severe
infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with
inflammatory bowel disease. Aliment Pharmacol Ther 2011;34:51–8
C insufficient data
Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O, et al. The temporal evolution
of anti-drug antibodies in patients with inflammatory bowel disease treated with infliximab.
Gut 2014;63:1258–64
C insufficient data
Van Assche G, Magdelaine-Beuzelin C, D’Haens G, Baert F, Noman M, Vermeire S, et al.
Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab
maintenance: a randomized trial. Gastroenterol 2008;134:1861–8
C insufficient data
Vermeire S, Noman M, Van Assche G, Baert F, D’Haens G, Rutgeerts P. Effectiveness of
concomitant immunosuppressive therapy in suppressing the formation of antibodies to
infliximab in Crohn’s disease. Gut 2007;56:1226–31
C insufficient data
Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y. Monitoring functional serum antitumor
necrosis factor antibody level in Crohn’s disease patients who maintained and those who
lost response to anti-TNF. Inflamm Bowel Dis 2010;16:1898–904
C insufficient data
Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD.
Am J Gastroenterol 2011;106:685–98
Review without
meta-analysis
C, correlation-type study; M, management-type study; RA, rheumatoid arthritis; SR, systematic review.
Excluded abstracts with reason
TABLE 47 Abstracts excluded from the review with reason for exclusion
Reference Reason for exclusion
Abraham B, Chiorean M. False positive infliximab levels detected in patients treated with
adalimumab for inflammatory bowel disease. Am J Gastroenterol 2012;107:S627
C insufficient data
Afif W, Loftus EV, Faubion WA, Hanson KA, Sandborn WJ. Clinical utility of measuring
infliximab and human anti-chimeric antibody levels in patients with inflammatory bowel
disease. Gastroenterology 2009;136(Suppl. 1):A147
Superseded by full text
Anonymous. New assay can detect infliximab levels and anti-infliximab antibodies from a
single serum sample. Clin Adv Hematol Oncol 2012;10:27
Editorial no original data
Armbruster S, Ally M, Maydonovitch C, Betteridge J, Veerappan G. The use of human
anti-chimeric antibody (HACA) and infliximab levels in the management of inflammatory
bowel disease. Am J Gastroenterol 2012;107:S641
M no algorithm
specified/acted on
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TABLE 47 Abstracts excluded from the review with reason for exclusion (continued )
Reference Reason for exclusion
Arranz MDM, Arranz EM, Salcedo DP, De Diego C, Senent SG, Cordon JP, et al. Infliximab
trough levels and antibodies: relationship with infusion reaction, immunomodulators and
biological parameters. Gastroenterology 2014;146(Suppl. 1):243
C insufficient data
Baert FJ, Drobne D, Ballet V, Cleynen I, Compernolle G, Rutgeerts PJ, et al. Early trough
levels and antibodies predict safety and success of restarting infliximab after long drug
holiday. Gastroenterology 2011;140(Suppl. 1):62
C insufficient data
Baert FJ, Lockton S, Hauenstein S, Singh S, Gils A, Vermeire S. Antibodies to adalimumab
predict inflammation in Crohn’s patients on maintenance adalimumab therapy.
Gastroenterology 2014;146(Suppl. 1):242
C insufficient data
Ben-Bassat O, Hauenstein S, Iacono A, Irwin SP, Singh S, Greenberg GR. Serum adalimumab
and immunogenicity in IBD patients after 80 mg biweekly maintenance therapy.
Gastroenterology 2013;144(Suppl. 1):771
C insufficient data
Ben-Horin S, Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, et al. The temporal
evolution of anti-drug antibodies in IBD patients treated with infliximab. J Gastroenterol
Hepatol 2013;28:145
C insufficient data
Bodini G, Savarino V, Dulbecco P, Baldissarro I, Savarino E. TNF-alpha levels strongly
correlated with disease activity based on HBI and CDEIS in patients with Crohn’s disease in
maintenance treatment with adalimumab. Gastroenterology 2014;5(Suppl. 1):238
C insufficient data
Bodini G, Savarino V, Dulbecco P, Baldissarro I, Savarino E. The influence of anti-adalimumab
antibodies on adalimumab trough levels, TNF-alpha levels and clinical outcome. J Crohns
Colitis 2014;8:S42
C insufficient data
Bodini G, Savarino V, Dulbecco P, Baldissarro I, Savarino EV. ELISA vs. HMSA: a comparison
between two different methods for measuring adalimumab serum concentration and
anti-adalimumab antibodies – preliminary data. Dig Liver Dis 2014;46:S67
Duplicate
Bodini G, Savarino V, Dulbecco P, Assandri L, Bruzzone L, Mazza F, et al. Correlation
between adalimumab trough serum concentration, anti-adalimumab antibodies and
TNF-alpha levels with clinical outcome in patients affected by Crohn’s disease.
Gastroenterology 2013;144(Suppl. 1):780
C insufficient data
Bodini G, Savarino V, Fazio V, Assandri L, Gemignani L, Dulbecco P, et al. Relationship
between drug serum concentration and clinical activity in patients with Crohn’s disease who
achieved remission with adalimumab. Dig Liver Dis 2012;44:S69–70
Duplicate
Bodini G, Savarino V, Fazio V, Assandri L, Dulbecco P, Gemignani L, et al. Relationship
between drug serum concentration and clinical activity in patients with Crohn’s disease
who achieved remission with adalimumab – a prospective study. Gastroenterology
2012;142(Suppl. 1):388
C insufficient data
Bortlik M, Duricova D, Malickova K, Komarek A, Machkova N, Bouzkova E, et al. Infliximab
trough levels may predict sustained response to infliximab in patients with Crohn’s disease:
a single cohort study. J Crohns Colitis 2012;6:S153
Superseded by full text
Cardile S, Costa A, Loddo I, Morabito G, Pidone C, Romano C. Impact of measurement of
infliximab and anti-infliximab antibodies levels in pediatric inflammatory bowel disease.
Dig Liver Dis 2013;45:e294–5
C insufficient data
Chauhan U, Dutta U, Armstrong D, Greenwald E, Marshall J, Tse F, et al. Does measuring
infliximab and human anti-chimeric antibody concentrations in patients with inflammatory
bowel disease impact clinical management? A Canadian experience. Inflamm Bowel Dis
2012;18:S82–3
M no algorithm
specified/acted on
Chauhan U, Dutta U, Armstrong D, Marshall J, Tse F, Greenwald E, et al. Does measuring IFX
and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease
impact clinical management? A Canadian experience. J Crohns Colitis 2013;7:S228
Duplicate
Chollet-Martin S, Nicaise-Roland P, De Chaisemartin L, Grootenboer-Mignot S, Hayem G,
Pelletier AL, et al. Simultaneous determination of anti-infliximab antibodies and residual
infliximab levels to monitor anti-TNF therapy. Ann Rheum Dis 2013;71:666
Not M, C or ATC
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TABLE 47 Abstracts excluded from the review with reason for exclusion (continued )
Reference Reason for exclusion
Church P, Guan J, Frost K, Muise A, Walters T, Griffiths A. Infliximab treatment for paediatric
Crohn’s disease: long-term outcomes at a single centre. J Crohns Colitis 2013;7:S198
Not M, C or ATC
Church P, Guan J, Salz L, Frost K, Muise A, Walters T, et al. Long-term outcomes with
infliximab treatment in children with Crohn’s disease at a single centre. Inflamm Bowel Dis
2012;18:S72–7
C insufficient data
Church P, Guan J, Salz L, Frost K, Muise A, Walters T, et al. Long-term outcomes with
infliximab treatment in children with Crohn’s disease at a single centre. Inflamm Bowel Dis
2012;18:S5–6
Duplicate
Cornillie F, Hanauer S, Diamond R, Wang J, Zelinger D, Xu Z, et al. Early serum infliximab
trough level, clinical disease activity and CRP as markers of sustained benefit of infliximab
treatment in Crohn’s disease: a post-hoc analysis of the ACCENT1 trial. Am J Gastroenterol
2011;106:S462–3
C insufficient data
Corstjens PL, Wiesmeijer K, Wolbink GJ, Tanke J, Hommes DW, Fidder H. A rapid test
for quantitative determination of infliximab trough levels in blood. Gastroenterology
2011;14:S276–7
C insufficient data
Daperno M, Lavagna A, Fracchia M, Guiotto C, Germano L, Rigazio C, et al. Infliximab
trough levels (IFX-TL) are higher in patients with inflammatory bowel disease (IBD) treated
with immunosuppressives: clinical correlations of IFX-LT and antibodies to infliximab (ATI) in
IBD. Gastroenterology 2013;144(Suppl. 1):781
C insufficient data
Daperno M, Lavagna A, Fracchia M, Guiotto C, Germano L, Rigazio C, et al. Clinical
correlations of infliximab trough levels (IFX-TL) and antibodies to infliximab (ATI) in
inflammatory bowel disease. J Crohns Colitis 2013;7:S239
C insufficient data
Daperno M, Frigerio F, Guiotto C, Laura G, Ercole E, Lavagna A, et al. Comparison of the
performance of two commercially available tests for determination of infliximab trough
levels (IFX-TL) and antibodies to infliximab (ATI), Promonitor and ImmunDiagnostik, in
inflammatory bowel disease. Dig Liver Dis 2013;45:S109
C insufficient data
Daperno M, Frigerio F, Guiotto C, Germano L, Ercole E, Arico S, et al. Identical diagnostic
performance of two commercially available tests for infliximab trough levels (IFX-TL) and
antibodies to infliximab (ATI) titration in inflammatory bowel disease (IBD): Promonitor and
ImmunDiagnostik tests. Gastroenterology 2013;144(Suppl. 1):780
Duplicate
Daperno M, Fracchia M, Guiotto C, Germano L, Ercole E, Rigazio C, et al. Clinical
implications and stability of determination of infliximab trough levels (IFX-TL) and antibodies
to infliximab (ATI) in inflammatory bowel disease. Dig Liver Dis 2013;45:S145
C insufficient data
De Bruyn M, Bessissow T, Billiet T, Cleynen I, Kirkland R, Liu X, et al. Biomarker panel for
prediction of mucosal healing in patients with Crohn’s disease under infliximab therapy.
J Crohns Colitis 2014;8:S45–6
C insufficient data
De Bruyn M, Bessissow T, Billiet T, Cleynen I, Kirkland R, Liu X, et al. Biomarker panel for
prediction of mucosal healing in patients with Crohn’s disease under infliximab therapy.
Gastroenterology 2014;146(Suppl. 1):428
Duplicate
Dotan I, Yanai H, Ron Y, Kariv R, Fishman S, Yahav L, et al. Population pharmacokinetic
evaluation of adalimumab reveals patient factors that increase adalimumab clearance
and shorten half-life in inflammatory bowel disease patients. Gastroenterology
2014;146(Suppl. 1):243
C insufficient data
Dotan I, Ron Y, Yanai H, Becker SA, Fishman S, Yahav L, et al. Population pharmacokinetic
evaluation of infliximab reveals patient factors that increase infliximab clearance and shorten
half-life in inflammatory bowel disease patients. Gastroenterology 2013;144(Suppl. 1):774
C insufficient data
Drastich P, Kozeluhova J, Jaresova M, Spicak J. Infliximab serum trough levels and deep
remission in patients with IBD. Gastroenterology 2011;140(Suppl. 1):292
C insufficient data
Drobne D, Bossuyt P, Breynaert C, Vande Casteele N, Compernolle G, Juergens M, et al.
Long term evolution and impact of immunomodulator co-treatment and withdrawal on
infliximab trough levels in 223 patients with Crohn’s disease. J Crohns Colitis 2011;5:S10–11
M no algorithm
specified/acted on
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TABLE 47 Abstracts excluded from the review with reason for exclusion (continued )
Reference Reason for exclusion
Drobne D, Bossuyt PJ, Breynaert C, Casteele NV, Compernolle G, Jurgens M, et al. Crohn’s
disease: infliximab trough levels and CRP during infliximab–immunomodulator combination
treatment are associated with clinical outcome after immunomodulator withdrawal.
Gastroenterology 2011;140(Suppl. 1):62
C insufficient data
Duricova D, Malickova K, Bortlik M, Machkova N, Komarek V, Bouzkova E, et al. Predictors
of sustained response to infliximab in patients with Crohn’s disease: a single cohort study.
Gastroenterology 2011;140(Suppl. 1):593
C insufficient data
Echarri A, Ferreiro R, Fraga-Iriso R, Barreiro-De Acosta M, Cid J, De-Castro L, et al. Drug
trough levels and primary nonresponse to antiTNF therapy in moderate-severe Crohn
disease. Results of the optimiza study. Gastroenterology 2014;146(Suppl. 1):247
C insufficient data
Eser A, Primas C, Shringarpure R, Hauenstein S, Wang SL, Reinisch W. Detection of anti
infliximab antibodies in patients with inflammatory bowel disease (IBD) in the presence of
infliximab by homogeneous liquid phase anti infliximab mobility shift assay. Am J
Gastroenterol 2012;107:S657
Duplicate
Fasanmade AA, Wagner C, Davis H, Graham M, Everitt D, Gottlieb A. Comparison of the
pharmacokinetics of infliximab in patients with psoriasis or Crohn’s disease not receiving
concomitant immunosuppressants or corticosteroids. J Invest Dermatol 2002;119:243
Not C, M or ATC
Fasanmade AA, Marsters P, Munsanje E, Graham MA, Davis HM, Van Deventer S. Infliximab
pharmacokinetics and improvement in fistulizing Crohn’s Disease. Gastroenterology
2003;124:A61
C insufficient data
Fasanmade AA, Zhu YW, Wagner C, Pendley C, Davis HM. Population pharmacokinetics of
single dose infliximab in patients with Crohn’s disease. Clin Pharmacol Ther 2002;71:P66
Not C, M or ATC
Fasanmade A, Olson A, Bao W, Pendley C, Davis H, Mayer L. Relationship between
infliximab pharmacokinetics and improvement in Crohns disease. Gastroenterology
2002;122:A617–18
C insufficient data
Garces S, Demengeot J, Benito-Garcia E. Clinical impact of immunogenicity of infliximab,
adalimumab and etanercept: a systematic review of the literature with a meta-analysis.
Ann Rheum Dis 2012;71(Suppl. 3):634–5
Superseded by full paper
Garces S, Demengeot J, Wolbink GJ, Aarden L, Benito-Garcia E. The immunogenicity of
infliximab, adalimumab and etanercept in rheumatoid arthritis, ankylosing spondylitis,
psoriatic arthritis, Crohn’s disease and ulcerative colitis a quantitative and a qualitative
review. Arthritis Rheum 2011;63(Suppl. 10):464
Superseded by full paper
Garces S, Demengeot J, Da Silva JC, Aarden L. Bridging ELISA as a screening
assay to monitor immunogenicity in routine clinical practice. Arthritis Rheum
2011;63(Suppl. 10):1841
< 50% CD
Garces S, Demengeot J, Canas-da-Silva J, Aarden L. Bridging ELISA as a screening assay to
monitor immunogenicity in routine clinical practice. Ann Rheum Dis 2013;71:711
Duplicate
Garces S, Freitas J, Canas-Silva J, Aarden L, Demengeot J. The impact of immunogenicity on
drug safety profile. Ann Rheum Dis 2013;72(Suppl. 3):A436
C insufficient data
Garimella TS, Peng JZ, Beck K, Noertersheuser PA, Lomax KG, Paulson SK, et al.
Pharmacokinetics of adalimumab in a long-term investigation of the induction and
maintenance of remission in patients with Crohn’s disease (CLASSIC I and CLASSIC II).
Gastroenterology 2006;130:A481
C insufficient data
Guilday C, Eastwood D, Zadvornova Y, Stein D, Naik AS, Best K, et al. Concomitant
use of immunomodulator therapy results in higher serum infliximab levels compared
to monotherapy without lowering serum haca levels. Gastroenterology
2013;144(Suppl. 1):429
C insufficient data
Guiotto C, Germano L, Vizzini M, Cerruti R, Frigerio F, Daperno M, et al. Determination of
infliximab trough levels (IFX-TL) and antibodies to infliximab (ATI) in inflammatory bowel
disease. Biochim Clin 2013;37:S475
Superseded
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TABLE 47 Abstracts excluded from the review with reason for exclusion (continued )
Reference Reason for exclusion
Hadigan CBR, Braegger CP, Vasilauskis E, Escher JC, Sinaasappel M, Ferry GD, et al.
Pharmacokinetics of infliximab (Anti-TNFx) in children with Crohn’s disease: a multicenter
trial. J Pediatr Gastroenterol Nutr 1999;29;525
C insufficient data
Hauenstein S, Salbato J, Lockton S, Singh S. Characterization of neutralizing anti-drug
antibody response in patients with loss of response to anti-TNF therapy. Gastroenterology
2013;144(Suppl. 1):418
C insufficient data
Hayes Inc. Use of Anti-Infliximab Antibody Levels to Monitor Infliximab Treatment in Patients
with Inflammatory Bowel Disease (IBD). Health Technology Brief Publication. Lansdale, PA:
Hayes Inc.; 2013
Not available
Hester KD, Liu X, Salbato J, Lockton S, Hauenstein S, Singh S. Improved homogeneous
mobility shift assay (HMSA) for the detection of neutralizing antibodies (NAB) in IBD patients
treated with infliximab or adalimumab. Gastroenterology 2014;146(Suppl. 1):248
Not M, C or ATC
Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Sato N, et al. Decrease in serum
infliximab level precedes loss of clinical response and can be easily detected by the elevation
of C-reactive protein in Crohn’s disease. Gastroenterology 2012;142(Suppl. 1):388
C insufficient data
Hoekman DR, Brandse JF, De Meij T, Hummel T, Lowenberg M, Benninga MA, et al. Large
variation in infliximab trough levels is associated with disease activity in paediatric
inflammatory bowel disease. Gastroenterology 2014;146(Suppl. 1):782
C insufficient data
Hoekman D, Brandse H, De Meij T, Hummel T, Lowenberg M, Benninga M, et al. Large
variation in infliximab trough levels is associated with disease activity in paediatric
inflammatory bowel disease. J Crohns Colitis 2014;8:S35
C insufficient data
Huang VW, Prosser C, Shalapay C, Fedorak DK, Dhami N, Wang H, et al. In IBD outpatients
knowledge of fecal calprotectin and infliximab trough levels significantly enhances infliximab
dose escalation decision making. J Crohns Colitis 2014;8:S255
M no algorithm specified/
acted on
Huang VW, Dhami N, Fedorak DK, Prosser C, Shalapay C, Kroeker KI, et al. Disparity
between infliximab trough level and infliximab associated adverse events. J Crohns Colitis
2014;8:S282
C insufficient data
Huang V, Kroeker KI, Wang H, Prosser C, Carol S, Dhami N, et al. In IBD outpatients
knowledge of fecal calprotectin and infliximab trough levels significantly alters clinical
decision making. Gastroenterology 2014;146(Suppl. 1):241–2
Duplicate
Huang V, Dhami N, Fedorak DK, Prosser C, Carol S, Kroeker KI, et al. Infliximab trough
levels are correlated with infliximab-associated adverse events. Gastroenterology
2014;146(Suppl. 1):1
Not M, C or ATC
Imaeda H, Andoh A, Ban H, Bamba S, Sasaki M, Tsujikawa T, et al. The new immunoassay
for the accurate determination of antibodies to infliximab, and relationship between
its serum level and inflammatory values in Crohn’s disease. Gastroenterology
2012;142(Suppl. 1):349
Superseded by full text
Imaeda H, Andoh A, Takahashi K, Fujimoto T, Ban H, Bamba S, et al. Serum infliximab
trough levels above 1.0 mg/ml are required to obtain clinical efficacy in patients with
Crohn’s disease. Inflamm Bowel Dis 2012;18:S59–60
C insufficient data
Imaeda H, Andoh A, Bamba S, Tsujikawa T, Fujiyama Y. Development of a new
immunoassay for the accurate determination of anti-infliximab antibodies in Crohn’s disease.
Inflamm Bowel Dis 2011;17:S42
Duplicate
Imaeda H, Takahashi K, Fujimoto T, Bamba S, Sasaki M, Tsujikawa T, et al. Accurate
determination of serum adalimumab and anti-adalimumab antibodies levels during
maintenance therapy for Crohn’s disease. Gastroenterology 2013;144(Suppl. 1):431
Not M, C or ATC
Irving PM, Arkir Z, Duncan J, Sastrillo M, Anderson S, Sanderson J. Initial experience with
infliximab levels in a tertiary IBD centre. Gut 2012;61:A238
C insufficient data
Jauregui-Amezaga A, Ordas I, Gallego M, Ramirez A, Pino S, Masamunt MC, et al. Impact of
serum drug level and human anti-drug antibody measurement on management of biologic
drugs in inflammatory bowel disease. J Crohns Colitis 2013;7:S202–3
C insufficient data
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TABLE 47 Abstracts excluded from the review with reason for exclusion (continued )
Reference Reason for exclusion
Juan G, Alvarino A, Oltra L, Maroto N, Cano N, Ferrer I, et al. Utility of ‘trough levels’
determination and anti-infliximab antibodies in patients with inflammatory bowel disease
Estimation of individual pharmacokinetic parameters (PK) through population
pharmacokinetic model. J Crohns Colitis 2014;8:S190
C insufficient data; M no
algorithm specified/acted on
Karmiris K, Paintaud G, Degenne D, Ferrante M, Duveau AC, Noman M, et al. Adalimumab
trough serum levels and clinical response in a single-center cohort of inflammatory bowel
disease patients: can trough serum levels serve as a predictor for future loss of response?
Gastroenterol 2008;134:A68
C insufficient data
Karmiris K, Noman M, Paintaud G, Ferrante M, Duveau AC, Degenne D, et al. A 3-week
course of 80 mg weekly administered adalimumab as a rescue therapy for patients with
Crohn’s disease who lost response to 40mg weekly: relationship with adalimumab trough
serum levels. Gastroenterology 2008;134:A640
C insufficient data
Karsan SS, Cohen ER, Targan SR, Ippoliti A, Shih DQ, Vasiliauskas EA, et al. Analysis of
clinical and serological associations, and the clinical consequences of the development of
human anti-chimeric antibodies (HACAS), and low serum infliximab (IFX) levels in
inflammatory bowel disease (IBD). Gastroenterology 2012;142(Suppl. 1):264
C insufficient data
M no algorithm
specified/acted on
Kerr J, Nair A, Hinds R. Variable practice in children with inflammatory bowel disease
requiring infliximab infusions across Australia. J Gastroenterol Hepatol 2013;28:141
M no algorithm
specified/acted on
Kong JY, Bundell C, Pawlik J, Hollingsworth P, Forbes G. Low trough serum infliximab and
antibodies to infliximab in smokers. Inflamm Bowel Dis 2013;19:E35–6
C insufficient data
Kong JY, Bundell CS, Pawlik J, Hollingsworth PN, Forbes GM. Smoking is associated with
low trough serum infliximab levels and presence of anti-infliximab antibody in maintenance
treatment of inflammatory bowel disease (IBD). J Gastroenterol Hepatol 2011;26:59
C insufficient data
Lamblin C, Aubourg A, Ternant D, Picon L, Lecomte T, Paintaud G. Concentration effect
relationship of infliximab in Crohn’s disease: results of a cohort study. J Crohns Colitis
2012;6:S142–3
C insufficient data
Leclerc M, Marotte H, Paul S, Del Tedesco E, Gonzalo P, Phelip JM, et al. Persistence of
antibodies to infliximab for more than two months strongly predicts loss of response to
infliximab in inflammatory bowel diseases. J Crohns Colitis 2014;8:S226–7
C insufficient data
Li JL, Paulson SK, Chiu YL, Robinson A, Lomax KG, Pollack PF. Evaluation of potential
correlations between serum adalimumab concentration and remission in patients with
Crohn’s disease in classic I and II. Gastroenterology 2010;138(Suppl. 1):101
C insufficient data
Lowenberg M, Brandse J, Vos L, Ponsioen C, Van Den Brink G, D’Haens G. High infliximab
trough levels are associated with impaired quality of life in IBD patients in clinical and
biochemical remission on maintenance IFX therapy. J Crohns Colitis 2014;8:S262–3
C insufficient data
Lowenberg M, Brandse JF, Vos LM, Ponsioen C, Van Den Brink GR, D’Haens GR. High
infliximab trough levels are associated with impaired quality of life in IBD patients in
clinical and biochemical remission on maintenance IFX therapy. Gastroenterology
2014;146(Suppl. 1):450
C insufficient data
Lukas M, Malickova K, Bortlik M, Duricova D. Anti-infliximab antibodies in routine clinical
practice – is it worth to assess them? Gastroenterology 2009;136(Suppl. 1):A679
C insufficient data
Malickova K, Janatkova I, Duricova D, Bortlik M, Lukas M. Serum infliximab levels, antibodies
to infliximab and albumin concentrations during infliximab treatment in patients with
inflammatory bowel disease. Clin Exp Rheum 2011;29:213
C insufficient data
Martin Arranz MD, Martin Arranz E, Pascual-Salcedo D, De Diego C, Jaquotot M, Gomez
Senent S, et al. Infliximab trough levels and antibodies: relationship with infusion reaction,
immunomodulators and biological parameters. J Crohns Colitis 2014;8:S251
C insufficient data
Mazor Y, Koplov U, Ben Hur D, Almog R, Waterman M, Ben-Horin S, et al. Evaluating
adalimumab drug and antibody levels as predictors of clinical and laboratory response in
Crohn’s disease patients. J Crohns Colitis 2013;7:S217
C insufficient data
McTigue M, Sandborn W, Levesque B, Patel D. Infliximab therapeutic drug monitoring in
clinical practice: indications and utility. Am J Gastroenterol 2013;108:S512
C insufficient data
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TABLE 47 Abstracts excluded from the review with reason for exclusion (continued )
Reference Reason for exclusion
Morgenstern J, Baestlein E, Leifeld L, Nguyen P, Stein J, Kruis W. Infliximab drug levels in
Crohn’s disease responding to the treatment. J Crohns Colitis 2012;6:S125
C insufficient data
Noman M, Baert F, Vermeire S, Van Assche G, D’Haens G, Carbonez A, et al. Post infusion
infliximab levels determine duration of response in Crohn’s disease and are directly related
to infusion reactions. Gastroenterology 2002;122:A100
C insufficient data
O’Donnell S, Stempak JM, Silverberg MS. Is there a higher rate of infliximab dose
optimization in initial responders between UC and CD cases? Gastroenterology
2014;146(Suppl. 1):462–3
C insufficient data; M no
algorithm specified/acted
on
Papamichail K, Casteele NV, Hauenstein S, Princen F, Singh S, Ferrante M, et al. Prediction of
sustained remission after discontinuation of infliximab in patients with Crohn’s disease.
Gastroenterology 2014;146(Suppl. 1):457
C insufficient data
Pariente B, De Chambrun GP, Desroches M, De Cassan C, Gornet JM, Desreumaux P, et al.
Clinical value of measuring trough levels and human anti-chimeric antibodies in patients
with inflammatory bowel disease who lost response to infliximab therapy. Gastroenterology
2011;140(Suppl. 1):277
Superseded by full text
Pariente B, Pineton De Chambrun G, Desroches M, De Cassan C, Gornet J, Desreumaux P,
et al. Clinical value of measuring trough levels and human anti-chimeric antibodies in
patients with inflammatory bowel disease who lost response to infliximab therapy.
J Crohns Colitis 2011;5:S111–12
Duplicate
Paul S, Del Tedesco E, Marotte H, Clavel L, Phelip JM, Peyrin-Biroulet L, et al. Therapeutic
drug monitoring of infliximab and mucosal healing in inflammatory bowel disease:
a prospective study. Gastroenterol 2013;144(Suppl. 1):92
Superseded by full text
Paul S, Del Tedesco E, Marotte H, Rinaudo-Gaujous M, Phelip JM, Peyrin-Biroulet L, et al.
Infliximab concentration is associated with mucosal healing in intestinal bowel disease (IBD).
J Crohns Colitis 2013;7:S199–200
C insufficient data
Paulson SK, Nocrtersheuser P, Pollack PF, Hoffman RS. Pharmacokinetics of adalimumab
from classic, a randomized phase 3 trial for the induction of clinical remission in patients
with Crohn’s. Gastroenterology 2005;128:A585
C insufficient data
Pradhan RS, Sharma S, Thakkar R, Robinson A, Hyams JS, Rosh JR, et al. Relationship
between adalimumab concentration and efficacy for the induction of clinical remission
in pediatric patients with moderate to severe Crohn’s disease. Gastroenterology
2013;144(Suppl. 1):230–1
Duplicate
Pradhan R, Sharma S, Thakkar R, Robinson A, Hyams J, Rosh J, et al. Relationship between
adalimumab concentration and efficacy for the induction of clinical remission in pediatric
patients with moderate to severe Crohn’s disease. J Crohns Colitis 2013;7:S164
C insufficient data
Rai T, Navaneethan U, Dalal D, Lashner B, Shen B. Clinical implications of measuring
infliximab levels and human anti-chimeric antibodies in patients with inflammatory bowel
disease. Am J Gastroenterol 2012;107:S634
M no algorithm specified/
acted on
Rekvig M, Gedde Dahl M, Bratlie J, Bolstad N, Moum B, Jahnsen J, et al. Anti-TNFalpha drug
level measurements in IBD patients. J Crohns Colitis 2014;8:S301–2
C insufficient data
Roblin X, Marotte H, Del Tedesco E, Rinaudo-gaujous M, Phelip JM, Paul S. Residual
adalimumab trough levels are associated with clinical remission and mucosal healing in IBD.
Gastroenterology 2013;144(Suppl. 1):778
C insufficient data; M no
algorithm specified/acted
on
Roblin X, Rinaudo M, Del Tedesco E, Phelip JM, Peyrin Biroulet L, Paul S. Development of an
algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
J Crohns Colitis 2014;8:S41
C insufficient data; M no
algorithm specified/acted
on
Roblin X, Rinaudo-gaujous M, Del Tedesco E, Phelip JM, Genin C, Peyrin-Biroulet L, et al.
Development of an algorithm incorporating pharmacokinetics of adalimumab in
inflammatory bowel diseases. Gastroenterology 2014;146(Suppl. 1):150
Duplicate
Rosenthal C, Melmed G, Tripuraneni B, Gebbia J, Callejas S, Farrior S, et al. Early infliximab
trough levels predict remission at one year in pediatric IBD patients. Inflamm Bowel Dis
2012;18:S81
C insufficient data
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TABLE 47 Abstracts excluded from the review with reason for exclusion (continued )
Reference Reason for exclusion
Rubin D, Hauenstein S, Singh S. Post-marketing review of serum adalimumab and antibodies
to adalimumab using the mobility shift assay platform. Am J Gastroenterol 2013;108:S532
C insufficient data
Scaldaferri F, Pecere S, Petito V, Cammarota G, Campanale MC, Rapaccini GL, et al.
Infliximab and TNF alfa measurement in intestinal mucosa of IBD patients: a new tool for the
clinic? Dig Liver Dis 2012;44:S189–90
C insufficient data
Schatz SB, Prell C, Freudenberg F, Schwerd T, Bufler P, Koletzko S. Correlation of infliximab
levels and antibodies with clinical outcome in children with IBD. J Pediatr Gastroenterol Nutr
2011;52:E45
C insufficient data
Semmler JM, Pilch A, Armbruster FP, Dignass A, Kruis W, Stein J. Development of a new
immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory
bowel disease. J Crohns Colitis 2014;8:S41
Duplicate
Semmler J, Pilch A, Armbruster FP, Dignass A, Stein J. Development of a new immunoassay
for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease.
Clin Chem Lab Med 2014;52:S1008
Duplicate
Settesoldi A, Giannotta M, Milla M, Genise S, Santini A, Bagnoli S, et al. Loss of efficacy
and adverse drug reactions during infliximab therapy in IBD patients are related to the
appearance of anti-infliximab antibodies. J Crohns Colitis 2012;6:S151
Duplicate
Settesoldi A, Giannotta M, Genise S, Santini A, Bagnoli S, Milla M, et al. Loss of efficacy
and adverse drug reactions during infliximab therapy in IBD patients are related to the
appearance of anti-infliximab antibodies. Dig Liver Dis 2012;44:S194
C insufficient data
Sharma S, Pradhan R, Thakkar R, Robinson A, Hyams J, Rosh J, et al. Relationship between
adalimumab concentration and efficacy for the maintenance of clinical remission in pediatric
patients with moderate to severe Crohn’s disease. J Crohns Colitis 2013;7:S163
C insufficient data
Sharma S, Pradhan RS, Thakkar R, Robinson A, Hyams JS, Rosh JR, et al. Relationship
between adalimumab concentration and efficacy for the maintenance of clinical remission
in pediatric patients with moderate to severe Crohn’s disease. Gastroenterology
2013;144(Suppl. 1):231
C insufficient data
Sorrentino D, Hauenstein S, Marino M, Lockton S, Zarifi D, Del Bianco T, et al. Low dose
infliximab for prevention of postoperative recurrence of Crohn’s disease: long term
follow-up and impact of infliximab trough levels and antibodies to infliximab.
Gastroenterology 2013;144(Suppl. 1):777
C insufficient data
Steenholdt C, Brynskov J, Thomsen O, Munck LK, Fallingborg J, Christensen LA, et al.
Treatment of secondary infliximab failure in Crohn’s disease based on serum levels of
infliximab and antibodies against infliximab: the Danish study of optimizing infliximab
therapy in Crohn’s disease (do it Crohn) randomized clinical trial. Gastroenterology
2013;144(Suppl. 1):22
Superseded by full paper
Steenholdt C, Brynskov J, Thomsen O, Munck LK, Fallingborg J, Christensen LA, et al.
Secondary infliximab treatment failure in Crohn’s disease: therapeutic implications of
measuring drug and anti-drug antibodies by three different binding assays. Gastroenterology
2013;144(Suppl. 1):773
Duplicate
Steenholdt C, Brynskov J, Thomsen O, Munck L, Fallingborg J, Christensen L, et al.
Secondary infliximab treatment failure in Crohn’s disease: therapeutic implications of
measuring drug and anti-drug antibodies by three different binding assays. J Crohns Colitis
2013;7:S159
Superseded by full text
Steenholdt C, Brynskov J, Thomsen O, Munck L, Fallingborg J, Christensen L, et al.
Comparison of techniques for monitoring infliximab and antibodies to infliximab in Crohn’s
disease patients with infliximab treatment failure. Am J Gastroenterol 2012;107:S622
Superseded by full text
Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Clinical implications of
measuring drug and anti-drug antibodies by different assays when optimizing infliximab
treatment failure in Crohn’s disease. J Crohns Colitis 2014;8:S291
Duplicate
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TABLE 47 Abstracts excluded from the review with reason for exclusion (continued )
Reference Reason for exclusion
Steenholdt C, Bendtzen K, Brynskov J, Thomsen O, Ainsworth MA. Clinical implications of
measuring drug and anti-drug antibodies by different assays when optimizing infliximab
treatment failure in Crohn’s disease. Gastroenterology 2014;146(Suppl. 1):240
Superseded by full text
Steenholdt C, Bendtzen K, Thomsen OO, Brynskov J, Ainsworth M. Discriminating between
response types in infliximab-treated patients with Crohn’s disease: sensitivity and specificity
of combined assessment of infliximab trough levels and anti-drug antibodies. Scand J
Gastroenterol 2010;45:59
Superseded by full text
Steenholdt C, Svenson M, Bendtzen K, Thomsen O, Brynskov J, Ainsworth MA. Can
measurements of anti-infliximab antibodies predict acute severe infusion reactions to
infliximab? Gastroenterology 2011;140(Suppl. 1):774
C insufficient data
Steenholdt C, Svenson M, Ainsworth MA, Thomsen O, Brynskov J, Bendtzen K. Comparison
of techniques for monitoring infliximab bioavailability and immunogenicity in Crohn’s
disease. Gastroenterology 2012;142(Suppl. 1):781
ATC insufficient data
Steenholdt C, Thomsen OO, Brynskov J, Bendtzen K, Ainsworth MA. Discriminating between
response types in infliximab-treated patients with Crohn’s disease: sensitivity and specificity
of combined assessment of infliximab trough levels and anti-drug antibodies.
Gastroenterology 2010;138(Suppl. 1):687–8
Insufficient data
Steenholdt C, Palarasah Y, Bendtzen K. Teisner A, Teisner B, Brynskov J, et al. Pre-existing
IgG antibodies to the Fab region of infliximab predict efficacy and safety in IBD patients
naive to anti-TNF agents. J Crohns Colitis 2013;7:S6–S6
C insufficient data
Steenholdt C, Palarasah Y, Bendtzen K, Teisner A, Brynskov J, Teisner B, et al. Pre-existing
IGG antibodies to the fab region of infliximab predict efficacy and safety in IBD patients
naive to anti-TNF agents. Scand J Immunol 2013;77:333
C insufficient data
Szepes Z, Kunstar E, Farkas K, Nagy F, Gyulai R, Kui R, et al. Clinical utility of measuring
serum TNF alpha level, anti TNF alpha levels and antibody titers in critical situations in
inflammatory bowel disease and in psoriasis. J Crohns Colitis 2013;7:S118–19
C insufficient data
Tang J, Gao X, Zhi M, Zhou H, Chen H, Zhang M, et al. Serum infliximab levels and early
mucosal healing in Crohn’s disease. J Crohns Colitis 2014;8:S209–10
C insufficient data
Turon J, Langseder A, Irizarry R, Ahuja K, Rosh JR. Clinical outcome of pediatric IBD patients
after measurement of infliximab drug and anti-drug antibody levels. Gastroenterology
2013;144(Suppl. 1):531
M no algorithm specified/
acted on
Ungar B, Anafy A, Yavzori M, Picard O, Fudim E, Kopylov U, et al. The clinical and
immunological significance of low level of infliximab in the absence of anti-infliximab
antibodies in patients with IBD. J Crohns Colitis 2014;8:S113
Duplicate
Ungar B, Kopylov U, Yavzori M, Fudim E, Picard O, Lahat A, et al. Predictors of formation of
antibodies to infliximab (ATI) and secondary loss of response in IBD patients treated with
infliximab. J Crohns Colitis 2014;8:S45
C insufficient data
Ussia V, Ceccarelli L, Maltinti S, Di Fluri G, Mumolo MG, Bolognesi V, et al. A prospective
assessment of anti-drug antibody response over time by a new ELISA in patients with IBD
treated with infliximab. J Crohns Colitis 2014;8:S298–9
C insufficient data
Van Der Woude CJ, Bultman E, Deuring J, West R, Zelinkova Z, Peppelenbosch M.
Adalimumab trough levels in a prospective cohort of Crohn’s disease patients. J Crohns
Colitis 2013;7:S250
C insufficient data
Van Der Woude CJ, Deuring JJ, West R, Zelinkova Z, Peppelenbosch MP. Adalimumab
trough levels in a prospective cohort of Crohn’s disease patients. Gastroenterology
2013;144(Suppl. 1):567
Duplicate
Van Moerkercke W, Ackaert C, Compernolle G, Jurgens M, Cleynen I, Van Assche GA, et al.
High infliximab trough levels are associated with mucosal healing in Crohn’s disease.
Gastroenterology 2010;138(Suppl. 1):60
C insufficient data
Van Moerkercke W, Compernolle G, Ackaert C, Gils A, Vermeire S, Jurgens M, et al.
Mucosal healing in Crohn’s disease is associated with high infliximab trough levels. J Crohns
Colitis Suppl 2010;4:30–1
C insufficient data
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TABLE 47 Abstracts excluded from the review with reason for exclusion (continued )
Reference Reason for exclusion
Vande Casteele N, Gils A, Compernolle G, Ballet V, Peeters M, Van Steen K, et al. Drug level
versus clinically based dosing of infliximab maintenance therapy in IBD: final results of the
randomized controlled taxit trial. Inflamm Bowel Dis 2013;19:S2–3
Superseded by full text
Vande Casteele N, Compernolle G, Ballet V, Van Assche G, Gils A, Vermeire S, et al. Results
on the optimisation phase of the prospective controlled trough level adapted infliximab
treatment (TAXIT) trial. Gastroenterology 2012;142(Suppl. 1):211–12
Superseded by full text
Vande Casteele N, Compernolle G, Ballet V, Van Assche G, Gils A, Vermeire S, et al.
Individualised infliximab treatment using therapeutic drug monitoring: a prospective
controlled Trough level Adapted infliXImab Treatment (TAXIT) trial. J Crohns Colitis
2012;6:S6
Duplicate
Vande Casteele N, Drake K, Hauenstein S, Levesque BG, Singh S, Sandborn W. Infliximab
and antibody to infliximab concentrations in 7,613 patients shows indication for testing,
association with loss of response and provides new insights into binding characteristics of
anti-drug antibodies. Gastroenterology 2014;146(Suppl. 1):242
C insufficient data
M no algorithm specified/
acted on
Vande Casteele N, Cuypers L, Singh S, Ohrmund L, Hauenstein S, Van Assche G, et al.
Antibodies to infliximab can either be persistent or transient: a retrospective case–control
study in IBD patients treated with infliximab maintenance therapy. Gastroenterology
2012;142(Suppl. 1):114
M no algorithm specified/
acted on
Vande Casteele N, Cuypers L, Singh S, Hauenstein S, Ohrmund L, Chuang E, et al. Transient
versus sustained antibodies to infliximab: possibility to overcome low titer antibody responses
by dose optimisation. J Crohns Colitis 2012;6:S110
M no algorithm specified/
acted on
Vande Casteele N, Peeters M, Ferrante M, Compernolle G, Van Assche G, Vermeire S, et al.
Functional cellular based assay reveals neutralising anti-drug antibodies in IBD patients
treated with maintenance adalimumab. J Crohns Colitis 2014;8:S268–9
Duplicate
Vaughn BP, Martinez-Vazquez M, Patwardhan V, Moss AC, Sandborn WJ, Cheifetz AS. A
pilot study of optimized monotherapy with infliximab for patients with inflammatory bowel
disease. Gastroenterology 2014;146(Suppl. 1):55
Superseded by full paper
Vaughn BP, Martinez-Vazquez M, Patwardhan V, Moss AC, Sandborn WJ, Cheifetz AS.
Prospective therapeutic drug monitoring to optimizing infliximab (IFX) maintenance
therapy in patients with inflammatory bowel disease (IBD). Gastroenterology
2014;146(Suppl. 1):54
Superseded by full paper
Vaughn B, Matinez-Vazquez M, Cheifetz A. Infliximab dosing changes based on trough
levels in a cohort of IBD patients in clinical remission. Inflamm Bowel Dis 2013;19:S59
M no algorithm specified/
acted on
Velayos FS, Sheibani S, Lockton S, Hauenstein S, Singh S, Terdiman JP, et al. Prevalence of
antibodies to adalimumab (ATA) and correlation between ATA and low serum drug
concentration on CRP and clinical symptoms in a prospective sample of IBD patients.
Gastroenterol 2013;144(Suppl. 1):91
C insufficient data
Veres G, Kaplan JL, De Greef E, Chuang E, Szabo D, Molnar K, et al. New assay to detect
infliximab levels and anti-infliximab antibodies from a single serum sample is useful in
measuring efficacy of treatment with infliximab in children with IBD. Gastroenterology
2012;142(Suppl. 1):386
C insufficient data
Wang SL, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P, et al. Evaluation of a novel
homogeneous mobility shift assay for the measurement of human antibodies-to-infliximab
and infliximab levels in patient serum. Arthritis Rheum 2011;63(Suppl. 10):1266
Duplicate
Wang SL, Hauenstein S, Ohrmund L, Shringarpure R, Wolf DC, Diab IA, et al. Influence of
trough serum drug level and immunogenicity on the lack of response to adalimumab
therapy in inflammatory bowel disease patients. Arthritis Rheum 2012;64:S819–20
C insufficient data
Wang SL, Hauenstein S, Ohrmund L, Shringarpure R, Wolf D, Diab I, et al. Influence of
trough serum drug level and immunogenicity on the lack of response to adalimumab
therapy in IBD patients. Am J Gastroenterol 2012;107:S680
Duplicate
Wolf DC, Hauenstein S, Lockton S, Singh S. Mechanisms of loss of response to adalimumab
in Crohn’s disease. Gastroenterology 2013;144(Suppl. 1):775
C insufficient data
continued
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TABLE 47 Abstracts excluded from the review with reason for exclusion (continued )
Reference Reason for exclusion
Wolf DC, Lockton S, Hauenstein S, Carroll S, Singh S, Chuang E. A multi-center
observational study in community gastroenterology practices evaluating the clinical usage of
testing for serum levels of infliximab and antibodies to infliximab. Gastroenterology
2013;144(Suppl. 1):423
M no algorithm specified/
acted on
Wolf D, Shringarpure R, Lockton S, Corey R, Woods S, Aguilar H, et al. Clinical experience
with measurement of serum infliximab and antibodies to infliximab using a new
homogenous mobility shift assay: results of a multi-center observational study. Am J
Gastroenterol 2012;107:S658
C insufficient data
Yamada A, Sono K, Takeuchi K, Suzuki Y. Clinical and basic studies to understand factors
associated with the loss of response to infliximab in patients with Crohn’s disease.
J Crohns Colitis 2013;7:S239
C insufficient data
Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A, et al. Anti-TNF and anti-drug
antibodies levels predict the outcomes of interventions after loss of response to adalimumab
and infliximab. Gastroenterology 2014;146(Suppl. 1):381
C insufficient data; M no
algorithm specified/acted
on
Yarur A, Trivella JP, Sussman DA, Drake K, Barkin JS, Hauenstein S, et al. Anti-tumor
necrosis factor drug levels and anti-bodies are associated with Crohn’s disease recurrence
at the level of the ileo-colonic anastomosis after ileal resection. Gastroenterology
2014;146(Suppl. 1):243–4
C insufficient data
Yarur A, Drake K, Kubiliun M, Dauer RM, Sussman DA, Hauenstein S, et al. Anti-tumor
necrosis factor levels are not associated with intestinal extent of mucosal inflammation in
patients with inflammatory bowel diseases. Gastroenterology 2014;146(Suppl. 1):244
Not M, C or ATC
Zelinkova Z, Peppelenbosch MP, Van Liere-Baron A, De Haar C, Van Der Woude CJ.
Naturally-occurring autoantibodies against TNF-alpha are present in sera of inflammatory
bowel disease patients and influence the response to adalimumab. Gastroenterology
2011;140(Suppl. 1):62
C insufficient data
ATC, assay-type comparison study; C, correlation-type study; M, management-type study.
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Appendix 7 Ongoing trials
Ongoing trials using an algorithm to determine treatment
change according to test results
TABLE 48 Ongoing trials using an algorithm to direct treatment
Title (acronym)
Status; start date; estimated
completion date URL
Pediatric Crohn’s disease AdalImumab
Level-based Optimization Treatment
(PAILOT)
Ongoing – not yet open for participant
recruitment; start: November 2014;
primary completion due: July 2018
http://clinicaltrials.gov/ct2/show/
NCT02256462 (accessed
11 November 2014)
A randomized controlled trial investigating
tailored treatment with infliximab for
active luminal Crohn’s disease (TAILORIX)
Ongoing; start: March 2012; primary
completion due: June 2015
www.clinicaltrialsregister.eu/
ctr-search/search?query=
eudract_number:2011-003038-14
(accessed 11 November 2014)
Adjusting infliximab dose in IBD patients in
remission, based on infliximab trough
levels: the study on Infliximab Levels in IBD
patients Steering Treatment, the ILIST pilot
(ILIST)
Ongoing; start: October 2013; primary
completion due: December 2014
www.trialregister.nl/trialreg/
admin/rctview.asp?TC=4067
(accessed 11 November 2014)
Ongoing correlation studies
TABLE 49 Ongoing studies aiming to correlate test results and clinical status
Title (acronym)
Status; start date; expected
completion date URL
Anti-TNF-alpha trough level measurements
in inflammatory bowel disease
Ongoing; study start: May 2013; study
primary completion due: May 2016
http://clinicaltrials.gov/ct2/show/
NCT02073526 (accessed
11 November 2014)
Improving treatment of inflammatory
bowel diseases through better
understanding infliximab drug and
antibody levels (OPTIMISE)
Ongoing; study start: March 2014;
study primary completion due:
March 2015
https://clinicaltrials.gov/ct2/show/
NCT01787786 (accessed
11 November 2014)
Personalised anti-TNF therapy in Crohn’s
disease (PANTS)
Ongoing; currently recruiting http://public.ukcrn.org.uk/Search/
StudyDetail.aspx?StudyID=14175
(accessed 11 November 2014)
Utilising drug levels and anti-drug
antibodies to predict response to
treatment in patients with Inflammatory
Bowel Disease
Ongoing; start: October 2012 www.clinicaltrialsregister.eu/
ctr-search/search?query=
eudract_number:2011-006084-22
(accessed 11 November 2014)
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Appendix 8 Excluded assay-type
comparison studies
TABLE 50 Studies of assay comparisons excluded from the review
Reference Reason for exclusion
Bodini G, Savarino V, Dulbecco P, Baldissarro I, Savarino E. ELISA vs. HMSA: a comparison
between two different methods for the evaluation of adalimumab serum concentration and
anti-adalimumab antibodies: preliminary data. J Crohns Colitis 2014;8:S278
Irrelevant comparison
Corstjens PL, Fidder HH, Wiesmeijer KC, de Dood CJ, Rispens T, Wolbink GJ, et al. A rapid
assay for on-site monitoring of infliximab trough levels: a feasibility study. Anal Bioanal Chem
2013;405:7367–75
Irrelevant comparison
Greathead L, Kelleher P, Steel A. Development and validation of ELISA to measure serum anti
TNFa levels. J Crohns Colitis 2014;8:S97–8
Irrelevant comparison
Imaeda H, Andoh A, Fujiyama Y. Development of a new immunoassay for the accurate
determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol
2012;47:136–43
Irrelevant comparison
Imaeda H, Takahashi K, Fujimoto T, Bamba S, Tsujikawa T, Sasaki M, et al. Clinical utility of
newly developed immunoassays for serum concentrations of adalimumab and anti-
adalimumab antibodies in patients with Crohn’s disease. J Gastroenterol 2014;49:100–9
Irrelevant comparison
Kopylov U, Mazor Y, Yavzori M, Fudim E, Katz L, Coscas D, et al. Clinical utility of antihuman
lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA
for the detection of anti-infliximab antibodies. Inflamm Bowel Dis 2012;18:1628–33
Irrelevant comparison
McTigue M, Sandborn W, Levesque B, Patel D. Clinical utility of next generation infliximab
and antibodies to infliximab assay. Am J Gastroenterol 2013;108:S527
Irrelevant comparison
Semmler J, Pilch A, Armbruster F, Dignass A, Stein J. Development of a new immunoassay
for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease.
Clin Chem Lab Med 2013;51:eA27–8
Irrelevant comparison
Steenholdt C, Ainsworth MA, Tovey M, Klausen TW, Thomsen OO, Brynskov J, et al.
Comparison of techniques for monitoring infliximab and antibodies against infliximab in
Crohn’s disease. Ther Drug Monit 2013;35:530–8
Irrelevant comparison
Ungar B, Anafy A, Kopylov U, Ron Y, Yanai H, Dotan I, et al. The clinical and immunological
significance of low level of infliximab in the absence of anti-infliximab antibodies in patients
with IBD. Gastroenterology 2014;146(Suppl. 1):245
Irrelevant comparison
Vande Casteele N, Peeters M, Compernolle G, Ferrante M, Van Assche GA, Vermeire S, et al.
TNF-responsive cellular based assay reveals neutralizing capacity of anti-adalimumab
antibodies in Crohn’s disease and ulcerative colitis patients. Gastroenterology
2014;146(Suppl. 1):242
Irrelevant comparison
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Appendix 9 Summary of studies evaluating the
clinical utility of measuring levels of anti-tumour
necrosis factor alpha and its antibodies
This appendix summarises the studies by Afif et al.,56 Pariente et al.,59 Roblin et al.57 and Paul et al.58 anddetails the studies’ proposed algorithms.
TABLE 51 Overview of study characteristics of studies evaluating the clinical utility of measuring levels of anti-TNF-α
and its antibodies
Item
Study (first author, year)
Afif et al., 201056
Pariente et al.,
201259 Roblin et al., 201457 Paul et al., 201358
Patients, n 155 76 82 52
Condition IBD (CD 78%) IBD (CD 72%) IBD (CD 58%) IBD (CD 65%)
Study design Retrospective Retrospective Prospective Prospective
Drug IFX IFX ADA IFX
Assay type ELISA (Prometheus
Laboratories)
LISA-TRACKER
Premium infliximab
ELISA kits
LISA-TRACKER
Premium adalimumab
ELISA kits
LISA-TRACKER
Premium infliximab
ELISA kits
Time of assessment of
clinical response
following treatment
change
Unclear 8 weeks and
6 months
6 and 12 months 8 weeks
Outcome: definition Complete response:
cessation of diarrhoea
and abdominal pain,
complete closure of
all fistulas
Clinical response:
(1) decrease of at least
2 points of HBI or
(2) overall assessment
by treating clinician
Clinical remission:
CDAI score of < 150,
FC < 250 µg/g
Clinical remission:
CDAI score of < 150,
mucosal healing: FC
< 250 µg/g
Reason for testing At discretion of
clinician (LOR or
partial response: 71%)
LOR LOR LOR
Treatment change Various according to
treating clinician
No change: n = 31
(41%)
(1) ADA 40mg e.o.w.
to ADA 40mg e.w.
IFX 5 mg/kg every
8 weeks to IFX
10mg/kg every
8 weeksIntensification: n= 39
(51%)
(2) Switch to IFX
5mg/kg at 0, 2 and
6 weeks
Switch to ADA: n= 5
(7%)
Surgery: n= 1 (1%)
Algorithm proposed Yes No Yes Yes
e.o.w., every other week; e.w., every week.
The two retrospective studies56,59 assessed response to any treatment change that was prescribed by the
treating clinician in response to treatment failure, and evaluated the relationship between clinical outcomes
and test outcomes. The prospective studies57,58 tested IBD patients once treatment failure occurred and
before a fixed treatment change (dose intensification) was applied. The response to the treatment change
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was then correlated with the test outcome. Afif et al.56 concluded that measurement of drug and anti-drug
antibodies impacts management and is clinically useful; Paul et al.58 concluded that measurement of drug
and anti-drug antibodies predicts clinical remission and may guide clinical decisions in practice; Roblin
et al.57 concluded that knowledge of drug and anti-drug antibody levels may have a strong impact on
the management of IBD patients with LOR; but Pariente et al.59 concluded that clinical response to drug
intensification cannot be accurately predicted by measurement of drug and anti-drug antibody levels.
The authors reported that a considerable number of patients (70%) showed a clinical response to dose
intensification even though the drug test result before dose intensification was positive.
The patients included in the studies were different between and within studies in terms of disease
(CD, UC), treatment duration before testing, cotreatment with immunosuppressants, disease duration and
time of disease assessment following anti-TNF-α optimisation. The proposed algorithms varied considerably
in terms of drug and anti-drug antibody levels used to predict response; however, the proposed treatment
changes were comparable but differed in detail.
Algorithm proposed by Afif et al.56
On the basis of the study results the following treatment algorithm for IBD patients with drug and
anti-drug antibody testing results was suggested:
l detectable anti-drug antibodies – switch to another anti-TNF-α agent and switch class of drug if
symptoms persist
l therapeutic IFX concentrations (> 12 µg/ml at 4 weeks or detectable trough level > 1.4 µg/ml) – for
active disease on endoscopy switch class of drug and for inactive disease on endoscopy investigate for
other causes of symptoms
l subtherapeutic IFX concentrations (< 12 µg/ml at 4 weeks or undetectable trough level < 1.4 µg/ml) –
IFX intensification or switch within class followed by switch of class if symptoms persist.
In summary, the study showed that clinical response depends on whether patients are anti-drug antibodies
positive or if they have subtherapeutic or therapeutic IFX levels and how they are managed according to
their serum levels of drugs and antibodies. Those who were anti-drug antibodies positive responded
better if switched to a different anti-TNF-α drug, whereas those with therapeutic IFX levels responded if
they stayed on the same dose of IFX. Patients with subtherapeutic IFX levels responded to dose
intensification of IFX. The study concluded that use of IFX and anti-drug antibody tests can potentially
avoid inappropriate management.
Algorithm proposed by Paul et al.58
On the basis of their study results the authors suggested the following treatment algorithm for IBD
patients with drug and anti-drug antibody testing results:
l subtherapeutic IFX levels (< 2 µg/ml) and anti-drug antibodies > 200 ng/ml – switch to another anti-TNF-α
agent, or optimise IFX and introduce immunosuppressant
l subtherapeutic IFX levels (< 2 µg/ml) and anti-drug antibodies < 200 ng/ml – IFX intensification
l therapeutic IFX levels (> 2 µg/ml) and anti-drug antibodies < 10 ng/ml – IFX intensification
l therapeutic IFX levels (> 2 µg/ml) and anti-drug antibodies > 10 ng/ml – switch class of drug.
The study found that therapeutic monitoring of drug can help predict response defined as mucosal healing
in patients with IBD following IFX dose intensification.
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Algorithm proposed by Roblin et al.57
On the basis of the study results the study suggested the following treatment algorithm for IBD patients
with drug and anti-drug antibody testing results:
l low trough ADA concentrations (< 4.9 µg/ml) and detectable anti-drug antibodies (> 10 ng/ml) – switch
to another anti-TNF-α agent
l high trough ADA concentrations (> 4.9 µg/ml) – switch class of drug
l low trough ADA concentrations (< 4.9 µg/ml) and no detectable anti-drug antibodies (< 10 ng/ml) –
ADA intensification (40 mg every week).
The findings of the study suggested that those with low trough levels of anti-TNF-α drug and undetectable
levels of antibodies or high trough levels of anti-TNF-α drug had the greatest chance of achieving clinical
remission following anti-TNF-α drug optimisation, whereas those with low levels of anti-TNF-α drug levels
and high levels of antibodies had the lowest chance of achieving clinical remission.
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Appendix 10 Quality appraisal of included
management studies
Cochrane’s tool for assessing risk of bias for a randomised
controlled trial (adapted from Higgins et al.70)
First author surname and year of publication: Steenholdt 2014123 and 2015124
Name of first reviewer: Paul Sutcliffe.
Name of second reviewer: Martin Connock.
Domain Description
Review authors’
judgement
Selection bias: sequence
generation
The authors state:
Randomisation was performed centrally by an independent
person (block randomisation in blocks of 20; sequentially
numbered opaque envelopes)
Using a block size of 20 may not be appropriate. There are
potential concerns about whether the allocation sequence was
adequately generated
Unclear risk of
bias
Selection bias: allocation
concealment
No further details are provided (see above). Allocation appears to
be appropriately concealed
Low risk of bias
Performance bias: blinding of
participants, personnel
The authors state:
Patients were blinded
Physicians were blinded to test results in the IFX
escalation group
Physicians were not blinded to test results in algorithm group
Results of analyses of serum IFX and IFX antibodies were used
in the treatment of patients in this group
Overall, the patient blinding appears appropriate and physician
knowledge of the allocated intervention was acknowledged;
physician knowledge in the algorithm arm has probably resulted
in treatment selection not conforming to algorithm for a
significant proportion of patients
High risk of bias
Detection bias: blinding of
outcome assessors
See above; no further details were provided related to blinding of
outcome assessors
Unclear risk of
bias
Attrition bias: incomplete
outcome data
The completeness of outcome data for each main outcome,
including attrition and exclusions from the analysis was
appropriate. Reasons for attrition/exclusions were reported.
Incomplete outcome data appears to be adequately addressed
Low risk of bias
Reporting bias: selective
reporting of the outcome,
subgroups or analysis
The study appears to be free of any selective outcome reporting
of outcome, subgroups or analysis
Low risk of bias
Other sources of bias: funding
source, adequacy of statistical
methods used, type of analysis
(ITT/PP), baseline imbalance in
important characteristics
We note that 42% of patients were not treated in accordance
with the algorithm, resulting in patients crossing over to
treatment more similar to the ‘control’ group
High risk of bias
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Summary assessment of the risk of bias across domains (please highlight
overall risk-of-bias rating)
Risk of bias across key domains Interpretation
Summary risk
of bias
Low risk of bias for all key domains Plausible bias unlikely to seriously alter the results Low risk of bias
Unclear risk of bias for one or more
key domains
Plausible bias that raises some doubt about the results Unclear risk of bias
High risk of bias for one or more
key domains
Plausible bias that seriously weakens confidence in the
results
High risk of bias
First author surname and year of publication: Vande Casteele 201573
Name of first reviewer: Paul Sutcliffe.
Name of second reviewer: Martin Connock.
Domain Description
Review authors’
judgement
Selection bias: sequence generation The authors state:
Randomization was performed by one person (VB) not in
charge of the clinical care of patients using a computer-
generated randomization schedule, with random
block sizes
The range of block sizes is not presented
Low risk of bias
Selection bias: allocation
concealment
No further details are provided (see above). Allocation
adequately appears to be appropriately concealed
Low risk of bias
Performance bias: blinding of
participants, personnel
The authors state:
Both patients and treating physicians were blinded to
individual IFX trough and ATI concentrations
This is unclear. No further information is provided; this limits
our rating of whether or not the knowledge of the allocated
intervention was adequately prevented during the study
Unclear risk of bias
Detection bias: blinding of outcome
assessors
The authors state:
Stable clinical response was assessed by the
treating physician
No further details were provided related to blinding of
outcome assessors
Unclear risk of bias
Attrition bias: incomplete outcome
data
The completeness of outcome data for each main outcome,
including attrition and exclusions from the analysis was
appropriate. Patients who discontinued the optimisation
phase because of personal reasons (non-compliant to
treatment algorithm or consent withdrawal) were described;
these were excluded from the analysis. Attrition and
exclusions were reported. Incomplete outcome data appear
to be adequately addressed
Low risk of bias
Reporting bias: selective reporting of
the outcome, subgroups or analysis
The study appears to be free of any selective outcome
reporting
Low risk of bias
continued
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Domain Description
Review authors’
judgement
Other sources of bias: funding
source, adequacy of statistical
methods used, type of analysis
(ITT/PP), baseline imbalance in
important characteristics
It is noted that the duration of the randomised maintenance
phase was only 1 year, which prevents the analysis of
long-term clinical and pharmacoeconomic outcomes
Low risk of bias
ATI, antibodies to IFX.
Summary assessment of the risk of bias across domains (please highlight
overall risk-of-bias rating)
Risk of bias across key domains Interpretation
Summary risk of
bias
Low risk of bias for all key
domains
Plausible bias unlikely to seriously alter the results Low risk of bias
Unclear risk of bias for one or more
key domains
Plausible bias that raises some doubt about the results Unclear risk of bias
High risk of bias for one or more key
domains
Plausible bias that seriously weakens confidence in the
results
High risk of bias
Downs and Black checklist71 for non-randomised primary
clinical studies
First author (year) study identification number: Vaughn 2014128
Name of first reviewer: Paul Sutcliffe.
Name of second reviewer: Martin Connock.
Criteria Rating
Reporting
1. Is the hypothesis/aim/objective of the study clearly described? (Yes/no) Yes
2. Are the main outcomes to be measured clearly described in the Introduction or
Methods section? (Yes/no) If the main outcomes are first mentioned in the Results
section, the question should be answered ‘no’
Yes
3. Are the characteristics of the patients included in the study clearly described? (Yes/no)
In cohort studies and trials, inclusion and/or exclusion criteria should be given.
In case–control studies, a case-definition and the source for controls should be given
Yes
4. Are the interventions of interest clearly described? (Yes/no) Treatments and placebo
(where relevant) that are to be compared should be clearly described
Yes
5. Are the distributions of principal confounders in each group of subjects to be
compared clearly described? (Yes/partially/no) A list of principal confounders
is provided
Partially – no list of principal
confounders
6. Are the main findings of the study clearly described? (Yes/no) Simple outcome data
(including denominators and numerators) should be reported for all major findings so
that the reader can check the major analyses and conclusions (this question does not
cover statistical tests which are considered below)
Yes
continued
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Criteria Rating
7. Does the study provide estimates of the random variability in the data for the main
outcomes? (Yes/no) In non-normally distributed data the interquartile range of results
should be reported. In normally distributed data the standard error, SD or CIs should
be reported. If the distribution of the data is not described, it must be assumed that
the estimates used were appropriate and the question should be answered ‘yes’
Yes
8. Have all important adverse events that may be a consequence of the intervention been
reported? (Yes/no) This should be answered ‘yes’ if the study demonstrates that there
was a comprehensive attempt to measure adverse events. (A list of possible adverse
events is provided)
Yes
9. Have the characteristics of patients lost to follow-up been described? (Yes/no)
This should be answered ‘yes’ where there were no losses to follow-up or where losses
to follow-up were so small that findings would be unaffected by their inclusion. This
should be answered ‘no’ where a study does not report the number of patients lost to
follow-up
Yes
10. Have actual probability values been reported (e.g. 0.035 rather than < 0.05) for the
main outcomes except where the probability value is less than 0.001? (Yes/no)
Yes
External validity
11. Were the subjects asked to participate in the study representative of the entire
population from which they were recruited? (Yes/no/unable to determine) The study
must identify the source population for patients and describe how the patients were
selected. Patients would be representative if they comprised the entire source
population, an unselected sample of consecutive patients or a random sample.
Random sampling is only feasible where a list of all members of the relevant
Unable to determine –
insufficient information is
provided
12. Were those subjects who were prepared to participate representative of the entire
population from which they were recruited? (Yes/no/unable to determine) The
proportion of those asked who agreed should be stated. Validation that the sample
was representative would include demonstrating that the distribution of the main
confounding factors was the same in the study sample and the source population
Unable to determine –
insufficient information is
provided
13. Were the staff, places and facilities where the patients were treated, representative
of the treatment the majority of patients receive? (Yes/no/unable to determine) For
the question to be answered ‘yes’ the study should demonstrate that the intervention
was representative of that in use in the source population. The question should be
answered ‘no’ if, for example, the intervention was undertaken in a specialist centre
unrepresentative of the hospitals most of the source population would attend
Unable to determine –
insufficient information is
provided
Internal validity: bias
14. Was an attempt made to blind study subjects to the intervention they have received?
(Yes/no/unable to determine) For studies where the patients would have no way of
knowing which intervention they received, this should be answered ‘yes’
No
15. Was an attempt made to blind those measuring the main outcomes of the
intervention? (Yes/no/unable to determine)
No
16. If any of the results of the study were based on ‘data dredging’, was this made clear?
(Yes/no/unable to determine) Any analyses that had not been planned at the outset of
the study should be clearly indicated. If no retrospective unplanned subgroup analyses
were reported, then answer ‘yes’
Yes – no data dredging
17. In trials and cohort studies, do the analyses adjust for different lengths of follow-up of
patients, or in case–control studies, is the time period between the intervention and
outcome the same for cases and controls? (Yes/no/unable to determine) Where
follow-up was the same for all study patients the answer should ‘yes’. If different
lengths of follow-up were adjusted for by, for example, survival analysis the answer
should be ‘yes’. Studies where differences in follow-up are ignored should be
answered ‘no’
Yes
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Criteria Rating
18. Were the statistical tests used to assess the main outcomes appropriate? (Yes/no/
unable to determine) The statistical techniques used must be appropriate to the data.
For example non-parametric methods should be used for small sample sizes. Where
little statistical analysis has been undertaken but where there is no evidence of bias,
the question should be answered ‘yes’. If the distribution of the data (normal or not) is
not described it must be assumed that the estimates used were appropriate and the
question should be answered ‘yes’
Yes
19. Was compliance with the intervention/s reliable? (Yes/no/unable to determine) Where
there was non-compliance with the allocated treatment or where there was
contamination of one group, the question should be answered ‘no’. For studies where
the effect of any misclassification was likely to bias any association to the null, the
question should be answered ‘yes’
Yes
20. Were the main outcome measures used accurate valid and reliable? (Yes/no/unable to
determine) For studies where the outcome measures are clearly described, the question
should be answered ‘yes’. For studies which refer to other work or that demonstrates
the outcome measures are accurate, the question should be answered as ‘yes’
Yes
Internal validity: confounding (selection bias)
21. Were the patients in different intervention groups (trials and cohort studies) or were
the cases and controls (case–control studies) recruited from the same population?
(Yes/no/unable to determine) For example, patients for all comparison groups should
be selected from the same hospital. The question should be answered ‘unable to
determine’ for cohort and case–control studies where there is no information
concerning the source of patients included in the study
Yes
22. Were study subjects in different intervention groups (trials and cohort studies) or were
the cases and controls (case–control studies) recruited over the same period of time?
(Yes/no/unable to determine) For a study which does not specify the time period over
which patients were recruited, the question should be answered as ‘unable
to determine’
Unable to determine –
insufficient information is
provided
23. Were the subjects randomised to intervention groups? (Yes/no/unable to determine)
Studies which state that subjects were randomised should be answered ‘yes’ except
where method of randomisation would not ensure random allocation. For example,
alternate allocation would score ‘no’ because it is predictable
No
24. Was the randomised intervention assignment concealed from both patients and
health-care staff until recruitment was complete and irrevocable? (Yes/no/unable to
determine) All non-randomised studies should be answered ‘no’. If assignment was
concealed from patients but not from staff, it should be answered ‘no’
No
25. Was there adequate adjustment for confounding in the analyses from which the main
findings were drawn? (Yes/no/unable to determine) This question should be answered
‘no’ for trials if the main conclusions of the study were based on analyses of treatment
rather than ITT; the distribution of known confounders in the different treatment
groups was not described; or the distribution of known confounders differed between
the treatment groups but was not taken into account in the analyses. In non-
randomised studies if the effect of the main confounders was not investigated or
confounding was demonstrated but no adjustment was made in the final analyses the
question should be answered as ‘no’
No; however, the study
reports continued use of IFX
for 700 weeks in therapeutic
concentration monitoring
group for ≈90% of patients;
this seems implausible
26. Were losses of patients to follow-up taken into account? (Yes/no/unable to determine)
If the numbers of patients lost to follow-up are not reported, the question should be
answered as ‘unable to determine’. If the proportion lost to follow-up was too small to
affect the main findings, the question should be answered ‘yes’
Yes
Power
27. Did the study have sufficient power to detect a clinically important effect where the
probability value for a difference being due to chance is < 5%? (Yes/no/unable
to determine)
No
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Quality Assessment of Diagnostic Accuracy Studies-269 tool
with index questions adapted to the review for studies
comparing performance of different tests: Steenholdt122,123
Name of first reviewer: Sian Taylor-Phillips.
Name of second reviewer: Martin Connock.
Phase 1: state the review question
What is the level of concordance between the index tests and reference standard tests for measurement of
drug and antibody levels?
Patients (setting, intended use of index test,
presentation, prior testing)
Patients with CD (adults and children) receiving IFX or ADA,
either whose disease responds to treatment with a TNF
inhibitor, or who experience secondary LOR during
maintenance treatment with TNF inhibitor
Index test(s) ELISA (LISA-TRACKER or Promonitor or Immundiagnostik)
Reference standard Spiked drug levels. Where this is not available tests for which
we have a prospective link to outcomes using a pre-specified
algorithm may be used (these are HPLC, RIA, PROMETHEUS
ELISA, or Leuven in-house ELISA)
Phase 2: draw a flow diagram for the primary study
Phase 3: risk of bias and applicability judgements
Quality Assessment of Diagnostic Accuracy Studies-2 is structured so that four key domains are each rated
in terms of the risk of bias and the concern regarding applicability to the review question (as stated in
phase 1). Each key domain has a set of signalling questions to help reach the judgements regarding bias
and applicability.
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection Study122 included 66 patients with CD with secondary LOR to
IFX, which were all part of a RCT. The RCT paper123 described
69 patients, recruited from six Danish centres. Inclusion criteria
stated but not selection method
Was a consecutive or random sample of patients
enrolled?
Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? Risk: high
B. Concerns regarding applicability
Describe included patients (prior testing, presentation,
intended use of intervention test and setting)
Patients with CD with secondary LOR to IFX
Range of drug/antibody concentrations From patients
Is there concern that the included patients or range of
drug/antibody concentrations do not match the review
question?
Concern: low
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Domain 2: index test(s)
A. Risk of bias
Describe the intervention test and how it was conducted and interpreted HMSA, PROMETHEUS ELISA and RGA
Were the number of failed results and measurement repeats reported? No
Was the threshold pre-specified? Yes
Were index tests interpreted without knowledge of reference standard? Yes
Could the conduct or interpretation of the intervention test have
introduced bias?
Risk: low
B. Concerns regarding applicability
They are comparing presence of drug at limit of quantisation of each test, rather than therapeutic drug levels. The anti-drug
part does not differ from the review question
Is there concern that the intervention test, its conduct, or interpretation
differs from the review question?
Concern: high
RGA, reporter gene assay.
Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted RIA on samples stored at room temperature
Were the reference standard results interpreted without knowledge of the
results of the index test?
Yes
Is the reference standard likely to correctly classify the target condition? No
Could the comparison test, its conduct or its interpretation have
introduced bias?
Risk: high
B. Concerns regarding applicability
Same test and threshold as used in RCT
Is there concern that the comparison test does not match that used in
studies assessing the link to outcomes?
Concern: low
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the intervention test and/or
comparison test(s) or who were excluded from the correlation calculations
Three patients received the reference
standard in the RCT but were not given the
index test. This is not described in this paper
Describe the time interval and any interventions between intervention test
and comparison test(s)
Comparator was conducted on samples
stored at room temperature at the time,
index tests were performed on frozen
samples at a later stage
Was there an appropriate interval between intervention test and
comparison test(s)?
No
Were both intervention test and reference standard conducted on all
samples?
No
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Risk: high
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Quality Assessment of Diagnostic Accuracy Studies-269 tool with
index questions adapted to the review for studies comparing
performance of different tests: Vande Casteele 2013126
Name of first reviewer: Sian Taylor-Phillips.
Name of second reviewer: Martin Connock.
Phase 1: state the review question
What is the level of concordance between the index tests and reference standard tests for measurement of
drug and antibody levels?
Patients (setting, intended use of index test, presentation,
prior testing)
Patients with CD (adults and children) receiving IFX or
ADA, either whose disease responds to treatment with
TNF inhibitor or who experience secondary LOR during
maintenance treatment with a TNF inhibitor
Index test(s) ELISA (LISA-TRACKER or Promonitor or Immundiagnostik)
Reference standard Spiked drug levels. Where this is not available, tests for
which we have a prospective link to outcomes using a
pre-specified algorithm may be used (these are HPLC,
RIA, PROMETHEUS ELISA or Leuven in-house ELISA)
Phase 2: draw a flow diagram for the primary study
Phase 3: risk of bias and applicability judgements
Quality Assessment of Diagnostic Accuracy Studies-2 is structured so that four key domains are each rated
in terms of the risk of bias and the concern regarding applicability to the review question (as stated in
phase 1). Each key domain has a set of signalling questions to help reach the judgements regarding bias
and applicability.
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection Selected from biobank based on index test results for
anti-drug levels
Was a consecutive or random sample of patients enrolled? No
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias Risk: high?
B. Concerns regarding applicability
Describe included patients (prior testing, presentation,
intended use of intervention test and setting)
Crohn’s and UC patients selected on basis of index test
results
Range of drug/antibody concentrations From patients
Is there concern that the included patients or range of drug/
antibody concentrations do not match the review question?
Concern: high
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Domain 2: index test(s)
A. Risk of bias
Describe the intervention test and how it was conducted and interpreted Leuven in-house ELISA administered in
same manner as described in Vande
Casteele et al. 201267
Were the number of failed results and measurement repeats reported? No
Was the threshold pre-specified? Yes
Were index tests interpreted without knowledge of reference standard? Yes
Could the conduct or interpretation of the intervention test have introduced bias? Risk: low
B. Concerns regarding applicability
Is there concern that the intervention test, its conduct or interpretation differs
from the review question?
Concern: low
Domain 3: reference standard
A. Risk of bias
Describe the comparison test and how it was conducted and interpreted HMSA at Prometheus Laboratories
from biobanked samples
Is the comparison test likely to correctly classify the target condition
(only matters if doing more than correlation studies)?
No
Were the reference standard results interpreted without knowledge of the results
of the index test?
Unclear
Could the comparison test, its conduct or its interpretation have introduced bias? Risk: high
B. Concerns regarding applicability
Is there concern that the comparison test does not match that used in studies
assessing the link to outcomes?
Correct HMSA test but using threshold
of 7.95 U/ml, authors suggest it
subsequently changed to 3.13 U/ml
Concern: low
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the intervention test and/or
comparison test(s) or who were excluded from the correlation calculations
Unclear
Describe the time interval and any interventions between intervention test and
comparison test(s)
HMSA was from biobanked samples,
Leuven ELISA was conducted at the
time
Was there an appropriate interval between intervention test and comparison
test(s)? (Ideally conducted at same time so samples can’t deteriorate)
No
Were both intervention test and reference standard conducted on all samples? Unclear
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Unclear
Could the patient flow have introduced bias? Risk: high
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Quality Assessment of Diagnostic Accuracy Studies-269 tool with
index questions adapted to the review for studies comparing
performance of different tests: Vande Casteele 201267
Name of first reviewer: Sian Taylor-Phillips.
Name of second reviewer: Martin Connock.
Phase 1: state the review question
What is the level of concordance between the index tests and reference standard tests for measurement of
drug and antibody levels?
Patients (setting, intended use of index test,
presentation, prior testing)
Patients with CD (adults and children) receiving IFX or ADA,
either whose disease responds to treatment with a TNF inhibitor
or who experience secondary LOR during maintenance treatment
with a TNF inhibitor
Index test(s) ELISA (LISA-TRACKER or Promonitor or Immundiagnostik)
Reference standard Spiked drug levels. Where this is not available, tests for which
we have a prospective link to outcomes using a pre-specified
algorithm may be used (these are HPLC, RIA, PROMETHEUS ELISA
or Leuven in-house ELISA)
Phase 2: draw a flow diagram for the primary study
Phase 3: risk of bias and applicability judgements
Quality Assessment of Diagnostic Accuracy Studies-2 is structured so that four key domains are each rated
in terms of the risk of bias and the concern regarding applicability to the review question (as stated in
phase 1). Each key domain has a set of signalling questions to help reach the judgements regarding bias
and applicability.
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection Unclear. Combination of spiked samples and samples from
departments of gastroenterology and rheumatology
Was a consecutive or random sample of patients
enrolled?
No
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Risk: high
B. Concerns regarding applicability
Describe included patients (prior testing, presentation,
intended use of intervention test and setting)
No details given except departments of origin. Those from
rheumatology may not be applicable, those from gastroenterology
with diseases other than CD may not be applicable
Range of drug/antibody concentrations Drug levels up to 30mg/l from visual inspection of plots. Antibody
levels NR
Is there concern that the included patients or range
of drug/antibody concentrations do not match the
review question?
Concern: high
NR, not reported.
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Domain 2: index test(s)
A. Risk of bias
Describe the intervention test and how it was conducted and interpreted LISA-TRACKER assays
according to manufacturer’s
guidelines
Were the number of failed results and measurement repeats reported? Yes
Was the threshold pre-specified? Yes
Were index tests interpreted without knowledge of reference standard? Yes
Could the conduct or interpretation of the intervention test have introduced bias? Risk: low
B. Concerns regarding applicability
Describe the preparation and storage of the sample before the intervention test was
applied
Unclear how sample was
stored before intervention
test
Is there concern that the intervention test, its conduct or interpretation differs from the
review question?
Concern: low
Domain 3: reference standard
A. Risk of bias
Describe the comparison test and how it was conducted and interpreted Leuven in-house ELISA
Is the comparison test likely to correctly classify the target condition (only matters if doing
more than correlation studies)?
No
Were the reference standard results interpreted without knowledge of the results of the
index test?
Yes
Could the comparison test, its conduct or its interpretation have introduced bias? Risk: high
B. Concerns regarding applicability
Is there concern that the comparison test does not match that used in studies assessing the
link to outcomes?
Concern: low
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the intervention test and/or comparison test(s) or
who were excluded from the correlation calculations
Unclear
Describe the time interval and any interventions between intervention test and comparison
test(s)
Unclear
Was there an appropriate interval between intervention test and comparison test(s)?
(Ideally conducted at same time so samples can’t deteriorate)
Unclear
Were both intervention test and reference standard conducted on all samples? Yes
Did patients receive the same reference standard? No
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Risk: high
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Quality Assessment of Diagnostic Accuracy Studies-269 tool
with index questions adapted to the review for studies
comparing performance of different tests: Wang 2012131
Name of first reviewer: Sian Taylor-Phillips.
Name of second reviewer: Martin Connock.
Phase 1: state the review question
What is the level of concordance between the index tests and reference standard tests for measurement of
drug and antibody levels?
Patients (setting, intended use of index test,
presentation, prior testing)
Patients with CD (adults and children) receiving IFX or ADA,
either whose disease responds to treatment with a TNF inhibitor
or who experience secondary LOR during maintenance
treatment with a TNF inhibitor
Index test(s) ELISA (LISA-TRACKER or Promonitor or Immundiagnostik)
Reference standard Spiked drug levels. Where this is not available, tests for which
we have a prospective link to outcomes using a pre-specified
algorithm may be used (these are HPLC, RIA, PROMETHEUS
ELISA, or Leuven in-house ELISA)
Phase 2: draw a flow diagram for the primary study
Phase 3: risk of bias and applicability judgements
Quality Assessment of Diagnostic Accuracy Studies-2 is structured so that four key domains are each rated
in terms of the risk of bias and the concern regarding applicability to the review question (as stated in
phase 1). Each key domain has a set of signalling questions to help reach the judgements regarding bias
and applicability.
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection Controls were from blood bank donors in California, and
cases were left over blood samples from tests carried out at
Prometheus Laboratories. No information is given on how
they selected samples from these sources
Was a consecutive or random sample of patients
enrolled?
No
Was a case–control design avoided? No
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? Risk: high
B. Concerns regarding applicability
Describe included patients (prior testing, presentation,
intended use of intervention test and setting)
100 inflammatory bowel patients as defined by index test and
100 healthy controls. No details of split between CD and UC
Range of drug/antibody concentrations From patients
Is there concern that the included patients or range of
drug/antibody concentrations do not match the review
question?
Concern: high
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Domain 2: index test(s)
A. Risk of bias
Describe the intervention test and how it was conducted and interpreted PROMETHEUS-bridging ELISA.
Threshold not specified at all
Were the number of failed results and measurement repeats reported? No
Was the threshold pre-specified? Unclear
Were index tests interpreted without knowledge of reference standard? Yes
Could the conduct or interpretation of the intervention test have introduced bias? Risk: high
B. Concerns regarding applicability
Threshold not given so applicability unclear
Is there concern that the intervention test, its conduct, or interpretation differs from the
review question?
Concern: high
Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted HMSA at Prometheus
Laboratories
Were the reference standard results interpreted without knowledge of the results of the
index test?
Unclear
Is the reference standard likely to correctly classify the target condition? Unclear
Could the comparison test, its conduct or its interpretation have introduced bias? Risk: unclear
B. Concerns regarding applicability
Is there concern that the comparison test does not match that used in studies assessing
the link to outcomes?
Concern: low
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the intervention test and/or comparison test(s)
or who were excluded from the correlation calculations
This is unclear from the report
Describe the time interval and any interventions between intervention test and
comparison test(s)
Unclear
Was there an appropriate interval between intervention test and comparison test(s)? Unclear
Were both intervention test and reference standard conducted on all samples? Unclear
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Unclear
Could the patient flow have introduced bias? Risk: high
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Appendix 11 Parametric modelling for Vaughn128
and the Trough level Adapted infliXImab
Treatment trial
Parametric models were fitted to reconstructed IPD of time to treatment failure for proactive drugmonitoring and control patients in remission who commenced maintenance IFX at the start of 2009.128
This was done so that treatment failure could be modelled to 10 years (the time horizon of the economic
model) with potential for use in the model.
According to the Akaike information criterion and Bayesian information criterion, the information criteria
that best fitted the data were provided by log-normal, log-logistic and Weibull models (Table 52); a
gamma model could not be fitted for the standard care arm.
Log-normal and Weibull models are shown in Figure 36.
Trough level Adapted infliXImab Treatment trial time to relapse
Parametric modelling of time to relapse based on the TAXIT study is shown below in Figure 37. Again, this
was done because of potential relevance to the economic model.
TABLE 52 Akaike information criterion and Bayesian information criterion values for parametric models for
time-to-treatment failure
Model Observations ll (model) df
Akaike information
criterion
Bayesian information
criterion
Standard care arm
Exponential 68 –54.9247 1 111.8493 114.0688
Weibull 68 –52.2516 2 108.5031 112.9422
Gompertz 68 –53.618 2 111.2359 115.6749
Log-normal 68 –51.55 2 107.0999 111.5389
Log-logistic 68 –51.7864 2 107.5728 112.0118
Proactive drug monitoring arm
Exponential 39 –19.2462 1 40.49236 42.15592
Weibull 39 –19.2257 2 42.45134 45.77846
Gompertz 39 –19.2243 2 42.44856 45.77569
Log-normal 39 –18.8709 2 41.74174 45.06886
Log-logistic 39 –19.1771 2 42.35412 45.68124
df, degrees of freedom.
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FIGURE 36 Log-normal and Weibull models extended to 10 years’ follow-up [Vaughn et al.:128 (a) with therapeutic
drug concentration monitoring; and (b) without therapeutic drug concentration monitoring study].
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FIGURE 37 Parametric modelling of time to relapse based on the TAXIT study.
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Appendix 12 Meta-analysis results
Correlation studies that permitted extraction of a 2 × 2 table for test result (positive or negative) andclinical status (response or loss/lack of response) were carried forward for hierarchical meta-analysis.
The major features of these studies are summarised in Table 53. Forest plots of sensitivity and specificity
for prediction of loss or lack response and summary ROC plots are presented according to the test applied.
Infliximab trough level tests for loss of response or lack of
regaining response
Eleven studies were included,38,47,78,82,85,98,99,103,120,123,134 of which two were reported as abstracts.78,134
Sensitivity and specificity pairs are summarised in Figure 38.
Hierarchical meta-analysis yielded the test accuracy results summarised in Table 54 and Figure 39.
Subgroup analyses examining responder populations only, and ELISA studies only, had little effect on
pooled estimates.
The random-effects pooled estimate for the prevalence of loss or lack of response was 0.335 (95% CI
0.289 to 0.382). If responder populations only were considered this changed slightly to 0.325 (95% CI
0.278 to 0.372). Given the meta-analysis values, sensitivity, specificity and prevalence (P) values, the point
estimate for the probability of positive and negative test results is as shown in Table 55.
TABLE 53 Major features of studies included for hierarchical meta-analysis
Study (first author and year) Drug Diagnosis Resp/LOR Test Res-def
IFX trough level as predictor of loss or lack of response
Ainsworth et al., 200847 IFX CD LOR RIA PJ
Ben-Basset et al., 201378 (abstract) IFX IBD ≈0.93 CD Resp HMSA HBI
Bortlik et al., 201382 IFX CD Resp ELISA PJ
Cornillie et al., 201485 IFX CD Resp ELISA CDAI
Hibi et al., 201498 IFX CD Resp ELISA CDAI
Imaeda et al., 201299 IFX CD Resp ELISA CDAI
Kopylov et al., 2012103 IFX CD Resp ELISA PJ
Maser et al., 200638 IFX CD Resp Unclear HBI
Steenholdt et al., 2011120 IFX CD Resp RIA PJ
Steenholdt et al., 2014123 IFX CD LOR RIA CDAI
Yanai et al., 2012134 (abstract) IFX CD Resp ELISA PJ
Trough antibodies to IFX as predictor of loss or lack of response
Ainsworth et al., 200847 IFX CD LOR RIA PJ
Baert et al., 201477 IFX IBD ≈0.8 CD LOR HMSA PJ
Ben-Horin et al., 201179 IFX IBD ≈0.82 CD Resp NR ST
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TABLE 53 Major features of studies included for hierarchical meta-analysis (continued )
Study (first author and year) Drug Diagnosis Resp/LOR Test Res-def
Ben-Horin et al., 201280 IFX ADA IBD ≈0.9 CD LOR ELISA PJ
Bodini et al., 201481 (abstract) IFX CD Resp HMSA HBI
Candon et al., 200683 IFX CD LOR ELISA UC
Dauer et al., 201388 (abstract) IFX CD ≈0.83 CD Resp NR PJ
Farrell et al., 200392 IFX CD Resp ELISA PJ
Hanauer et al., 200440 IFX CD Resp ELISA CDAI
Imaeda et al., 201299 IFX CD Resp ELISA CDAI
Kong et al., 2011102 (abstract) IFX IBD ≈0.83 CD Resp ELISA PJ
Kopylov et al., 2012103 IFX CD Resp ELISA PJ
Marzo et al., 2014106 (abstract) IFX NR Resp ELISA CDAI
Nagore et al., 2015110 (abstract) IFX IBD ≈0.86 CD Resp ELISA PJ
Pariente et al., 201259 IFX CD and UC LOR ELISA PJ or HBI
Steenholdt et al., 2011120 IFX CD Resp RIA PJ ST
Steenholdt et al., 201352 IFX CD Resp ELISA PJ
Steenholdt et al., 2014123 IFX CD LOR RIA CDAI
Vande Casteele et al., 2013126 IFX IBD ≈0.70 CD LOR HMSA CRP TC
Vande Casteele et al., 2013126 IFX IBD ≈0.70 CD Resp HMSA CRP TC
ADA trough level as predictor of loss or lack of response
Chiu et al., 201384 ADA CD LOR ELISA CDAI
Frederiksen et al., 201494 ADA IBD Resp RIA PJ BM
Imaeda et al., 2014100 ADA CD Resp ELISA CRP
Mazor et al., 2014108 ADA CD Resp ELISA PJ
Roblin et al., 2014115 ADA IBD ≈0.55 CD Resp ELISA CDAI
Trough antibodies to ADA as predictor of loss or lack of response
Frederiksen et al., 201494 ADA IBD Resp RIA PJ BM
Imaeda et al., 2014100 ADA CD Resp ELISA CRP
Mazor et al., 2014108 ADA CD Resp ELISA PJ
West et al., 2008133 ADA CD Resp RIA PJ
Ben-Horin et al., 201280 IFX ADA IBD ≈0.9 CD LOR ELISA SA
Roblin et al., 2014115 ADA CD Resp ELISA CDAI
NR, not reported; PJ, physicians’ judgement; PJ BM, physicians’ judgement and biological measure; resp, responding
patients; SA, switch anti-TNF-α; ST, stop anti-TNF-α; TC, Trough Concentration.
Diagnosis refers to study patient population. Res-def refers to the method used for defining clinical response.
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TABLE 54 Test accuracy results from hierarchical meta-analysis
Studies included Parameter Point estimate 95% CI
All 11 studies Sens 0.657232 0.546288 to 0.753299
Spec 0.80625 0.744166 to 0.85618
DOR 7.978975 4.119972 to 15.45254
LR+ 3.392169 2.35152 to 4.893351
LR– 0.425139 0.305104 to 0.592398
1/LR– 2.352175 1.688056 to 3.277573
Responder populations only Sens 0.681452 0.592117 to 0.759178
Spec 0.790873 0.723301 to 0.845468
DOR 8.090128 4.353039 to 15.03551
LR+ 3.258549 2.287802 to 4.641198
LR– 0.402781 0.298559 to 0.543385
1/LR– 2.482739 1.840315 to 3.349423
ELISA studies only Sens 0.652104 0.564027 to 0.730877
Spec 0.789041 0.691592 to 0.861849
DOR 7.010794 3.450232 to 14.24578
LR+ 3.091133 1.959085 to 4.877331
LR– 0.440911 0.329778 to 0.589495
1/LR– 2.268033 1.696367 to 3.032348
LR, likelihood ratio; Sens, sensitivity; Spec, specificity.
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FIGURE 39 Trough IFX levels for predicting LOR; hierarchical meta-analysis of test accuracy. The blue square
represents the summary point estimate on the HSROC curve. (a) All 11 studies; and (b) responder studies only.
HSROC, hierarchical summary receiver operating characteristic. (continued )
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Antibodies to infliximab tests for loss of response or lack of
regaining response
Nineteen studies were included,40,47,52,59,77,79–81,83,88,92,99,102,103,106,120,123,126,182 of which five were reported as
abstracts.81,88,102,106,110 Sensitivity and specificity pairs are summarised in Figure 40.
Hierarchical meta-analysis yielded test accuracy results summarised in Table 56 and Figure 41.
Subgroup analyses removing two outlier studies, examining responder populations only and ELISA studies
only, had little effect on pooled summary point estimates.
The random-effects pooled estimate for the prevalence of lack of response was 0.390 (95% CI 0.302 to
0.477). If responder populations only were considered, this changed slightly to 0.411 (95% CI 0.312 to
0.511). Given the meta-analysis values, sensitivity, specificity and prevalence values the point estimate for
the probability of positive and negative test results is as shown in Table 57.
(b)
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FIGURE 39 Trough IFX levels for predicting LOR; hierarchical meta-analysis of test accuracy. The blue square
represents the summary point estimate on the HSROC curve. (a) All 11 studies; and (b) responder studies only.
HSROC, hierarchical summary receiver operating characteristic.
TABLE 55 Probability of a positive and negative test result (range based on 95% CI prevalence)
Item Calculation Value
Probability of positive test result (P × Sens) + [(1 – P) × (1 – Spec)] 0.349 (0.328 to 0.371)
Probability of negative test result [(1 – P) × Spec] + [P × (1 – Sens)] 0.651 (0.629 to 0.672)
Sens, sensitivity; Spec, specificity.
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TABLE 56 Test accuracy results from hierarchical meta-analysis
Studies included Parameter Point estimate 95% CI
All 20 studies Sens 0.559745 0.444812 to 0.668611
Spec 0.792243 0.688105 to 0.868267
DOR 4.848283 2.519589 to 9.329239
LR+ 2.694226 1.72293 to 4.213088
LR– 0.555707 0.426575 to 0.72393
1/LR– 1.799509 1.38135 to 2.344251
All studies minus outliers Sens 0.597 0.477 to 0.707
Spec 0.807 0.742 to 0.859
DOR 6.183 3.805 to 10.050
LR+ 3.088 2.311 to 4.127
LR– 0.500 0.381 to 0.655
1/LR– 2.002 1.528 to 2.623
Responder populations only Sens 0.570 0.445 to 0.687
Spec 0.849 0.787 to 0.896
DOR 7.460 4.544 to 12.250
LR+ 3.778 2.722 to 5.244
LR– 0.506 0.388 to 0.660
1/LR– 1.974 1.514 to 2.574
ELISA studies only Sens 0.482 0.355 to 0.611
Spec 0.880 0.841 to 0.911
DOR 6.830 3.872 to 12.050
LR+ 4.022 2.805 to 5.768
LR– 0.589 0.459 to 0.755
1/LR– 1.698 1.324 to 2.178
LR, likelihood ratio; Sens, sensitivity; Spec, specificity.
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FIGURE 41 Antibodies to IFX for predicting LOR; hierarchical meta-analysis of test accuracy. The blue square
represents the summary point estimate on the HSROC curve. (a) All 20 studies; (b) ELISA studies only;
(c) all studies excluding two influential outliers; and (d) responder populations only. HSROC, hierarchical summary
receiver operating characteristic. (continued )
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Adalimumab trough level test for loss of response or lack of
regaining response
Four studies of responders were included.94,100,108,115 The study of Roblin et al.115 included 18 UC and 22 CD
patients. Mazor et al.108 reported results by test rather than by patient (there were 118 tests in 71 patients;
authors stated that using the first test result for each patient did not alter the results). Sensitivity and
specificity pairs are summarised in Figure 42.
A single study of patients with LOR was identified84 (as shown in Figure 43). This study appeared to be an
outlier and meta-analysis was restricted to responder populations).
Hierarchical meta-analysis yielded test accuracy results summarised in Table 58 and Figure 44.
The random-effects pooled estimate for the prevalence of lack of response was 0.489 (95% CI 0.372 to
0.606); this is likely to be an overestimate owing to double-counting of patients from the Mazor et al.108
study. Given the meta-analysis values and the sensitivity, specificity and prevalence values, the point
estimate for the probability of positive and negative test results is 0.444 (range 0.389–0.499) and 0.556
(range 0.501–0.611), respectively.
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FIGURE 41 Antibodies to IFX for predicting LOR; hierarchical meta-analysis of test accuracy. The blue square
represents the summary point estimate on the HSROC curve. (a) All 20 studies; (b) ELISA studies only;
(c) all studies excluding two influential outliers; and (d) responder populations only. HSROC, hierarchical summary
receiver operating characteristic.
TABLE 57 Probability of a positive and negative test result, all studies (range based on 95% CI prevalence)
Item Calculation Value
Probability of positive test result (P × Sens) + [(1 – P) × (1 – Spec)] 0.345 (0.324 to 0.365)
Probability negative test result [(1 – P) × Spec]+ [P × (1 – Sens)] 0.655 (0.635 to 0.686)
Sens, sensitivity; Spec, specificity.
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Antibodies to adalimumab as test for loss of response or lack
of regaining response
Six studies of responders or secondary starters were included.80,94,100,108,115,133 Mazor et al.108 reported results
by test rather than by patients (there were 118 tests in 71 patients; authors stated that using the first
test result for each patient did not alter the results). Sensitivity and specificity pairs are summarised
in Figure 45.
Hierarchical meta-analysis yielded test accuracy results summarised in Table 59 and Figure 46.
The random-effects pooled estimate for the prevalence of LOR was 0.435 (95% CI 0.330 to 0.540); this
is likely to be an overestimate owing to double-counting of patients from the Mazor et al.108 study.
Given the meta-analysis values and the sensitivity, specificity and prevalence values, the point estimate
for the probability of positive and negative test results is 0.253 (range 0.212–0.293) and 0.747
(range 0.707–0.788), respectively.
95% prediction region
95% confidence region
HSROC curve
0.0
0.2
0.4
0.6
0.8
1.0
Se
n
si
ti
vi
ty
0.00.20.40.60.81.0
Specificity
Summary point
FIGURE 44 Trough ADA levels for predicting LOR; hierarchical meta-analysis of test accuracy. Only responder
studies are included. HSROC, hierarchical summary receiver operating characteristic.
TABLE 58 Test accuracy results from hierarchical meta-analysis (four studies)
Parameter Point estimate 95% CI
Sens 0.684 0.591 to 0.764
Spec 0.786 0.643 to 0.883
DOR 7.971 3.646 to 17.428
LR+ 3.201 1.822 to 5.623
LR– 0.402 0.297 to 0.542
1/LR– 2.490 1.844 to 3.363
LR, likelihood ratio; Sens, sensitivity; Spec, specificity.
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Predictive values for drug and anti-drug antibodies tests for
LOR or failure to regain response
Figure 47 summarises PPVs and NPVs according to prevalence of the clinical state of interest. The dashed
vertical lines indicate the pooled prevalence and 95% CI and what is probably a meaningful clinical range
across which the tests might be employed.
The predictive values are indicative of moderate test accuracy so that between about 20% and 30% of
positive and negative test results are likely to be incorrect.
TABLE 59 Test accuracy results from hierarchical meta-analysis (five studies)
Parameter Point estimate 95% CI
Sens 0.471206 0.2903357 to 0.66
Spec 0.915467 0.7939073 to 0.968
DOR 9.65022 4.387759 to 21.22
LR+ 5.574189 2.646268 to 11.74
LR– 0.577623 0.4208713 to 0.793
1/LR– 1.731233 1.261422 to 2.376
LR, likelihood ratio; Sens, sensitivity; Spec, specificity.
HSROC curve
95% prediction region
95% confidence region
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FIGURE 46 Antibodies to ADA for predicting LOR; hierarchical meta-analysis of test accuracy. HSROC, hierarchical
summary receiver operating characteristic.
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FIGURE 47 Positive predictive values and NPVs according to prevalence of LOR (or inability to regain response)
at the sROC model estimate of sensitivity and specificity; (a) ADA; (b) antibodies to ADA; (c) IFX; and
(d) antibodies to IFX. As prevalence increases PPV increases and NPV decreases. The data points are PPV and NPV
at sROC sensitivity and specificity and pooled prevalence. Dashed vertical lines are pooled prevalence and 95% CI.
Thick curves are PPV and NPV at hierarchical model sensitivity and specificity across at pooled prevalence and
95% CI.
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Appendix 13 List of excluded cost-effectiveness
studies with reason
TABLE 60 List of excluded studies from the literature review
Reference Reason(s) for exclusion
Blackhouse G, Assasi N, Xie F, Marshall J, Irvine EJ, Gaebel K, et al.
Canadian cost–utility analysis of initiation and maintenance treatment
with anti-TNF-alpha drugs for refractory Crohn’s disease. J Crohns Colitis
2012;6:77–85
No testing kits used to monitor anti-TNF-α
or antibodies to anti-TNF-α levels
Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for
Crohn’s disease: Markov cohort analyses incorporating United Kingdom
patient-level cost data. Aliment Pharmacol Ther 2009;30:265–74
No testing kits used to monitor anti-TNF-α
or antibodies to anti-TNF-α levels
Buchanan J, Wordsworth S, Ahmad T, Perrin A, Vermeire S, Sans M, et al.
Managing the long term care of inflammatory bowel disease patients:
the cost to European health care providers. J Crohns Colitis 2011;5:301–16
No testing kits used to monitor anti-TNF-α
or antibodies to anti-TNF-α levels
Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, et al.
A systematic review and economic evaluation of the use of tumour
necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab,
for Crohn’s disease. Health Technol Assess 2011;15(6)
No testing kits used to monitor anti-TNF-α
or antibodies to anti-TNF-α levels
Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs.
initiation of adalimumab for loss of response in Crohn’s disease: a
cost-effectiveness analysis. Aliment Pharmacol Ther 2007;26:1509–20
No testing kits used to monitor anti-TNF-α
or antibodies to anti-TNF-α levels
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Appendix 14 Data extraction sheets of included
health economic studies
Name of first reviewer: Hema Mistry.
Name of second reviewer: Peter Auguste.
Study details Notes
Study title A test-based strategy is more cost effective than empiric dose escalation for patients
with Crohn’s disease who lose responsiveness to infliximab157
First author Fernando S Velayos
Coauthors Ames G Kahn, William J Sandborn and Brian G Feagan
Source of publication: journal
year;volume:pp.
Clinical Gastroenterology and Hepatology 2013;11:654–66
Language English
Publication type Journal article
Inclusion criteria/study eligibility/PICOS
Population Patients with CD who become unresponsive to therapy with TNF antagonists – IFX
Intervention(s) Testing-based strategy
Comparator(s) Empiric dose escalation strategy
Outcome(s) Cost per QALY gained
Study design Cost-effectiveness analysis
Methods
Target population and subgroups Patients with moderate to severe active CD
Setting and location Not reported
Study perspective Third-party payer
Time horizon 1-year time horizon with a 4-week cycle duration
Discount rate Not reported
Measurement of effectiveness QALYs
Measurement and valuation of
preference-based outcomes
Not reported
Resource use and costs Direct medical costs included: cost of the interventions – IFX, ADA, certolizumab,
natalizumab and surgery; and the cost of diagnostics: anti-IFX antibody/serum IFX
measurement, computerised tomography enterography and colonoscopy
Currency, price date and
conversion
US dollars
Model type Decision-analytical model
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Study details Notes
Assumptions Adverse side effects causing discontinuation of medical therapy were considered to
not have a significant effect on QALYs
The overall rate of response to IFX dose escalation was assumed to be equal to that
of ADA switching
The presence of drug antibody, drug concentration and inflammation accurately
categorises the mechanism for LOR and the proposed interventions represent the best
approach to remedy a given mechanism
Analytical methods ICERs were presented. Extensive one-way sensitivity analyses were conducted and
PSAs using 10,000 simulations determined uncertainty in model results
Results
Study parameters Proportion with mild/minimal inflammation with symptoms
l Initial response: switching to ADA, anti-IFX antibody present, subtherapeutic and
therapeutic IFX concentrations, IFX increase to 10mg/kg, anti-IFX antibody
present, subtherapeutic and therapeutic IFX concentration
l Sustained response at 1 year: ADA switch, IFX increase to 10mg/kg, ADA
increase to 40 mg every week, IFX 5 mg/kg maintenance, surgery switch,
sustained responders in remission, restart biological for post-operative recurrence
and proportion sustained responders in remission
l Mortality: after biological therapy and after surgery
Incremental costs and outcomes The testing strategy yielded similar QALYs compared to the empiric strategy (0.801 vs.
0.800, respectively), but was less expensive (US$31,870 vs. US$37,266, respectively).
The testing strategy dominated the empiric strategy
Characterising uncertainty One-way sensitivity analysis: key observations – the testing strategy was superior with
regard to cost in almost every circumstance and the empiric strategy was less
expensive when the cost of surgery was tested at fivefold more than the base case.
PSAs of the base case showed that 68.9% of results were within quadrant 4 (testing
strategy was both less costly and more effective)
Discussion
Study findings The results showed that the testing strategy was cheaper and more effective than the
empiric strategy
Limitations A prospective trial is needed to provide more precise estimates for the data such as
data on the efficacy of biological therapy in the minimal/mild inflammation subgroup,
data on the efficacy of biological therapy after failing standard- and high-dose
biological therapy, as well data on efficacy of TNF-α switching and IFX dose escalation
in the setting of the various drug antibody and drug-level subgroups
Generalisability The model was defined a priori and does not reflect all possible permutations of
managing LOR
Other
Source of funding Supported by an investigator-initiated research grant from Prometheus Laboratories
Conflicts of interest Disclosed
Comments None
Authors’ conclusion
The results support the hypothesis that a testing-based strategy is a more cost-effective alternative than the currently
advocated strategy of empiric dose escalation. The basis for this difference is lower cost at similar outcomes
Reviewer’s conclusion
The authors used appropriate modelling techniques to demonstrate the cost-effectiveness of a testing-based strategy
compared with empiric strategy
PICOS, participants, interventions, comparisons, outcomes, study design.
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Name of first reviewer: Hema Mistry.
Name of second reviewer: Peter Auguste.
Study details Notes
Study title Individualised therapy is more cost-effective than dose intensification in patients with
Crohn’s disease who lose response to anti-TNF-α treatment: a randomised, controlled
trial123
First author Casper Steenholdt
Coauthors Jørn Brynskov, Ole Østergaard Thomsen, Lars Kristian Munck, Jan Fallingborg,
Lisbet Ambrosius Christensen, Gitte Pedersen, Jens Kjeldsen, Bent Ascanius Jacobsen,
Anne Sophie Oxholm, Jakob Kjellberg, Klaus Bendtzen and Mark Andrew Ainsworth
Source of publication: journal
year;volume:pp.
Gut 2014;63:919–27
Language English
Publication type Journal article
Inclusion criteria/study eligibility/PICOS
Population Eligible adult patients with CD
Intervention(s) Receive treatment based on serum concentrations of IFX and IFX antibodies at the
time of IFX treatment failure in accordance with the algorithm
Comparator(s) Receive IFX at an increased dose frequency of 5 mg/kg every 4 weeks
Outcome(s) Cost per ITT and cost PP population
Study design Randomised, controlled, single-blind, clinical trial
Methods
Target population and subgroups All patients had secondary IFX treatment failure on IFX maintenance therapy defined
as recurrence of active disease with a CDAI score of ≥ 220 and/or a minimum of one
draining perianal fistula
Subgroup analyses included: proposed mechanisms for therapeutic failure,
assessment of coprimary end points in patients stratified for CRP level at inclusion,
disease phenotype and grouping in algorithm
Setting and location Six Danish hospitals
Study perspective Not reported
Time horizon 12 weeks with scheduled visits at weeks 0, 4, 8 and 12
Discount rate Not applicable
Measurement of effectiveness Clinical response rates – LOR to IFX maintenance therapy
Measurement and valuation of
preference-based outcomes
Not applicable
Resource use and costs All costs of inpatient and outpatient contacts in hospitals recorded in the National
Patient Registry relating to treatment of CD such as diagnoses and diagnostic and
treatment procedures were recorded, as well as standardised IFX doses. Expenses
related to CD in the 12 months before inclusion were comparable between
randomisation groups
Currency, price date and
conversion
Danish kroner and converted into Euros. Price date 1 January 2012
Model type Not applicable
Assumptions Not applicable
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Study details Notes
Analytical methods Costs were compared using arithmetic means and were assessed by non-parametric
bootstrap analysis to determine statistical significance. Data were analysed by ITT and
PP population. One-way sensitivity analyses of key primary and secondary end points
conducted
Results
Study parameters Primary end points: costs of CD and clinical response
Secondary end points included CDAI 100 response, clinical remission, CDAI decrease,
PDAI decrease and IBDQ increase
Incremental costs and outcomes Costs were significantly lower in the algorithm group than in the IFX intensification
group in both the ITT population (mean difference per patient –€3141) and the PP
population (mean difference per patient –€5116)
Response rates in the ITT population were 58% in the algorithm group and 53% in
the IFX intensification group (RR 1.091, 95% CI 0.713 to 1.673). The difference
between response rates was 5% in favour of the algorithm group. In the PP
population, 47% in the algorithm group and 53% in the IFX intensification group
showed a clinical response (RR 0.898, 95% CI 0.510 to 1.580)
ICERs were not reported
Characterising uncertainty One-way sensitivity analyses included (1) estimated administrative costs for biological
drugs, (2) use of actual IFX dosing and (3) price reductions on biological agents.
Findings were similar to the base-case analysis
Discussion
Study findings The present clinical trial testing of whether or not a personalised patient treatment
based on IFX bioavailability and immunogenicity at the time of therapeutic failure
proved more cost-effective than standard IFX intensification. That is, the interventions
based on the algorithm achieved similar clinical, biological and life quality outcomes
to dose intensification, but at a lower cost. Findings were also robust and consistent
in subgroups
Limitations Small numbers
Generalisability Only reported in terms of costs
Other
Source of funding Disclosed
Conflicts of interest Disclosed
Comments None
Authors’ conclusion
Managing secondary IFX treatment failure by an algorithm based on serum IFX and IFX antibodies to define the mechanistic
basis and corresponding interventions is more cost-effective than an intensified IFX regimen
Reviewer’s conclusion
Although patient numbers were small, the authors used appropriate trial evidence to demonstrate the cost-effectiveness of
an algorithm-based strategy compared with an intensified dose strategy
PICOS, participants, interventions, comparisons, outcomes, study design.
APPENDIX 14
NIHR Journals Library www.journalslibrary.nihr.ac.uk
252
Name of first reviewer: Hema Mistry.
Name of second reviewer: Peter Auguste.
Study details Notes
Study title Trough concentrations of infliximab guide dosing for patients with inflammatory
bowel disease73
First author Niels Vande Casteele
Coauthors Marc Ferrante, Gert Van Assche, Vera Ballet, Griet Compernolle, Kristel Van Steen,
Steven Simoens, Paul Rutgeerts, Ann Gils and Séverine Vermeire
Source of publication: journal
year;volume:pp.
Gastroenterology 2015;148:1320–9
Language English
Publication type Journal article
Inclusion criteria/study eligibility/PICOS
Population Patients with a diagnosis of moderate to severe CD or UC
Intervention(s) Concentration-based IFX dosing
Comparator(s) Clinically based IFX dosing
Outcome(s) Cost per QALY
Study design RCT
Methods
Target population and subgroups Cohort of CD (and UC) responder patients. Patients needed to be treated with
maintenance IFX therapy for at least 14 weeks and needed to be in stable clinical
response
Setting and location Tertiary referral centre, Belgium
Study perspective Third-party payer
Time horizon 1 year
Discount rate Not applicable
Measurement of effectiveness QALYs
Measurement and valuation of
preference-based outcomes
EQ-5D used to calculate QALYs
Resource use and costs Drug costs per patient per year; resource use and costs not reported in detail
Currency, price date and
conversion
Euros, price year 2012
Model type Not applicable
Assumptions Not applicable
Analytical methods QALYs were adjusted for differences in baseline utility scores using a multiple
regression approach
ICERs were presented. Uncertainty in incremental QALYs and costs was determined
by non-parametric bootstrapping consisting of 1000 iterations and plotted onto a
cost-effectiveness plane
Results
Study parameters Primary end points: clinical and biochemical remission at 1 year after the optimisation
phase (increasing and maintaining remission)
Secondary end points: durable remission, relapse, IFX trough concentration within the
optimal interval, antibodies to IFX positivity, total cost of IFX treatment and QALYs
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Study details Notes
Incremental costs and outcomes Concentration-based dosing: QALY = 0.8227; costs = €20,723
Clinically based dosing: QALY= 0.8421; costs = €21,023
Incremental QALYs = –0.0193
Incremental costs = –€300
ICER = €15,525
Characterising uncertainty Cost-effectiveness plane showing probabilistic sensitivity analyses found that 58.4%
of simulations were in quadrant 3 where concentration-based dosing was less costly
and less effective
Discussion
Study findings Concentration-based dosing was slightly less effective and less costly than clinically
based dosing, but overall differences were small
Limitations Duration of randomised treatment was 1 year
Generalisability Not reported
Other
Source of funding Disclosed
Conflicts of interest Disclosed
Comments None
Authors’ conclusion
Concentration-based dosing was slightly less effective and less costly than clinically based dosing
Reviewer’s conclusion
The authors used appropriate trial evidence to demonstrate the cost-effectiveness of concentration-based dosing compared
with clinically based dosing
PICOS, participants, interventions, comparisons, outcomes, study design.
Name of first reviewer: Hema Mistry.
Name of second reviewer: Peter Auguste.
Study details Notes
Study title Individualized therapy is a long-term cost-effective method compared to dose
intensification in Crohn’s disease patients failing infliximab124
First author Casper Steenholdt
Coauthors Jørn Brynskov, Ole Ø Thomsen, Lars K Munck, Jan Fallingborg, Lisbet A Christensen,
Gitte Pedersen, Jens Kjeldsen, Bent A Jacobsen, Anne Sophie Oxholm, Jakob Kjellberg,
Klaus Bendtzen and Mark A Ainsworth
Source of publication: journal
year;volume:pp.
Dig Dis Sci 2015;60:2762–70
Language English
Publication type Journal article
Inclusion criteria/study eligibility/PICOS
Population Eligible adult patients with CD
Intervention(s) Receive treatment based on serum concentrations of IFX and IFX antibodies at the
time of IFX treatment failure in accordance with the algorithm
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Study details Notes
Comparator(s) Receive IFX at an increased dose frequency of 5 mg/kg every 4 weeks
Outcome(s) Cost per ITT and cost PP population
Study design Randomised, controlled, single-blind, clinical trial
Methods
Target population and subgroups All patients had secondary IFX treatment failure on IFX maintenance therapy defined
as recurrence of active disease with a CDAI score of ≥ 220 and/or a minimum of one
draining perianal fistula
Setting and location Six Danish hospitals
Study perspective Not reported
Time horizon 1 year with cost evaluations at 20 weeks and 1 year
Discount rate Not applicable
Measurement of effectiveness Clinical response was defined as a ≥ 70-point reduction in CDAI from baseline in
luminal disease and a reduction in active fistulas of ≥ 50% from baseline in fistulising
disease. Clinical remission was defined as a CDAI score of ≤ 150 and complete
closure of all fistulas despite gentle pressure
Measurement and valuation of
preference-based outcomes
Not applicable
Resource use and costs All costs of inpatient and outpatient contacts in hospitals recorded in the National
Patient Registry relating to treatment of CD such as diagnoses and diagnostic and
treatment procedures were recorded, as well as standardised IFX and anti-IFX doses
Currency, price date and
conversion
Danish kroner and converted into US dollars. Price date 1 January 2012
Model type Not applicable
Assumptions Not applicable
Analytical methods Costs were analysed using arithmetic means and were compared by non-parametric
bootstrap analysis to determine statistical significance. Data were analysed by ITT,
PP population, PP completion at end of trial week 12, and PP completion at end of
follow-up week 20. One-way sensitivity analyses of key primary and secondary end
points conducted
Results
Study parameters End points: costs of CD, clinical response and clinical remission
Incremental costs and outcomes Incremental costs in favour of the algorithm group; that is, costs were substantially
and highly significantly lower in the algorithm group than in the infliximab
intensification group:
20 weeks
l ITT: –US$5296
l PP: –US$8494
l PP end of trial week 12: –US$8546
l PP end of follow-up week 20: –US$10,720
1 year
l ITT: –US$7006
l PP: –US$13,383
l PP end of trial week 12: –US$13,265
PP end of follow-up week 20: –US$16,618
Characterising uncertainty One-way sensitivity analyses at both 20 weeks and 1 year included (1) estimated
administrative costs for biological drugs, (2) use of actual infliximab dosing and
(3) price reductions on biological agents. Findings were similar to the 20-week and
1-year time frames
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Study details Notes
Discussion
Study findings The algorithm group had significantly lower costs than the infliximab intensification
group at the 20 week follow-up and this was maintained throughout the 1 year
Limitations Small sample size for the study
Generalisability Compared findings with other studies and some studies have used their algorithm
Other
Source of funding Disclosed
Conflicts of interest Disclosed
Comments None
Authors’ conclusion
Clinical interventions at IFX treatment failure based on monitoring of IFX and anti-IFX antibodies are long-term
cost-effective method compared with IFX dose intensification
Reviewer’s conclusion
Although patient numbers were small, the authors used appropriate trial evidence to demonstrate the cost-effectiveness of
algorithm-based strategy compared with intensified dose strategy over a 1-year time period
PICOS, participants, interventions, comparisons, outcomes, study design.
Name of first reviewer: Hema Mistry.
Name of second reviewer: Peter Auguste.
Study details Notes
Study title A systematic review and economic evaluation of the use of tumour necrosis
factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s disease5
First author J Dretzke
Coauthors R Edlin, J Round, M Connock, C Hulme, J Czeczot, A Fry-Smith, C McCabe and
C Meads
Source of publication: journal
year;volume:pp.
Health Technology Assessment 2011;15(6)
Language English
Publication type Monograph
Inclusion criteria/study eligibility/PICOS
Population Adult patients with moderate to severe CD
Intervention(s) Anti-TNF-α therapy for CD – IFX and ADA
Comparator(s) Standard care for CD
Outcome(s) Cost per QALY gained
Study design Cost-effectiveness analysis
Methods
Target population and subgroups Adult patients with moderate to severe CD where response was defined as remission
within 8 weeks
Setting and location Not reported
Study perspective NHS and PSS perspective
Time horizon 1-year time horizon with a 4-week cycle duration
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Study details Notes
Discount rate Not reported
Measurement of effectiveness QALYs
Measurement and valuation of
preference-based outcomes
Choice-based time-trade off measure providing utility value
Resource use and costs Cost of anti-TNF-α treatment for both induction and maintenance therapy, plus
administration costs. Type-specific health-state costs were also included. Costs for
surgery were modelled as the cost of inpatient IBD interventions, whereas moderate
and severe relapse costs were modelled as the cost of IBD outpatient major and
intermediate interventions. Post-surgery remission costs were based on outpatient
surgical gastrointestinal follow-up. Relapse costs were based on a gastrointestinal
admission to hospital. Remission costs were modelled using literature. Unit costs were
obtained from the NHS reference costs
Currency, price date and
conversion
Price year 2005–6
Model type Markov model
Assumptions Model did not take into account mortality. Used Silverstein et al.150 for all transition
probabilities in the intervention arm
Analytical methods ICERs and cost-effectiveness acceptability curves were presented. One-way sensitivity
analyses and PSAs using 10,000 simulations were conducted to characterise
uncertainty in the model
Results
Study parameters For the three arms, standard care, induction and maintenance, the parameters
included transition probabilities, costs and utilities for the following health states:
remission, relapse (moderate and severe), surgery and post surgery
Incremental costs and outcomes For induction therapy for severe CD, both ADA and IFX dominated standard care
(i.e. cheaper and more effective). For maintenance therapy for severe CD, neither
drug was cost-effective (well above NICE thresholds)
For moderate CD, for maintenance therapy for both drugs and induction therapy for
IFX, these were not cost-effective (well above NICE thresholds); however, for
induction therapy for ADA dominated standard care
Characterising uncertainty Patients who had severe disease, IFX induction treatment was found to be cost-
effective relative to maintenance treatment and standard care in > 99% of cases at
all points up to £100,000 per QALY. Likewise, ADA induction treatment was found
to be cost-effective relative to maintenance treatment and standard care for
thresholds up to £100,000 per QALY
Discussion
Study findings The results for induction, both ADA and IFX were cost-effective (dominant relative to
standard care) for severe CD and that ADA was cost-effective (dominant relative to
standard care) for moderate CD. Induction therapy with IFX was not cost-effective for
moderate CD. Neither drug was cost-effective as maintenance therapy for moderate
or severe disease
Limitations l Exclusion of death from the model
l A 1-year time horizon
l No RCT data available for maintenance therapy
l Silverstein et al.150 data had its own problems, that is surgery rates are higher and
relapse rates much lower than in routine practice
Generalisability Not reported
Other
Source of funding Disclosed
Conflicts of interest Not reported
Comments None
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Study details Notes
Authors’ conclusion
IFX is not likely to be cost-effective in the management of moderate CD. Although ADA may be cost-effective, there is
uncertainty regarding the ICERs value. Neither of these therapies is likely to be as cost-effective as maintenance therapy for
moderate or severe disease. Both treatments are highly cost-effective, with no meaningful uncertainty, as induction therapy
in severe disease
Reviewer’s conclusion
The authors used appropriate modelling techniques to demonstrate the cost-effectiveness of the interventions for two
anti-TNF-α drug therapies compared with standard care; although there are some limitations in terms of how the transition
probabilities and utility values were estimated
PICOS, participants, interventions, comparisons, outcomes, study design.
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Appendix 15 Quality assessment of included
health economic studies
Consolidated Health Economic Evaluation Reporting Standards
quality assessment checklist for economic evaluation studies
Assessment
Study (first author and year of publication)
Velayos
et al., 2007157
Steenholdt
et al., 2014123
Vande Casteele
et al., 201573
Steenholdt
et al., 2015124
Dretzke
et al., 20115
Title Y Y N Y Y
Abstract Y Y Y Y Y
Introduction
Background and objectives Y Y Y Y Y
Methods
Target population and subgroups P Y Y Y Y
Setting and location N Y Y Y N
Study perspective Y N Y N Y
Comparators Y Y Y Y Y
Time horizon Y Y Y Y Y
Discount rate N N/A N/A N/A N/A
Choice of health outcomes Y Y Y Y Y
Measurement of effectiveness Y Y Y Y Y
Measurement and valuation of
preference-based outcomes
N N Y N Y
Estimating resources and costs Y Y UNC Y Y
Currency, price date and conversion P Y P Y Y
Choice of model Y N/A N/A N/A Y
Assumptions Y N N N Y
Analytical methods Y Y Y Y Y
Results
Study parameters Y Y Y Y Y
Incremental costs and outcomes Y Y Y Y Y
Characterising uncertainty Y Y Y Y Y
Discussion
Study findings Y Y Y Y Y
Limitations Y Y Y Y Y
Generalisability P P N P N
Other
Source of funding Y Y Y Y Y
Conflicts of interest Y Y Y Y N
N/A, not applicable; N, no; P, partial; UNC, unclear; Y, yes.
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Philips’ quality assessment checklist for studies that included
an economic model
Philips’ criteria
Studies (first author and
publication year)
Velayos
et al., 2007157
Dretzke
et al., 20115
Structure
Is there a clear statement of the decision problem? Y Y
Is the objective of the model specified and consistent with the stated decision
problem?
Y Y
Is the primary decision-maker specified? N Y
Is the perspective of the model stated clearly? Y Y
Are the model inputs consistent with the stated perspective? Y Y
Has the scope of the model been stated and justified? Y Y
Are the outcomes of the model consistent with the perspective, scope and overall
objective of the model?
Y Y
Is the structure of the model consistent with a coherent theory of the health
condition under evaluation?
Y Y
Are the sources of the data used to develop the structure of the model specified? Y Y
Are the causal relationships described by the model structure justified appropriately? UNC Y
Are the structural assumptions transparent and justified? Y Y
Are the structural assumptions reasonable given the overall objective, perspective
and scope of the model?
Y Y
Is there a clear definition of the options under evaluation? Y Y
Have all feasible and practical options been evaluated? Y Y
Is there justification for the exclusion of feasible options? Y Y
Is the chosen model type appropriate given the decision problem and specified
casual relationships within the model?
Y Y
Is the time horizon of the model sufficient to reflect all important differences
between the options?
Y Y
Are the time horizon of the model, the duration of treatment and the duration of
treatment described and justified?
Y Y
Do the disease states (state transition model) or the pathways (decision tree
model) reflect the underlying biological process of the disease in question and the
impact of interventions?
Y Y
Is the cycle length defined and justified in terms of the natural history of disease? Y Y
Data
Are the data identification methods transparent and appropriate given the
objectives of the model?
Y Y
Where choices have been made between data sources are these justified
appropriately?
UNC Y
Has particular attention been paid to identifying data for the important parameters
of the model?
Y Y
Has the quality of the data been assessed appropriately? Y Y
Where expert opinion has been used are the methods described and justified? UNC N/A
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Philips’ criteria
Studies (first author and
publication year)
Velayos
et al., 2007157
Dretzke
et al., 20115
Is the data modelling methodology based on justifiable statistical and
epidemiological techniques?
UNC Y
Is the choice of baseline data described and justified? UNC Y
Are transition probabilities calculated appropriately? UNC N
Has a half-cycle correction been applied to both costs and outcomes? N N
If not, has the omission been justified? N N
If relative treatment effects have been derived from trial data, have they been
synthesised using appropriate techniques?
N/A Y
Have the methods and assumptions used to extrapolate short-term results to final
outcomes been documented and justified?
UNC Y
Have alternative extrapolation assumptions been explored through sensitivity
analysis?
Y Y
Have assumptions regarding the continuing effect of treatment once treatment is
complete been documented and justified?
UNC Y
Have alternative assumptions regarding the continuing effect of treatment been
explored through sensitivity analysis
UNC Y
Are the costs incorporated into the model justified? Y Y
Has the source for all costs been described? Y Y
Have discount rates been described and justified given the target decision-maker? N N
Are the utilities incorporated into the model appropriate? Y Y
Is the source of utility weights referenced? N Y
Are the methods of derivation for the utility weights justified? N Y
Have all data incorporated into the model been described and referenced in
sufficient detail?
Y Y
Has the use of mutually inconsistent data been justified (i.e. are assumptions and
choices appropriate?)
Y Y
Is the process of data incorporation transparent? Y Y
If data have been incorporated as distributions, has the choice of distributions for
each parameter been described and justified?
Y Y
If data have been incorporated as distributions, is it clear that second order
uncertainty is reflected?
UNC Y
Have the four principal types of uncertainty been addressed? N N
If not, has the omission of particular forms of uncertainty been justified? N N
Have methodological uncertainties been addressed by running alternative versions
of the model with different methodological assumptions?
N Y
Is there evidence that structural uncertainties have been addressed via sensitivity
analysis?
N Y
Has heterogeneity been dealt with by running the model separately for different
subgroups?
Y Y
Are the methods of assessment of parameter uncertainty appropriate? Y Y
If data are incorporated as point estimates, are the ranges used for sensitivity
analysis stated clearly and justified?
Y Y
DOI: 10.3310/hta20830 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 83
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Freeman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
261
Philips’ criteria
Studies (first author and
publication year)
Velayos
et al., 2007157
Dretzke
et al., 20115
Is there evidence that the mathematical logic of the model has been tested
thoroughly before use?
N Y
Are any counterintuitive results from the model explained and justified? Y Y
If the model has been calibrated against independent data, have any differences
been explained and justified?
N UNC
Have the results been compared with those of previous models and any
differences in results explained?
N N
N/A, not applicable; N, no; UNC, unclear; Y, yes.
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Appendix 16 Decision tree structure for the
responders’ model
This appendix summarises the underlying decision tree structure of the model for responders to anti-TNF-αtherapy in several figures for:
l concurrent testing (Figures 48–53)
l no testing (Figures 54 and 55)
l reflexing testing (Figures 56–59).
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FIGURE 54 Decision tree structure for the no-testing strategy.
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Appendix 17 Transition probabilities derived
from published studies
Transition from response to infliximab to loss of response in
primary responders
There was insufficient published information to model an ADA test-based treatment strategy. The model
therefore addresses patients responding to IFX maintenance therapy (the transition probabilities used are
summarised in Table 35). It should be emphasised that there were no prospective or other test-directed
management studies describing outcomes for IFX responders followed from maintenance treatment
through to treatments subsequent to LOR to maintenance. Therefore, by necessity, model structure for the
intervention arm is based on the algorithms used in the two identified RCTs describing test-based patient
management, specifically the TAXIT trial73 for responders and Steenholdt et al.123 for patients with LOR to
maintenance IFX (see Chapter 3, Objective B: description of algorithms prescribing patient management
following test outcomes for drug and/or anti-drug antibody levels); we aimed to use as many data from
these RCTs as possible to populate the model. Unfortunately the control arm in the TAXIT trial does not
provide information for the model’s standard care arm (a no-test management strategy) because all
patients in the TAXIT trial were dose-optimised according to test results prior to randomisation;
consequently, the model structure for the standard care arm is based on expert clinical advice and
alternative studies were examined for model input.
Standard care arm: loss of response to infliximab maintenance
For the standard care arm, three studies that reported reasonable quality data for time to LOR or to
cessation of IFX treatment for patients on maintenance treatment with IFX were identified.82,128,159
Reconstructed Kaplan–Meier plots with candidate parametric models are shown in Figure 60. For the
Juillerat et al.159 study, several models provided reasonable fit to 130 cycles.
These three studies generate fairly different transition probabilities. Because of its size, the availability of
observed data to 130 cycles (model time horizon), and the inclusion of only CD patients, the Juillerat et al.
study159 was selected for model inputs. In Juillerat et al.,159 21% of patients received dose escalation, but
the time to escalation was not reported. However, Ma et al.161 have reported the time to LOR requiring
dose escalation for patients with CD on IFX maintenance therapy; Weibull and Gompertz models provided
best fits to the Ma et al.161 data.
Figure 61 shows both Juillerat et al.159 and Ma et al.161 data with Weibull parametric models. Transition
probabilities generated by these Weibull models were used for economic model input. These allow
estimates of the percentage of time over 130 cycles spent in each of the following conditions:
(1) untreated with IFX, (2) in standard dose treatment with IFX and (3) in escalated dose treatment
with IFX. The resulting percentages were 35.6%, 24.0% and 40.4%, respectively.
Standard care arm treatment after loss of response to infliximab
On failure of response to IFX maintenance (with or without dose escalation) it is assumed patients are
switched to ADA induction therapy followed by maintenance on ADA for those responding to induction.
We classify those that fail induction as patients who have lost response during the first cycle of treatment.
We have taken this from the Gauging Adalimumab Efficacy in Infliximab Nonresponders (GAIN) RCT,162
which investigated ADA for patients who had failed IFX. Thereafter, the transition probability for LOR to
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FIGURE 60 Reconstructed Kaplan–Meier plots for time to LOR or to cessation of treatment of responders on
maintenance IFX therapy by 4-week cycle. (a) Bortlik et al.82 (n= 84); (b) Juillerat et al.159 (n= 1014); and (c) Vaughn
et al.128 (n= 68).
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ADA was derived from the study by Karmiris et al.48 of 152 CD responders receiving ADA followed up
prospectively (Figure 62). Exponential and Weibull distributions provided a reasonable fit to reconstructed
IPD. Combined data from Sandborn et al.162 for induction failure on ADA (after IFX failure) and Karmiris
et al.48 for failure after successful induction with ADA, provided a transition probability of 0.058553 per
cycle that was used in the model.
After failure of ADA we have assumed patients remain in a LOR state until such time that they receive
surgery. This assumption was necessitated by lack of data and was based on advice of clinical experts.
The transition to surgery was based on a large Canadian study.163
Time to surgery
No data were found for time to surgery for patients who experience LOR or a failure to regain response
after a treatment switch aimed to reinstate a response. We identified three studies163,183,184 that provided
time from diagnosis to surgery for recent cohorts of patients with CD (i.e. coincident with the era of
Juillerat: time to cessation of treatment
Ma: time to loss of response
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FIGURE 61 Reconstructed Kaplan–Meier plots and exponential fits for time to cessation of IFX treatment and time
to LOR requiring dose escalation of IFX by 4-week cycle (studies of Juillerat et al.159 and Ma et al.161).
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FIGURE 62 Reconstructed Kaplan–Meier and Weibull model for time to LOR for patients with CD on maintenance
therapy with ADA by 4-week cycle.48
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anti-TNF-α therapies for CD). Vester-Anderson et al.183 reported surgical relapse rates of 6%, 18% and
23% at 1, 5 and 7 years (91 cycles) after diagnosis, respectively; similarly a UK study175 that included 137
patients observed approximately 24% primary surgery 5 years after diagnosis (Figure 63) and a larger
Canadian study163 included > 1000 patients and also data for recurrent surgery (see Figure 63). Figure 63
shows the time to primary surgery was similar in the UK and Canadian studies. As a result of its size and
because it provided data for both primary and recurrent surgery, the Canadian study was used in the
economic modelling for both primary and recurrent surgery.
Crohn’s disease patients in the TAXIT trial73 and Steenholdt et al.123,124 management studies varied
considerably in the time from diagnosis to study entry and also in if they had experienced previous surgery
(e.g. TAXIT trial73 patients, on average, were diagnosed 13.7 years prior to entry and 70% had received
previous surgery; in Steenholdt et al.123,124 patients were diagnosed, on average, 9 years before entry).
Surgery was not a primary or secondary outcome measure in these studies, but each reported that one
patient received surgery (1/69 by week 20 in Steenholdt et al.123,124 and 1/251 by week 52 in the TAXIT
trial73). It appears that during the short follow-up periods observed the use of surgery was a relatively rare
event. The Weibull and Gompertz parametric models (see Figure 63) of time to surgery generated
probabilities of progressing to surgery that varied considerably according to time from diagnosis; the
economic model was not based on newly diagnosed patients, and data for other health states used in
modelling were not based on newly diagnosed patients; in the absence of more appropriate data transition
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FIGURE 63 Time from diagnosis of CD (a) to primary surgery in the UK; (b) to primary surgery in Canada; and
(c) time from first surgery to second surgery in Canada.
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probability to surgery we used an exponential (constant hazard) fit to the Canadian data so as to capture an
approximate average transition probability (see Table 37). It is recognised that these selections are somewhat
arbitrary and that modelling extends beyond the observed data.
Maintenance of surgery-induced remission
The scant evidence about maintenance of surgically induced remission in CD was reviewed by Gordon
et al.164 in a Cochrane systematic review. It should be noted that the authors’ rated the included studies
to be at high risk of bias for these outcomes. At 2 years across three studies there was no difference in risk
of clinical relapse between patients receiving purine analogues and those receiving 5-ASA (fixed-effects
pooled RR 1.01, 95% CI 0.81 to 1.24). The total events were 146 among 265 patients. Assuming a
constant hazard the estimated transition probability to post-surgical clinical relapse is 0.023971 per cycle
(95% CI 0.025398 to 0.035624 per cycle). In the economic model, this was taken to apply for both
therapies (5-ASA and purine analogues). Relative to purine analogues, the review data suggest that
patients receiving no therapy (placebo group in two studies) were at 1.35 (95% CI 1.06 to 1.72) greater
risk of clinical relapse. Assuming a constant hazard provided an estimated transition probability of
0.050961 per cycle (95% CI 0.033248 to 0.108412 per cycle); this was used in the model for the group
given no therapy. One study185 included in the Gordon et al.164 review found a RR for clinical relapse of 0.5
for IFX versus purine analogues; this study observed only three events among 22 patients giving, on
assumption of constant hazard, a transition probability to clinical relapse for IFX-treated patients of
0.0119855 per cycle.
In view of the considerable uncertainty necessarily associated with this estimate of response loss with IFX,
and the lack of information on timing of events, we looked for alternative data. Baert et al.77 reported
time-to-event data for reintroduction of IFX following at least 15 months after LOR despite dose
optimisation. During the ≥ 15-month IFX holiday some patients received surgery. Time to LOR after IFX
reintroduction is shown in Figure 64 together with the exponential fit used to estimate transition
probabilities for the economic model. Owing to a lack of data, we have assumed the same transition
probabilities for patients receiving anti-TNF-α in combination with immunosuppressants to be the same as
that for IFX alone.
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FIGURE 64 Reconstructed Kaplan–Meier plot and Weibull fit for time to LOR after reintroduction of IFX after
surgery by 4-week cycle (based on data from Baert et al.77). (a) Weibull; and (b) exponential.
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Intervention arm: loss of response to test-directed
infliximab maintenance
Only two management studies of IFX responders were found and one of these, Vaughn et al.,128 was a
retrospective study at considerable risk of selection bias such that the large reported advantage for the
poorly defined test-based strategy lacks face validity (Figure 65). The TAXIT73 randomised controlled
management study of responders to IFX maintenance did not report time to LOR. ‘Durable remission’
among the TAXIT trial IBD patients at week 52 post randomisation (13 cycles) was reported to be almost
the same for test algorithm strategy patients who were dose escalated, or who received no dose
adjustment, or whose dose was reduced (28.6%, 26.4% and 25%, respectively). On this basis we have
assumed that LOR was also unlikely to differ significantly between these groups. The p-value for the
comparison of test-based dosing with clinically based dosing was 0.88. Of patients with CD in the TAXIT
trial intervention arm, 79.77% were in clinical remission at randomisation and 62.6% in clinical and
biological remission at week 52. There was no time-to-event data for clinical remission; however, if a
constant hazard is assumed for loss of remission the resulting transition probability is 0.018477165 per
cycle (Figure 66). This represents a very severe test for LOR because patients without clinical remission are
likely to be retained in anti-TNF-α treatment because of a partial response. The retrospective management
study of Vaughn et al.128 reported vastly superior performance for 39 IBD patients receiving a test
algorithm strategy relative to 68 patients given a clinically based dosing strategy; when time to treatment
cessation for these 39 patients was fitted with an exponential distribution a transition probability of only
0.003928414 per cycle is generated (see Figure 66). These transition probabilities are very different and it
is doubtful that either generates an appropriate input for the economic model.
In the TAXIT study before dose optimisation, 131 out of 178 (73.59%) patients with CD were in clinical
remission; after dose optimisation with a test-directed dose adjustments, 138 out of 173 (79.77%) were in
remission (five patients with CD could not be optimised to target trough level). According to ITT analysis,
this represents a 3.9% improvement. With continued test-directed dosing post randomisation, 62.6% of
patients with CD were in remission (clinical and biological) at 52 weeks, whereas 54.9% were in remission
with clinically based post-randomisation dosing, implying a small advantage for the testing strategy
(approximately 7.7%) (p = 0.353 for comparison between groups). These small differences (3.9% and
7.7%) can be explained by the play of chance and are obviously associated with considerable uncertainty.
We found no other evidence of clinical benefit from a test algorithm-based strategy. In the absence of
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FIGURE 65 Log-normal models for retention in IFX maintenance therapy for IFX responders (based on Vaughn
et al.128 and used in sensitivity analysis).
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other evidence demonstrating an advantage for a test algorithm-based strategy the model uses the same
probability for LOR to IFX as used for the standard care arm (fit to Juillerat et al.159 data).
Intervention arm: regain of response with test-directed
treatments following response loss to maintenance infliximab
The treatments for patients with LOR to maintenance IFX were informed by the management study
of Steenholdt et al.123 [Chapter 3, Objective C2: studies relating test results to clinical state of patients
(correlation studies)]. Patients enrolled in this study had failed IFX maintenance in which patients received
‘regular infusions of 5 mg/kg’. It is recognised that this regimen does not exactly correspond to the dose
being received by patients during the 52 weeks of the TAXIT trial,73 in which dose was variously adjusted
to bring trough IFX to a target range. In Steenholdt et al.123 patients received concurrent testing at the time
of IFX failure and subsequent treatment followed an algorithm based on test results and was aimed at
regaining response.
Concurrent testing identified four groups of intervention patients in the following proportions: (1) IFX
negative and antibodies positive (n = 5; 15.15%); (2) IFX negative and antibodies negative (n = 1; 3.03%);
(3) IFX positive and antibodies negative (n = 26; 78.79%); and (4) IFX positive and antibodies positive
(n = 1; 3.03%). The study reported the proportion who regained a response by 12 weeks, but time-to-event
data were not reported. We have assumed that those who had not regained response by week 12 have lost
response at a rapid rate over three cycles and remained in the non-response state (until surgery was
implemented), and those who were in a response state at week 12 then proceeded to lose response at a
given rate dependent on their algorithm-directed treatment regimen. The number of patients in all groups
except group 3 was small, and so outcomes are associated with great uncertainty. We have assumed that
the single group 4 individual (positive test results for both IFX and antibodies to IFX) had the test results
confirmed and was subsumed according to the treatment algorithm into group 3, which then accounts for
27 out of 33 (81.8%) of intervention patients. Unfortunately, the various treatments used for the group 3
patients were insufficiently prescribed to be usable (e.g. surgery ‘should be considered’).
For intervention group 1 patients (15.15% of IFX failures), the algorithm-prescribed treatment was a switch
to maintenance therapy with ADA: at 12 weeks 2 out of 5 had regained response. This is a poor response
rate, but is based on only five patients and is uncertain. We have therefore used the same transition
probabilities for these patients as for ADA-treated patients in the standard care arm (based on the GAIN
RCT and on the study by Karmiris et al.48 described in Figure 62).
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FIGURE 66 Time to event for responders receiving a test algorithm strategy. Time to clinical remission in the TAXIT
trial and retention in treatment in Vaughn et al.128 by 4-week cycle.
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The single group 2 patient (3.03% of intervention patients) received IFX intensification and failed to regain
response by week 12. However, all control arm patients in the trial also received IFX intensification and at
12 weeks 19 out of 36 had regained response; which, when combined with the single group 2 patient,
provides an estimate of 19 out of 37 (51.3%) in response at week 12. We assume the last patients move
to non-response at constant hazard over the first three cycles (12 weeks) providing a transition probability
of 0.19948 per cycle. However, using this transition probability would considerably disadvantage the
model intervention arm relative to the control arm, and is based on a single time point estimate for a small
group of patients. Therefore, the rate of loss of regained response for group 2 was assumed to be the
same as that for dose-escalated IFX patients described by Ma et al.,161 which is based on 6 years of time-
to-event data (see Figure 61 for the model based on data from Ma et al.161).
In groups 3 and 4 (81.81% of IFX failures), 16 out of 27 had regained a response at 12 weeks and 11 out
of 27 were in a state of non-response. We assume that the latter group lost response at constant hazard
over the 12 weeks providing a transition probability of 0.16004 per cycle. As the treatment for group 3
patients was not prescribed, other than that it lacked anti-TNF-α, we have assumed that after cycle 4
(12 weeks) LOR occurs at constant hazard based on the Rutgeerts et al. RCT165 placebo arm (background
therapies including purine analogues, steroids, methotrexate and 5-ASA), in which about half of patients
had previously received previous anti-TNF-α therapy. This suggested a transition probability of 0.08617343
per cycle.
In the Steenholdt et al. study123 about half of group 3 patients likely received IFX in contradiction to the
specified treatment according to the algorithm.
Of these, 12 patients continued IFX (nine patients from group 3 and one patient from group 4).
The applied IFX regimen was (all received 5 mg/kg):
l IFX q8 regimen (two infusions during the trial, i.e. weeks 0 and 8) – n = 5
l IFX q4 regimen (four infusions during the trial, i.e. weeks 0, 4, 8 and 12) – n = 2
l IFX q4 regimen but not throughout the entire trial (three infusions during the trial) – n = 1
l IFX q4 regimen but not throughout the entire trial (two infusions during the trial) – n = 2
l IFX q4 regimen but not throughout the entire trial (one infusions during the trial) – n = 2.
The remaining two patients had been switched to ADL because of misinterpretation of test results
(see Figure 2). Both patients were in group 3.
The applied ADL regimen was:
l ADL induction (160 mg–80 mg–40 mg) and followed by 40 mg every other week.
This indicates the various treatments received by the 14 patients in the intervention arm who did not
receive algorithm-directed treatments. In view of these difficulties it is difficult to discern how treatment
received relates to response observed at cycle 3.
The patients with LOR from all groups remain on palliative care in a LOR state until surgery. It is possible
that some of these patients (and also those patients with LOR after ADA in the standard care arm),
at some time may be reintroduced to IFX (or possibly ADA) prior to surgery and may regain response;
however, lack of evidence precluded modelling this. We have assumed that after surgery various
treatments are administered in attempts to maintain post-surgical remission and that these are the same
as for the standard care arm.
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Appendix 18 Resource-use data
In this appendix, we report on the unit costs derived for monitoring IFX and antibodies to IFX, treatmentcosts for patients receiving IFX maintenance therapy and cost of a surgical procedure.
TABLE 61 Unit costs for monitoring IFX and antibodies to IFX
Resource use Quantity Description
Unit costs
(£, 2014) Source
LISA-TRACKER assays for monitoring IFX and antibodies to IFX (concurrent testing)
Assay kit used to monitor
IFX and antibodies to IFX
(concurrent testing)
1 Total cost of kits for monitoring IFX and
antibodies to IFX is £1568. Number of
patient samples per kit is 42
37.33 Sarah Bond (NICE,
2014, personal
communication)
Laboratory technician 1 Assay takes 3 hours to perform in the
laboratory. Based on a clinical support
worker as a proxy (£21 per hour)
1.50 PSSRU170
LISA-TRACKER assays for monitoring IFX and antibodies to IFX (reflex testing)
Assay kit used to monitor
IFX
1 Total cost of kit for monitoring IFX is
£850. Number of patient samples per
kit is 42
20.24 Sarah Bond (NICE,
2014, personal
communication)
Assay kit used to monitor
antibodies to IFX
1 Total cost of kit for monitoring
antibodies to IFX is £850. Number of
patient samples per kit is 42
20.24 Sarah Bond (NICE,
2014, personal
communication)
Laboratory technician 1 Assay takes 3 hours to perform in the
laboratory. Based on a clinical support
worker as a proxy (£21 per hour)
1.50 PSSRU170
Estimated total cost for monitoring IFX and antibodies, per person (concurrent testing) 38.83
Estimated total cost for monitoring IFX and antibodies to IFX, per person (reflex
testing)
43.48
Estimated total cost for monitoring IFX, per person 21.74
PSSRU, Personal Social Services Research Unit.
TABLE 62 Treatment of CD with IFX and ADA
Resource use Quantity Description
Unit costs
(£, 2014) Source
IFX treatment
IFX (Remicade)a 1 5 mg/kg intravenous infusion over
a 2-hour period every 8 weeks
100 mg/vial = £419.62. Four vials
required 4 × £419.62 = £1678.48
1678.48 BNF 2013/14166
Administration cost 1 287.93 PSSRU 2014170
Estimated cost per individual receiving IFX maintenance therapy every 8 weeks 1966.41
ADA treatment
ADA (Humira) 1 40 mg every 2 weeks 352.14 BNF 2013/14166
PSSRU, Personal Social Services Research Unit.
a Patients on maintenance therapy receiving IFX treatment are given a 5 mg/kg intravenous infusion over a 2-hour period
every 8 weeks. We assumed that patients are, on average, weighing 70kg.
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TABLE 63 Cost of a surgical procedure
Resource use Quantity Description
Unit costs
(£, 2014) Source
Investigations
Laparoscopic ileocolic
resection
1 FZ74F elective inpatients – complex
large intestine procedures, aged ≥ 19
years, with a CC score of 0–2
6803 NHS Reference Costs
2013 to 2014167
Outpatient visits
(follow-up consultation)
1 WF01A colorectal surgery – consultant-
led outpatient attendance non-
admitted
105 NHS Reference Costs
2013 to 2014167
Cost of laparoscopic ileocolic resection 6908
CC, complications or comorbidities.
TABLE 64 Additional costs associated with occupying health states
Health state Quantity Description
Unit costs
(£, 2014) Source
Responder
Outpatient visits 2 WF01A colorectal surgery –
consultant-led outpatient attendance
non-admitted
105 NHS Reference Costs
2013 to 2014167 and
expert opinion
Colonoscopy 1 Weighted average of NHS reference
cost outpatient for FZ51Z diagnostic
colonoscopy without biopsy, or FZ52Z
diagnostic colonoscopy with biopsy
370.69 NHS Reference Costs
2013 to 2014167 and
expert opinion
MRI 1 Outpatient RA01A MRI 145 NHS Reference Costs
2013 to 2014167 and
expert opinion
Cost for the responder health state 725.69
Regain response
Outpatient visits 2 WF01A colorectal surgery –
consultant-led outpatient attendance
non-admitted
105 NHS Reference Costs
2013 to 2014167 and
expert opinion
Colonoscopy 1 Weighted average of NHS reference
cost outpatient for FZ51Z diagnostic
colonoscopy without biopsy or FZ52Z
diagnostic colonoscopy with biopsy
370.69
MRI 1 Outpatient RA01A MRI 145
Cost for the regain response health state 725.69
LOR
Outpatient visits 2 WF01A colorectal surgery –
consultant-led outpatient attendance
non-admitted
105 NHS Reference Costs
2013 to 2014167 and
expert opinion
Colonoscopy 2 Weighted average of NHS reference
cost outpatient for FZ51Z diagnostic
colonoscopy without biopsy or FZ52Z
diagnostic colonoscopy with biopsy
370.69
MRI 2 Outpatient RA01A MRI 145
Cost for the LOR health state 1241.38
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TABLE 64 Additional costs associated with occupying health states (continued )
Health state Quantity Description
Unit costs
(£, 2014) Source
Post surgery (remission)
Outpatient visits 4 WF01A colorectal surgery –
consultant-led outpatient attendance
non-admitted
105 NHS Reference Costs
2013 to 2014167 and
expert opinion
Colonoscopy 1 Weighted average of NHS reference
cost outpatient for FZ51Z diagnostic
colonoscopy without biopsy or FZ52Z
diagnostic colonoscopy with biopsy
370.69
Cost for the post-surgery (remission) health state 790.69
MRI, magnetic resonance imaging.
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